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Abstract 
HIV remains a key public health issue, despite the introduction of effective antiretroviral 
therapy (ART) which has led to huge improvements in the prognosis of HIV-positive 
individuals. In order to be best informed about an HIV epidemic, it is desirable to have 
estimates to complement data already available from national and international 
surveillance, not only on the total number of people living with HIV, but which also 
describe the characteristics of HIV-positive populations such as the number diagnosed, 
CD4 count and viral load distribution and the cascade of care. The aims of this thesis 
were to develop a method based on an individual-based progression model of HIV and 
the effect of ART to reconstruct and hence better understand the HIV-positive population, 
for use in Europe. Using this model, I first investigated the projected life expectancy of 
men-who-have-sex-with-men (MSM) according to timing of diagnosis. I then updated the 
model to incorporate new data after a review of the literature as well as statistical 
analyses of viral load and CD4 count changes in the absence of ART, based on data 
from a large pan-European cohort collaboration. Next, I developed a method using data 
on MSM in the UK, which calibrates the model to observational and surveillance data of 
HIV from European countries, and then uses the parameter sets which best fit to the 
observed data to describe the status of their HIV-positive populations. Plausibility ranges 
are also estimated to reflect the uncertainty regarding any model parameters. The 
method is also applied to data on MSM in the Netherlands, and for all HIV-positive 
individuals in Spain and Estonia.  The advantages and disadvantages of this approach 
compared with other existing approaches are considered. To conclude, I reflect on 
future modelling needs that are particularly relevant to informing public health in Europe. 
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Chapter 1 Introduction 
1.1 Aims and objectives of this thesis 
The aim of this thesis is to develop a calibration method to reconstruct and hence better 
understand HIV-positive populations in Europe. I use a novel method, based on an 
individual-based stochastic simulation model of the human immunodeficiency virus (HIV).  
Despite the availability of effective HIV treatment, HIV remains a key public health issue 
in most regions of the world, including Europe. A range of epidemiological data is 
required to understand an HIV epidemic in detail. It is useful to have in depth information 
on such populations so that epidemiologists, policymakers and public health experts can 
make informed decisions about matters including prevention, diagnosis and treatment of 
HIV. Modelling can generate useful estimates to complement the sometimes limited data 
already available from surveillance systems. It may also provide additional insights into 
national and regional reports on the epidemic and its impact on public health, as well as 
enhancing the current evidence base in the literature. 
Chapter 1 first provides an overview of the natural history of HIV by introducing the 
characteristics and properties, life cycle, origin, routes of transmission and the stages of 
disease progression. Next, I present how HIV treatment works, the types of antiretroviral 
drugs available and the limitations of treatment such as drug resistance and side effects. 
I also mention co-infections in this chapter because this can accelerate the progression 
of HIV and complicate the management of treatment. 
In Chapter 2, the global, and specifically, European epidemiology of HIV is described. 
The epidemics in the 18 European countries with the largest HIV-positive populations 
are also discussed. I also review the available estimation methods and a summary of 
how and what HIV surveillance is conducted. 
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Chapter 3 reviews the types of mathematical models which are available and how they 
are used in the context of HIV epidemic modelling. Here I also review other existing HIV 
stochastic simulation models before presenting the HIV Synthesis V5 model in detail. 
This version of the model already existed when I started this thesis. It should be noted 
that this thesis focuses on progression of disease in HIV-positive people and so 
transmission of HIV is not modelled.  
In Chapter 4, I use the HIV Synthesis V5 model to estimate the projected life expectancy 
of men-who-have-sex-with-men (MSM) infected with the virus in 2010. This provides a 
good means of showing how the model works, as well as providing useful estimates to 
inform people with HIV, clinicians and public health practitioners. 
Chapter 5 documents how I developed the HIV Synthesis V6 model. This new version of 
the model was developed based on the results of a number of analyses I performed 
using data from a large pan-European observational study, as well as a series of 
literature reviews. 
Chapter 6 gives details on the approach I developed to calibrate the model to the 
available European data. This is in order to reconstruct the HIV-positive population of 
interest, so that I can provide estimates with plausibility ranges that are useful for 
describing the infected population. The calibration method was developed using data on 
MSM in the UK. Further analyses were performed using pseudo data to assess the 
impact of different availability of data on calibration of the model.  
In Chapter 7 I present a modified version of the calibration method, adapted such that it 
now includes migration of people who originate from sub-Saharan Africa, who are either 
infected with HIV in SSA or once they reach Europe. This adapted method was 
developed using data from the UK, which has a large number of such migrants with HIV. 
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Chapter 8 demonstrates the application of the calibration method to three other settings: 
MSM in the Netherlands as well as all HIV-positive people in Spain and Estonia.  
Finally in Chapter 9 I provide an overall summary and discussion of each of the chapters 
in this thesis, as well as considering the implications and applications of the results. 
1.2 Human Immunodeficiency Virus 
1.2.1 Introduction 
HIV is a blood-borne retrovirus which attacks the immune system. The virus 
predominantly infects and destroys the CD4+ T-lymphocyte cells (CD4 cells) found in 
the body. CD4 cells are responsible for coordinating the immune system response when 
a foreign object such as a bacteria or virus invades. Viruses require a host cell in order 
to replicate and it is the CD4 cells which are predominantly the host cells in the case of 
HIV. A retrovirus is a type of virus where the genetic material is in the form of RNA 
(ribonucleic acid), which is converted into double-stranded DNA (deoxyribonucleic acid) 
by the process of reverse transcription[1]. 
1.2.2 Life cycle of HIV 
The HIV life cycle (Figure 1-1) can be summarised by the following processes: 
attachment and entry, reverse transcription, integration, transcription, translation and 
virus assembly[2,3].  
Once the virus is transmitted and enters the human body, it attaches itself to the CD4 
receptors found on the host CD4 cell[4]. The virus then fuses with the cell’s membrane 
by activating and binding to co-receptors found on the CD4 cell membrane surface and 
enters the cell[5]. An enzyme called reverse transcriptase is then released and used by 
the virus to convert viral RNA into double-stranded DNA; a process known as reverse 
transcription. This process is necessary so that the viral information is then in a form that 
can be inserted into the host genome[6, 7]. Facilitated by the integrase enzyme, the 
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HIV-DNA is then inserted into the host chromosomal DNA. This process is called 
integration. Once integration occurs, the viral information permanently stays within the 
host cell and may remain latent for some time[8]. When the host cell becomes activated, 
transcription and translation follows. Transcription occurs when the double-stranded 
DNA divides into two and forms mRNA (messenger RNA). Some of the mRNA is then 
translated into viral proteins, in particular the enzyme protease, whilst others are used to 
form new HIV components. The final stage of the HIV life cycle is viral assembly. The 
enzyme protease helps form the functioning structures of other viral proteins such as 
reverse transcriptase and integrase, which is required in the production of new viruses. 
Virions (virus particles) are assembled from the RNA and viral proteins at the host cell 
membrane then released into the bloodstream where it is now able to infect other cells. 
In an infected individual who is not receiving any HIV treatment, it is estimated that over 
one billion virions are produced in a day, implying that HIV replication is very rapid and 
highly productive[9]. 
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Figure 1-1: HIV life cycle [3] 
 
1.2.3 Types, groups, subtypes and tropism 
The rate that mutations occurs in HIV replication is very high, due to the rapid replication 
process of the virus, combined with the sheer number of virions which exist in the host 
human[10] and the high rate at which errors occur during reverse transcription[11, 12]. 
This results in high genetic variability of the virus.  
There are two types of HIV recognised; HIV-1 and HIV-2. HIV-1 was discovered first[13, 
14]. It is usually referred to as ‘HIV’, and is also the type discussed in this thesis.  
 
Figure not available due to copyright restrictions 
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Phylogenetic analyses of HIV-1 have shown that it can be further categorised into 
groups and subtypes[15]. There have been four phylogenetic groups discovered to date: 
M, N, O and P. Group M is responsible for the majority of HIV-1 infections in the world.  
Types are further categorised into subtypes, also known as clades. Within group M, 
there are currently nine known subtypes, all of which are thought to have originated from 
Africa: A, B, C, D, F, G, H, J and K[16]. Global studies of subtype distribution have found 
that subtype C is responsible for approximately half of HIV-1 infections in the world[17, 
18]. The prevalence of subtypes differs according to geographical region. For example, 
subtype C is predominantly found in Southern Africa, Ethiopia and India but can also be 
found in other areas of Africa and Asia as well as Latin America[18]. On the other hand, 
subtype B is the most common in Western Europe and North America, even though 
globally speaking, it constitutes just 10% of all HIV-1 infections[17]. Most of the 
diagnostic tests and antiretroviral drugs have been developed in these regions and are 
therefore based on the clinical findings of a population largely infected by subtype B[15, 
19].  
Tropism refers to the type of cell which is infected by HIV. Viruses which bind to the 
CCR5 co-receptor (found on the host cell membrane) are termed R5-tropic (R5), 
whereas those which bind to the CXCR4 co-receptor are termed X4-tropic (X4). There is 
also a type which uses both and these are known as X4R5-tropic or dual-tropic[20]. The 
majority of HIV transmissions involve the R5-strain and therefore most people are 
initially infected with the R5 virus[21]. For reasons that are still not very clear, it has been 
found that the R5 virus frequently converts to the X4 virus over time; this is termed a ‘co-
receptor switch’[22]. This is a concern as the emergence of X4 virus has been 
associated with faster HIV disease progression[23, 24]. 
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1.3 History of HIV and AIDS 
1.3.1 The origin of the virus 
It is now generally accepted that HIV (both HIV-1 and HIV-2) originated in the form of 
the simian immunodeficiency virus (SIV) which affects monkeys[25]. The key discovery 
occurred in 1999 when a group of researchers found that a strain of SIV which occurred 
in chimpanzees was near identical to that of HIV-1[26]. The date of cross-species 
transmission is yet to be determined but the origin of the group M virus is thought to be 
between 1915 and 1941[27].  
1.3.2 First cases of AIDS and the discovery of its aetiological agent, 
HIV 
In 1981, the US Centers for Disease Control and Prevention (CDC) was notified of 
several cases of young homosexual men in different cities of the US being affected by 
two diseases; Kaposi’s sarcoma (KS) and Pneumocystis carnii pneumonia (PCP)[28-30]. 
Both KS and PCP are rare diseases in healthy people so the fact that deathly cases 
occurred in quick succession attracted much attention. These reports were subsequently 
followed by similar accounts of PCP occurring in people who inject drugs (PWID)[31], 
Haitians[32], haemophiliacs[33] and Africans[34], as well as cases of other opportunistic 
infections such as mycobacterial infections, toxoplasmosis and non-Hodgkin’s 
lymphoma[35]. By then, it was known that these diseases all occurred because of one 
single cause, which was the result of immune deficiency. The term ‘Acquired Immune 
Deficiency Syndrome’ (AIDS) was first used by the CDC in 1982[36].   
The virus responsible for AIDS was first isolated from a sample from a patient with AIDS 
in 1983 and named lymphadenopathy-associated virus (LAV)[13]. It was also isolated by 
another research group in 1984 who named it human T-cell lymphotropic virus type III 
(HTLV-III)[37]. These two viruses were found to be the same in the following year, when 
it was identified that it was the aetiological agent of AIDS[38]. A common name for the 
virus was given in 1986: human immunodeficiency virus[39, 40].  
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1.3.3 Classification system of HIV infection 
When an individual infected with HIV presents with one or more AIDS-defining 
conditions (ADC, also known as AIDS-defining illnesses), they are said to have AIDS. 
The most recently published list of AIDS-defining conditions according to the CDC is 
shown in Appendix I. Classification of HIV/AIDS according to the 2008 revision[41], is 
summarized in Table 1-1. A confirmed case of HIV infection requires meeting the 
laboratory criteria (a positive result from an antibody test or detectable quantity of HIV 
viral material, see more in Section 1.5.1) and classification into one of four stages. AIDS 
is defined in the US by the presence of an ADC or a CD4 count measurement <200 
cells/mm
3
.  
Table 1-1: CDC classification of HIV/AIDS [41]   
 Clinical criteria  CD4 count criteria 
(CD4% criteria) 
Stage 1 No AIDS-defining condition and >500 cells/mm3 (>29) 
Stage 2 No AIDS-defining condition and 200-499 cells/mm3 (14-28) 
Stage 3 (AIDS) AIDS-defining condition or <200 cells/mm3 (<14) 
Stage Unknown No information and No information 
AIDS:Acquired Immune Deficiency Syndrome; CDC:Centers for Disease Control and 
Prevention. 
 
The World Health Organisation (WHO) classification system of HIV infection is primarily 
designed for use in settings with limited laboratory facilities, and are therefore based on 
degree of symptoms[42]. WHO clinical stages are: 1 (asymptomatic), 2 (mild symptoms), 
3 (advanced symptoms) and 4 (severe symptoms).   
In Europe, the choice of HIV staging system used for HIV and AIDS surveillance differs 
by country. A 2006 survey of HIV/AIDS surveillance in the WHO European region found 
that out of the countries which recorded the clinical stage at HIV diagnosis, three 
different clinical staging systems were in use: 2005 revised WHO clinical staging system, 
1990 WHO clinical staging system and 2005 CDC clinical staging system[43]. The same 
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survey found that most European countries used the 1993 European AIDS surveillance 
case definition[43]. The European definition for AIDS is the same as that used in the US 
(1993 CDC definition) but with the omission of the CD4 count criteria[44]. 
1.4 Transmission of HIV 
HIV can be found in the bloodstream as well as other bodily fluids such as semen, 
cervical secretions and breast milk. The virus can be transmitted via blood or any of 
these fluids. The main modes of transmission are sexual (between men and women, 
and between men), through injecting drug use (IDU), mother-to-child transmission 
(MTCT) and transfusion-related transmissions. Sexual transmission accounts for the 
vast majority of transmissions that have occurred globally since the beginning of the 
epidemic[45, 46]. 
Estimates from modelling studies strongly suggest that the rate of HIV transmission 
depends on the stage of disease of the infected individual, through the viral load. It is 
highest soon after seroconversion and during the advance stages of the disease, and 
lower when in the latent period of the disease[47-50].  
1.4.1 Transmission between men-who-have-sex-with-men 
The first cases of AIDS at the beginning of the epidemic were reported in MSM. Soon 
after it was established that condomless (or ‘unprotected’) anal intercourse was the main 
mode of HIV transmission among MSM[51, 52]. A meta-analysis has found that the HIV 
transmission risk during anal intercourse may be approximately 18 times greater than in 
vaginal intercourse[53]. The rate of MSM transmission is estimated to be approximately 
0.005 to 0.030 per coital act[54-56]. The likelihood of transmission is greater with 
receptive unprotected anal intercourse compared to insertive unprotected anal 
intercourse[55]. 
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1.4.2 Heterosexual transmission 
The rate of heterosexual transmission has been estimated to be between approximately 
0.0001 and 0.0040 per coital act[57]. Male-to-female transmissions are two to 8-fold 
more likely compared to female-to-male transmissions[58, 59]. HIV viral load is a strong 
predictor of the rate of heterosexual transmission[60]. Studies in couples in stable 
relationships have found that very few transmissions occur where the seropositive 
individual has suppressed viral load, especially when taking HIV treatment[61, 62]. 
1.4.3 Transmission via injecting drug use  
Transmission of HIV occurs when infected needles or syringes are shared or reused 
between PWID. The probability of infection is estimated to be approximately 0.0067 to 
0.0080 per injection with an infected needle or syringe[63, 64]. PWID are also more 
likely than MSM and haemophiliacs to be co-infected with hepatitis B and/or C[65]. 
Needle-syringe programmes (NSP) and opioid substitution therapy (OST) with 
methadone or buprenorphine are the two main harm reduction approaches to IDU. 
1.4.4 Mother-to-child transmission 
MTCT, also known as vertical or perinatal transmission, is the transmission of the virus 
from mother-to-child during pregnancy, labour, delivery or breastfeeding[66]. Successful 
interventions to reduce the rate of MTCT include delivery by elective caesarean section, 
formula feeding and particularly, the use of antiretroviral drugs[67]. 
1.4.5 Transfusion-related transmission 
HIV can also be transmitted through blood transfusions and blood products. 
Haemophiliacs were disproportionately affected by HIV, especially in the early 1980s 
before HIV testing was available[68]. The risk of transmission through blood products is 
extremely high; one study has reported a figure of 90%[69]. Nowadays, transfusion-
49 
 
related transmissions are very rare due to HIV testing of donated blood as well as donor 
screening. 
1.4.6 Healthcare associated transmission 
Although rare, transmission of HIV can occur in healthcare settings, known as 
nosocomial infections or hospital-acquired infections [70, 71]. Healthcare workers are at 
an occupational risk through contact with infected blood and most transmissions occur 
via percutaneous exposure[72]. Although the risk of transmission depends hugely on the 
extent of exposure to the infected blood, such as length of time exposed and volume of 
blood exposed to, the probability of transmission after percutaneous exposure is thought 
to be approximately 0.03%[73].  
1.5 Disease progression 
1.5.1 Diagnosis and monitoring 
A person is diagnosed to be infected with HIV (HIV-positive) when antibodies to HIV are 
detected. The diagnostic test most commonly used for HIV is called the ELISA antibody 
test (enzyme-linked immunoabsorbent). ELISA tests are cheap but also extremely 
sensitive and therefore are a reliable tool in the diagnosis of HIV. 
HIV infection is typically characterised by a significant depletion in the number of CD4 
cells[74], known as the CD4 cell count, which is measured as the absolute number of 
CD4 cells per cubic millimetre of blood (cells/mm
3
). It is the most important marker of 
HIV disease progression because HIV infection causes the CD4 count to decline and 
immune deficiency is the direct consequence of the decline in CD4 count. The CD4 
count for a healthy HIV-negative adult can vary, but is usually between 500 to 1500 
cells/mm
3
[75, 76]. Factors which can affect this include gender, age and smoking 
status[76, 77]. Depletion in CD4 cells results in the lack of a healthy immune system and 
therefore the body is vulnerable to opportunistic infections. Despite decades of research, 
the exact mechanism of CD4 cell depletion caused by HIV infection is still unclear[74]. It 
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is thought to be a combination of direct destruction of CD4 cells by the virus itself, as 
well as interference by the virus in the activation and regeneration processes[78]. In an 
HIV-positive adult who is not receiving any treatment, the CD4 count gradually declines 
over time at a rate of approximately 50 to 80 cells/mm
3
 per year[79-81], although this 
rate can vary quite considerably between individuals.  
The CD4 percentage is the proportion of CD4 cells out of the total number of 
lymphocytes. In adults, unlike the CD4 count, the CD4 percentage alone is not used as 
a marker to guide HIV treatment initiation in adults[82]. The CD4 percentage is 
correlated with the CD4 count, but not perfectly; the correlation coefficient was 
calculated to be approximately 0.5 in one study[83]. The CD4 percentage is thought to 
be less variable than the CD4 count so when there is a discrepancy between the two 
measurements, the CD4 percentage can potentially add prognostic information[84].  
The HIV viral load is another marker of HIV progression. Both the CD4 count and viral 
load can independently predict the risk of AIDS and death[85-88]. The viral load can 
also predict the rate of CD4 count decline. The viral load refers to the quantity of HIV-
RNA present in the blood plasma, measured as copies of RNA per millilitre (copies/ml) 
or sometimes as log10 copies of RNA per millilitre (log copies/ml). The viral load is 
termed to be undetectable if it is lower than the detection limit of the viral load assay. 
This cut-off used to be <1000, <500 or <400 copies/ml[89, 90], and whilst <50 copies/ml 
is generally used nowadays, some of the ultra-sensitive assays can detect even lower 
levels[91, 92]. The phrase ‘undetectable viral load’ is often synonymous with ‘viral 
suppression’.  
1.5.2 Natural history of HIV (in absence of treatment) 
Once transmission of HIV has occurred, the progression of HIV infection in the absence 
of treatment can be divided into four stages (Figure 1-2): primary infection, 
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asymptomatic infection (or clinical latency), symptomatic infection and opportunistic 
infections, i.e. AIDS. 
Figure 1-2: Natural course of HIV infection [93]   
 
1.5.2.1 Primary infection 
Primary infection is also known as acute/early HIV infection or seroconversion illness 
and is the first stage following transmission of the virus. This phase usually lasts for 
between several weeks to three months. During primary infection, viral replication 
triggers the development of anti-HIV antibodies. The process in which the body starts 
producing antibodies is termed seroconversion, which usually takes place within three 
months of infection[94].  
Primary infection is characterised by a sudden increase in the viral load followed by a 
slight decrease where it then settles to what is known as the ‘set point’[95, 96]. 
Individuals who are experiencing primary infection are especially infectious because of 
the high levels of viral load reached in this phase[48, 97, 98]. The peak of the sudden 
increase in viral load can be higher than 10 million copies/ml, and the set point is 
approximately 10,000 copies/ml, but both these values have large inter-person 
 
Figure not available due to copyright restrictions 
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variability[86, 99, 100]. As the viral load rapidly rises and then drops during 
seroconversion, the CD4 count concomitantly declines rapidly but then rises and returns 
towards normal levels (Figure 1-2) [101, 102]. A recent meta-analysis has shown a 
statistically significant increase in the viral load set point together with a possible 
decrease in the initial CD4 count with calendar time, indicating an increase in virulence 
over time since the epidemic began[103].  
Clinical symptoms are observed in 40% to 90% of adults and these generally emerge 
around two to six weeks after seroconversion[104, 105]. Symptoms include rash, fever, 
lymphadenopathy, sore throat, headaches, diarrhoea, arthralgia, ulceration and weight 
loss[104, 106]. Studies have found that patients who develop symptoms during primary 
infection are more likely to have an accelerated progression to AIDS compared to non-
symptomatic patients[99, 107]. 
1.5.2.2 Asymptomatic infection 
The asymptomatic phase of infection continues for a median of ten years[93]. Although 
this period is sometimes also labelled as ‘clinical latency’, this is somewhat misleading 
as a key feature of this period is the deterioration of the immune system as a result of 
the steady decline in the CD4 count[93, 108]. Whilst the CD4 count decreases over time, 
the counts generally stay within normal levels or at least above 350 cells/mm
3
 during 
this asymptomatic phase[106]. The viral load increases gradually (although less steeply 
than depicted in Figure 1-2) as the CD4 count declines[109]. The increase in viral load is 
estimated to be between 0.08 and 0.18 log copies/ml per year[95].  
1.5.2.3 Symptomatic infection 
The CD4 count continues to fall as the individual enters the symptomatic phase of 
infection[93]. Once the CD4 count declines to levels where the immune system cannot 
work effectively, symptoms start emerging which would not in someone with a healthy 
immune system[110]. This usually occurs once the CD4 count decreases to levels below 
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350 cells/mm
3
[111]. Early symptoms include rash, fever, weight loss and headaches. 
Other manifestations which can occur between the CD4 counts of 200 and 350 
cells/mm
3
 include herpes zoster, oropharyngeal candiasis and oral hairy 
leucoplakia[112].  
1.5.2.4 AIDS 
Once the CD4 count drops to below 200 cells/mm
3
, opportunistic infections such as 
PCP, oesophageal candidiasis, toxoplasmosis and KS can occur[112]. As described in 
Section 1.3.3, the occurrence of any of these ADC marks the diagnosis of AIDS.  
The time from seroconversion to AIDS, which is known as the incubation period (to 
AIDS) can vary significantly between individuals. The CASCADE (Concerted Action on 
SeroConversion to AIDS and Death in Europe) study, which is a large cohort study of 
people with well-estimated dates of seroconversion, estimated that the median time from 
seroconversion to AIDS is between five to 11 years[113]. The CD4 count[114-117] and 
viral load[85, 86, 95, 101], both individually but also together[101, 118], are the most 
important predictors of the risk of AIDS development. The risk of AIDS is higher in those 
with higher viral loads and lower CD4 counts both at the time of seroconversion and in 
relation to current measurements. Older age is strongly associated with shorter time to 
onset of AIDS[113, 114, 119-121]. Estimates of the effects of other covariates such as 
transmission risk group, gender, race and calendar year, have been fairly inconsistent 
between studies[122-126].  
1.5.2.5 Rate of death from HIV 
The time from seroconversion to death in the absence of treatment can also vary widely 
between individuals, and the estimated median time from the CASCADE study is 
between 7.9 to 12.5 years[113]. Faster progression to death is associated with older age 
and lower CD4 count at HIV infection[120, 127-129]. The median time from AIDS to 
death in the absence of ART was estimated to be 17 months, whilst the proportion 
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surviving after three years from AIDS was 16% in the EuroSIDA study[124]. This is 
consistent with other natural history studies which took place in the same era[130, 131].  
The incubation period to AIDS and survival time has changed dramatically since the 
introduction of effective ART. The beneficial effect of potent treatment is the key reason 
that the incidence of AIDS and death has declined significantly in the last decade[132-
134]. In some rare cases, there are HIV-positive people who continue to be healthy 
without HIV treatment, with no evidence of immune system deterioration many years 
after seroconversion. These people are often termed ‘long-term non-progressors’. A 
small proportion of these people have also been found to have undetectable viral load 
levels, and such individuals are known as ‘elite controllers’.  
1.6 Antiretroviral drugs 
Drugs to treat HIV are known as antiretroviral drugs and the treatment regimen is 
referred to as antiretroviral therapy (ART). There are currently six different classes of 
antiretroviral drugs which are licensed by the European Medicines Agency (EMA) and 
the US Food and Drugs Administration (FDA): nucleoside reverse transcriptase 
inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase 
inhibitors and two classes of entry inhibitors (fusion inhibitors and CCR5-inhibitors). 
Each class targets different phases of the HIV life cycle. Antiretroviral drugs licenced in 
the European Union (EU) are listed in Appendix II. 
1.6.1 Nucleoside reverse transcriptase inhibitors 
The first antiretroviral drug to gain regulatory approval was a nucleoside reverse 
transcriptase inhibitor (NRTI). NRTIs work by disrupting the process of reverse 
transcription during the HIV life cycle. They do so by acting as an inhibitor of the reverse 
transcriptase enzyme by competing with the body’s naturally occurring nucleotide bases. 
The NRTI enzyme is incorporated into the double-stranded DNA instead of the viral 
RNA. This therefore disrupts the synthesis of viral DNA and the remaining viral RNA 
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becomes vulnerable to destruction by cellular enzymes[135]. Nucleotide reverse 
transcriptase inhibitors (NtRTI) are closely related to NRTIs and work in a similar but 
slightly more efficient manner[136]. They are therefore usually regarded as one drug 
class.  
Zidovudine (also known as azidothymidine, AZT) was the first licensed drug for the 
treatment of HIV, approved by the FDA in 1987[137]. Other NRTIs currently licenced are 
lamivudine (3TC), abacavir (ABC) and emtricitabine (FTC). The only NtRTI currently 
licenced is tenofovir disoproxil fumarate (tenofovir, TDF). There are other NRTIs which 
have been used in the EU: didanosine (ddI), stavudine (d4T) and zalcitabine (ddC). ddI 
and d4T are now rarely used because of side effects (the most severe but commonly 
seen side effect being peripheral neuropathy)[138, 139], although they are still 
sometimes used in low and middle income countries (LMIC). ddC has now been 
discontinued by the manufacturer due to the availability of newer antiretroviral drugs. 
There is some development of new NRTIs and prodrugs due to the importance of NRTIs 
as part of current ART regimens[140].  
1.6.2 Non-nucleoside reverse transcriptase inhibitors 
Non-nucleoside reverse transcriptase inhibitors (NNRTI) are similar to NRTIs as they 
both target the reverse transcription process. NNRTIs bind to a hydrophobic pocket of 
the HIV reverse transcriptase which results in changes to the active site of the enzyme, 
which in turn inhibits the enzyme from working properly[135]. There are currently four 
NNRTIs licenced in the EU and US: efavirenz (EFV), etravirine (ETV), nevirapine (NVP) 
and rilpivirine (RPV). Due to concerns with side effects, most notably excess rash and 
liver toxicity, NVP is generally only used to prevent MTCT in LMIC because of its non-
teratogenic properties[252]. RPV is the newest antiretroviral to be approved.  
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1.6.3 Protease inhibitors 
Protease inhibitors (PI) inhibit the activity of the viral protease enzyme. This does not 
prevent HIV from replicating but the resulting virions are immature particles unable to 
infect other cells[135, 141-143]. 
PIs currently approved in the EU are tipranavir (TPV), lopinavir (LPV), ritonavir (RTV), 
darunavir (DRV), atazanavir (ATV) and fosamprenavir (FPV). Almost all PIs in current 
use are pharmacokinetically ‘boosted’ with low-dose RTV, which enhances the 
concentrations of other PIs in the blood. As a result, bioavailability is improved, the drug 
half-life is extended (and so the patient is less likely to develop drug-resistant virus), and 
it is now clear that RTV-boosted PIs (denoted PI/r) are far more potent than unboosted 
PIs[144-148]. LPV is the only PI which is co-formulated with RTV as a single pill 
(kaletra). A number of other PIs are infrequently used nowadays, mainly in highly 
treatment-experienced patients, including indinavir (IDV), saquinavir (SQV), amprenavir 
(APV) and nelfinavir (NFV). 
1.6.4 Integrase inhibitors 
Integrase inhibitors (INIs) obstruct the function of the integrase enzyme, thereby 
preventing the integration of the HIV-DNA into the host DNA. It is the newest class of 
antiretroviral drugs to be approved. There are now three drugs in this class, raltegravir 
(RAL), elvitegravir (EVG) and dolutegravir (DTG).  
1.6.5 Entry inhibitors  
Unlike the previous classes of drugs already approved (NRTIs, PIs, NNRTIs and INIs) 
which are active once HIV has infected the host CD4 cell, entry inhibitors prevent the 
entry of the virus into the potential host cell[149].  
There are currently two types of entry inhibitors which act at different stages of the entry 
process: CCR5 inhibitors (or CCR5 antagonists), which target the co-receptor binding 
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process, and fusion inhibitors which target the fusion process. There is currently one 
approved CCR5 inhibitor, maraviroc (MVC), which is only effective for R5-tropic virus 
(which binds only to CCR5 co-receptors)[150, 151]. There is also only one fusion 
inhibitor that is seldom used, enfuvirtide (T-20). Unlike all other antiretroviral drugs, it is 
administered subcutaneously by injection[152]. 
1.6.6 Fixed-dose combinations and single tablet regimens 
In order to reduce pill burden, multiple antiretroviral drugs are combined into a single pill 
known as fixed-dose combinations (FDC) or co-formulations. FDCs may contain only a 
single class of antiretroviral drugs or can combine different classes. Single tablet 
regimens (STR) are a type of FDCs which combine different classes of drugs and can 
be taken as a ‘one pill once a day’ regimen. 
There are several NRTI FDCs currently licenced in the EU (Appendix II): combivir 
(3TC+AZT), kivexa (ABC+3TC), trizivir (ABC+3TC+AZT) and truvada (FTC+TDF). 
There are two NNRTI-based STRs and two INI-based STRs: atripla (EFV+FTC+TDF), 
eviplera (RPV+FTC+TDF), stribild (EVG+COBI+FTC+TDF), and triumeq 
(DTG+ABC+3TC). Stribild, also known as the ‘quad pill’, includes the pharmacokinetic 
boosting agent cobicistat (COBI) which improves the efficiency of the combination of 
drugs, similarly to RTV.  
1.6.7 Drug-drug interactions and contraindications 
The clinical consequences of drug-drug interactions include therapeutic failures as well 
as drug side effects[153]. Drug-drug interactions are uncommon with NRTIs, INIs and 
fusion inhibitors. In contrast, NNRTIs, PIs and CCR5 inhibitors are metabolised through 
a different mechanism and are far more vulnerable to drug-drug interactions, either with 
other antiretrovirals or other drugs such as statins, antivirals and antibiotics. This results 
in higher or lower drug levels within the host compared to when the drugs are used in 
isolation[154]. The University of Liverpool developed and maintains an up to date 
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website, www.hiv-druginteractions.org, which provides comprehensive information on 
drug-drug interactions.  
A drug contraindication is any factor which makes the administration of a drug 
inappropriate. Similar to the clinical consequences of drug-drug interactions, 
contraindications can result in reduced efficacy of regimens and drug side effects[155]. 
An important contraindication is the use of abacavir in the presence of the HLA allele 
B5701, which increases the rates of hypersensitivity reactions; patients are now 
screened for this allele before initiating an ABC-containing regimen[156, 157]. Another 
example of a contraindication is the use of EFV in women who are pregnant or 
considering becoming pregnant due to teratogenicity concerns[158].  
Drug-drug interactions and drug contraindications are a larger issue in LMIC than high 
income countries (HIC), where drug availability is better, allowing greater flexibility in 
constructing suitable regimens. 
1.7 Treatment regimens and strategies 
Currently available treatment for HIV cannot cure HIV; instead the aim is to suppress 
viral replication and therefore stop clinical progression. If the viral load levels are 
reduced, then the person’s CD4 count usually rises gradually over time, which allows 
the immune system to recover. Usually, the CD4 count rises rapidly in the first few 
months following treatment initiation in most people, but then it is followed by a more 
gradual increase over time. There is conflicting evidence on whether the CD4 count 
continues to rise until it returns to levels seen in HIV-negative individuals or whether it 
reaches a sub-optimal level and then plateaus in people with long-term viral 
suppression[159-165]. In previously ART-naïve patients receiving effective treatment for 
the first time, the predictors of slower clinical progression to AIDS and to death include 
higher CD4 count (at treatment initiation, current or at the nadir)[166-170], lower current 
viral load[169-171] and younger age[166].  
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Treatment of HIV has undergone dramatic changes since antiretroviral therapy first 
became available, owing to the large number of controlled clinical trials carried out over 
time which have demonstrated the efficacy of newer drugs and treatment strategies[172]. 
Initially, HIV-positive people were treated with a single drug regimen (or mono-therapy). 
Treatment with a two-drug regimen is referred to as dual-therapy and treatment with 
three or more are referred to as combination therapy (cART), highly active antiretroviral 
therapy (HAART) or triple therapy regimens. 
1.7.1 Mono-therapy 
AZT was licensed following results from a US randomised controlled trial (RCT) which 
showed that in patients with advanced HIV disease, there was a large reduction in short-
term mortality in the group receiving AZT compared to placebo[137]. This was 
subsequently followed by two more large RCTs (ACTG 019 and Concorde). Results 
from ACTG 019 showed that AZT was effective in delaying the progression to AIDS in 
people with low CD4 counts in the short-term. Yet results from the Concorde trial also 
demonstrated that there was no significant clinical benefit in the longer term[173, 174]. 
During these trials however, some people receiving AZT experienced severe side 
effects[175], or acquired drug resistance to AZT rendering it ineffective[176, 177]. ddI 
and ddC were the next NRTIs to be developed and studied as mono-therapy, but 
similarly to AZT (which used much higher doses at that time), they had very bad side 
effects and were only effective in the short-term due to development of resistance[178-
182]. 
1.7.2 Dual-therapy 
Interest in the use of dual-therapy regimens grew as it was hoped that such regimens 
would be more effective in the long-term, be less toxic (by way of lower doses of each 
drug) and delay onset of resistance mutations[183, 184]. Three major RCTs compared 
the benefits of dual-therapy over mono-therapy (Delta, ACTG 175 and CPCRA 
007)[185-187]. These trials all demonstrated that dual-therapy boosted survival and 
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slowed the progression of HIV disease compared to mono-therapy[185-187]. In addition, 
the CAESAR RCT investigated the effects of adding 3TC to AZT-containing regimens 
and found that adding another antiretroviral improved survival and slowed disease 
progression. Together, these trials set a precedent for future studies evaluating the 
effects of combining antiretroviral drugs[185-189]. 
1.7.3 Combination therapy 
The success of cART was initially demonstrated when both the ACTG 320 and Merck 
035 RCTs convincingly showed the superiority of an IDV-containing triple-therapy 
regimen over an NRTI-only dual-therapy regimen[190, 191]. Not only did the triple-
therapy regimen slow the progression of HIV and subsequent death, but it also lowered 
viral load levels to below the limit of detection of HIV RNA assays for the first time. By 
1998, analyses of cohort data started to confirm that cART had changed the landscape 
of HIV treatment by dramatically reducing rates of both AIDS and mortality[133, 134]. 
cART regimens traditionally consist of three (or more) antiretroviral drugs which include 
two NRTIs, often referred to as the ‘nucleoside backbone’. Factors which can affect the 
choice of regimen include possible side effects, emergence of resistance mutations, 
drug-drug interactions and adherence[147, 192, 193]. The initial cART regimen taken by 
people who have never had treatment before is referred to as ‘initial regimen’, ‘first-line 
therapy’ or ‘first-line treatment’. The most common initial regimens are PI-based cART 
(boosted PI plus two NRTIs) and NNRTI-based cART (NNRTI plus two NRTIs). In recent 
years, INI-based cART regimens (INI plus two NRTIs) are now also recommended[82, 
194, 195].  
1.7.3.1 PI-based cART 
The first PIs to be approved in the EU, often referred to as first generation PIs, were 
RTV, SQV, IDV and NFV. RCTs initially found that addition of RTV, compared to 
placebo, to an existing regimen led to better survival[196, 197], although now they are 
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not used except as a pharmacologic booster. The immunological and virological benefits 
of SQV-containing triple-therapy regimens compared with dual-therapy regimens 
(AZT/ddC and SQV/AZT) were seen in the ACTG 229 trial[198]. However, first 
generation PIs were sometimes intolerable, had high pill burden and in addition, use of 
these as a single drug regimen commonly resulted in the development of resistance 
mutations[199-204].  
The second generation PIs which were subsequently developed are APV, FPV, LPV, 
ATV, TPV and DRV. These second generation drugs are effective against strains of HIV 
which have developed resistance to the first generation PIs[147]. FPV was introduced 
as the prodrug of APV to improve the bioavailability and therefore reduce the number of 
pills required[205]. The NEAT trial found that an FPV-based cART regimen was more 
efficacious than an NFV-based cART regimen[206].  
Many trials in both treatment-naïve and treatment-experienced people have been 
carried out to compare the efficacy of RTV-boosted regimens with unboosted regimens, 
as well as with regimens with a different boosted-PI[207-210]. For example, the M98-
863 showed that patients in the LPV/r arm compared with patients in the unboosted PI 
arm were more likely to have viral load <400 copies/ml after 48 weeks[207]. The 
CASTLE study found antiviral efficacy was similar between the LPV/r and ATV/r 
arms[209]. TPV is only used in treatment-experienced patients (efficacy demonstrated in 
the RESIST trials) as it was shown that it was less effective than LPV/r at reducing viral 
loads and that it caused high rates of hepatotoxicity[211, 212]. There have been several 
RCTs studying the effects of DRV/r, namely POWER, TITAN, ARTEMIS and 
MONET[213-217], which has led to DRV being approved for both treatment-naïve and 
treatment-experienced people. 
1.7.3.2 NNRTI-based cART 
NVP and EFV are sometimes referred to as first generation NNRTIs, and ETV and RPV 
as second generation NNRTIs. Even though early trials found that NNRTI-based 
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regimens were just as good as or slightly better than PI-based regimens at suppressing 
viral load[218, 219], the use of first generation NNRTIs led to higher risk of development 
of drug-resistant virus as they have a lower genetic barrier than PIs (Section 
1.8.3.1)[220], which meant they were not initially widely used.  
At the time of NVP development, triple-therapy was not yet conventional[220] and early 
trials compared mono-therapy with NVP-containing dual-therapy regimens[221, 222]. A 
number of RCTs subsequently showed that adding NVP to AZT+ddI was effective in 
terms of both immunological and virological response in treatment-naïve patients[223-
225]. EFV almost always performed better than the comparator drug in triple-therapy 
RCTs: superior to IDV, NFV and ABC in the ACTG 006, ACTG 384 and ACTG 5095 
RCTs respectively[218, 219, 226, 227]. EFV was also compared to NVP in the 2NN 
study, which showed that the two drugs were similar in terms of virological efficacy, but 
that the NVP-arm was associated with more side effects than the EFV-arm[228].   
The development of the first second generation NNRTI, ETV was well-received because 
it was effective even in people with virus that was resistant to NVP and EFV[229]. It was 
approved for the use in treatment-experienced patients on the basis of the results from 
the DUET I and II trials[230-232]. RPV was approved due to pooled results from two 
trials, ECHO and THRIVE, which demonstrated that RPV was non-inferior to EFV in 
terms of suppressing viral load in treatment-naïve patients[233, 234].  
1.7.3.3 INI-based cART 
The first INI, RAL, was approved in 2007. The use of RAL in treatment-experienced 
patients was approved following results from the BENCHMRK I and II trials, which 
investigated its efficacy against triple-class drug resistant virus[235, 236]. Use in 
treatment-naïve patients was approved following results of the STARTMRK trial[237].  
EVG and DTG are the two most recently licensed antiretroviral drugs. EVG is 
administered as part of the STR, stribild, or together with a RTV-boosted PI. STR was 
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approved based on results from Study 102 and Study 103, which demonstrated non-
inferiority of viral suppression rates in treatment-naïve individuals compared to Atripla 
and ATV/r with Truvada respectively[238, 239]. DTG demonstrated superiority to the 
comparison arms in the SINGLE and SAILING trials[240, 241]. Although long-term data 
on DTG is yet to be seen, it so far seems to be a very promising drug in terms of its 
efficacy and safety profile[240, 241]. 
1.7.3.4 Other non-standard regimens 
There are a number of treatment strategies which have been tried in studies but have 
not been justified for widespread clinical use. These include triple NRTI regimens, class-
sparing regimens and boosted-PI mono-therapy.  
Triple NRTI regimens were of interest in the early 2000s because of no drug-drug 
interactions, low pill burden, protection of other drug classes for future use and reduced 
side effects, especially compared to PIs being used at the time[242, 242]. The 
combination of AZT+3TC+ABC was used in first-line therapy because it was available 
as an STR (trizivir). However, trials have since shown that triple NRTI regimens were 
not as efficacious as PI-based or NNRTI-based cART regimens[227, 243-246], and so 
they are now are rarely used as first-line treatment[242].  
NRTI-sparing regimens are an attractive option in people with extensive resistance to 
NRTIs, but also due to a reduced risk of NRTI-associated mitochondrial toxicity[247]. 
Most commonly used regimens of this type include the use of boosted-PIs together with 
one or more of RAL, MVC and ETV[248].  
Controversy still remains about the use of boosted-PI mono-therapy despite numerous 
studies over the last few years[249]. Most RCTs have in particular studied the efficacy of 
LPV/r[250]. A systematic review conducted in 2009 concluded that the overall efficacy of 
boosted-PI mono-therapy is inferior to standard cART, but that efficacy was better when 
the regimen was started after more than six months of virological suppression[251]. 
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There is some evidence that boosted-PI mono-therapy may be a good option in patients 
who do not have many active NRTI drugs options or for those who have experienced 
serious side effects related to NRTIs and/or NNRTIs[251, 252]. 
1.7.4 Initiation of ART 
1.7.4.1 Treatment guidelines 
Variations in drug availability, financial constraints and differing policies mean that 
treatment for HIV can differ between (and sometimes even within) countries. For this 
reason, HIV treatment guidelines, consisting of evidence-based recommendations to 
assist practicing clinicians, are assembled by different establishments and working 
groups. The most commonly used or referred guidelines are those written by the 
European AIDS Clinical Society (EACS), International Antiviral Society-USA (IAS-USA), 
US Department of Health and Human Services (US DHHS), WHO and British HIV 
Association (BHIVA)[82, 194, 195, 253, 254]. Treatment guidelines are frequently 
revised to take new and emerging data into account. 
1.7.4.2 When to start treatment 
An editorial entitled “Time to hit HIV, early and hard” was published in 1995, outlining a 
strategy arguing for initiation of treatment soon after diagnosis[255]. However, not 
everyone has agreed with this strategy, citing the risks associated with use of 
antiretroviral drugs, such as side effects and the risk of development of resistant strains 
as a result of higher rates of insufficient adherence[256]. The CD4 count criteria for 
starting treatment has changed quite dramatically since then (Figure 1-3). All the main 
treatment guidelines currently recommend that treatment should be started when the 
CD4 count drops below 350 cells/mm
3
. They are not in agreement over the 
recommendations for CD4 counts above 350 cells/mm
3
 however. A recent observational 
study demonstrated that earlier initiation of treatment (starting at 500 cells/mm
3
 as 
opposed to 350 cells/mm
3
) leads to better survival[257]. The START trial was designed 
explicitly to answer the question of whether ART-naïve individuals with a CD4 count 
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>500 cells/mm
3
 should initiate ART immediately or defer until the CD4 count reaches 
350 cells/mm
3
 or when clinical AIDS develops[258]. The trial is anticipated to be 
completed in 2017. The decision of when to start ART is important because it needs to 
be taken for life without interruption[259]. 
Figure 1-3: Changes in the CD4 count eligibility criteria over time [260] 
 
1.7.4.3 What to start 
The choice of first-line ART regimen depends upon a number of considerations, 
including presence of drug-resistant virus, drug-drug interactions (between 
antiretrovirals as well as other medication), anticipated adherence, pill burden and 
pregnancy. Figure 1-4 shows the recommended first-line treatment regimens according 
to the current EACS guidelines (Version 7.1)[82].  
 
Figure not available due to copyright restrictions 
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Figure 1-4: Recommended first-line treatment regimens according to EACS 
guidelines (Version 7.1) [82] 
 
 
1.7.5 Adherence  
Within the context of HIV medication, adherence refers to the patient’s ability to take 
their antiretroviral doses correctly. This implies actually taking the drugs with the right 
dosage and at the right time. It is often quantified as a percentage, where 100% 
adherence implies all medication was taken correctly and 0% implies no medication was 
taken correctly, or not taken at all. Adherence to antiretroviral regimens is arguably the 
most important component for people on ART nowadays in order to achieve a 
successful treatment response[261].  
Inadequate adherence is associated with detectable viral loads and faster progression of 
disease[262-266]. Poor levels of adherence also result in inadequate drug levels, which 
are associated with development of resistance mutations (see Section 1.8.2.1) [263, 
 
Figure not available due to copyright restrictions 
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267]. Poor adherence can be a result of forgetting the occasional dose, being on short 
trips away or a deviation from normal routine[268].   
ART-related side effects can negatively impact adherence[269, 270]. Other factors 
associated with suboptimal adherence include younger age, transmission of HIV via IDU, 
black ethnicity, high dosing frequency of antiretroviral drugs, depressive symptoms and 
a lack of familial support[271-276]. 
Assessment of adherence can be measured through patient self-reporting (using 
questionnaires and surveys), healthcare- or pharmacy-based approaches and pill counts. 
Although none are perfect, self-reported adherence is thought to be one of the better 
measures of adherence as it has been shown to be strongly associated with detectable 
viral load levels[277, 278].    
1.7.6 Treatment interruption 
A treatment interruption refers to the discontinuation of all antiretroviral therapy and may 
be planned (structured treatment interruptions) or unplanned (unstructured treatment 
interruptions). Development of side effects is one of the main reasons for treatment 
interruptions or discontinuations[279, 280]. One study found that the incidence of 
stopping treatment due to side effects or intolerance has declined over time, whereas 
treatment simplification has increased[281].  
Initially, researchers hypothesised that structured treatment interruptions, or short-term 
‘treatment breaks’, were a possible treatment strategy, that could mitigate some of the 
negative aspects of ART such as high pill burden and side effects. However, the 
SMART (Strategies for Management of Antiretroviral Therapy) study demonstrated that 
treatment interruptions are not beneficial and are indeed harmful[259]. Patients 
randomised to the drug conservation arm (ART received only if CD4 count <250 
cells/mm
3
 or if HIV symptoms were present) were 2.6 times more likely to develop an 
opportunistic disease or die compared to the viral suppression arm (uninterrupted ART). 
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These results were mirrored in the DART study conducted in Africa, which showed that 
patients randomised to take treatment breaks after cycles of ART were significantly 
more likely to develop AIDS-defining conditions[282]. 
1.7.7 Treatment as prevention 
The use of ART as an intervention to reduce the rate of transmission is now commonly 
termed ‘treatment as prevention’. The idea is based on reducing the person’s HIV viral 
load, which is the single biggest risk factor for onward transmission of HIV therefore 
making the individuals less infectious[283]. Results from the HPTN 052 trial and interim 
results from the PARTNER study suggest that HIV-positive people on suppressive 
treatment have a very low risk of transmitting HIV, either by vaginal or anal sex[284, 
285]. ART is also widely used to prevent HIV transmission from mother-to-child and also 
in the form of post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP). 
PEP is use of short-course ART administered to individuals who have been exposed to 
HIV, whereas PrEP involves HIV-negative people taking antiretroviral drugs to prevent 
infection[286]. 
1.7.8 Virologic failure 
Virologic (or viral or virological) failure occurs when ART fails to suppress or control viral 
replication. Virologic failure therefore largely occurs as a result of sub-optimal drug 
levels (poor adherence, poor drug metabolism or drug-drug interactions) or development 
of drug resistance (Section 1.8).  
There is currently no consensus definition for virologic failure and it can vary by 
treatment guideline, but is usually considered to be one or more detectable viral load 
measurements following a period of ART. Current EACS guidelines define virologic 
failure as a ‘confirmed viral load >50 copies/ml six months after starting therapy 
(initiation or modification) in persons that remain on ART’[82]. Current BHIVA guidelines 
define it as ‘failure to achieve a viral load <50 copies/ml six months after commencing 
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ART or following viral suppression to <50 copies/ml a viral load rebound to >400 
copies/ml on two consecutive occasions’[194].  
The risk of initial virologic failure has declined over time due to improved ART 
regimens[287]. Current regimens tend to lead to viral suppression in the majority of 
patients[288-290]. Data from the French Hospital Database on HIV (FHDH) has shown 
that the proportion of patients experiencing virologic failure (defined as two consecutive 
viral load values >500 copies/ml or one value >500 copies/ml followed by a treatment 
switch following at least six months on ART) has decreased significantly (p<.0001) from 
61.5% in the period 1997-1998 to 9.7% in 2009-2011[291].  
1.8 Drug resistance 
Most research into drug resistance has been limited to subtype B infections[292], 
because it is the most prevalent subtype in many HIC where ART is most accessible 
(despite accounting only for about 10% of global HIV infections)[17]. Consequently, the 
following section is focused on subtype B virus. 
1.8.1 Viral population dynamics 
As described earlier, the HIV replication process is very rapid but also highly error 
prone[10-12]. It is estimated that on average, one error (single mutation) is made per 
10,000 bases per viral replication cycle[293]. This means that any HIV population is 
usually made up of different types of HIV species (termed quasispecies)[294]. These 
errors are referred to as ‘mutations’. Whilst some of these mutations will result in 
defective virus which will not be able to replicate, other mutations result in the 
occurrence of drug-resistant strains. In this context, ‘wild-type’ virus can be thought of as 
a strain of HIV which develops from “correct” replication. Wild-type virus is the most 
common strain, and is also known as a drug-sensitive virus because it is sensitive to 
antiretroviral drugs, i.e. viral replication can be inhibited by the drug.  
70 
 
The term ‘viral fitness’ refers to the measure of a virus’ ability to survive and replicate in 
a certain environment[295, 296]. In a neutral environment (i.e. in the absence of ART), 
wild-type viruses have a higher level of viral fitness than drug-resistant strains and 
therefore become the predominant strain[297]. In the presence of ART, drug-resistant 
strains have a higher level of fitness compared to wild-type virus. However, in drug-
resistant strains, the mutation which confers the resistance to the drug often also lowers 
the efficacy to replicate (reduces the ‘replicative capacity’) by reducing the efficiency of 
enzymes (reverse transcriptase and protease in particular) required during the 
reproduction process[296, 298-300]. For this reason, in the presence of NRTI or PI 
exposure, wild-type HIV is still generally the dominant strain in an HIV population 
because it replicates more efficiently (although this is also heavily dependent on 
adherence levels)[267, 301]. If an individual discontinues their HIV treatment once drug-
resistant strains have emerged, the wild-type strain definitively thrives over the drug-
resistant strain due to its replication capacity advantage[297, 302]. Therefore to 
summarise, ART does not directly cause the development of resistant strains, but 
reduces the rate of replication of wild-type virus. 
1.8.2 Acquired drug resistance 
Drug-resistant strains of HIV are often acquired as a result of sub-optimal drug levels in 
the bloodstream which allows the virus to replicate, mutate and produce strains which 
are drug-resistant. Since the drug is present, the environment is such that these strains 
can thrive when they do arise (as opposed to when they arise in people off drug). 
Resistance was therefore common in in the mono- and dual-therapy cART era when 
non-suppressive regimens were used. Treatment interruptions, higher baseline viral 
loads and suboptimal treatment regimens are also associated with a higher risk of 
resistance development[296, 303-306]. 
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1.8.2.1 Relationship between adherence and drug resistance 
Initially it was thought that non-adherence would inevitably result in development of 
drug-resistance, and that over 95% adherence was required in order to achieve viral 
suppression[264, 304, 307]. Such beliefs were based on results from adherence studies 
of unboosted PI-based regimens[262-264]. However, researchers have since found that 
the relationship between adherence and drug resistance is more complex and is class-
specific[308]. With modern, more potent treatment regimens, such as boosted PI- and 
NNRTI-based regimens, viral suppression rates are still reasonably high even with less 
than 95% adherence[309, 310]. Generally speaking, the risk of developing resistance is 
most common at moderate levels of adherence (around 60-85% adherence)[267, 311, 
312]. This is indeed the case for boosted PI-based regimens. However as shown in 
Figure 1-5, resistance to NNRTI-based regimens occurs most often at low levels of 
adherence and resistance to unboosted PI-based regimens occurs most at moderate to 
high levels of adherence[301, 308].  
Figure 1-5: Relationship between adherence and risk of resistance by drug class 
[308] 
 
1.8.3 Resistance mutations 
The genetic sequence of HIV is essentially a long chain of HIV RNA, which is in turn 
made up of a sequence of codons (where codons are formed from three nucleotides). 
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Codons determine the order of the amino acids which together form an enzyme, such as 
reverse transcriptase. A ‘mutation’ is an error in this sequence of amino acids. There are 
twenty different amino acids, each represented by a single letter of the alphabet. It is this 
substitution of an amino acid which alters the shape of the resulting enzyme and 
consequently prevents antiretroviral drugs from working properly. 
A resistance mutation is referred to by a combination of a letter, then a number, followed 
by another letter. The first letter represents the amino acid found in wild-type virus and 
the second letter represents the amino acid that confers resistance which was 
substituted in its place. The number identifies the codon in which the amino acid 
substitution, i.e. the mutation, took place. Mutations to NRTIs and NNRTIs occur in the 
reverse transcriptase (RT) gene and mutations to PIs occur in the protease gene. 
Common resistance mutations in the RT gene include M184V and K65R. 
1.8.3.1 Mutations associated with individual antiretroviral drugs 
Drug resistance mutations can confer resistance to a specific drug, or class-wide 
resistance (known as cross-resistance, see Section 1.8.3.2). The extent to which drug 
resistance mutations affect the susceptibility of an antiretroviral drug depends largely on 
drug class but also varies by specific drug. A list of drug mutations according to IAS-
USA (July 2014 update[313]) is given in Appendix III. 
The genetic barrier to resistance of a drug is defined as the likelihood of developing 
drug-resistance virus. It is largely determined by the number of mutations necessary to 
confer resistance. Figure 1-6 shows the relative genetic barriers and potencies of a 
number of commonly used antiretroviral drugs. A drug with high potency does not 
always have a high genetic barrier to resistance.  
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Figure 1-6: Potency and genetic barrier to resistance by antiretroviral drug [314] 
 
Mutations that confer resistance to NRTIs include M184V, thymidine analogue mutations 
(TAMs), non-thymidine analogue mutations (non-TAMs) and multi-nucleoside resistance 
mutations (more in Section 1.8.3.2). M184V is the most commonly occurring NRTI 
mutation and causes a high level of resistance to 3TC and FTC in particular. In the case 
of monotherapy with 3TC, viruses with the M184V mutation can become the dominant 
strain in just two weeks[315]. TAMs are a group of resistance mutations associated with 
thymidine analogues, AZT and d4T (i.e. a sub-class of drugs within the NRTI class). 
TAMs can occur in one of six codon positions: 41, 67, 70, 210, 215, and 219[316]. Non-
TAMs are the group of resistance mutations associated with resistance to NRTIs that 
are not thymidine analogues.  
NNRTIs have a low genetic barrier, in that only one or two resistance mutations are 
required for a high level of resistance which makes the NNRTI drug class 
ineffective[317]. The accumulation of a number of resistance mutations leads to a 
reduced virologic response[317, 318]. The most common NNRTI mutations are K103N 
and Y181C[319, 320]. Compared to NRTIs in particular, NNRTIs have long half-lives so 
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in the event of complete treatment interruption of an NNRTI-based regimen, NNRTI-
resistance mutations often arise as a result of functional NNRTI mono-therapy[321].  
Unlike NNRTIs, PIs have the highest genetic barrier of all drug classes and are able to 
retain the ability to suppress viral replication even in the occurrence of resistance 
mutations[322-325]. Therefore, in order to reduce the susceptibility to a PI, more than 
one mutation is often required[323]. The development of resistance to a PI is a two-step 
process: the first stage involves the emergence of the major mutations which initially 
reduce the susceptibility to the drug. This is followed by the emergence of minor 
mutations, which alone would not have any substantial effect, but which together 
improve viral replication of those viruses with the major mutation in order to further 
reduce the susceptibility to the drug[146, 324, 326].  
RAL and EVG have a low to moderate genetic barrier, although detection of resistance 
mutations remains rare[327]. The primary or signature mutations associated with 
reduced susceptibility to RAL and EVG are at the codons Y143, Q148 and N155[236]. 
Resistance to DTG is not selected as readily and so remains even rarer.    
There are currently no resistance mutations which are associated with reduced MVC 
susceptibility[326]. However, the main concern with CCR5 inhibitors is the possibility of 
a co-receptor switch from R5 virus to X4 virus which renders CCR5 inhibitors 
ineffective[328].  
1.8.3.2 Cross-resistance 
Certain mutations can cause the virus to develop resistance to similar drugs in the same 
drug class. This phenomenon is known as cross-resistance and is highly problematic, 
especially in LMIC where drug options are limited[292].  
Although TAMs primarily make the virus less susceptible to AZT and d4T, they also to a 
lesser extent reduce the susceptibility to all other NRTIs and are thus considered to 
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confer cross-resistance[329, 330]. Within the NNRTI class, EFV and NVP have similar 
resistance profiles[331-333] and RPV resistance is seen in nearly 20% of individuals 
failing the three other NNRTI drugs, with it being more common following ETR or NVP 
than EFV[334]. Cross-resistance occurs frequently between many PIs, with mutations at 
positions 82, 84 and 90 being those which cause the most cross-resistance[335]. RAL 
and EVG are thought to have a relatively high degree of cross-resistance within the 
class of INIs[336, 337]. 
1.8.3.3 Genotypic and phenotypic resistance 
There are two different ways to measure the extent of drug resistance: genotypic and 
phenotypic. Genotypic resistance relates to the specific mutations within the viral genetic 
sequence, which are associated with resistance to individual antiretroviral drugs[338]. 
For example, the mutation M184V is associated with a high level of resistance to 3TC. 
On the other hand, phenotypic resistance is a measure of the adeptness of the virus to 
replicate in the presence of an antiretroviral drug in cells in vitro. Understanding levels of 
resistance in vivo using these two measures is not always straightforward. Some 
mutations can confer high level resistance on their own, whereas sometimes multiple 
mutations are necessary to confer a medium level of resistance to a particular drug. 
The extent to which each mutation confers resistance to a certain antiretroviral drug can 
be scored using a measure known as genotypic sensitivity. The genotypic sensitivity for 
each drug usually takes a value between 0 and 1, where 0 indicates that there is 
complete resistance (there is genotypic sensitivity) and 1 indicates that there is no 
resistance to a certain drug (no genotypic sensitivity). Note that sometimes the scale is 
reversed in terms of level of resistance or drug sensitivity. The overall genotypic 
sensitivity score (GSS) for an individual is defined as the sum of the genotypic sensitivity 
of each drug in the treatment regimen[339]. Thus a person on a three drug regimen and 
with no resistance mutations would have a GSS of 3. There are several different 
genotypic resistance interpretation systems available, all of which use their own 
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algorithm to calculate the GSS[340]: Stanford University HIV Drug Resistance Database 
(http://hivdb.stanford.edu/), French ANRS AC11 Resistance group algorithm 
(http://www.hivfrenchresistance.org/) and REGA algorithm 
(https://rega.kuleuven.be/cev/avd/software/rega-algorithm).  
1.8.3.4 Genotypic and phenotypic resistance testing 
Genotypic resistance tests work by amplifying a region of the viral genetic sequence, 
such as the RT gene, usually by PCR and identifying the mutations which are known to 
be associated with resistance to certain drugs. Phenotypic resistance tests assess the 
quantity of drugs which are needed to supress viral replication in vitro. Both types of test 
are useful as they identify the antiretroviral drugs which are unlikely to be effective in a 
patient[341]. Studies have shown that resistance testing is clinically useful and an 
important aspect in the management and consideration of treatments for HIV-positive 
people[342-344]. However, because both types of tests are expensive and results take a 
long time to be processed[338], treatment guidelines recommend that these tests are 
only done before any ART is started or if resistance is suspected with failure of a 
regimen. If tests are conducted because resistance is suspected, then they must be 
performed at the point of virologic failure. This is because once the drug pressure is 
removed the virus will revert to wild-type.  
Most resistance assays used in current clinical practice are unreliable or do not function 
if the patient’s viral load is less than 500 copies/ml because there are insufficient virus 
levels to amplify and then analyse[338, 341]. Further, drug-resistance viruses will only 
generally be detected if they make up at least 20% of the viral population being 
analysed[345].  
Genotypic tests are more commonly used compared to phenotypic tests because they 
are often cheaper and quicker. They are also able to identify mutations which are 
present as mixtures, even if they are a minority species which may not yet be detected 
in a phenotypic test[346]. The main disadvantage is that interpretation of genotypic test 
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results is often complex and requires expert knowledge, especially when there are 
several existing resistance mutations[347]. 
1.8.4 Implications of drug resistance 
1.8.4.1 Resistance and virologic failure 
Development of drug resistance can lead to virologic failure in individuals. Individuals 
who experience failure because of drug resistance are more likely to have an increased 
risk of death compared with individuals who have wild-type virus[296, 348, 349]. 
Resistance tests are done in patients who have experienced virologic failure to 
determine whether to carry on with the current treatment regimen or whether to carry out 
a treatment switch. A regimen change can include swapping one drug for another from 
the same or different drug class, adding another drug to strengthen or boost the current 
regimen or changing all drugs for a completely new regimen. Resistance to antiretroviral 
drugs results in decreased future drug options and increased costs as drugs usually 
used for second- and third-line regimens are generally more expensive[350] .  
Patients who have experienced virologic failure whilst on PI-based and NNRTI-based 
cART regimens are referred to as having experienced triple class virologic failure 
(TCVF). Although the incidence of TCVF is not very common, at 9% after nine years of 
ART, it still poses a problem because of limited future drug options for the patient[351]. 
INIs are often used as the replacement third-drug in a regimen for people with TCVF 
due to their different resistance profiles. 
Patients who are running out of drug options because of multi-class resistance or due to 
insufficient immune response may be put on a ‘salvage regimen’. This may involve 
recycling previously-used drugs, or adding further drugs to an existing regimen to boost 
the antiviral effects. On the other hand, drugs not having much antiviral effect can 
occasionally be excluded from the regimen to lessen side effects and drug-drug 
interactions.  
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1.8.4.2 Transmitted drug resistance 
Transmitted drug resistance (TDR) indicates the transmission of a drug-resistant strain 
of virus from one individual to another. This implies that people who have never been 
exposed to antiretroviral drugs can carry viruses with resistance mutations[352]. The 
prevalence of TDR in Europe is thought to have declined over time from around 15% in 
the late 1990s and early 2000s to under 10% in the late 2000s[353-356]. 
1.9 Side effects associated with use of antiretroviral 
drugs 
Effective ART has significantly reduced rates of AIDS and death and consequently has 
essentially transformed HIV infection into a chronic disease in settings with wide 
availability of ART[133, 134]. This means that as HIV-positive people are now living 
longer, they are subject to more drugs for longer periods of time. Side effects are also 
referred to as adverse events or adverse drug reactions.  
Side effects as a result of ART are not uncommon and present additional problems to 
the management of patients with HIV[357, 358]. This is particularly the case for some 
individuals who are more susceptible to developing side effects than others. For 
example, people who are co-infected with hepatitis B and/or C have an elevated risk of 
liver toxicity[359]. Side effects can also be a reason for treatment interruptions or 
switches[279, 280].  
There is a wide range of side effects; some are mild events whilst others could be life-
threatening events and some are short-term whilst others can be long-term. The risk of 
specific side effects can also vary by antiretroviral drug or drug class. Common side 
effects seen when taking specific antiretrovirals are listed in Appendix II. Minor side 
effects such as nausea, headache and diarrhoea are the most common. 
One of the serious side effects associated with NRTIs is mitochondrial toxicity, which 
can lead to hepatotoxicity, peripheral neuropathy, lactate elevation and pancreatitis[360, 
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361]. Lactate elevation causes a build-up of lactic acid in the blood, which is known as 
hyperlactaemia, but if lactic acid levels are extremely high then it is referred to as lactic 
acidosis, which is associated with a high risk of mortality (up to 57%)[362]. Lactate 
elevation is also associated with pancreatitis. This is severe but uncommon with an 
incidence rate of around 0.1 per 100-person years[363-365]. Other major side effects 
which can occur with the use of NRTIs include lipodystrophy, hypersensitivity reactions, 
myocardial infarction and nephrotoxicity. HIV-associated lipodystrophy is a metabolic 
disorder which involves abnormal body fat distribution and is associated especially with 
use of d4T and AZT[366-369]. Hypersensitivity reactions are defined by a confluent rash, 
with or without fever and occur in about 4% of patients who are taking an ABC-
containing regimen and are more common in individuals with the HLA allele B5701 (as 
described in Section 0)[111, 370]. In addition, ABC has also been associated with an 
increased risk of myocardial infarction[371]. Nephrotoxicity (kidney toxicity) is measured 
by creatinine levels in the blood, and is mainly associated with the use of TDF-
containing regimens[372, 373].   
NNRTIs are generally considered safe and well-tolerated when compared to other 
classes of antiretroviral drugs. Nevertheless, they are not completely free of side effects, 
which include hypersensitivity reactions, hepatotoxicity and central nervous system 
(CNS) toxicity. Rashes from hypersensitivity reactions are seen in approximately 15%, 
10% and 18% respectively of patients using NVP, EFV and ETV[232, 374, 375, 375-
377]. The risk of NVP-induced hypersensitivity and associated hepatotoxicity is greater 
in women and in people with higher CD4 counts[111, 378, 379]. Severe hepatotoxicity is 
also observed in up to 5% of people using NVP[380-382]. CNS toxicity caused by EFV 
is fairly common; symptoms are only short-term and include dizziness, insomnia and 
abnormal dreams[111, 226, 383, 384]. RPV has a favourable safety profile and appears 
to cause significantly fewer cases of rashes, neurological side effects and lipid 
abnormalities when compared to EFV[385, 386].  
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The majority of PIs are associated with metabolic disorders such as hyperlipidaemia 
(raised lipid levels), insulin resistance and changes in glucose metabolism (which can 
cause diabetes)[111, 387-389]. Other short-term side effects observed with PIs include 
gastrointestinal disturbances such as nausea, diarrhoea and vomiting[208, 375, 390-
393]. Long-term exposure to PIs has also been associated with an increased risk of 
hyperlipidaemia and myocardial infarction[394].  
The CCR5 inhibitor MVC and the INIs are in general well-tolerated, but minor symptoms 
such as diarrhoea, headache and nausea can develop, similarly to most other 
antiretrovirals [151, 235, 395-398]. EVG when given with COBI however leads to 
increased levels of serum creatinine concentration[398]. T-20 is given subcutaneously 
and therefore local injection site reactions are very common, with 98% of patients 
experiencing at least one reaction[399].  
1.10 Co-infections 
In people infected with HIV the most common co-infections are hepatitis C virus (HCV), 
hepatitis B virus (HBV) and tuberculosis (TB). Other co-infections which are frequently 
seen among HIV-positive people include malaria, cytomegalovirus and leishmania, as 
well as sexually transmitted infections (STIs) such as herpes simplex virus-2, 
gonorrhoea, chlamydia and syphilis. There is clinical evidence that some co-infections 
can accelerate the progression of HIV disease and increase the risk of morbidity and 
mortality[400-403].  
1.10.1 Hepatitis C 
HCV is most commonly found in people with percutaneous exposure to infected blood, 
such as people who have received blood through transfusions or PWID who share drug 
injecting equipment[404]. In people infected with HIV, HCV co-infection is most 
prevalent in PWID, with estimates in the range of 70-90%[405-407]. HCV is less 
commonly transmitted through unprotected sex and from mother to child, although there 
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have been a number of reported outbreaks of HCV transmission among HIV-positive 
MSM[408, 409]. 
In HCV mono-infected patients (i.e. only infected with HCV and not HIV), approximately 
20% to 25% are able to spontaneously clear their HCV infection[410-412]. However, if 
co-infected with HIV, rates of spontaneous clearance decrease to 5% to 10%[413, 414]. 
Those who are not able to spontaneously clear their HCV infection develop chronic 
infection. In people with HIV, chronic infection with HCV is an independent risk factor for 
progressive liver disease[415-417], which includes fibrosis, cirrhosis, hepatocellular 
carcinoma (liver cancer) and end stage liver disease[407, 413]. There is strong evidence 
that the presence of HIV infection accelerates the progression of HCV, particularly in 
people with advanced HIV disease[401, 418-420]. Current HCV treatment regimens 
have lower cure rates in HIV-positive individuals than those seen in HIV-negative 
individuals[421]. On the contrary, there is no clear evidence yet that HCV also 
accelerates the progression of HIV infection[400, 401]. 
Studies have shown that the use of cART can slow down the progression of liver 
disease[422, 423]. cART is however also associated with an increased risk of 
hepatotoxicity, which can sometimes lead to treatment interruptions, as well as 
increased morbidity and mortality[359, 424].    
1.10.2 Hepatitis B 
The prevalence of HBV infection differs by region and can range from 5% in Western 
Europe and the US to 20% in sub-Saharan Africa (SSA) and South East Asia[425]. HBV 
shares the same routes of transmission as HIV and HCV, but rates are highest in MSM, 
moderate in PWID and quite rare among heterosexuals[426]. The availability of a 
vaccine has dramatically reduced transmission rates and transformed the epidemiology 
of HBV[427]. Treatment for HBV is given to prevent progression of the disease mainly in 
those with chronic infection as opposed to people with acute infection. There are 
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antiretroviral drugs which have dual activity against HIV and HBV, namely 3TC, FTC 
and TDF. 
Although co-infection with HBV is not thought to accelerate the progression of HIV, it 
does increase the risk of AIDS and death[428, 429]. Co-infection with HIV results in 
higher rates of development of chronic HBV infection, as well as an increased 
progression of liver disease and higher rates of liver cirrhosis and liver-related 
mortality[430-432]. 
1.10.3 Tuberculosis (TB) 
TB is a disease caused by the Mycobacterium tuberculosis bacterium and is a leading 
cause of deaths globally[433]. The infected person initially develops latent TB infection, 
which is an inactive form of TB. However, untreated latent TB infection can advance to 
active TB and co-infection with HIV is one of the strongest risk factors associated with 
this progression[434, 435]. The progression of HIV disease is also accelerated by the 
presence of TB co-infection[436]. TB is an AIDS-defining condition. Treating HIV/TB co-
infection is complicated by the fact that there are important drug-drug interactions 
between antiretroviral drugs and rifampicin/rifabutin, which are commonly used to treat 
TB. 
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Chapter 2 Epidemiology of HIV in Europe 
In this chapter, I describe epidemiological measures and concepts, and the various 
sources of data available and methods which are used in the European setting in order 
to estimate the number of people living with HIV within a country. A brief overview of the 
global HIV epidemic and specifically the situation in Europe is then given. Finally I 
review in further detail the epidemics in 18 European countries with the largest HIV-
positive populations.   
2.1 Epidemiological measures and concepts 
It is crucial to assess the impact of a disease on a population to inform public health 
policies as well as to be able to introduce and recommend interventions. Two commonly 
used epidemiological measures to describe the occurrence of a disease are the 
prevalence and incidence. 
2.1.1 Incidence 
The incidence measures the rate of occurrence of new cases of a disease or a condition. 
In our context of interest, HIV, it is calculated as follows: 
HIV incidence (between time 𝑡 and 𝑡 + 1)
=
the number of new HIV infections between time 𝑡 and 𝑡 + 1 
the total person­years at risk of acquiring HIV
 
This method to calculate incidence is known as the ‘person-year method’. The incidence 
can also be presented as a percentage of the population which acquires the disease or 
condition in a given period of time (which is referred to as the cumulative incidence risk).  
Other than providing us with a measure of new HIV infections arising over a period, 
estimation of the HIV incidence can also be used to understand patterns of HIV 
transmission and can be useful as an outcome of interest when evaluating the 
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effectiveness of prevention interventions and treatment interventions[437]. In the case of 
HIV infection, where infection is not always followed by prompt diagnosis, it is not 
possible to estimate incidence directly through surveillance. 
2.1.2 Prevalence 
The prevalence is a measure of disease occurrence in a population at a specific point in 
time. In our context of interest, HIV, it is calculated as follows: 
HIV prevalence (at time 𝑡) =
the number of people with HIV at time 𝑡 
the total number of people at time 𝑡
 
The prevalence can be presented as a percentage or simply as the number of cases. If 
the prevalence is low, then it can be presented as the number of cases per 1,000 or 
100,000 of the population, for example. With increasing life expectancy due to the 
effectiveness of ART, the prevalence of HIV is expected to increase over time (even if 
incidence doesn’t increase).  
2.1.3 Epidemiological state 
The extent to which HIV is prevalent amongst different populations greatly determines 
the approach at which it is managed and controlled. For the purpose of HIV surveillance, 
the Joint United Nations Programme on HIV/AIDS (UNAIDS) have defined three types of 
epidemiological states: ‘low-level’, ‘concentrated’ or ‘generalised’[438]. Low-level 
epidemics are those where HIV prevalence has not exceeded 5% in any sub-population. 
The sub-populations can include MSM, PWID and commercial sex workers. In a 
concentrated epidemic, the prevalence of HIV exceeds 5% in one or more sub-
populations, but is less than 1% in the general population. HIV prevalence in the general 
population is often measured among pregnant women attending antenatal clinics. A 
setting is defined to have a generalised epidemic if the prevalence of HIV in the general 
population is greater than 1%.   
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2.2 Sources of data 
Information to describe the current state of the HIV epidemic is collected in a multitude 
of manners. These include the use of prevalence surveys, collection of case reports of 
HIV diagnoses, AIDS diagnoses and reports of deaths in people with HIV, as well as 
data from cohort studies. These are used together to form the components of a 
surveillance system for HIV. 
2.2.1 Prevalence surveys 
Prevalence surveys are surveys which are conducted at a given point in time in order to 
estimate the prevalence of a disease or condition in a defined population. In the field of 
HIV, the population is usually defined by a specific risk group, such as MSM or PWID. 
One difficulty associated with prevalence surveys is the issue of defining the risk group, 
as it is hard to make unbiased selections of such populations[439, 440]. Examples of 
settings in which prevalence surveys are conducted include STI clinics, drug treatment 
centres and antenatal clinics.  
In the UK, the Gay Men’s Sex Survey is a notable example of prevalence surveys 
conducted among MSM and there have also been many studies done in PWID[441, 
442]. Unlinked anonymous prevalence studies, wherein blood specimens leftover after 
diagnostic testing purposes were irreversibly unlinked from identifying information, are 
another example[443]. In countries with generalised epidemics however, such as South 
Africa and Zimbabwe, prevalence surveys are conducted on a national scale[444].  
2.2.2 Case reports 
A case report is a notification to the appropriate health authorities or organisation 
conducting surveillance, of a confirmed case of HIV diagnosis, AIDS diagnosis or death. 
Data on case reports can be detailed, as other data on the patient is often also 
requested when a case of HIV or AIDS is reported. This includes demographic data, 
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probable mode of HIV acquisition, whether AIDS was simultaneously diagnosed along 
with HIV, and CD4 count at HIV diagnosis. 
HIV case report data captures only the number of new diagnoses and does not 
necessarily reflect trends in incidence. This is because the number of diagnosed HIV 
cases depends heavily on HIV testing patterns, as well as the number of infections to 
have taken place.  
Limitations associated with case report data include reporting delays, under-reporting of 
data (especially if voluntary) and duplicate records (as HIV data is often anonymous). 
Another limitation, as mentioned in Chapter 1, is that HIV and especially AIDS case 
definitions have changed over time[44, 445].  
2.2.3 Data from cohorts 
There are also vast quantities of clinical data collected as part of cohort studies across 
Europe. In fact, there are many countries’ such as the Netherlands (Section 2.6.2) and 
Sweden (Section 2.6.14), which have national cohorts comprising of all diagnosed HIV-
positive people under care. There are also hospital cohorts, regional cohorts within a 
country, and cohorts including only a subgroup of people such as people with 
haemophilia or children. Many are also part of the EuroCoord network (Chapter 3) in 
Europe. These cohort databases often contain data relating to HIV and AIDS diagnoses, 
but also data which relates to HIV care over time, such as regular CD4 count and viral 
load measurements and use of antiretroviral drugs. Therefore such databases provide 
additional data to those available from national surveillance. Although this means that a 
much wider range of data could be available for diagnosed individuals, this ultimately 
depends on what data are collected, something which varies by cohort. 
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2.2.4 Surveillance systems 
One definition of surveillance is the  
“systematic and continuous collection, analysis, and interpretation of data, 
closely integrated with the timely and coherent dissemination of the results 
and assessment to those who have the right to know so that action can be 
taken”[446].  
 
It forms an essential element of public health and epidemiological practice within 
disease prevention and control within a population. Specifically for HIV, surveillance is 
important because countries affected by an epidemic need information about the trends 
of new cases and the affected populations so that it can swiftly act and implement any 
necessary interventional measures. 
Surveillance can be broadly categorised into passive, active or sentinel. Passive 
surveillance refers to the collection of disease data where public health authorities do 
not encourage it nor is it obligatory for healthcare workers to report the disease of 
interest. This means that such data is often reported late and/or incomplete or not 
reported at all. In contrast, active surveillance refers to the collection of data where 
healthcare workers are urged or required to report to the public health authorities at 
regular intervals. This means that data collected through active surveillance is generally 
of better quality and completeness than passive surveillance, but it does require more 
time and resources. Sentinel surveillance is surveillance conducted on a selected 
sample of the affected population, instead of monitoring the whole population with 
disease. Samples of a population can be defined by a specific location or area, in which 
case these locations are usually referred to as ‘sentinel sites’, or they can be defined by 
person characteristics (e.g. in the case of HIV, MSM or sex workers). The advantages of 
sentinel surveillance are that each sentinel site is monitored more intensely and more 
detailed data can be collected, however this also means that this type of surveillance 
also needs more time and resources than passive surveillance. 
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The WHO has so far proposed two types of surveillance for HIV/AIDS: first generation 
surveillance (FGS) and second generation surveillance (SGS)[438]. FGS consists of 
data mainly on AIDS case reports together with some sentinel studies on HIV 
prevalence. SGS, introduced in 2000, refers to a more sophisticated surveillance system 
which is tailored to the individual epidemiological states of a country, where data is 
collected systematically at regular intervals from various sources such that trends over 
time can be captured and analysed[438]. SGS is therefore formed from a number of 
components (Figure 2-1). Examples of these components include prevalence surveys, 
surveys on behaviour or testing (which could be conducted in antenatal clinics, sexual 
health clinics and amongst PWID), case reporting systems, mortality and morbidity data 
based on death certificates, surveillance of immunological and virological status, 
surveillance and detection of recent infections, data collection on the number of people 
seen in HIV care and the number receiving ART from clinic or hospital records[447].  
Figure 2-1: Components of the WHO HIV second generation surveillance [438]  
 
Surveillance systems can vary greatly between and within countries. Therefore care 
needs to be taken when aggregating and interpreting information on the international 
level. Data from different surveillance systems will have varying quality, accuracy and 
completeness, and rates of under-reporting and under-ascertainment of cases will differ.  
 
Figure not available due to copyright restrictions 
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2.3 HIV estimation methods 
In any HIV-positive population, there are a substantial proportion of people who will be 
unaware of their HIV status because HIV can be asymptomatic at the time of infection. 
In the EU approximately 20 to 30% of all HIV infections are thought to be 
undiagnosed[448, 449]. This makes accurate estimation of prevalence difficult.  
Currently there is no consensus approach in Europe to estimate the total number of 
people living with HIV in a country or region[450]. Instead there exists a number of 
different methods which vary in terms of the data required and the types of estimates 
they can generate. The choice of method is often determined by the epidemiological 
state (low-level, concentrated or generalised). Two commonly used approaches are 
referred to as ‘direct methods’ (Section 2.3.1) and ‘back-calculation methods’ (Section 
2.3.2). There are also methods which are based on incidence assays (Section 2.3.3), 
case reports of HIV diagnosed in the presence of HIV-related symptoms (Section 2.3.4) 
and transmission models (Section 2.3.5). A summary of each type of methods is given in 
Table 2-1. 
Table 2-1: HIV estimation methods and the main measures estimated by each type 
Type of method Main measures the method estimates 
Direct methods Size of the total infected population, size of the 
undiagnosed population 
Back-calculation methods Incidence, size of the total infected population, 
size of the undiagnosed population 
Methods based on incidence 
assays 
Incidence 
Method based on case reports of 
HIV diagnosed in the presence of 
HIV-related symptoms 
Size of the undiagnosed population 
Method based on transmission 
models 
Varies by model 
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2.3.1 Direct method 
Methods to estimate the number of people with HIV based on data from prevalence 
surveys are commonly referred to as ‘direct methods’[451-453]. The underlying principle 
is as follows. First, the population of interest (for a country, or perhaps a region within a 
country) is divided into mutually exclusive HIV risk groups, e.g. MSM, PWID. Within 
each of these groups, the number of people with HIV is calculated as the prevalence of 
HIV multiplied by the estimated risk group size. The number of undiagnosed people can 
then be calculated by subtracting the number of diagnosed HIV cases from this overall 
figure. The total number of people with HIV in the total population is then the sum of all 
the people with HIV across the separate risk groups. Alternatively, if the prevalence of 
the undiagnosed population is available for a risk group, then this can be multiplied by 
the risk group size to directly give the total number of undiagnosed people in that risk 
group.  
2.3.1.1 UNAIDS approach: Workbook method and Estimation and Projection 
Package 
The Workbook method and Estimation and Projection Package (EPP) are direct 
methods that were developed jointly by UNAIDS and WHO and have been revised and 
improved since they were first used[454-462]. The estimates of prevalence and 
incidence generated using either of these packages can then be incorporated into the 
Spectrum projection package to determine the consequences of these estimates[454]. 
Figures which can be produced by Spectrum include demographic indicators such as life 
expectancy and mortality rates, the number of people living with HIV and the number of 
people needing ART[454, 463].  
Workbook was initially developed for use in countries with concentrated epidemics or 
those with low HIV prevalence[462]. The approach is based on the identification of 
groups of people at risk of HIV infection, through their own risk behaviour or through the 
risk behaviour of their partners. Workbook then uses upper and lower bounds of the size 
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and HIV prevalence of each of these groups to calculate four different group-specific 
estimates, and the average of these four resulting estimates is taken as the group-
specific prevalence. Workbook can be used in situations where it is not possible to use 
EPP, i.e. when prevalence data is not available for three or more time points. However, 
this also means that workbook does not make full use of available surveillance data, 
which has recently led UNAIDS and WHO to encourage the use of EPP over Workbook 
where possible[464]. 
EPP was initially developed for generalised epidemics to provide estimations and short-
term projections of HIV prevalence and HIV incidence[459]. It is now also used for 
concentrated epidemics as well as for epidemics with a low prevalence. In essence, 
EPP fits a simple transmission model to a set of risk-group specific prevalence data from 
at least three different time points. The transmission model is defined by three 
differential equations which determine the sizes of three groups within the population of 
interest (a group of people who are not at risk of HIV, a group of people who are at risk 
of HIV and a group of people who are infected with HIV) over time. The estimates of 
prevalence and incidence for each of these risk groups at each of the different time 
points are then combined to produce national estimates over time.  
2.3.1.2 Multi-Parameter Evidence Synthesis (MPES) approach 
The MPES method differs from more traditional direct methods by its ability to 
incorporate all available relevant data, both direct and indirect, into the estimation 
process of risk group sizes and prevalence[465-467]. In particular, it is able to also use 
case report data (which it is not possible to do in Workbook or EPP) and it has the 
further advantage that it allows the use of multiple sources of data to inform on the same 
parameter. MPES takes into account all the available data in a coherent way, checking 
that different sources of data provide consistent evidence and resolving inconsistencies 
if and when they arise. This is done by performing a statistical ‘triangulation’ on the data 
within a Bayesian framework. Therefore limitations of MPES include that this method is 
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only suitable for settings where there are large amounts of data available, but also that 
expert opinion is required to inform initial priors to be used in this Bayesian approach. 
MPES has been applied in the UK and more recently, in the Netherlands[468-470]. 
2.3.2 Back-calculation method 
Back-calculation methods are generally used to reconstruct the HIV incidence curve, 
that is, the HIV incidence over a past period of time (i.e. going back in time). The original 
back-calculation methods used early in the HIV epidemic when effective treatment did 
not yet exist, were based on the number of reported AIDS cases[471]. As the incubation 
period from the time of HIV infection to AIDS was known with reasonable accuracy, it 
was thus possible to back-calculate the number of infections which must have taken 
place in the past to result in the number of AIDS cases which were eventually observed. 
The number of people living with HIV could therefore be estimated from this 
reconstructed incidence curve, by subtracting the number of deaths among HIV-positive 
people.  
Now that effective ART is available, back-calculation methods based purely on AIDS 
case reports are no longer appropriate, because the disease takes much longer to 
progress to AIDS, if at all[450, 471]. Modifications were therefore made to this original 
back-calculation method which would use HIV case reports rather than AIDS case 
reports[472, 473]. There are numerous variations on this revised back-calculation 
approach, which differ by factors such as data requirements (Table 2-2), smoothing 
technique of the resulting incidence curve and allowance for reporting delays[450].  
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Table 2-2: Summary of available back-calculation methods and data required [450] 
Method Cambridge Atlanta Bordeaux Ottawa/Sydney Paris 
HIV diagnoses √ √ √ √ √ 
AIDS diagnoses   √ √  
Simultaneous HIV/AIDS 
diagnoses 
 √   √ 
Deaths √ √ √ √ √ 
CD4 counts √     
Recent infections    √ √ 
 
2.3.3 Method based on incidence assays 
The original approach developed by the CDC to estimate HIV incidence using incidence 
assays was termed the Serological Testing Algorithm for Recent HIV Seroconversion 
(STARHS) method[474]. The assays used in the STARHS method were developed 
specifically to be able to distinguish between recent and long-standing HIV infections 
based on the evolution of antibodies following seroconversion. The definition of a ‘recent 
infection’ depends on the assay used but may be four to six months. The HIV incidence 
is then calculated using the knowledge of the recency of infection together with data 
from prevalence surveys.  
Many different assays have been developed which have varying degrees of sensitivity 
and specificity, but there is currently no internationally standardised approach to assay 
evaluation[475]. The most commonly used assay is the BED assay[476]. The Recent 
Infection Testing Algorithm (RITA) was consequently developed as it became apparent 
that many STARHS assays had a high rate of misclassifying long-standing infections as 
recent infections[437, 477]. Many countries now incorporate testing for recent infections 
as part of routine surveillance[478, 479].  
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2.3.4 Method based on case reports of HIV diagnosed in the presence 
of HIV-related symptoms 
For undiagnosed people with a given CD4 count, it is possible to estimate the rate of 
occurrence of AIDS or other HIV-related clinical symptoms which lead to presentation 
for care and hence diagnosis of HIV. The number of case reports of HIV diagnosed in 
the presence of HIV-related symptoms, together with the CD4 count at diagnosis can 
therefore be used to estimate the number of undiagnosed people[450]. This method is 
most suitable for estimating the number of undiagnosed people with CD4 count <200 
cells/mm
3
 due to the low rate of developing HIV-related symptoms at higher CD4 counts. 
A potential source of bias is under-diagnosis and under-reporting of diagnoses with HIV-
related symptoms.  
2.3.5 Method based on transmission models 
Transmission models of HIV, which aim to describe and model the spread of HIV within 
a population, can also be used to estimate the prevalence and incidence of HIV[480, 
481]. Variables included in transmission models which determine the rate of HIV 
transmission include the viral load, CD4 count, type of partnership, level of condom-use, 
frequency of sexual acts, and whether the individual is on ART. By modifying the 
assumptions and levels of different variables in the model, it is possible to analyse and 
figure out why certain trends occur, but also to generate hypothetical scenarios and 
make projections into the future. The models are validated by fitting to multiple sources 
of data. 
2.4 Global epidemiology 
Although the focus of this thesis is on HIV infection in Europe, it is important to consider 
the European epidemic in the context of the global situation. UNAIDS estimate 
(according to EPP/Spectrum methods) that in 2013, there were 35 million (range 33.2-
37.2 million) people living with HIV worldwide (Figure 2-2)[482]. The estimated number 
of new HIV infections has fallen by 38% since 2001, with 3.4 million (range 3.3-3.6 
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million) newly infected in 2001, down to 2.1 million (1.9-2.4 million) newly infected in 
2013[482].  
As shown in Figure 2-2, the impact of HIV worldwide differs substantially by region. 
Some countries such as the Czech Republic are estimated to have a low adult 
prevalence of <0.1%, whereas in Swaziland, which has the world’s highest adult HIV 
prevalence, it is over 27%[483]. The region of SSA is the area that is worst affected by 
HIV and is where the vast majority of the world’s new infections occur: an estimated 1.5 
million (1.3-1.6 million) people became newly infected in 2013. Although SSA makes up 
approximately 10% of the world’s population, it accounts for almost 70% of the world’s 
new HIV infections. This is despite an estimated 33% decline in the incidence seen 
between 2005 and 2013[482].  
Figure 2-2: Number of people estimated to be living with HIV in 2013 by WHO 
region [482] 
 
 
Deaths from AIDS-related causes worldwide are estimated to have declined since its 
peak in 2005, and in 2013 there was an estimated 1.5 million (1.4-1.7 million) 
cases[482]. ART has contributed much to this decline in AIDS-related mortality, 
especially in SSA where access to treatment was considerably expanded from 2004 
 
Figure not available due to copyright restrictions 
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onwards[484]. By the end of 2013, 12.9 million adults living with HIV, which equates to 
37%, had access to ART.  
An estimated 240,000 (210,000-280,000) new HIV infections occurred worldwide 
amongst children in 2013, which is a large decline from 2001 in which 580,000 
(530,000-640,000) were thought to have been infected[482]. ART coverage is poorer in 
children than in adults, such that only 24% had access to ART in 2013. A large 
proportion of new paediatric infections are thought to have resulted from transmission 
during pregnancy, labour or delivery, or due to breastfeeding. MTCT rates have 
dramatically declined since the use of maternal and neonatal ART, elective caesarean 
section delivery and avoidance of breastfeeding in developed countries, to the extent 
that UNAIDS is targeting virtual elimination of mother-to-child transmission by 2015. In 
Europe, where observed rates of mother-to-child transmission have decreased to 
around 1%, this goal is already almost achieved[485].  
2.5 HIV in Europe 
2.5.1 Background 
Although on a much smaller scale compared to SSA, HIV remains an important public 
health issue in Europe. The adult HIV prevalence was estimated to be approximately 
0.3% (range 0.3-0.5%) in 2013[483]. At the end of 2012, 2.2 million adults and children 
were estimated to be living with HIV in the WHO European region (see section 2.5.2). 
136,000 new cases of HIV were diagnosed in 2013, of which 105,000 were reported 
across countries in Eastern Europe[486]. The numbers of deaths from AIDS remain far 
from negligible; there were estimated to be 99,000 in 2012, with the vast majority in the 
eastern region[487]. There is therefore large regional variability even within the WHO 
European region, with Eastern Europe being more affected compared to the Western 
and Central European areas. 
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In Europe, national epidemics tend to be concentrated within high risk groups. In most 
Western European countries MSM have historically accounted for the majority of HIV 
infections, although there have also been significant epidemics amongst PWID in 
several countries. In addition, some countries have seen relatively large numbers of 
people who have acquired HIV heterosexually[488]. This has predominantly been 
caused by an increase in migrants from countries with generalised epidemics[489]. In 
Eastern Europe and Central Europe, where epidemics have generally been fairly small, 
the predominant mode of transmission is IDU and heterosexual transmission 
respectively[490]. HIV infection in children accounts for <1% of the total number of new 
cases of HIV diagnosed in Europe[486].  
The rate of new AIDS diagnoses is decreasing in general across Western Europe, 
whereas Central Europe and Eastern Europe have seen a rise since 2004[486]. Almost 
half of new diagnoses in Europe (among all diagnoses which reported a CD4 count at 
diagnosis) were classified as a ‘late diagnosis’, which is where the CD4 count is less 
than 350 cells/mm
3 
at diagnosis[486], suggesting delays in HIV testing. Indeed, the 
proportion of people living with HIV who are undiagnosed is thought to be in the region 
of 20% to 30%[448].  
2.5.2 Geographical and political status of Europe 
There are currently 53 countries in the WHO European region, which can be divided into 
three geographical regions; West, Centre and East (Figure 2-3). In the EU there are 28 
member state countries and a further three countries in the European Economic Area 
(EEA). For this thesis, I am mainly interested in countries within the EU, although given 
the growing epidemic in Eastern Europe, I touch briefly on a number of key countries 
outside the EU too (Section 2.6).   
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Figure 2-3: Geographical and epidemiological division of the WHO European 
Region [486] 
 
 
 
2.5.3 Evolution of HIV/AIDS surveillance network in Europe 
In most countries within Europe, HIV and AIDS case reporting has traditionally formed 
the basis of national HIV surveillance. AIDS case reporting on the European level (as 
opposed to country level) began in 1984, and was coordinated by the WHO 
Collaborating Centre on AIDS in Paris[486]. At the time, AIDS surveillance was the only 
way in which the HIV/AIDS epidemic was monitored in Europe. The WHO Collaborating 
Centre on AIDS was later renamed the European Centre for the Epidemiological 
Monitoring of AIDS, which was subsequently established as EuroHIV. 
Once combination therapy was in widespread use, there was a call to initiate 
surveillance of HIV by collecting data on HIV case reports[491]. This was because 
treatment delayed the onset of AIDS and therefore AIDS case reporting was not an 
accurate reflection of the true epidemic as people on therapy were not presenting with 
AIDS until much later, if at all. European HIV case reporting began in 1999[492]. 
Although back-calculation methods no longer rely predominantly on AIDS case reporting, 
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such data is still useful because it provides measures of disease burden and delayed 
HIV diagnosis which can be used as advocacy tools.  
Since January 2008, the European HIV/AIDS surveillance programme has been jointly 
conducted by the European Centre for Disease Prevention and Control (ECDC) and 
WHO Regional Office for Europe (WHO/Europe). ECDC and WHO/Europe jointly 
publish an annual surveillance report, based on surveillance data submitted by countries 
in the WHO European region through a joint database known as The European 
Surveillance System (TESSy, Section 2.5.4). This report includes information for each 
country on the number and rates of new HIV diagnoses, number and rates of AIDS 
cases, number of deaths among AIDS cases, as well as proportion of late diagnoses 
and number of HIV tests performed. The first report published by the WHO Collaborating 
Centre on AIDS in 1984 included data on AIDS from 11 countries[493]. Now, almost all 
53 countries in the WHO European region report national HIV and AIDS cases[486].  
2.5.4 The European Surveillance System (TESSy) 
Data from the European countries are submitted through a web-based platform directly 
into TESSy. Data submission is usually done by the country representatives, who are 
the main contact points for communication with ECDC. A set of validation rules, 
implemented in an automated way ensure that the uploaded data is of good quality. 
Countries are encouraged to submit data for their entire surveillance period (including 
historical data, where available) to ensure quality and completeness. TESSy collects 
data on a variety of diseases, of which HIV/AIDS is one of 49. Liechtenstein, Russian 
Federation, Turkmenistan and Uzbekistan did not report any HIV or AIDS data for 2013.  
Three types of data are collected in TESSy for HIV/AIDS surveillance: HIV case-based, 
HIV aggregated and AIDS case-based. In the 2013 report, two countries (Ukraine and 
Kazakhstan) submitted only aggregated HIV data. Access to case-based data in TESSy 
is available only on request. The aggregated database contains fewer variables than the 
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case-based database. This has an impact on the overall European figures and tables 
which can be presented and interpreted in the annual reports. Aggregated data are 
available to the public in the form of the annual surveillance reports. Aggregated data 
presented in recent annual reports have been adjusted for reporting delay. In the 2007 
report it was quoted that,  
“around 50% of AIDS cases and 65% of AIDS deaths are reported within 6 
months of the event; around 10% are reported after more than 1 year”[494].  
 
The completeness of data in TESSy varies very much by variable. It is generally very 
good for those variables which are compulsory; mandatory variables for case-based 
data are age (completeness in 2009 = 99%), gender (99%), route of HIV transmission 
(63%) and date of diagnosis of HIV (84%) and date of diagnosis of AIDS (100%). CD4 
cell counts (for the HIV dataset only) were only reported by 23 countries whereas age 
and gender were both reported by 49 countries out of 53.  
2.5.5 Case reporting at the national-level in Europe 
Data on case reports of HIV diagnoses, AIDS diagnoses and deaths within people with 
HIV is routinely collected by many European countries. Sometimes case reports are 
collected at a regional-level which is then assembled to produce national-level data. 
Completeness can vary significantly by country, because notification of HIV and AIDS 
case reports can be mandatory or voluntary. Appendix IV summarises information on 
HIV/ AIDS case reporting surveillance for selected European countries with substantial 
HIV epidemics.  
2.6 Epidemiology of HIV by country 
In this section, I review the epidemiological characteristics for 18 countries in Europe 
which have the most substantial epidemics. A summary of key figures are shown in 
Table 2-3. These are the main European countries which I have in mind for eventual 
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application of the method developed in this thesis, i.e. the countries for which the HIV 
calibration method will be targeted. The four countries for which I will actually implement 
the calibration method in Chapters 6, 7 and 8, i.e. UK, Netherlands, Spain and Estonia, 
are reviewed in more detail. 
Table 2-3: Total population, number of cases of HIV diagnosed in 2013, UNAIDS 
estimates of the number of people living with HIV and adult HIV prevalence  
Country Total population 
as of July 2014 
in millions [495] 
Number of 
cases of HIV 
diagnosed in 
2013 [486] 
Number of people 
living with HIV 
(range) [496] 
Adult HIV 
prevalence 
(range) [496] 
UK 63.7 5,994 130,000 
(100,000-160,000) 
0.3 
(0.3-0.4) 
Netherlands 16.9 949 - - 
Spain 47.7 3,278 150,000 
(130,000-160,000) 
0.4 
(0.4-0.5) 
Estonia 1.3 325 8,600 
(6,900-11,000) 
1.3 
(1.0-1.6) 
Germany 81.0 3,263 - - 
France 62.8 4,002 - - 
Italy 61.7 3,608 120,000 
(110,000-140,000) 
0.3 
(0.2-0.3) 
Denmark 5.6 233 5,800 
(4,900-6,900) 
0.2 
(0.1-0.2) 
Switzerland 8.1 574 20,000 
(15,000-27,000) 
0.4 
(0.2-0.5) 
Portugal 10.8 1,093 - - 
Belgium 10.4 1,115 - - 
Greece 10.8 807 - - 
Austria 8.2 260 - - 
Sweden 9.7 354 - - 
Poland 38.3 1,089 - - 
Romania 21.7 507 16,000 
(13,000-21,000) 
0.1 
(<0.1-0.2) 
Ukraine 44.3 17,875 210,000 
(180,000-250,000) 
0.8 (0.7,1.0) 
Russian 
Federation 
142.5 79,728 - - 
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2.6.1 UK 
AIDS case reporting has been in place since 1982 and HIV case reporting since 1984 in 
the UK[488, 497]. Data were originally obtained in England, Wales and Northern Ireland 
by the Public Health Laboratory Service Communicable Disease Surveillance Centre 
(PHLS CDSC) and in Scotland by the Communicable Diseases (Scotland) Unit 
(CD(S)U)[497]. These authorities are now known as Public Health England (PHE) and 
Health Protection Scotland respectively. The current HIV surveillance system is 
coordinated by PHE. Other than the surveillance of new diagnoses of HIV and AIDS 
through HARS (HIV and AIDS reporting system), PHE also conducts an annual (twice 
yearly in London) cross-sectional survey of all HIV-positive individuals attending care 
(Survey Of Prevalent HIV Infections Diagnosed, SOPHID) as well as monitoring of CD4 
cell counts (CD4 surveillance scheme). Other components of the surveillance system 
include the Gay Men's Sexual Health Survey as well as various unlinked anonymous 
surveys such as those conducted in genitourinary medicine (GUM) clinic attendees, 
pregnant women and in PWID[443].   
The UK accounts for a significant proportion of the epidemic in Western Europe. Cases 
of AIDS were almost entirely attributed to men in the 1980s and early 1990s due to the 
majority of infections being present in people with haemophilia, blood transfusion 
recipients and MSM[497]. It was only in Scotland where these were not the main routes 
of HIV exposure during this early period, which instead was through intravenous drug 
use[497]. Routine screening of blood donations for HIV antibodies have been in place 
since October 1985[498], which lead to a rapid decrease in the number of AIDS cases in 
people with haemophilia[497].  
The trends over time in the annual new number of reported HIV diagnoses, AIDS 
diagnoses and deaths in the UK are shown in Figure 2-4. The number of diagnosed 
AIDS cases and number of deaths reached its peak in 1994 and 1995 respectively[499]. 
Following the availability of HIV testing in 1984, the first peak in number of HIV 
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diagnoses was reached in 1985[499, 500]. Since then, the highest number of HIV 
diagnoses was observed in 2005, with 7,890 cases being reported that year[501]. In 
2013, there were 6,000 cases of HIV reported in the UK[501].  
Figure 2-4: Number of new HIV and AIDS diagnoses and deaths in the UK [501] 
 
MSM has continued to be the predominant risk group for the UK ever since the start of 
the epidemic[469, 502-504]. The incidence of HIV did not appear to decrease even after 
the introduction of cART[503], and since 2002 the prevalence in MSM has remained at 
about 5% each year[469]. Over half (3,250 out of 6,000) of all new HIV diagnoses in 
2013 were in MSM.  
Historically, the UK has had strong links with Africa and migration of people to and from 
Africa has been fairly common[505]. This is reflected in the high proportion of diagnoses 
reported as heterosexually acquired among individuals originally from countries in 
SSA[499, 506]. It is estimated that up to two thirds of all HIV infections in heterosexuals 
in the UK is in African-born people[451, 499, 506]. The number of new diagnoses 
4 HIV in the United Kingdom: 2014
Annual new HIV and AIDS diagnoses and deaths: 
UK, 1981-2013
 
Figure not available due to copyright restrictions 
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reported among African-born heterosexual people has decreased since it peaked in the 
mid-2000s, from 4,850 to 2,490 in 2013[501].  
By the end of 2013, the number of people living with HIV in the UK was estimated to be 
107,000 (credible interval:101,600-115,800) according to estimates made using the 
MPES method (Figure 2-5, although note that the UNAIDS estimate was higher in Table 
2-3)[501]. This is mainly the result of effective antiretroviral treatment prolonging the 
lives of people. The proportion of people with HIV who are undiagnosed is estimated to 
have decreased in recent years [469], but even in 2013 it is estimated that 26,100 (24%) 
are undiagnosed. The proportion of people who are diagnosed late (defined as CD4 
count <350 cells/mm
3
) has also decreased, but testing rates still need to increase 
considerably to reduce further the number of late diagnoses (in 2013, 42% of all 
diagnoses in adults were classified as a late diagnosis)[501].  
Figure 2-5: Public Health England estimates for the number of people living with 
HIV (both diagnosed and undiagnosed) in the UK in 2013 [501] 
 
 
Estimated number of people living with HIV (both diagnosed 
and undiagnosed): UK, 2013
2 HIV in the United Kingdom: 2014
 
Figure not available due to copyright restrictions 
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2.6.2 Netherlands 
The first case of AIDS in the Netherlands was diagnosed in 1982[507]. Since then, AIDS 
surveillance data, although limited in the early years of the epidemic, has been collected 
by the Inspectorate of Health (national AIDS registry, IGZ) until 2002[508]. The national 
AIDS registry was terminated in 2002 with the adoption of a new HIV/AIDS reporting 
system by the Dutch HIV Monitoring Foundation (Stichting HIV Monitoring, SHM)[508]. 
SHM is the national monitoring foundation for HIV, which has been collecting data on 
almost all HIV-positive individuals who are registered at an HIV treatment centre since it 
was established in 2001[509]. ATHENA (AIDS Therapy Evaluation in the Netherlands) is 
a national observational cohort of all registered HIV-positive patients in follow-up in any 
of the 30 HIV treatment centres in the Netherlands[1045]. The largest proportion of HIV-
positive people in care are located in Amsterdam (33%), followed by Rotterdam 
(10%)[470].  
As of 2008, the total number of people living with HIV in the Netherlands was estimated 
to be between 21,000 and 24,000[470]. 40% (95% credible interval: 25-55%) of these 
people were estimated to be undiagnosed[470]. The prevalence among all adults is 
estimated to be 0.2%[470], but in MSM it is much higher at 5%[510].  
HIV infection has mainly affected MSM over the whole course of the epidemic[509, 511] 
(Figure 2-6), to the extent that in the first few years of the 1990s, AIDS was the leading 
cause of death for men between the ages of 25 and 54 in Amsterdam[512]. Even after 
the introduction of ART, the epidemic among MSM still does not seem to be under 
control and modelling studies have shown that there has been a rise in the number of 
infections in MSM in recent years[480, 510]. This resurgence is thought to be 
predominantly fuelled by an increase in sexual risk behaviour[513]. Testing rates among 
MSM have improved over time, however they are still lower compared to other cities 
which also have large gay communities; the proportion of MSM visiting an Amsterdam 
STI clinic who had never tested for HIV before was over 30%[514]. The HIV incidence in 
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MSM is thought to be between one to four infections per 100 person-years, with the 
higher end of the estimate seen in older men in the Amsterdam STI clinic[511]. 
Figure 2-6: Number of HIV diagnoses by year of diagnosis and transmission risk 
group for the Netherlands [515]  
Dotted lines show the projected number of diagnoses when the backlog in registration of HIV 
cases (3% in 2012, 11% in 2013) is taken into account. 
 
Heterosexual acquisition of HIV increased greatly between 2000 and 2004 and the 
number of diagnoses in this group was the same as that of MSM for the first time in this 
time period (Figure 2-6) [508]. The maximum number of diagnoses was observed in 
2004, where it accounted for 40% of all HIV diagnoses, but it has since declined[508, 
509]. A high proportion of HIV-positive heterosexuals are unaware of their serostatus; an 
anonymous prevalence survey revealed that only 19% of heterosexuals knew they were 
HIV-positive at the time of STI consultation[516]. Up to a half of all heterosexually 
acquired infections in the Netherlands are in people who originate from countries with 
generalised epidemics, but in particular SSA[509, 517]. There are also a large number 
of heterosexually acquired infections in individuals originally from Latin America and the 
Caribbean, mostly from countries in the former Netherlands Antilles and Suriname[518].  
HIV resulting from IDU has declined since 1985 and is now rarely reported, reflecting 
both the decreasing popularity of IDU and good accessibility to NSP and OST[509, 519].   
 
Figure not available due to copyright restrictions 
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The Netherlands started actively promoting HIV testing only once cART was 
available[516]. Opt-out HIV testing at antenatal screenings for pregnant women was 
introduced in 2004[520], but was not incorporated as routine care within an STI screen 
until 2007 in the STI outpatient clinic in Amsterdam[521]. Nevertheless, testing for HIV 
has improved over time, which shows in the declining proportion of late presenters 
(Figure 2-7).  
Figure 2-7: Proportion presenting with late-stage infection (left, A) and advanced-
stage (right, B) by year of first HIV clinic visit for the Netherlands [515]  
Late-stage infection is defined as CD4 count <350 cells/mm
3
 or AIDS at diagnosis. 
Advanced-stage infection is defined as CD4 count <200 cells/mm
3
 or AIDS at diagnosis. 
 
 
2.6.3 Spain 
Spain is formed of 19 autonomous regions, each with their own regional authority. Case 
reports on AIDS (Figure 2-8) are collected by each region’s AIDS register which then 
reports to the Registro Nacional de Sida (National AIDS Registry)[522]. Whilst all 
regions use the same case definition, the degree of active surveillance can differ 
between the regions[522]. Much surveillance data from Spain is therefore based on 
case reports of AIDS. HIV case reporting did not exist in all regions until 2013. 
 
Figure not available due to copyright restrictions 
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Figure 2-8: Reported and corrected (for reporting delay) number of AIDS cases in 
Spain by year of diagnosis and transmission risk group[523] 
 
Spain was the first European country to recognise that PWID contributed 
disproportionately to the number of AIDS cases[524]. Whilst the epidemic had a slower 
start compared to the rest of Western Europe, it then escalated exponentially over the 
next decade, perhaps linked to the fact that heroin injection became widespread during 
this era[525].  
Early policies to control drug injection, which consisted of promoting abstinence and 
controlling the drug supply, failed to contain the epidemic due to the magnitude of the 
problem[525]. This resulted in a steady increase of the annual incidence of AIDS cases 
throughout the mid to late 1980s and early 1990s[524]. Whilst only 177 cases of AIDS 
were observed during 1985, 7,482 AIDS cases were observed during the peak of the 
epidemic in 1994 (Figure 2-8) [526]. More than 60% of all AIDS cases were observed in 
PWID, which meant that Spain had the highest annual AIDS incidence in PWID of all 
HIC[526]. Although the annual AIDS incidence declined significantly from 1994 onwards, 
the AIDS situation in Spain remained problematic (relatively to other EU countries) for at 
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least the following decade. In 2005, it still had the highest number of PWID with AIDS, 
as well as the highest cumulative total of AIDS cases, and of PWID with AIDS of any 
European country[527]. 
Although a limited number and range of harm reduction programmes have existed in 
Spain since the mid-1980s, they only became widespread in the mid-1990s[525]. These 
programmes, which included OST, NSP, counselling and educational interventions, 
contributed greatly towards the decline in both the HIV and AIDS incidence after 
1994[525, 528]. This decline is also thought to be due to the availability of cART and the 
decrease in IDU, as more people took up other consumption methods such as 
smoking[529]. In 2010, the proportion of new HIV diagnoses and proportion of AIDS 
cases which were attributed to IDU was only 6% and 32% respectively, which is a 
substantial decline from 2001, where these proportions were 50% for new HIV 
diagnoses and 53% for AIDS cases[526]. 
The fall in the number of transmissions between PWID resulted in a transition in the 
demographics of the HIV-positive population in Spain. Therefore, whilst the number of 
sexual transmissions had not experienced much change in the same era, it by default 
became the predominant cause of new infections[530, 531]. Cohort studies have 
similarly observed an increase in new HIV diagnoses in MSM and women[532]. 
However, much of the early transmissions through heterosexual contact were probably 
between PWID and their non-injecting partners[527]. High rates of MTCT were also 
observed at the height of the AIDS epidemic, but rates have since declined and are now 
comparable with the rest of Western Europe[533].  
Spain has experienced an increase in the number of migrants from around the 1990s. 
Many of the migrants originate from Morocco, but there are also a large number of 
migrants from other European countries, African countries and Latin American countries, 
especially Ecuador[534, 535]. A high prevalence of HIV has been observed in migrants 
through anonymous testing, and part of the rise in sexually acquired HIV is thought to be 
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due to the relative as well as the absolute increase in migrants[534, 536]. Spain also has 
a substantial Roma population, which is its largest ethnic minority group, who although 
are Spanish by nationality do not exist in official records[535, 537]. There is no definitive 
data on the impact of HIV within the Roma community, though limited data from cohort 
studies have shown high prevalence of IDU-related HIV infection, high incidence of 
AIDS and faster disease progression[537-539]. 
2.6.4 Estonia 
Estonia, formerly part of the USSR, is one of the smallest countries in the European 
Union with a population of 1.3 million. HIV surveillance began in 1987 and the first case 
of HIV was reported the following year[540]. HIV incidence in Estonia continued to be at 
a very low level until 1999, at which time fewer than 100 cases had been reported[541]. 
The number of infections reported then increased, reaching its peak of over 1,400 cases 
in 2001 and was higher than any other country in the Eastern European region (Figure 
2-9).  
Figure 2-9: Number of new HIV diagnoses per million, by reporting year, in 
selected countries in Eastern Europe for 1993-2001 [542] 
 
Although prior to 1999 most cases of HIV were thought to be acquired sexually, cases in 
1999-2001 were predominantly (around 85-90%) among PWID[540, 541, 543]. HIV 
infections in Estonia have mainly been concentrated in two regions: in the capital city of 
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Tallinn and in Ida-Viru county, which is located in the most eastern area of Estonia, 
bordering Russia. These two regions also have the highest prevalence of PWID, many 
of whom are male, Russian-speaking, socially-disadvantaged and have experience of 
sharing injecting equipment[544]. NSP and OST are available, but use of these services 
needs to be improved. In particular, OST coverage (estimated to be 12%) is low[544].  
Following 2001, the number of diagnosed cases reported gradually declined: 743 new 
cases in 2003, 545 new cases in 2008, and 315 new cases in 2012[486]. However 
according to UNAIDS estimates, adult prevalence in 2013 still remains high at around 
1.3% (uncertainty range: 1.0-1.6%) [496]. Although the numbers of people affected by 
HIV is comparatively low in Estonia compared to other European countries, Estonia has 
the highest rate of HIV diagnosis among all EU countries at 23.5 per 100,000 population 
in 2012[486]. HIV remains concentrated in Estonia among at-risk sub-populations, 
namely PWID, partners of PWID, commercial sex workers and MSM[544]. Data on 
mode of HIV acquisition are not very well collected, but a study in 2012 found that 35%, 
62% and 2% of new infections were due to IDU, heterosexual transmission and MTCT 
respectively[544]. The extent to which MSM are affected are not fully known due to the 
ever-present stigma.  
Surveillance of HIV/AIDS was revised in 2008, as previously anonymous case reports 
were included in national figures which may have led to some double-counting of 
cases[545]. Approximately 30% of new HIV diagnoses between 2000 and 2008 were 
diagnosed anonymously in HIV counselling and testing centres[545]. Data on CD4 count 
at HIV diagnosis has not been routinely collected, although efforts are currently being 
made to improve completeness; it is thought that 30-40% of new diagnoses are late 
presenters (CD4 count <350 cells/mm
3
)[544]. HIV testing is available on a voluntary 
basis, but especially recommended in pregnant women, prisoners, people with TB, STIs, 
experience of IDU and high risk sexual behaviour.  
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HIV-related healthcare services, including clinic visits and ART, are either free or incur a 
modest charge for all Estonians covered under the national health insurance system. A 
small proportion (around 6%) of Estonians who are not covered, are more likely to be 
economically inactive and are also likely to be PWID. The Ministry of Social Affairs (akin 
to the national department of health) is responsible for ART procurement for the whole 
country. ART coverage has been improving over the years, but still remains lower than 
necessary (Figure 2-10). Reasons for this are thought to include poor linkage to care 
after diagnosis, lack of knowledge relating to HIV and treatment, or financial difficulties 
(lack of health insurance, need for fees, or fear of losing disability pension available only 
for people living with HIV and with CD4 count <200 cells/mm
3
). 
Figure 2-10: Number of people receiving ART (projection from 2009 onwards) and 
the modelled number of people in need of in Estonia [546] 
 
I was invited to accompany a WHO country mission to Estonia in May 2014 to get some 
experience in the field, talking to people in charge of the clinical care system, public 
health and surveillance in the country[544]. 
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2.6.5 Germany 
The incidence and prevalence of HIV over the years have remained at a low level in 
Germany, considering it is the most populated country in the EU. The total number of 
people infected with HIV from 1982 to 2004 is estimated to be 73,000[547]. The 
estimated prevalence of HIV in Germany was approximately 56,000 at the end of 
2006[548].  
AIDS surveillance began in 1982 and the first cases of AIDS were also reported in this 
year[549]. Case reports of AIDS gradually increased until it reached a peak of about 
2000 cases in 1993. The amount then declined dramatically from 1995 onwards when 
combination therapy became available[549]. The number of newly diagnosed HIV 
infections also reached a high of 2360 cases in 1993, before continuing to decline over 
the next 8 years until 2001[550]. However since 2001, when an estimated 1443 new HIV 
diagnoses were reported, there has been a continual steady increase. During 2010, a 
total of 2918 new diagnoses were reported[550, 551]. Possible reasons for this increase 
include increased HIV transmission, increased HIV testing and implementation of the 
Protection against Infection Act in 2001 which improved case-detection and case 
reporting[550, 552].  
The most affected risk group in recent years are MSM, followed by heterosexuals and 
migrants from high prevalence countries[547]. MSM have always been the predominant 
risk group, and the proportion of cases attributed to MSM has increased from 48% to 
65% between 1993 and 2007[550]. Germany therefore has a high male-to-female ratio 
at over 5:1 for both the number of new HIV diagnoses and the cumulative number of 
people living with HIV[547, 553]. 
PWID used to be the second largest risk group after MSM in the early 1990s and up to 
18% of all new HIV cases were attributed to this group[550]. This proportion has 
decreased to less than 6% by 2004, predominantly as a result of NSP[547].   
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The proportion of HIV infections attributed to heterosexual transmission has remained 
roughly constant at approximately 15 to 20% throughout the epidemic in Germany[548]. 
Surveillance data in Germany differentiates transmissions occurring in people originating 
from high prevalence countries and so these are categorised as a separate transmission 
risk group (even though the main mode of transmission is through heterosexual contact). 
Most HIV infections in this risk group are thought to have occurred in the high 
prevalence country rather than in Germany. The proportion of infections attributed to 
people from high prevalence countries has also remained constant, at about 20% of the 
total HIV infections[548]. 
2.6.6 France 
The HIV epidemic in France is typically compared to that of the UK because the overall 
population sizes of the two countries are similar (Table 2-3). Like the UK, it also 
accounts for a large proportion of all HIV infections found in Western Europe. In the 
early 1990s, the rate of AIDS cases per million population in France was one of the 
highest in Europe[554]. By the mid-1990s, the incidence of AIDS was 3-fold higher in 
France than in the UK, despite the similar size populations[555]. The total number of 
people estimated to be living with HIV in France in 2013 according to UNAIDS estimates 
is between 120,000 and 180,000, slightly higher than for the UK[483]. 
AIDS notification in France has been in place since June 1986 and is centrally 
coordinated by the Institut de Veille Sanitaire (InVS)[556]. HIV notification was not 
introduced until March 2003[557, 558]. At the same time as starting the HIV reporting 
system, the InVS also created and implemented a virological surveillance system which 
identified if infections were recent, to help estimate the incidence of HIV[558]. Both HIV 
and AIDS notification are mandatory. 
France has a number of HIV cohorts, surveys and study groups, such as the FHDH, 
AQUITAINE, APROCO/Copilote, Mortalité and VESPA. In particular, the FHDH is a 
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national, hospital-based multi-centre open cohort which has been recruiting people 
diagnosed with HIV-1 or HIV-2 since 1989. It is representative of the whole French HIV 
population. The database contains data on over 120,000 patients who had been seen in 
one of 70 hospitals or wards at least once between January 1992 and December 
2009[559]. Patients included in the cohort represented 56% of new AIDS cases 
diagnosed in France between 2004 and 2006[560]. 
Until the year 2000, the greatest number of AIDS cases were reported among MSM[479]. 
Between 2003 and 2008, MSM were the only risk group to have reported an increase in 
the number of new diagnoses; the proportion of MSM among all new diagnoses was 
25% in 2003 but increased to 37% in 2008[479]. Of all new HIV infections which 
occurred in 2008, 48% of these were in MSM, which amounted to 3320 new HIV 
infections[561].  
Heterosexual transmission only represented 12% of all reported cases of AIDS in 
1991[562], but has increased considerably since then. Between 2003 and 2005, 
approximately 56% of new diagnoses were attributed to heterosexual transmission[563]. 
A higher number of new infections were diagnosed in non-French-national 
heterosexuals compared to French-national heterosexuals[564]. The incidence was 
higher in female non-French-national heterosexuals compared to male non-French-
national heterosexuals, but the opposite was true in French-national heterosexuals 
where the incidence was higher in males than in females[564]. The majority of non-
French-national heterosexuals are originally from SSA. Similarly to the UK, France also 
has a migrant population which makes up approximately 8% of the total French 
population. Non-French nationals comprise roughly 40% of the estimated people living 
with HIV in France[565]. 
The number of new HIV infections due to IDU is minimal (approximately 1% in 
2008)[561]. These low rates are thought to be in part due to the greatly improved access 
to and uptake of sterile syringes and substitution treatment[566]. 
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HIV testing and antiretroviral medication is free in France, although testing was mainly 
voluntary until recently[567, 568]. However despite such access, there were estimated 
to be 29,000 people living with undiagnosed HIV at the end of 2010, of which 29% were 
infected less than one year ago and 16% were infected over five years ago[569]. 60% of 
these people are thought to have CD4 count <500 cells/mm
3
[569], which makes them 
eligible for ART according to national guidelines. Indeed of people who have been 
diagnosed, 30 to 40% were observed to already having developed AIDS or a CD4 count 
measuring <200 cells/mm
3 
at the time of diagnosis[570]. 
2.6.7 Italy 
The HIV epidemic in Italy varies greatly by region (of which there are 20). Higher rates of 
HIV and AIDS incidence are seen in regions in the north half of Italy (especially 
Lombardia, Liguria and Lazio) compared to regions in the south (such as Calabria and 
Basilicata)[571-574]. This variation by region is thought to be explained to a certain 
extent by differences in risk behaviour and drug treatment strategies[575].  
The AIDS Surveillance System has been in place since 1982, although case reporting 
only became mandatory in 1986[571, 576]. All case reports of an AIDS diagnosis are 
submitted by the physician to the coordinating centre for the surveillance system, which 
is the Centro Operativo AIDS (National AIDS Centre) of the Istituto Superiore di Sanitá 
(the Italian National Institute of Health), and also to the appropriate regional health 
authority[576]. Separate region- or province-specific surveillance systems for HIV have 
been in existence from as early as 1985 until March 2008, however surveillance 
methods differed by region/province[575]. Italy’s national surveillance system of new 
HIV diagnoses was established and implemented at the end of March 2008, making the 
reporting of new cases of HIV now mandatory. Seventeen regions and provinces 
submitted data in 2010 (total coverage of Italy’s HIV surveillance system was 72%)[573] 
and data was first complete for all regions in 2013. HIV case reports are also 
coordinated and analysed by the COA.  
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The trend of the overall HIV/AIDS epidemic in Italy is similar to Spain, such that HIV was 
most prevalent in PWID until the early 1990s with very high rates of HIV incidence 
observed[573, 575, 577, 578]. The proportion of HIV and AIDS cases attributed to PWID 
has fallen since then due to successful harm reduction programmes. Concurrently, the 
proportion attributed to MSM and heterosexual transmission gradually increased and the 
composition of risk groups thus shifted from high risk groups (specifically PWID) to the 
general low-risk population (generally heterosexual exposure, but also including MSM 
exposure)[572, 573, 579, 580]. In 1988, 75% of all HIV cases were in PWID, but in 2000, 
59% were acquired through sexual transmission[581].  
Similarly to other countries in Western Europe, there has been an increase in the 
number of migrants, especially from Eastern European and African countries, where the 
HIV prevalence can be very high[582]. Studies have indicated that the proportion of new 
HIV diagnoses in non-Italian nationals has increased steadily over time[573]. Late 
diagnoses of HIV have been a large problem since sexual transmission of HIV became 
the predominant mode of acquisition[583]. The rise in late presenters seen in the last 
decade is thought to be largely related to the rise in migrants who are more likely to be 
diagnosed late[583, 584]. 
Since the beginning of the epidemic there have been approximately 63,000 cases of 
AIDS reported up until 2010, of which almost 40,000 have died[573]. Despite AIDS 
incidence increasing until 1995, there has since been a progressive decline in the 
incidence of AIDS since the introduction of cART[573, 585, 586]. The incidence of new 
HIV diagnoses stabilised between 1999 and 2009[573, 586]. In 2013, 3608 new HIV 
diagnoses were reported, which equates to an incidence rate of 6.0 per 100,000 
population[486].   
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2.6.8 Denmark 
The epidemic in Denmark is characteristic of the epidemic which developed in other 
Western European countries (excluding Spain and Italy): initially established within MSM, 
then spread to heterosexual groups[587]. In the early 1980s, Denmark had the highest 
incidence of AIDS in Europe[588]. By the late 1990s, once combination therapy had 
been made available, the AIDS incidence had dramatically decreased, and by 2001 it 
was lower than the European average[589, 590]. There are now approximately 50 
diagnosed AIDS cases per year[591]. On the other hand, cases of HIV since the 1990s 
has been stable, with approximately 150 to 300 new diagnoses per year[588].  
HIV and AIDS case reporting in Denmark is near complete. For HIV case reporting a 
reminder system is put in place for laboratories performing confirmatory antibody tests to 
submit necessary data on the reporting form. For AIDS case reporting, patients with 
AIDS can only be treated in a restricted number of hospitals[588, 592]. Although 
treatment can only be given in specific medical centres, cART is universally available to 
all HIV-positive people for no charge. In general, HIV testing rates have been quite high, 
especially in MSM in Denmark, and many Danes are tested more than once[592-594].  
Of the 274 newly diagnosed HIV infections in 2010, 127 were in Danish men, 11 in 
Danish women, 60 in non-Danish men and 51 in non-Danish women (the rest were 
tourists). Thus non-Danish nationals made up approximately a third of all newly 
diagnosed males and over 80% of all newly diagnosed females[591]. This is in contrast 
to previous years; in 1990, 16% of all cases were in non-Danish nationals, and in 2000 
this figure was 37%[588]. The region of origin of these non-Danish nationals is primarily 
SSA (particularly Somalia and Sudan), but also includes Europe, Asia, America and 
North Africa[589, 591].  
Although MSM is still the primary risk group in Denmark (about 45% of all new HIV 
diagnoses are among MSM), the number of new diagnoses in heterosexual people has 
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gradually increased and is now nearly the same as that of MSM[588, 590, 595]. A rise in 
the number of immigrants from countries with high HIV prevalence is thought to have 
contributed greatly towards the increase in HIV diagnoses among heterosexuals in both 
Danish and non-Danish nationals, and non-Danish nationals now represent around 50% 
of all heterosexually acquired HIV[588, 589].  
Despite the fact that the number of people living with HIV has increased due to the 
availability of cART, this has not translated into an increase in the incidence of HIV 
diagnoses, particularly among MSM[591]. Studies have shown that this is most likely to 
be due to effective HIV therapy limiting further transmission, something which has also 
offset a concurrent increase in risky sexual behaviour[594, 596]. 
PWID only account for a very small number of diagnoses (fewer than 30 cases per year), 
but the overall proportion of HIV infections attributed to PWID (which is between 5 and 
10%) is slightly larger than that of other Western European countries[588, 590, 591].  
2.6.9 Switzerland 
Switzerland had the highest rate of new HIV diagnoses and the highest prevalence of 
AIDS during the start of the epidemic. The vast majority of cases were shared between 
MSM and PWID[597, 598]. Like all other developed countries, increasing use of 
combination therapy was succeeded by a steady decline in cases of AIDS in the years 
which followed. The trend in the number of new HIV diagnoses has been more 
changeable. The number increased between 1988 and 1991 from around 1600 to 2100 
new diagnoses per year[599]. After 1992, as a direct result of prevention measures put 
in place by the Swiss Federal Office, as well as a reduction in risk behaviour among high 
risk groups, the number of new HIV diagnoses declined to around 600 cases in 
2000[599]. Between 2001 and 2002, there was a 25% increase in the number of new 
HIV diagnoses[600]. MSM (particularly Swiss-nationals) and heterosexuals (particularly 
non-Swiss nationals who mainly originated from SSA) were the two risk groups most 
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affected by this increase[601]. This is thought to be due to an increase in incidence, 
given that the proportion of primary infections among HIV diagnoses increased by more 
than half in 2002. 
After 2002 the overall number of new HIV diagnoses stabilised, however this was a 
result of both an increase in the number of positive HIV test results in MSM (around 40% 
of all infections were classified as recent) and a decrease in all other risk groups, 
especially among female heterosexuals[602, 603]. An increase in risk behaviour is 
thought to be behind the increase in HIV transmissions in MSM[604]. The number of 
new HIV diagnoses in MSM has subsequently declined from 2009 onwards[605].  
IDU as a whole has fallen in Switzerland, which has aided the reduction in HIV 
transmissions in PWID[598]. Many harm reduction programmes have been available in 
Switzerland since the 1980s[606]. Despite PWID being disproportionately affected by 
HIV initially, they now only account for about 5% of all infections[599, 607].  
All case reporting and other epidemiological surveillance is coordinated and carried out 
by the Federal Office of Public Health. HIV surveillance in Switzerland is therefore 
centralised at country-level and well-organised. Furthermore, clinical surveillance in the 
form of the Swiss HIV Cohort Study (SHCS) and behavioural surveillance is also carried 
out (by the Institute of Social and Preventive Medicine of the University of 
Lausanne)[605]. Based on data up to March 2012, there are an estimated 22,000 
people living with HIV in Switzerland, and the distribution of mode of transmission 
amongst recent infections is as follows: MSM (48%), heterosexuals (46%), PWID (5%) 
and mother-to-child (1%)[605]. 
2.6.10 Portugal 
Although the first case of AIDS was diagnosed in 1983, the HIV epidemic in Portugal 
evolved at a slower rate in comparison to other Western European countries[608]. 
Portugal’s epidemic has had a fairly similar history to its neighbouring country Spain, in 
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that the epidemic is primarily associated with IDU and the incidence of AIDS has 
consistently been one of the highest in Western Europe[609].  
Rates of HIV infection increased rapidly after 1991, and by the end of 2002 an estimated 
20,526 people had been diagnosed with HIV[610]. HIV and AIDS case reporting have 
been in place since 1983 but as asymptomatic cases of HIV prior to 2000 were not 
reported, the evaluation of the HIV epidemic before this time is difficult[527, 608]. In the 
last 10 years however, Portugal’s rates of new HIV diagnoses have been one of the 
highest in Europe (217 new diagnoses per million population in 2007)[488, 490, 609].  
The effect of cART did not impact Portugal as hugely as it did for other European 
countries, as no sudden decline in AIDS incidence was seen. Nonetheless, the 
introduction of cART did coincide with a plateauing of the AIDS incidence in the late 
1990s, at around 1000 cases per year, before it gradually declined from 2002 
onwards[611]. The number of AIDS-related deaths peaked in 1996 with 561 cases but 
this has also since declined[527] to 350 AIDS diagnoses and 63 AIDS-related deaths in 
2010 [611]. 
The predominant mode of transmission of HIV in Portugal has been via IDU and the HIV 
prevalence among PWID has been estimated to be over 20% in some regions[612]. 
Data from 2006 have shown that of all HIV infections among PWID in Western Europe, 
Portugal reported almost 30% of these cases[527]. PWID also account for a large 
proportion (almost half in 2010) of all AIDS cases[611].  
Since the initial stage of the epidemic, which was driven by infections in PWID, the 
proportion of HIV and AIDS cases attributed to sexual transmission has increased 
progressively. Heterosexual transmission of HIV is now almost as common as 
transmission through IDU[488, 611]. The risk group distribution of people with HIV in 
Portugal is now approximately 50% PWID, 40% heterosexuals, 10% MSM and <1% 
MTCT.  
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Portugal has close connections with several African countries with generalised HIV 
epidemics because of former colonial ties, such as Mozambique, Guinea-Bisseau and 
Angola. Portugal therefore has large numbers of immigrants from these countries, as 
well as from Brazil and Eastern European countries. Estimates suggest that 20% of all 
new HIV diagnoses are in immigrants, many of whom acquire their infections 
heterosexually[535].  
2.6.11 Belgium 
Scientists in Belgium were some of the first to hypothesise that AIDS could be 
transmitted in ways other than through MSM transmission, after observing a series of 
various opportunistic infections develop in 18 previously healthy African patients 
hospitalised in Belgium[613]. This led to the rapid establishment of reference 
laboratories and subsequently of AIDS reference centres, in order to deal with the rising 
number of presenting AIDS patients[614]. As of 2012, HIV and AIDS surveillance in 
Belgium is conducted through nine AIDS reference centres and seven AIDS reference 
laboratories which are accredited and financed by the Belgian government. Only these 
AIDS reference laboratories are funded and permitted to carry out confirmatory tests of 
HIV status (once screenings test positive) and therefore these test results provide a 
complete record of the total number of HIV diagnoses made in Belgium[615]. AIDS 
reference centres are specialised centres for HIV and STI testing, treatment and care 
and at least 75% of patients  attend one of the nine centres[616].  
The lowest number of yearly diagnoses to date was in 1997, when 700 new HIV 
diagnoses were made[615]. This was followed by a 9 and 15% increase respectively in 
the number of newly diagnosed cases for 1998 and 1999, attributed mainly to a 
significant increase in cases in females[617]. There has been a moderate increase year 
on year since then, with 1070, 1072, 1132 and 1183 cases respectively in 2005, 2007, 
2009 and 2011[486]. This has resulted in 2012 seeing the highest number of new HIV 
diagnoses since the epidemic began, which was 1,229[486].      
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Heterosexual transmission has always been the main mode of HIV transmission in 
Belgium and has consistently accounted for over 40% of all new HIV diagnoses[615]. 
Over 90% of all women acquired HIV heterosexually, whereas this proportion ranges 
from 30% to 40% for men[615]. The majority of women who are diagnosed with HIV in 
Belgium are not of Belgian nationality and instead originate from (in order of frequency) 
Western Europe, North Africa and Middle East, Central Europe and SSA[535].  
Similarly to that observed in other Western European countries, the HIV epidemic 
among MSM has substantially increased during the last decade[504, 618, 619]. In 2002, 
MSM only accounted for 23% of all new HIV diagnoses, but this proportion increased to 
45% in 2010. This now makes homosexual/bisexual acquisition of HIV just as common 
as heterosexual acquisition[615]. However, this increase in new diagnoses is not due to 
increases in testing rates, because these have stayed relatively stable[620].  
HIV infections occurring through other routes of transmission are very uncommon now in 
Belgium, although they are still occurring at a small rate[620]: in 2010, the distribution of 
mode of HIV acquisition was <2% via IDU, <1% via MTCT and <3% via transfusion-
related causes[615].  
2.6.12 Greece 
The HIV epidemic in Greece from the early 1980s until the mid-1990s was mainly 
attributed to MSM transmission[621]. In comparison, the prevalence of HIV in PWID 
during the same time period and beyond has been considerably lower in Greece 
compared to other Mediterranean countries, namely Italy and Spain [622]. This has 
always been surprising given the low coverage of NSP and OST, as well as the 
substantial prevalence of IDU-related hepatitis[623]. The number of heterosexual 
transmissions has been increasing steadily over the years, although the majority of 
people who acquire HIV heterosexually have HIV-positive partners from high-risk groups, 
such as PWID, bisexual people and people originating from high prevalence 
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countries[624]. There has also been a huge rise in the number of migrants in Greece 
over the last 10 to 15 years, which has resulted in an increase in the number of HIV 
infections in migrants too, many of whom are from SSA and Central and Eastern 
Europe[621, 625]. 
The incidence of AIDS increased only very gradually from 1981 onwards, but due to the 
expanded AIDS case definition implemented in 1993, higher numbers of AIDS cases, 
approximately 200 cases per year, were diagnosed between 1993 and 1996. This rise 
was subsequently followed by a decline in AIDS incidence due to the availability of 
cART. In the last decade, there has been around 100 AIDS cases diagnosed each 
year[626].  
AIDS case reporting and HIV case reporting was implemented in Greece in 1984 and 
1998 respectively. A new system for HIV surveillance was introduced at European level 
in January 1999. Cases of HIV infection which were identified earlier than 1998 have 
been collected retrospectively in addition. Case report data are reported from all 
infectious diseases units, AIDS reference centres and hospitals and are then managed 
and analysed by the Hellenic Center for Disease Control and Prevention[626]. A 
significantly large proportion of case reports are categorised as ‘undetermined mode of 
transmission’, which arises because some case reports are based only on laboratory 
findings[621].  
There was a sudden large increase in the number of cases of HIV observed in 1999, 
which is thought to be attributed to the change in the surveillance system in that 
year[626]. However, the overall trend in the HIV epidemic has been rising since then. 
The estimated prevalence of HIV in 2009, derived using EPP was 0.13% overall, but in 
MSM it was 6.5% and in PWID 0.4%[627]. An outbreak of HIV infection occurred in 2011, 
where the number of reported HIV cases increased by 57% from 2010 to 2011[626]. 
During 2011, the number of HIV infections reported in Greece was as follows: 340 MSM, 
241 PWID, 148 heterosexual, 4 perinatal, 1 transfusion-related infection and 220 
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undetermined infections. The outbreak was particularly apparent among PWID, where 
the number of HIV diagnoses increased 15-fold from 2010 to 2011; prior to 2011, there 
were between 9 and 19 cases of HIV diagnosed among PWID annually[626, 628, 628]. 
Whilst part of the rise in HIV case reports in PWID can be related to improved 
surveillance, other available evidence suggests that there is a real increase in 
transmission[629]. Possible reasons for the increase include the country’s economic 
crisis, decreases in harm reduction programmes, and changes in patterns of use of 
drugs[629]. 
2.6.13 Austria 
Management of public health in Austria is controlled by the Federal Ministry of Health, 
but is operated by each of the nine provinces themselves. The National Reference 
Centre for AIDS and the Reference Laboratory verifies HIV screening test results 
performed in one of 157 HIV screening laboratories[630]. The HIV screening 
laboratories have been required to report the cumulative numbers of newly confirmed 
HIV diagnoses every quarter since 1994 to the National Centre for HIV/AIDS. No case-
based HIV surveillance (i.e. only aggregate) is present in Austria and no data are 
reported at the European level due to national legal reasons concerning confidentiality of 
data[488, 609, 630]. Case-based surveillance for AIDS has been in place since 1984. 
HIV surveillance is also conducted through the Austrian HIV Cohort study, which is a 
hospital-based cohort[630].  
HIV infection has predominantly affected MSM and PWID in Austria[43, 630], although 
the epidemic among PWID is thought to have occurred slightly later compared to some 
other European countries such as France, Italy and Spain[631, 632]. The introduction of 
prevention interventions such as methadone maintenance programs and NSP 
particularly helped to decrease the prevalence of HIV in PWID between 1987 and 
1992[633]. It is thought that much of the transmissions among heterosexuals and MTCT 
are in some way associated with IDU[631]. Heterosexual transmissions have been 
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increasing gradually over the last twenty years and now constitute the largest proportion 
of all cases since the late 1990s[488, 630].  
Although there was a peak in the number of people diagnosed with AIDS around the 
beginning of the cART era (around 250 cases per year), this has steadily dropped since 
and now amounts to less than 100 cases per year[486]. The number of new HIV 
diagnoses has been reasonably stable over the last ten years at around 450 to 500 
cases per year[630]. Of the people diagnosed in 2010 who are followed in the Austrian 
HIV cohort, approximately 70% were Austrian nationals[634]. Despite Austria having 
one of the highest European HIV testing rates, a fifth of all patients are diagnosed with 
immune deficiency (i.e. CD4 count <200 cells/mm
3
)[634]. UNAIDS estimates from 2010 
state that there are approximately 15,000 adults and children living with HIV in Austria in 
2009, which is an increase of about 10,000 since 2001.  
2.6.14 Sweden 
The HIV epidemic in Sweden has progressed very similarly to that of other Western 
European countries. There was initially a sudden peak during the mid-1980s in the 
number of reported cases of HIV, mainly among MSM and PWID[635]. Since then, the 
annual number of HIV diagnoses has remained at around 300 to 400 cases[486]. In 
2013, there were 458 cases reported, corresponding to a rate of 4.8 per 100,000 
population[486]. 
The virus is thought to have been introduced to the MSM population of Sweden between 
1979 and 1980[636]. At its peak in 1986 there were over 550 cases of HIV reported in 
MSM. The incidence level subsequently declined and throughout the next 15 years there 
was an annual incidence of approximately 100 cases[635]. The peak in incidence 
among PWID occurred around the same time as for MSM, with the annual number of 
cases approximately 200 at its highest. HIV seroprevalence in PWID was quite high 
(around 11-13%) in the mid-1980s, but particularly so in opiate users (46%) compared to 
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amphetamine users (6%)[637, 638]. The rate of infection among PWID is thought to 
have decreased since then because of a fall in sharing of injecting equipment as well as 
PWID being repeatedly offered HIV testing[639]. Following a stable period of about 20 
cases per year among PWID, there was a small rise in incidence in 2001 (38 cases), 
although this was eventually found to not be linked with the HIV outbreak in nearby 
Eastern European countries[640].  
1990 was the first time that the reported number of HIV infections acquired through 
heterosexual exposure exceeded the number acquired through MSM exposure[635, 
639]. The number of new HIV diagnoses among heterosexuals remained stable for the 
next decade, but numbers have gradually increased after 2002, especially among those 
infected abroad[635, 641]. Sweden now has one of the highest proportions (60%) of 
diagnoses in heterosexuals reported in migrants, many of whom are from SSA or 
countries in South East Asia[535, 553].  
AIDS has been a notifiable disease since 1983 and HIV has similarly been notifiable 
since 1985. Case reporting of AIDS ceased to be mandatory after 2005 and 
subsequently the national AIDS surveillance system was discontinued in 2008[635]. As 
of the end of 2011, there have been a total of 9,891 cases of HIV reported to the SMI 
(Smittskyddsinstitutet), the Swedish Institute for Communicable Disease Control[642]. 
There have also been a total of 2,428 AIDS diagnoses. The number of reported AIDS 
cases peaked in 1995, but has declined and stabilised since then to about 50 to 60 
cases per year[635]. 5,800 people were thought to be living with a known diagnosis of 
HIV by the end of 2011, which corresponds to a prevalence of roughly 60 per 100,000 
people[642]. It is thought that up to 70% of people diagnosed between 2009 and 2011 
were late presenters (CD4 <350 cells/mm
3
 at diagnosis), many of whom were 
immigrants from non-European countries but having lived in Sweden for more than a 
year had the opportunity to be diagnosed earlier[643]. 
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2.6.15 Poland 
In Poland, the first cases of HIV were diagnosed in 1985 and the first case of AIDS was 
reported in 1986[644]. Although many of the initial cases were in MSM and some in 
people with haemophilia, there was a rapid spread of HIV infection among PWID from 
1988 onwards, such that cases of HIV in PWID represented 60% of all reported cases in 
the country[542, 645]. The HIV prevalence among PWID reached around 9% between 
1988 and 1989, although it did drop to around 3% by 1993[542]. In particular, the capital 
city of Warsaw is known to have one of the largest PWID populations in the world[646], 
and one study conducted in detoxification centres in Warsaw estimated the HIV 
prevalence in PWID to be 45.9%[647].  
The total number of new HIV diagnoses was at its highest in 1990, where 809 cases 
were reported[645]. It then declined to 384 cases in 1993, before slowly increasing 
again to 560 cases in 2001[542, 645]. PWID still accounted for the majority of all 
reported cases of HIV (60%) and AIDS (50%) during this decade[648]. Post-2000, there 
has been a gradual shift in the predominant mode of HIV transmission from IDU to 
sexual transmission (both among MSM and heterosexuals)[648, 649]. More than half of 
all diagnosed HIV cases however, have unknown or unreported routes of 
transmission[644, 649]. Although the incidence of AIDS has remained stable from about 
1995 onwards, the number of late diagnoses (defined here as an AIDS diagnosis within 
three months of HIV diagnosis) has been rising in the same period[650]. Between 1999 
and 2004, over a third of all HIV diagnoses in adults were classified as a late diagnosis, 
where the majority of adults acquired their HIV through sexual contact[644]. This is 
thought to be because people infected sexually are more likely to be unaware of being 
at risk and are only tested for HIV on a voluntary basis[651]. By 2009, over 55% of all 
HIV diagnoses were late diagnoses[649].  
MTCT rates have remained high in Poland despite the availability of good prophylactic 
measures including use of ART, though transmissions occur mainly in women who are 
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unaware of their serostatus[652-654]. Furthermore as of August 2012, in contrast to 
other European countries, pregnant women are not routinely offered HIV testing in 
Poland, which contributes to the fact that HIV testing rates in Poland are some of the 
lowest in Europe[650].  
Surveillance of HIV and AIDS in Poland is managed by the National Institute of Public 
Health – National Institute of Hygiene (NIZP-PZH) and has been implemented since 
1985[644, 650]. It is based on the notifications of diagnoses of HIV, AIDS and HIV-
related deaths. The notification of an AIDS case is mandatory and is carried out by the 
diagnosing clinician[644]. The notification of a positive HIV test result is carried out by 
the laboratories carrying out the confirmatory tests[644]. Consequently, records on 
newly diagnosed cases of HIV infection are often incomplete (especially data on the 
mode of transmission), because it is not always possible to collect all the information at 
laboratory-level[650]. Data which is accumulated through HIV testing is also collected in 
the form of aggregated data to add to the surveillance data based solely on case 
reports[650].  
The number of new cases of diagnosed HIV has risen slowly in the last five years, from 
675 cases in 2004 to 960 cases in 2009 (which is higher than the previous peak reached 
in 1990)[609]. There were 927 cases of HIV reported in 2010, which may be slightly 
underestimated due to reporting delays or it may indicate that the diagnosis rate has 
stabilised[609]. By the end of 2011, there had been a total of 15,196 cases of HIV 
diagnosed in Poland since the beginning of the HIV epidemic in 1985[655]. Furthermore, 
there have been a total of 2,704 cases of AIDS and 1,136 HIV-related deaths in the 
same time period[655].  
2.6.16 Romania 
There were only 13 cases of AIDS reported in Romania until December 1989, but by 
December 1990, there were a total of 1,168 AIDS cases reported to the Romanian 
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Ministry of Health[656]. Astonishingly, over 90% of these AIDS cases were in children 
aged 13 years or under, many of whom were younger than four[656]. Romania at the 
time had many orphaned or abandoned children living in public institutions as a result of 
the then-communist government’s social policies[657]. Children who were 
institutionalised were frequently given blood transfusions and multiple injections as 
treatment when they became ill[70, 656]. Inadequate care was taken during these 
procedures which meant that blood was unscreened, needles and syringes were reused 
and other medical equipment was not sterilized[658, 659]. The HIV epidemic among 
these children is therefore almost wholly attributed to nosocomial transmissions[656, 
660]. These transmissions have eventually shaped the overall epidemic in Romania. A 
large proportion of the currently diagnosed HIV-positive population are long-term 
survivors infected between 1987 and 1991 and who are now between 20 and 25 years 
old[661]. Only a very small proportion of HIV infections were a result of vertical 
transmission[656, 662]. 
The first case of AIDS was diagnosed in 1985, yet medical professionals were forbidden 
to publish any information about AIDS at the time, as the government’s view was that 
AIDS was non-existent in Romania[663]. Following the collapse of the regime in 
December 1989, a national AIDS surveillance system, including HIV sentinel 
surveillance, blood screening and anonymous testing, was put in place during the spring 
of 1990 by the Romanian Ministry of Health and WHO[663, 664]. Due to irregularities in 
past case reporting, estimated numbers of people living with AIDS are thought to be 
inaccurate, despite two extensive reviews of the surveillance system[665]. Surveillance 
of HIV and AIDS is now conducted on a case reporting basis, where hospitals and 
infectious disease units report confirmed cases to regional HIV/AIDS centres which in 
turn report to the National Institute for Infectious Diseases (Prof. Dr. Matei Bals)[666].  
Cases of HIV in Romania constitute approximately 30% of all cases in Central European 
countries, making it the second largest epidemic behind Poland. Access to ART is free 
in Romania, but there have been reports of treatment interruptions due to a lack of 
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supply of medication[666]. As of June 2012, a cumulative total of 17,819 cases of HIV 
and AIDS have been reported in Romania and the total number of people known to be 
living with HIV infection is 11,189[667]. UNAIDS estimates from 2010 suggest that the 
actual numbers of people living with HIV are likely to range between 12,000 and 
20,000[484]. In recent years, over 70% of new HIV diagnoses were reported to have 
acquired their infection through heterosexual transmission. The proportion of infections 
acquired through MSM transmission, IDU and MTCT have remained low[667]. However, 
similarly to Greece, there was an outbreak of HIV infections among PWID in Romania in 
2011[629]. There were approximately three to seven cases annually from 2007 to 2009, 
but this increased to 14 cases during 2010 and 129 cases during 2011[667]. 
Contributing factors to this increase include a change in drug-use patterns and a 
reduction in NSP due to funding cuts[668]. Availability of OST in Romania has been and 
still is very limited.    
2.6.17 Ukraine 
Ukraine is a former USSR state. HIV surveillance based on case reporting has been in 
place since 1987[669]. Together with Russia, Ukraine is responsible for 90% of all newly 
reported HIV diagnoses in the Eastern Europe and Central Asia area in the last 
decade[670]. The number of AIDS cases was initially low in 2002, with a cumulative total 
of 3,633 (and 1,413 cumulative AIDS deaths)[542]. By the end of 2007, the cumulative 
total of AIDS cases had risen to 22,424 (and 12,490 cumulative AIDS deaths)[669]. 
Between 1988 and 1994, there were only 40 to 80 cases of HIV reported per year[671], 
most of which were due to sexual transmission in both MSM and heterosexuals[672]. 
This was followed by a sharp increase, mostly among PWID. The epidemic first affected 
areas along the Black sea including the cities of Odessa and Mykolayiv, where drug use 
is widespread[672, 673]. The number of cases of HIV diagnosed among PWID 
continued to rise, reaching 1021, 4,360 and 7,448 in 1995, 1996 and 1997 
respectively[674]. A brief decline was seen in the late 1990s and early 2000s (with 3700 
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to 4000 cases diagnosed in PWID per year) but the number of cases has slowly risen 
again. In 2013, there were 17,875 cases of HIV diagnosed in Ukraine, of which 33% 
were thought to be acquired through IDU[486]. Now, IDU is not the most common route 
of HIV acquisition. According to data from prevalence surveys, the prevalence of HIV 
among PWID in 2011 was estimated to be 22%, however when restricting only to PWID 
under the age of 25, the prevalence was 7%[675]. There is fairly good availability of 
NSP and other support programmes for PWID, but OST is only available to a 
minority[676, 677]. 
Major transmission risk groups other than PWID include prisoners and commercial sex 
workers. The prevalence of HIV is estimated to be 15% and 9% in these groups 
respectively[674]. In female sex workers who did inject drugs and who did not inject 
drugs, the estimated prevalence is 41% and 6% respectively.  
Heterosexual transmission has been increasing in the last decade, which probably 
initially resulted from increased sexual risk behaviour in PWID[542, 609]. Now, over 60% 
of new cases of HIV diagnosed in Ukraine are acquired heterosexually[486]. In particular, 
there has been a large growth in cases in women; they accounted for 37% of all cases 
in 1995, rising to 42% in 2006[678]. As many of these women are of child-bearing age, 
there are also a considerable number of infants infected through vertical 
transmission[679]. Initial uptake of preventative measures for mother-to-child 
transmission (mainly short-course AZT and/or single-dose NVP) has seen promising 
results[680].  
The HIV prevalence estimated in 2011 among MSM in a study conducted in 27 cities 
was reported to be 6.4%, although this is thought to widely differ by region[674]. 
However, it is thought that any figures for MSM are commonly misreported or 
underestimated due to the stigma surrounding homosexuality. 
133 
 
2.6.18 Russian Federation 
The HIV epidemic which had spread rapidly across Western Europe in the 1980s did not 
greatly affect the former Soviet Union state due to its isolation at the time. The 
dissolution of the USSR in 1991 led to tough economic conditions, which in turn led to 
an increase in drug users and sex work. The first acknowledged case of HIV in Russia 
was in 1987, in a person who had acquired it in a high prevalance African country[671]. 
A number of cases followed in the next few years, most notably a major outbreak of 
hospital-acquired infections in about 250 Russian children[671, 673], but due to the 
relatively low number of reported HIV cases in the whole country[681], not much 
attention was paid by health officials.  
There were no reported cases of HIV in PWID before 1994[672]. The majority of drugs 
which were used for recreational purposes in former USSR countries were until then 
produced in the countries themselves, but the mid-1990s saw countries such as 
Afghanistan, Turkmenistan, Uzbekistan and Tajikistan become mass producers of 
opium and the close proximity of these countries to much of Eastern Europe meant that 
drug trafficking in these areas rose[542, 671, 672]. Sharing of injecting equipment such 
as needles and syringes was also very common in many regions, estimated at 
approximately 40%[542, 682].[683] As a result, the period between 1995 and 2000 saw 
multiple outbreaks of HIV in PWID. These were reported across many regions of the 
Russian Federation, especially in Kaliningrad, but also including Moscow, Irkutsk, 
Krasnodar, Nizhny Novgorod, Tumen, Tver and Saratov[542, 632, 671, 672, 683-686]. 
The number of case reports increased significantly during this period; hardly any reports 
were made in 1995, but by the end of 1997 the annual figure was over 7,000[671]. This 
meant that over 70% of new infections were among PWID in 1997[673]. This large 
increase was the beginning of an exponentially growing epidemic. In 2000 and 2001, the 
peak of the epidemic in PWID, the total number of new HIV cases reported during the 
year exceeded 56,000 and 82,000 respectively[672]. Methadone and buprenorphine, 
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both of which are used for treatment of drug usage as substitution therapy, are illegal in 
Russia[676]. 
Sex workers and prisoners, many of whom also inject drugs, account for a large number 
of cases of HIV. In addition, Russia has one of the world’s largest prison populations for 
whom NSP and antiretroviral drugs are unavailable in most cases[687, 688]. In 2000 to 
2005, the prevalence of HIV in female sex workers who inject drugs differed significantly 
by region, ranging from 15% to 65%[689, 690]. Data from a similar time period found 
that HIV prevalence in prisoners who inject drugs in St. Petersburg was as high as 
46%[687].  
A large proportion of heterosexual transmissions have been between PWID and their 
partners. Much of this is thought to have been caused by increases in drug use and 
sexual risk behaviour, especially among young adults[691, 692]. Since 2001 there has 
been a substantial increase in HIV infections attributable to heterosexual transmission; 
in 2001 it accounted for fewer than 10% of all infections, but by 2008 it was estimated to 
be 35%[670].  
Transmission in MSM comprises only a small proportion of infections in Russia; 
probably less than 1% of the total number of infections[484]. Before the epidemic in 
PWID began, MSM transmission accounted for roughly 30% of all reported HIV 
cases[670, 693]. However, the epidemic among MSM has most likely been 
underestimated in this group due to ongoing stigmatisation. The prevalence of HIV 
among MSM is now thought to be in the region of 6%[694].   
Co-infection with hepatitis is an emerging problem, particularly in PWID, although there 
are very few estimates of the prevalence in Russia. One unlinked anonymous survey 
conducted in Togliatti reported the prevalence of hepatitis C co-infection in HIV-positive 
PWID to be 93%, but only 23% were aware of their hepatitis status[695].  
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HIV surveillance relies mainly on the number of new HIV cases reported. In 2010, 
62,581 cases were reported to the ECDC, which is a substantial proportion of the 
122,907 cases reported for the total WHO European Region[486]. There is no data on 
the number currently living with diagnosed HIV and no consensus estimates of the total 
number of people living with HIV in Russia[696]. UNAIDS estimates from 2009 suggest 
that the number of people living with HIV was between 840,000 and 1.2 million people in 
that year[484].  
Although ART is available, treatment coverage is very low. Even in people who are 
receiving treatment, supplies are inadequate such that people are either not receiving 
them entirely or are having to switch[697]. PWID are particularly affected because they 
are likely to be refused ART until they cease injecting drugs[697]. Recent estimates of 
treatment coverage are in the range of 16% to 23%[484].  
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Chapter 3 Mathematical models of HIV 
In this Chapter, I review what types of mathematical models are available and how they 
are used in the context of HIV epidemic modelling, to help put my thesis in context. I 
also present a description and characteristics of other existing HIV stochastic simulation 
models, before presenting the model I started with (Synthesis V5) for this thesis in detail.  
3.1 Introduction 
Mathematical models, where population parameters are described by symbols and 
mathematical formulae, are commonly used in infectious disease epidemiology because 
of the complexity of the interplay between the human immune system and the 
aetiological agent[698]. In the case of HIV infection, where this relationship is even more 
complicated compared to other infectious diseases[699], modelling has become a vital 
tool to better understand the dynamics of the disease. This thesis focuses on population 
models, where units within the models are individuals, as opposed to host cells and 
virus strains as in within-host models. 
The focus and quality of HIV models have evolved with time and knowledge of the 
aetiology of the virus; the more observed data there are available and the more we 
understand about HIV infection, the more we can improve model structure and 
parameter values to improve quality and accuracy. Although clinical trials are widely 
accepted to be the gold-standard in terms of the highest quality of evidence, model 
parameters and structures are also often based on data from large observational 
studies[700]. As Wilson and Garnett summarised in a recent editorial comment,  
“models are only as good as the behavioral, biological, clinical, and 
epidemiological assumptions on which they are based”[701].  
 
During the early stages of the epidemic, modelling was practically limited to short-term 
outcomes because of the lack of reliable data on long-term effects (and any which did 
138 
 
predict long-term effects had much uncertainty)[698]. The increase in computing power 
has also contributed to the progress made in the field of modelling to some extent;[700] 
methods such as Markov Chain Monte Carlo had not really had much of an impact in 
statistics until very recently[702]. 
3.2 Categorisation of models 
To date, there exists a considerable variety of models describing HIV infection, ranging 
from simple prognostic models to complicated dynamic simulation models, each 
developed to suit their purpose and research question. Table 3-1 summarises the types 
and properties of several commonly used mathematical models[703, 704]. 
Table 3-1: Examples of types of model [703]  
Type Description 
Role of 
probability 
Deterministic Variables are determined by the model parameters 
by approximating an infinitely large population. 
Therefore every time the model is run, the outcomes 
are the same given that the set of initial parameter 
values used are also the same.  
Stochastic Variables are determined based on probability 
distributions and therefore every time a model is run, 
the outcomes can differ as a result of chance, even 
when the same set of initial parameters are used.  
How the 
individuals 
are 
modelled 
Compartmental 
(also state-
transition 
models) 
Individuals in the model population are grouped 
together in ‘compartments’, e.g. the disease stage is 
grouped as ‘susceptible’, ‘infected’ and ‘died’. Markov 
models assume a compartmental model.   
Individual-
based (also 
microsimulation 
models) 
The model explicitly tracks the course of infection for 
each individual in the model population. 
Feedback 
in the 
model 
system 
Dynamic Model takes into account the element of time, usually 
represented with differential equations. Typically used 
when modelling disease transmission, so that the 
prevalence of infectious people are fed back into the 
model at each time point. 
Static Model outputs do not feed back into the system. 
Typically used to model chronic disease progression 
but not to model effects of interventions involving 
changes in disease prevalence. 
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3.3 The role of models in HIV epidemic modelling 
There is huge variety in the use and type of models in the field of HIV research[705]. 
The role of mathematical models can be largely categorised into the following: 
estimation of HIV incidence; exploration of the impact of various programs and 
interventions, such as ‘treatment as prevention’ and its implications to policy-making; 
predictions and forecasting; transmission dynamics; estimation of the progression of 
disease or incubation periods; and applications in immunology. The main aims of the 
SSOPHIE project (see Section 3.5) and therefore the aims of this thesis address a 
combination of the first three applications. Below I explain in brief what each of these 
three roles involves. 
3.3.1 Estimation of HIV incidence 
As explained in Chapter 2, estimating the incidence of HIV is important to assess the 
extent of the epidemic and to be able to prepare and implement appropriate policies. 
Unlike the prevalence, which is useful for quantifying the overall impact of the disease 
but is a somewhat historical measure of the epidemic, the incidence conveys the current 
status[706]. The use of mathematical models is one of a number of approaches from 
which the HIV incidence can be estimated. These models use prevalence data, either 
from prevalence surveys or surveillance systems, in order to estimate the number of 
infections that needed to have taken place. The EPP approach used by UNAIDS is one 
example where longitudinal prevalence data is used to fit a model which determines 
incidence in this way[707].  
3.3.2 Models of HIV/AIDS interventions and their implications for policy 
Models can also be used to inform epidemiologists and policymakers by predicting and 
assessing the likely outcomes of interventions or programs[708, 709]. The impact of 
interventions is often assessed using outcome measures such as the HIV prevalence, 
proportion of people on ART and rates of TDR. Alternatively it could be cost-
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effectiveness or long-term outcomes such as life years or quality-adjusted life years that 
are assessed. Table 3-2 shows the variety of interventions which have been studied 
using mathematical models within the HIV field. 
Table 3-2: Studies which have assessed the impact of HIV/AIDS interventions 
using mathematical models [708] 
Intervention Number of studies (%)* 
Antiretroviral treatment 45 (25.7%) 
HIV vaccines 28 (16.0%) 
Behaviour change communications 23 (13.1%) 
Treatment of STIs 23 (13.1%) 
Prevention of mother-to-child transmission 19 (10.9%) 
Harm reduction in PWID 9 (5.1%) 
Male circumcision 9 (5.1%) 
TB treatment in the context of HIV 8 (4.6%) 
Microbicides 6 (3.4%) 
Pre-exposure prophylaxis 5 (2.9%) 
Other 15 (8.6%) 
PWID:people who inject drugs; STI:sexually transmitted infections; TB:tuberculosis. 
*This column sums to >100% as models could assess interventions in more than one 
category. 
 
3.3.3 Predictions and forecasting 
It has always been crucial to know the number of people with HIV or AIDS because of 
implications for national health services in terms of resource allocations[710]. Therefore 
predicting the number of future cases of HIV and AIDS has always been at the forefront 
of HIV modelling. Predictions and forecasts from mathematical models generally rely on 
fitting models to available surveillance data and then extrapolating into the future[711].    
3.4 Individual-based stochastic simulation models 
There are a number of mathematical models used in HIV research that would be 
categorised as an individual-based stochastic simulation model. Such models are 
commonly used in this field because it allows flexibility in modelling of complicated 
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stochastic processes (i.e. the natural course of HIV and the effect of ART). They all 
share the similarity that they are highly detailed, which enables the researchers to 
address a much wider variety of questions than is otherwise possible. 
Although the concepts behind individual-based stochastic simulation models are intuitive, 
it is regarded as one of the most computationally intensive types of method because it 
keeps track over time of what happens to each individual simulated in the model. As the 
models are stochastic, the results are different each time the model is run, because 
parameter values are selected at random from probability distributions. Individual-based 
stochastic models are therefore often run multiple times to reduce or remove the effects 
of sampling variability, and the results are pooled together to provide the distribution in 
which the outcomes of interest are likely to lie (see Figure 3-1). The number of 
simulation runs is typically decided by the number required until the distribution of the 
outcomes does not change any further.  
Figure 3-1: Overview of mechanism of stochastic simulation models [712] 
 
Stochastic simulation models of the progression of HIV can be sufficiently detailed to 
model the use of each individual antiretroviral drug separately (rather than just model 
 
Figure not available due to copyright restrictions 
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whether an individual is on treatment or not). This has therefore allowed for research 
into specific side effects and the acquisition or emergence of specific resistant mutations, 
for example[713]. In the following subsections, I briefly introduce three such models 
which have been extensively described and published, by describing some key features 
and referencing examples of research questions that the models have been used to 
answer.  
3.4.1 Braithwaite et al. model 
Braithwaite et al. have developed a simulation model of the progression and treatment 
of HIV, in which a cohort consisting of 10,000 newly-diagnosed treatment-naïve patients 
is simulated from initiation of treatment and followed until death[714]. The model was 
originally programmed using Decision Maker for Windows (now the authors use C++). 
Although patient characteristics were initially equivalent with respect to a number of 
baseline variables, each patient enter the model one at a time and follow a different 
clinical trajectory depending on their particular patient- and time-specific characteristics. 
Figure 3-2 shows the influence diagram summarising the main concepts in the model. 
Events in the model are updated monthly. Parameter values in the model were 
estimated using data from the Veterans Aging Cohort Study based in the US.  
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Figure 3-2: Diagram of key concepts in the Braithwaite et al. model [714]   
 
The authors originally developed this model in order to be able to predict the duration of 
effectiveness of ART and also to estimate the proportion of HIV-positive patients who 
will die from causes directly attributed to HIV[714]. In this study, model outcomes were 
calibrated with data from the CHORUS cohort and validated with data from the ART-
Cohort Collaboration (ART-CC). The model has also been used to assess the long-term 
relationship between adherence and resistance mutation accumulation[715], as well as 
to estimate and evaluate the impact of alcohol consumption on life expectancy[716].  
3.4.2 CEPAC model 
The CEPAC (Cost-Effectiveness of Preventing AIDS Complications) model has been 
used extensively to evaluate various clinical outcomes, costs and cost-effectiveness of 
HIV treatment strategies[717, 718]. It is a state-transition (compartmental) Monte Carlo 
simulation model programmed in C. The basic health states are shown in Figure 3-3. 
Similarly to the Braithwaite model, events are updated in monthly intervals. Clinical 
events (such as occurrence of opportunistic infections, adverse events and death) and 
health-state transitions (such as changes in CD4 count or viral load levels) are 
determined by probabilities which are estimated from clinical trials and observational 
 
Figure not available due to copyright restrictions 
144 
 
data. The model has been revised frequently as new data has become available, both in 
relation to the disease itself and the increasing range of new treatment options.  
Figure 3-3: Basic health states in the CEPAC model [718]  
 
CEPAC:Cost-Effectiveness of Preventing AIDS Complications 
 
The CEPAC model was first developed with a focus on the epidemic in the USA, where 
characteristics of the simulated individuals were based on data from the ACTG 320 
study. The researchers initially showed that HIV treatment consisting of a triple therapy 
regimen was a cost-effective use of resources[717]. The model has subsequently been 
used to project the lifetime cost of medical care for HIV-positive adults using current 
ART standards and to estimate the long-term effectiveness and cost-effectiveness of 
using generic ART in the US[719, 720]. It has also been modified to enable analyses in 
LMIC and can provide information about testing and treatment strategies for AIDS-
related complications such as tuberculosis[721, 722].  
3.4.3 HIV Synthesis model 
The HIV Synthesis model was originally developed by Phillips and colleagues to 
reconstruct the HIV-positive population in the UK[723]. Similarly to the above two 
models, it incorporates our understanding of the underlying processes of HIV disease 
progression and the effect of ART, based on data from clinical trials and epidemiological 
 
Figure not available due to copyright restrictions 
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data. Individuals in the model are simulated from the time of infection and followed for a 
specific time period, or until emigration or death. Variables are updated every three 
months. The model is programmed in SAS software (SAS Institute Inc., Cary, NC, USA). 
Further details are described in Section 3.6. The model has been used to investigate the 
proportion of people who will experience triple class virologic failure in the UK and to 
estimate the projected life expectancy of MSM in the UK (see Chapter 4)[724, 725]. An 
adaptation of the model to LMIC was used to assess the differences in outcomes from 
CD4 cell count monitoring, viral load monitoring and clinical observation alone[726]. The 
model has also been further developed to incorporate transmission (both MSM and 
heterosexual) to assess the effectiveness and cost-effectiveness of interventions which 
affect the incidence of HIV[727-729]. As of September 2010, the HIV Synthesis model 
was on its 5
th
 version (hereafter referred to as ‘Synthesis V5’). Synthesis V5 is the model 
I started with and developed further (Chapter 5) to answer the research questions posed 
in my thesis.  
3.5 SSOPHIE project 
3.5.1 EuroCoord 
EuroCoord is a Network of Excellence of four major European cohorts and 
collaborations: PENTA, CASCADE, EuroSIDA and COHERE[730]. Collectively, these 
cohorts and cohort collaborations have data on approximately 270,000 HIV-positive 
individuals. In addition to these four cohorts and collaborations, there are three work 
packages of research within EuroCoord, which are TB (WP13), migrants (WP14) and 
modelling (WP15).   
3.5.2 Background and objectives of the modelling work package within 
EuroCoord 
Quantifying and characterising the HIV-positive population living in Europe (for example 
by diagnosis, treatment and disease status), is achieved by producing estimates with 
suitable plausibility ranges (the range in which the estimate is likely to lie within, 
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reflecting the uncertainty of the estimate). UNAIDS has been publishing HIV estimates 
regularly for over a decade and efforts like theirs have enabled us to build a global 
picture of the HIV epidemic and have led to improvements in surveillance systems to 
capture more data, which is necessary to produce these estimates themselves[484].  
However, we would be able to provide a much more detailed overview of the concerned 
population by characterising it further and producing estimates that describe not only the 
number of people living with diagnosed/undiagnosed HIV, but also a breakdown of other 
important aspects of the status of those with HIV. These aspects could include the CD4 
count, viral load, proportion in need of treatment and proportion of people on treatment 
who have drug resistance. This is the overall aim of the modelling work package within 
EuroCoord, which is also known as the SSOPHIE (Stochastic Simulation of Outcomes 
of People with HIV In Europe) project. More specifically, the SSOPHIE project’s 
objectives are to: 
• To build a stochastic simulation model of HIV infection and the effect of ART that 
can be used to reconstruct and project the status of HIV infected individuals in a 
given country 
• To fit the model to national-level surveillance and other data from European 
countries 
• To estimate the status of HIV infected populations across Europe, in terms of 
diagnosis, treatment usage, resistance, pregnancy, and rates of AIDS and death 
The contents of this thesis aim to satisfy the aims and objectives of the SSOPHIE 
project. The focus of my thesis is on the adult epidemic and I do not consider modelling 
of progression or effect of ART in children.  
A full list of the members of the SSOPHIE project working group and EuroCoord are 
given in Appendix V.  
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3.6 HIV Synthesis V5 model 
In the first SSOPHIE project working group meeting (held 31
st
 March 2011 in London, 
UK), the group agreed to use Synthesis V5 as a starting point for the SSOPHIE project, 
after reviewing other available mathematical models of HIV progression and treatment. 
Here I describe the model features of Synthesis V5 at that time, prior to the updates 
which were made following a complete re-evaluation of every parameter value and (sub-
structures) within the model. The updates which were made are presented in Chapter 5, 
along with the statistical analyses and literature reviews conducted to inform the updates.   
As mentioned in Section 3.4.3 above, Synthesis V5 is an individual-based stochastic 
simulation model of HIV progression and the effect of ART. Examples of variables which 
are simulated at the time of infection include calendar date, age, CD4 count, viral load 
and presence of transmitted resistance mutations. The use of specific antiretroviral 
drugs, adherence, accumulation of resistance mutations and clinical events are also 
modelled in order to incorporate the effect of ART. The version of the model used in this 
thesis only simulates from HIV infection onwards. In other words, transmission of HIV is 
not modelled, and so calendar date of infection is a simulated variable. This also implies 
that all simulated individuals in the model population are HIV-positive throughout. The 
model simulates and keeps track of all key aspects associated with HIV infection and 
the effect of ART for each person. An example dataset for one simulated individual is 
shown in Table 3-3. The table shows values simulated for a number of key variables per 
time point, which is updated three-monthly.  
 
148 
 
Table 3-3: Example dataset for one individual, showing a select number of 
variables simulated using Synthesis V5 
Variables in the model Years from HIV infection 
0 0.25 0.5 0.75 1 1.25 
Calendar year 1980 1980.25 1980.5 1980.75 1981 1981.25 
Age (years) 31.5 31.75 32.0 32.25 32.5 32.75 
CD4 count (cells/mm3) 674 578 602 595 543 569 
Viral load (log copies/ml) 4.2 4.3 4.2 4.4 4.5 4.5 
Diagnosed* 0 0 0 1 1 1 
On ART* 0 0 0 0 0 0 
On TDF* 0 0 0 0 0 0 
Previous TDF* 0 0 0 0 0 0 
Failed TDF* 0 0 0 0 0 0 
K65R mutation* 0 0 0 0 0 0 
Adherence . . . . . . 
ART:antiretroviral therapy; TDF:tenofovir.  
*Variables in these rows are modelled as binary variables: yes (1) and no (0). 
 
The HIV Synthesis model was originally developed to mimic the characteristics of the 
UK HIV epidemic. Although parameter values to describe the progression of disease 
and effect of ART were calibrated to data from large multinational cohort collaborations, 
much of the data to inform HIV care practices and demographics were based on the 
epidemic in the UK[723]. The large majority were assumed to be infected, diagnosed 
and followed in the UK. As reviewed in Chapter 2 however, the HIV-positive population 
in the UK includes a large number who acquire their infection in countries with 
generalised HIV epidemics. So in order to replicate this, a group of people were 
simulated to be living outside the UK at the time of infection, of whom some migrate to 
the UK. This is to ensure that the AIDS incubation period also applies to this group of 
people. However, it is assumed that those who develop AIDS outside the UK will not 
migrate to the UK, due to being too ill.  
The number of people infected with HIV was inferred using an informal back-calculation 
approach. In other words, these numbers were arrived at by informally ‘fitting’ to 
available longitudinal and cross-sectional data, such as estimates from prevalence 
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surveys of the numbers of people infected (both diagnosed and undiagnosed), number 
of HIV diagnoses, number of first AIDS diagnoses and deaths, and surveillance data on 
the number of people seen for care. This fitting involved choosing parameter values 
such as incidence, diagnosis rate and UK arrival rate (for those infected in SSA), then 
seeing how closely the model simulations agreed with the data and adjusting 
accordingly. This is a time consuming process, and one that cannot be routinely 
implemented across settings, but a set of parameter values giving a good fit was 
eventually obtained (Figure 3-4). 
Figure 3-4: Fit of Synthesis V5 to UK surveillance data (observed) on a) number of  
deaths, b) number of new AIDS diagnoses and c) cumulative number of deaths by 
risk group [723]  
 
The rates of HIV diagnosis, parameterised as the probability of being diagnosed per 
three-month period (given the person is HIV-positive and undiagnosed), have been 
inferred for each transmission risk group, using data on the number of new HIV 
diagnoses by year and the median CD4 count at diagnosis. The diagnosis rate is also 
assumed to vary by HIV disease stage. For example, a person in the MSM risk group 
has a 10% probability of being diagnosed with HIV during primary infection (i.e. during 
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the first three months of infection). Development of any HIV-related symptoms 
(excluding AIDS-defining conditions) leads to a 5-fold increased probability of diagnosis 
compared to base rates and if a person develops AIDS then they are diagnosed with 
HIV at the same time. People who have a general tendency to be non-adherent (both to 
care and to ART if and when they start treatment) have a 2-fold reduced rate of 
diagnosis compared to base rates[724, 725].  
In the following sections, I describe Synthesis V5, which is the version of the model as it 
stood before I started my thesis. Although the model is coded and run in a single 
program, I have divided the descriptions into four distinct sections: 
 Part 1: Natural history (Section 3.6.1) 
 Part 2: Effect of ART (Section 3.6.2) 
 Part 3: Resistance (Section 3.6.3) 
 Part 4: Miscellaneous (includes treatment interruptions, loss to follow-up and 
side effects) (Section 3.6.4) 
3.6.1 Part 1: Natural History 
The main parameters which are modelled to describe the natural history are listed in 
Table 3-4 and a simplified influence diagram is shown in Figure 3-5. There are a number 
of fixed parameters at the time of infection, although for simplicity it is assume that 
seroconversion has already taken place and that both the viral load and CD4 count have 
reached their settled state at the first time point (i.e. t=1). This means that the dynamics 
of these two markers which occur during primary infection are not modelled. The initial 
log viral load, i.e. the viral load ‘set point’, is assumed to follow a Normal distribution with 
mean 4 and variance 0.5
2
, hereafter denoted Normal(4,0.5
2
). The maximum viral load 
set point is defined to be 6.5 log copies/ml, and so individuals whose simulated initial 
viral loads exceed this value are assumed to have a value of 6.5 log copies/ml. The 
initial CD4 count is modelled on the square root scale and is determined as, 
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√CD4 count  = 32 − (2 × viral load set point)  + Normal(0, 22). 
The minimum and maximum initial CD4 count is defined to be 324 and 1500 cells/mm
3
 
respectively. These initial values were determined from a number of studies of the 
natural history of HIV, however they do not incorporate previously observed differences 
by gender, age and race[85, 95, 108, 109, 731].  
Table 3-4: Key variables modelled to describe the natural history in Synthesis V5 
Variables simulated at time of infection Variables updated three-monthly 
Calendar date of infection Calendar date 
Age at infection Current age 
Sex  
Route of HIV infection / risk group  
Initial CD4 count Change in CD4 count from (t-1) to t 
Viral load set point Change in viral load from (t-1) to t 
Presence of TDR (separately by mutation, 
e.g. M184V) 
 
Smoking status  
Presence of chronic HBV/HCV co-infection  
 Probability of AIDS 
 Probability of HIV-related symptoms 
 Probability of HIV-related deaths 
HBV:hepatitis B virus; HCV:hepatitis C virus; TDR:transmitted drug resistance. 
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Figure 3-5: Simplified Synthesis V5 model diagram to describe HIV progression in 
the absence of treatment 
 
PCP:Pneumocystis carnii pneumonia 
 
The change in viral load from time t-1 to t (i.e. in a three-month period) is dependent on 
the underlying viral load at t-1. Values are given in Appendix VI but in brief, the higher 
the viral load at t-1, the greater the mean viral load change. The maximum viral load is 
defined to be 6.5 log copies/ml. The measured viral load is given by the underlying viral 
load (the true value) plus error (sampled from Normal(0,0.25
2
) on the log copies/ml 
scale). The change in CD4 count from time t-1 to t is dependent on the underlying viral 
load at t-1. Values are given in Appendix VI but in brief, the higher the viral load at t-1, 
the steeper the CD4 count decline. The change in CD4 count is also dependent on age 
(greater decline with older age) as well as presence of X4-tropic virus. The measured 
CD4 count is given by the underlying CD4 count plus error (sampled from Normal(0,2
2
) 
on the square root cells/mm
3
 scale). The parameter values and formulae chosen to 
determine the changes in viral load and CD4 count from t-1 to t, were derived based on 
the synthesis of evidence from natural history studies and selected in conjunction with 
other relevant parameter values to provide a good fit to observed natural history data on 
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the time from infection to AIDS, death, and CD4 count <200, <350 and <500 
cells/mm
3
[85, 86, 95, 100, 101, 108, 109, 113, 731, 732]. 
The initial virus is assumed to be R5-tropic, but there is a probability of 10
v
 x 0.0000004 
in a three-month period of shifting to X4-tropic virus, where v is the most recent log viral 
load. This probability means a shift at the rate of 5% and 16% per year in persons with 
viral load 30,000 copies/ml and 100,000 copies/ml respectively, which are broadly 
consistent with observed data[23]. 
The rate of occurrence of AIDS, HIV-related symptoms (excluding AIDS-defining 
conditions) and death is inversely correlated with the most recent CD4 count. Values are 
given in Appendix VI. The occurrence of HIV-related symptoms is modelled to be 8-fold 
higher than the rate for AIDS. The rate of HIV-related death is modelled to be 4-fold 
lower than the rate for AIDS. These factors were chosen to provide results consistent 
with observed data on the incubation period to death and the time from AIDS to 
death[124, 128, 733]. For all HIV-related causes of deaths, there are additional factors 
which affect the rate of death modelled. These are viral load, age, whether on PCP 
prophylaxis and whether on ART (and if so, how many drugs are in the current 
regimen)[116, 119, 734-736]. Age and gender specific national mortality statistics are 
used to determine rates of deaths from non-HIV-related causes. There is also an 
increased risk of death (1.5-fold) modelled for all individuals in the model compared to 
the general population, based on increasing evidence that HIV-positive people may 
have a raised risk of common clinical conditions such as non-AIDS cancers, renal, liver 
and cardiovascular disease[737-744]. Other parameters that are associated with a 
raised clinical risk of death in the model are smoking (associated with 2-fold increase in 
all-cause mortality), transmission by injection drug-use and transmission by causes 
other than sexual transmission, injection drug-use or MTCT (i.e. haemophilia or 
transfusion)[745-748].  
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After 1990, PCP prophylaxis is used with a 60% probability in a given 3-month period in 
people with CD4 count <200 cells/mm
3 
who are diagnosed and in care. Viral subtype is 
not explicitly modelled in Synthesis V5, because it is thought that there is not a 
significant subtype effect on the natural history. The model is fitted to data mainly from 
Europe where the main subtype in circulation is subtype B.  
3.6.2 Part 2: Effect of ART 
The main parameters used to model the effect of ART are summarised in Table 3-5 and 
a simplified influence diagram of the key factors modelled within Synthesis V5 in the 
presence of ART is shown in Figure 3-6. 
Table 3-5: Key variables modelled to describe the effect of ART in Synthesis V5 
Variables simulated at time of infection Variables updated three-monthly 
Underlying tendency to adhere Use of individual antiretroviral drugs 
Underlying propensity for CD4 count rise 
whilst on ART 
Number of active drugs in regimen 
Maximum potentially attainable CD4 count Change in CD4 count from (t-1) to t 
 Change in viral load from (t-1) to t 
ART:antiretroviral therapy 
 
 
Individual antiretroviral drugs are modelled (23 in total) in Synthesis V5. These include 
eight NRTIs (AZT, d4T, ddI, ddC, 3TC, FTC, ABC and TDF), three NNRTIs (NVP, EFV 
and ETR), nine PIs (SQV/r, RTV/r, IDV/r, NFV/r, LPV/r, FPV/r, ATV/r, TPV/r and DRV/r), 
and three drugs from the new classes (ENF, MVC and RAL). SQV and IDV are 
assumed RTV-boosted only after 2001, FPV after 2003 and LPV, ATV, TPV and DRV 
are assumed RTV-boosted from introduction. The choice of regimens reflects those that 
were used in the treatment period that the patient is in. 
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Figure 3-6: Simplified model diagram to describe HIV progression in the presence 
of ART 
ART:antiretroviral therapy; PCP:Pneumocystis carnii pneumonia 
Italic font indicates additional variables (in comparison to a situation without ART) modelled 
to incorporate the effect of ART. 
 
The effects of ART on the individual, in terms of viral load and CD4 count changes in 
any three-month time period depends on the current number of active drugs in the 
regimen, viral load and adherence. Specific values (Appendix VII) for the change in viral 
load and CD4 count whilst an individual is on ART, were chosen to provide estimates 
consistent with observed long-term virologic failure rates and CD4 count rises[228, 288, 
749-752]. Each person is assumed to have a different underlying propensity for CD4 
count rise whilst on ART. This is modelled by including a parameter (distributed log 
normally with mean ln1 and variance 0.5
2
, hereafter denoted lnNormal(ln1,0.5
2
)), which 
is multiplied by the calculated CD4 count change to introduce further stochasticity into 
the model. The underlying propensity for CD4 count rise reduces 4-fold after two years 
on any given regimen to reflect the fact that the rate of CD4 count rise also declines over 
time[163, 753]. The maximum CD4 count potentially attainable for each individual whilst 
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on ART is sampled from Normal(800,150
2
) and is based on observed CD4 counts in 
HIV-negative people[75, 76].   
An individual’s overall adherence to ART is modelled using the concept of ‘effective 
adherence’, which reflects the predicted adequacy of drug levels. Values of variables 
(Appendix VII) to model adherence are based partially on direct estimates from the 
literature[262, 308, 754-757] but, due to the reporting bias associated with adherence, 
are also chosen such that they lead to modelled rates of virologic failure, resistance 
development, and presence of resistance mutations at virologic failure, that are 
consistent with those observed in studies[287, 758, 759]. The effective adherence for 
each individual depends on a number of components: 
 the person’s underlying tendency to adhere (categorised as very high, high, 
moderate and low) 
 within-person period-to-period variability in adherence 
 calendar year[287, 759] (adherence is assumed to have improved over time) 
 whether current CD4 count <200 cells/mm
3
 and with prior or current experience 
of triple-class failure (adherence is increased for these time periods based on 
the assumption of increased motivation to adhere to ART),  
 receipt of NNRTI-based regimen[321] (increased effective adherence due to 
longer half-life of NNRTIs).  
Additionally in some individuals on ART, an occasional severe drop in adherence is 
modelled, to explain virologic failures which occur in the absence of resistance, which 
are more common on PI-based regimens[760-762]. 
A regimen switch is defined as a change in drug regimen to a new line of therapy. 
Regimen switching is modelled such that firstly it is decided whether the person should 
switch and then subsequently considering which antiretrovirals to switch to. The 
probability of switching depends on whether the switch is being considered because of 
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improvements in regimen over time (from mono-therapy to dual-therapy and from dual-
therapy to cART), or because the patient has experienced virological failure. After 
virologic failure of a first-line cART regimen, patients are switched to a second-line cART 
regimen. Similarly, after virologic failure of a second-line cART regimen, they are then 
are switched to a third-line cART regimen. Switching after the initial third-line cART 
regimen is possible but only after 2003, where this decision is based on the resistance 
profile of the individual. The probability of switching due to virologic failure of a regimen 
depends mainly on the calendar year (more likely with recent years) and measured viral 
load (more likely with higher viral load), but also depends on the measured CD4 count 
(less likely if CD4 count >200 cells/mm
3
) and regimen type (more likely if on NNRTI-
based regimen)[279, 280, 763].  
A drug substitution is defined as the replacement of one or more drugs due to side 
effects (see more in Section 3.6.4). If a person develops a side effect to a drug then the 
probability it is substituted depends on what side effects are present. The choice of 
drugs to substitute tries to capture clinical decisions taken at the time. If a drug has been 
switched due to side effects then this drug will not be re-used in the future.   
3.6.3 Part 3: Resistance 
The main parameters which are used to model resistance and the resistance mutations 
which are considered in Synthesis V5 are listed in Table 3-6 and Table 3-7 respectively. 
The mutations chosen are based on those considered to be major mutations as defined 
in the IAS-USA mutations list (December 2010 update)[764]. 
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Table 3-6: Key variables modelled to describe resistance in Synthesis V5 
Variables simulated at time of infection Variables updated three-monthly 
Presence of TDR, separately by mutation Presence of resistance mutations in 
majority virus, separately by mutation 
 Presence of resistance mutations (virus 
with mutation is present at all), separately 
by mutation 
 Probability of development of ≥1 
resistance mutation given current regimen 
(‘new mutation risk’) 
 Level of resistance to an antiretroviral drug 
(1-genotypic sensitivity)  
 Number of active drugs in regimen (GSS) 
GSS:genotypic sensitivity score; TDR:transmitted drug resistance. 
 
 
The choice of the number of mutations to model represents a compromise between 
making the model sufficiently realistic whilst retaining a parsimonious model. Further, as 
seen from Table 3-7, the mutated amino acid at each position is not specified. Therefore, 
it is assumed that the mutations considered are those that confer resistance (e.g. for 
M184 a mutation to I or V is assumed to have occurred). The exceptions to this are the 
mutations at codon 50 on the protease gene, where changes in amino acid to V and L 
are modelled separately. Resistance mutations can be present in majority or minority 
virus and this is also captured in the model. The only exception is for the M184 mutation, 
which is assumed not to persist as a majority virus after HIV infection, although like all 
other mutations, it does persist as a minority virus. 
Resistance mutations acquired at infection are also explicitly modelled. These are 
sampled randomly based on prevalence data from the UK on resistance in newly 
diagnosed people and are calendar-year specific (Appendix VIII). 
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Table 3-7: Resistance mutations modelled in Synthesis V5 
Class  
of drug 
Mutation Notes 
NRTI M184  
 TAMS TAMS are modelled such that it is the number of TAMS 
which affect the drug activity, rather than the specific 
mutations itself 
 K65  
 L74  
 Q151  
 NUCx A specific resistance mutation to an NRTI yet to be 
identified 
NNRTI Nn A specific resistance mutation (or mutations) which 
confers resistance to first generation NNRTI (NVP and 
EFV)  
 NNx A specific resistance mutation to an NNRTI yet to be 
identified  
PI D30  
 V32  
 L33  
 M46  
 I47  
 GR48  
 I50V  
 I50L  
 I54  
 L76  
 V82  
 I84  
 N88  
 L90  
CCR5  
inhibitor 
CCR5m A specific resistance mutation to a CCR5 inhibitor yet to 
be identified (this is separate from presence of X4 virus, 
which is modelled separately) 
INI IIm A specific resistance mutation to an INI yet to be identified 
Fusion  
Inhibitor 
FIm A specific resistance mutation to a fusion inhibitor yet to 
be identified 
EFV:efavirenz; INI:integrase inhibitor; NRTI:nucleoside reverse transcriptase inhibitor; 
NNRTI:non-nucleoside reverse transcriptase inhibitor; NVP:nevirapine; PI:protease inhibitor; 
TAMS:thymidine analogue mutations. 
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The risk of resistance emergence in any three-month time period is modelled using a 
conceptualised factor, ‘new mutation risk’ in Synthesis V5. This risk is defined as the 
probability of development of one or more resistance mutations, given the current 
regimen. The risk of resistance emergence depends on the current number of active 
drugs in the regimen, viral load, adherence and current length of time on continuous 
ART. Specific values for the risk of resistance emergence were chosen to provide 
estimates consistent with observed development of resistance mutations and long-term 
virologic failure rates[228, 287, 288, 750-752]. More details are given in Appendices VII 
and VIII.  
Presence of resistance mutations leads to a reduction in the number of active drugs in a 
regimen. Resistance to a particular antiretroviral drug is determined on a scale of 0 (no 
resistance) to 1 (complete resistance) in 0.25 increments. The total resistance a 
patient’s virus may have to an ART regimen is calculated by summing these scores over 
all antiretroviral drugs in their current regimen. The activity level of a drug is given by (1 
– level of resistance to the drug). The total number of drugs taken by the patient minus 
the total resistance is effectively a GSS[339].  
Loss of resistance mutations after stopping a regimen and starting another non-cross-
resistant regimen are modelled such that mutations can be lost in majority virus but are 
considered to remain permanently in minority virus (as described in Table 3-6). Thus, 
mutations are regained in majority virus once a drug (which the person has resistant 
virus to in their minority virus) is restarted. The probabilities of losing a mutation in 
majority virus are based on studies from people interrupting ART[765-770].  
3.6.4 Part 4: Miscellaneous 
The additional main parameters which are modelled for each individual in Synthesis V5 
are listed in Table 3-8.  
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Table 3-8: Key variables modelled to describe all other patient characteristics and 
disease trajectories in Synthesis V5 
Variables updated three-monthly 
Probability of interrupting ART 
Length of treatment interruption 
Probability of restarting ART after interruption 
Probability of being lost to follow-up at the time of interruption 
Probability of being lost to follow-up at any point whilst individual is off ART 
Probability of returning to clinic after loss to follow-up 
Probability of a single missed clinic visit 
Presence of ART-related side effects 
ART:antiretroviral therapy 
 
The probability of interruption to ART in any given three-month period depends on the 
patient’s most recent viral load, their underlying tendency to adhere, presence of any 
side effects and most recent CD4 count[174, 279, 771-773]. These factors are modelled 
such that the probability of interruption is greater with higher viral load, lower underlying 
tendency to adhere, presence of one or more side effects and higher CD4 counts. 
Calendar year also affects the probability of interruption: it is 5-fold more likely in the 
AZT mono-therapy era (before 1993) and 10-fold more likely after the negative results of 
the Concorde trial (1993 to October 1995)[174, 773]. There is a 30% probability that the 
clinician is not aware of treatment interruption; this occurrence has been modelled so 
that if such an event occurs and the viral load increases to detectable levels, this will be 
interpreted as virologic failure.  
During treatment interruption, CD4 count decline depends on the length of interruption 
(steeper initial decline followed by more gradual subsequent decrease) and also on 
current viral load (steeper decline with higher viral load)[771, 774-777]. Once the CD4 
count nadir is reached, the rate of CD4 count decline is then modelled in the same way 
as if the individual had never received ART (i.e. using the same probabilities as for 
natural history changes). Viral load levels return to the maximum viral load achieved 
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before the time of interruption (in one three-month period) and adopt natural history 
changes thereafter[774, 776, 778]. 
The probability of restarting ART after a period of treatment interruption depends on the 
current calendar year (later periods more likely to restart) and the most recent CD4 
count (lower CD4 counts more likely to restart)[770, 779]. Individuals who develop an 
AIDS defining condition restart treatment immediately.  
The probability of being lost to follow-up at the time of interruption depends on the 
person’s underlying tendency to adhere (lower with higher adherence). There is also a 
5% probability modelled of being lost to follow-up in any three-month period whilst the 
patient is off ART (includes both ART-naïve individuals and those already interrupting). 
This rises to 15% if the person’s previous measured CD4 count was >500 cells/mm3[780, 
781].  
The probability of returning to clinic after loss to follow-up, depends on the person’s 
underlying tendency to adhere (higher with higher adherence). Individuals who develop 
an HIV-related symptom are 5-fold more likely to return, but those who develop an 
AIDS-defining condition are assumed to return to care with 100% probability[782]. If the 
patient is on ART, there is also a probability of a single missed clinic visit, despite 
remaining on ART. The probability of this occurring also depends on the person’s 
underlying tendency to adhere (lower with lower adherence).  
Side effects can occur with certain probability, at a given time t, when the individual is on 
a certain drug which causes it. Table 3-9 lists all side effects modelled in Synthesis V5. 
These side effects are modelled as binary variables: either the side effect is absent or 
present in a given three-month period. All individuals have no side effects at the time of 
infection. Side effects are only present for those receiving ART (e.g. if on a RTV-
containing regimen, there is a 50% chance that they will get nausea in any three-month 
period).  
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Table 3-9: Side effects modelled in Synthesis V5 
Nausea 
Diarrhoea 
Rash 
CNS toxicity 
Lipodystrophy 
Hypersensitivity reaction 
Peripheral neuropathy 
Hepatotoxicity 
Nephrolithiasis 
Anaemia 
Headache 
Pancreatitis 
Lactic acidosis 
Renal dysfunction 
General side effect, with unknown profile 
 
Once someone develops a side effect, there is then another set of probabilities which 
determines whether they retain it in the next three-month period. The exceptions are for 
lipodystrophy, renal dysfunction and peripheral neuropathy, which are modelled as 
lifelong conditions (though peripheral neuropathy is only present whilst on ddI).  
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Chapter 4 Estimates of projected life 
expectancy 
The aim of this chapter is to estimate the current life expectancy of HIV-positive people. 
I first define what life expectancy is and outline the main methods of calculation. I then 
review estimates of life expectancy in people living with HIV, which has changed greatly 
over time, especially with the introduction of cART. Finally, I use Synthesis V5 to 
estimate the projected life expectancy of HIV-positive people infected in 2010 and also 
to assess the possible impact of delays in diagnosis. This Chapter also provides a good 
means of showing how the HIV Synthesis model works, in addition to producing useful 
estimates to inform people with HIV, clinicians and public health practitioners. 
4.1 Introduction 
Life expectancy is commonly perceived as a useful indicator of population health and 
mortality, since it answers one of the most important questions in public health – how 
long can a person expect to live? The concept of life expectancy is also easier to 
understand and interpret than other indicators, such as the mortality rate. In this Chapter, 
I use the term ‘life expectancy’ to refer to the expected age at death, as opposed to the 
additional years expected to live at a given age. 
As mentioned in Chapter 2, the number of people living with HIV in the world has never 
been higher. This reflects both an increase in the number of new infections, but also the 
rise in access to ART which has dramatically reduced mortality and morbidity[65, 133, 
134, 747, 783-785]. Consequently, life expectancy has substantially improved to the 
extent that HIV is now considered a chronic illness where a near-normal lifespan is 
achievable with successful care and treatment[786]. However, there are still many 
people who present for care at an advanced stage of HIV disease and late diagnosis 
has been associated with increased mortality[787]. 
166 
 
Life expectancy of those living with HIV is of interest because it is an important measure 
of current health on the population level, but it will also have significant implications on 
an individual-level, such as access to and cost of health insurance, life insurance[788] 
and more generally for lifetime planning. Estimating life expectancy not only allows us to 
quantify the improvements which have been made in the prognosis of HIV, but it also 
allows us to develop an understanding of the benefits of early HIV testing when 
considered together with the impact of timing of diagnosis. 
4.2 Methods to calculate life expectancy 
The most accurate method to estimate average life expectancy would be to follow a 
large cohort for a very long time, such that 50% of deaths are observed. Although this 
approach would directly provide the median life expectancy, it is firstly infeasible, and 
secondly by the time such data were available, any estimates would be outdated and 
therefore perhaps not applicable to those infected or diagnosed with HIV today. 
More practical methods to estimate life expectancy can be broadly categorised into one 
of two approaches. One approach uses life tables and the other uses mathematical 
models. Both approaches rely on data from cohort studies to either construct life tables 
or to inform the models.  
4.2.1 Life tables 
Life tables summarise the mortality and survival patterns in populations[446]. Period life 
tables are constructed from the mortality experiences of a cohort over a short period of 
time (at least a year) assuming the cohort is subject to age-specific death rates in any 
given year. Life tables can be complete (unabridged) or abridged, depending on whether 
death rates were discrete at each year of age, or grouped for similar ages (e.g. five-year 
groups), respectively. The life expectancy of an individual of a certain age is then 
calculated using projections of these age and sex-specific death rates assuming they 
apply throughout an individual's lifespan[789].  
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4.2.2 Mathematical models 
An alternative method is to use mathematical models to estimate life expectancy. 
Mathematical models can simulate ‘what-if’ scenarios and therefore offer the flexibility to 
model a wide range of populations and interventions. One significant advantage of using 
mathematical models is the ability to account for the long-term durability of ART. This is 
important as the positive effects of ART, including rises in CD4 counts and the ability to 
induce and maintain viral suppression, take many years to be established[749, 790, 791]. 
Drugs and drug regimens have also improved considerably over time. If the full effects 
of ART on death rates are not taken into account, then estimates of life expectancy may 
be underestimated. 
4.2.3 Limitations 
The main limitation with both approaches is the assumption that current age-specific 
death rates will apply throughout an individual’s entire lifespan in order to project the life 
expectancy. This is especially the case when using the life table approach, as 
alternative assumptions are technically possible to incorporate into mathematical models, 
although not commonly done. This assumption means that potential improvements in 
mortality rates over time, which have been observed in both the HIV-positive population 
and the general population[792-794] are not taken into account. This may lead to 
underestimations of life expectancy.  
Another limitation is the under-ascertainment of death in people with HIV, which would 
lead to an overestimation of life expectancy. Deaths may be under-ascertained because 
either a patient never seeks care and is thus never registered as being HIV-positive, or a 
patient may die outside of clinic settings and their deaths are not captured by the 
relevant surveillance systems due to incomplete linkage to death registries. Furthermore, 
the extent of the HIV epidemic so far only extends to 40 years at most, so there is a lack 
of mortality data in older age groups, where the majority of the deaths occur in the 
comparator background population. 
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Additional care needs to be taken when results from the life table method are interpreted 
because unlike regression analyses, life tables are not adjusted for covariates. Sub-
group specific analyses can be used in principle if mortality data is available by those 
sub-groups.  
On the other hand, it is important to note that mathematical models make many 
assumptions about the natural course of HIV progression as well as the effects of ART. 
Such assumptions therefore need to be thoroughly understood in order to interpret 
results from a modelling approach appropriately. Additionally in the case of estimating 
life expectancy, uncertainty is introduced by simulating very long periods of time (the 
longer the timeframe, the greater the uncertainty), which requires making assumptions 
regarding whether current trends are likely to continue into the future.  
4.3 Estimates of life expectancy in the literature 
4.3.1 Before treatment for HIV was available (1980-1987) 
During the 1980s when effective treatment for HIV had not yet been developed, survival 
of people infected with HIV was very poor and the natural history of HIV was not well 
understood[795]. Estimates of the time from infection to AIDS and death during this era 
had considerable variability due to inaccurate dates of seroconversion, in addition to the 
natural between-person variation. For sexually active adults, the mean time from 
seroconversion to AIDS was estimated to be between seven and ten years[796, 797]. 
The mean survival time following an AIDS diagnosis was estimated to be in the range of 
nine and 13 months[795]. A study conducted after this period in a seroconverter cohort 
estimated that without HIV treatment, the median incubation time from seroconversion to 
AIDS and death was nine and ten years respectively, but the authors also found that it 
varied substantially by age at seroconversion[113].  
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4.3.2 Once ART became available (1988-2010) 
Even after antiretroviral drugs became available, HIV infection remained one of the top 
ten causes of deaths worldwide in 1997 due to the ineffectiveness of treatment at this 
time (i.e. before the introduction of cART) and the exclusive availability in HIC[798]. In 
LMIC, ART was practically unavailable for most people until the late 1990s or even the 
early 2000s and so HIV was responsible for a large proportion of adult deaths. In 
Uganda for example, life expectancy is estimated to have declined from 58.6 to 42.5 
years as a result of the HIV epidemic[799]. South Africa similarly also saw a decline in 
life expectancy at age 15 from 67.4 years in 1990 to 58.7 years in 2009[800].  
However, the introduction of effective ART in HIC quickly resulted in reduced mortality 
and corresponding increased life expectancy from 1997 onwards. Figure 4-1 shows the 
changes in the cumulative probability of survival for the HIV-positive population (by 
calendar time periods) and the general population in Denmark[801]. It shows that 
median life expectancy for a 25 year old HIV-positive person has increased from 
approximately 32 years in 1995-1996 to approximately 63 years in 2000-2005. It is now 
widely accepted that increasingly effective and tolerable treatment regimens have 
contributed to high rates of virologic suppression which have led to the improvements in 
survival[159, 802, 803]. 
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Figure 4-1: Cumulative survival curve for Danish HIV-positive individuals (without 
hepatitis C co-infection) and individuals in the general population [801] 
  
Dashed lines indicate 95% confidence intervals. 
 
Studies since the mid-2000s have demonstrated that the life expectancy of people living 
with HIV has risen substantially over time[719, 786, 801, 804-808]. For example, 
estimates for life expectancy at age 20 from the UK Collaborative HIV Cohort (UK CHIC) 
study has increased from 30.0 years during 1996-9 to 45.8 years during 2006-8[806]. An 
estimate using the CEPAC model predicted that the additional years of life after entry 
into healthcare (at mean age 39) was 24.2 years in 2006[807], compared to 4 years 
estimated in 1997[809]. One of the most optimistic estimates was seen using data from 
the Dutch ATHENA cohort, which found that the median number of years lived from age 
25 was over 50 years[786]. This analysis however, was restricted to a selective group of 
healthy people who were still not eligible for treatment nor had experienced a HIV-
related symptomatic event (except one associated with primary HIV infection) or AIDS 
as of 24 weeks from HIV diagnosis. The estimate may also be biased upwards 
somewhat due to losses to follow-up with consequent under-ascertainment of deaths.  
 
Figure not available due to copyright restrictions 
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4.3.3 Most recent estimates (2011 onwards) 
Several studies have been conducted in the last few years to quantify the anticipated 
further rises in life expectancy in people with HIV[800, 806, 810-818]. All studies 
(findings summarised in Appendix IX) demonstrate that HIV-positive people generally 
have a lower life expectancy than HIV-negative people, although the gap has narrowed 
over time. The extent to which the life expectancy is lower in HIV-positive people differs 
from study to study. However, a number of recent studies now estimate that people on 
suppressive treatment regimens have the same life expectancy as the general 
population under certain assumptions[810, 811, 814]. These estimates are difficult to 
compare directly against one another because the populations, settings and 
assumptions in which the estimates are made can vary considerably.  
Although most of studies on life expectancy have generally been conducted in HIC, 
there have been a number of studies published since 2011 investigating life expectancy 
in LMIC. One study from Uganda found that life expectancy at age 20 was approaching 
the overall rate for all young adults, despite the fact that people in Uganda were treated 
with older ART regimens than those currently used in Western Europe and the US 
(although first- and second-line regimens are now the same or similar)[817]. In Kwazulu-
Natal in South Africa, adult life expectancy since extensive roll-out of ART into the 
community has also increased to 60.5 years, which is an 11.3 year gain from 2003 to 
2011[800].  
4.3.4 Factors affecting life expectancy 
There are a number of factors, other than age, which affect life expectancy in people 
living with HIV, some of which are specific to HIV and some of which are also seen in 
the general population. As seen in HIV-negative populations, females have longer life 
expectancy than males. This was observed in the UK CHIC study (at age 20: 69 in 
women vs. 68 years in men), ATHENA cohort (at age 25: 57.8 vs. 52.7 years) and NA-
ACCORD cohort collaboration (at age 20: 43.9 vs. 42.4 years)[786, 810, 814]. As 
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expected, smoking also has a large impact on life expectancy; one study found that on 
average eight years of life were lost due to smoking, whereas HIV-positive non-smokers 
with suppressed viral load had a similar life expectancy to non-smokers in the general 
population[811]. Other factors which have been found to be associated with lower life 
expectancy among people living with HIV include lower CD4 count at treatment 
initiation[806, 814, 816-819] and presenting late to care[818], but also not being virally 
suppressed[810], non-white race[814], mode of HIV transmission[814] and 
adherence[820].  
4.4 Estimates of projected life expectancy 
4.4.1 Methods 
In the following analyses, I use Synthesis V5 to predict the course of infection of MSM 
who were infected with HIV in 2010 in the UK, assuming that current standards of care 
are maintained. The main outcome of interest is projected life expectancy. I also 
consider the effect of timing of diagnosis of HIV on this outcome. National population 
death rates were used to estimate the risk of non-HIV causes of deaths (data from 2009 
for UK males), so the resulting estimates apply to MSM living in countries with similar 
rates of deaths. 
4.4.1.1 Synthesis V5  
Synthesis V5 was described in Chapter 3, and its fit to various aspects of HIV 
progression and outcomes of treatment have also been previously published[723, 724]. 
As the model is able to incorporate current estimates of virologic response to ART and 
the subsequent long-term rises in CD4 counts, it has good predictive ability of the 
course of infection and effect of treatment over a long period of time. Life expectancy in 
HIV-positive people has already been estimated for the US at 24 additional years of life 
after entry into healthcare, also using an individual-based stochastic model[807]. 
However, there has since been extensive data reported from routine clinic cohorts 
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providing longer-term estimates on rates of viral suppression which can now be 
utilised[287, 289, 303, 724].  
4.4.1.2 Base case scenario 
In this analysis, the base case scenario considered was a 30 year old MSM infected in 
with HIV in the UK 2010 with drug-sensitive virus. Outcomes were then simulated for 
10,000 men for this scenario, who were all followed over 80 years (to 2090) or to death. 
All individuals were assumed to remain under follow-up and in care throughout their 
lifetime. This would then result in a distribution of possible outcomes for such a person. 
Only MSM were considered in this analysis because I thought that other HIV risk groups 
may have a higher prevalence of factors other than HIV infection itself which could be 
associated with lower life expectancy when compared to the general population. 
I assumed that the man in this base case scenario has no hepatitis co-infections. I also 
assumed that there was a 40% chance that the man would be a lifelong smoker, in 
which case they were assumed to have an all-cause mortality risk which was 1.4-fold of 
that found in the general population. Non-smokers were assumed to have a mortality 
risk 0.7-fold of that found in the general population, which would be consistent with a 
previously observed 2-fold increase in all-cause mortality associated with smoking[745].  
There is increasing evidence in the literature which shows that HIV-positive people may 
have a higher risk of common clinical conditions, including renal disease, liver disease, 
cardiovascular diseases and non-AIDS cancers[737-742]. In addition, data from 
observational studies suggest that the risk of death in HIV-positive people with CD4 
count >500 cells/mm
3
 is slightly greater than the general population[743, 744]. Based on 
these findings, I also assumed a 1.5-fold increased risk of all non-AIDS deaths 
throughout life. This is in addition to the risk of non-AIDS deaths already modelled for 
people with HIV, which is related to both CD4 count (lower risk of death with higher 
current CD4 count) and viral load (lower risk of death with lower current viral load), as 
previously explained in Chapter 3.  
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In terms of treatment options, each simulation assumed that the MSM started ART with 
a regimen that included an NRTI-backbone (consisting of two NRTIs such as TDF and 
FTC). Seventy percent of patients were assumed to start on a regimen containing an 
NNRTI, with a boosted PI-based regimen used in the event of virologic failure. Newer 
drugs such as MVC (available only in the absence of X4 virus) and RAL were used only 
if the patient experienced extensive virologic failure or if the NNRTI and PI classes were 
exhausted due to toxicity. The population distribution of adherence whilst on ART, 
modelled such that people were assumed to have a fixed tendency to adhere with 
period-to-period variability, were fit to data on high rates of viral suppression and low 
rates of viral rebound as seen in the UK. Specifically, it was assumed that 5%, 10%, 
65% and 20% of men were assumed to have an average adherence of 0.5, 0.8, 0.9 and 
0.95 respectively (where an adherence of 0.5-0.8 corresponds to the range which the 
risk of resistance development is highest). 
4.4.1.3 Diagnosis rates considered 
Two main rates of HIV diagnosis were considered (Table 4-1). The ‘high’ rate of 
diagnosis was defined as a 4.5% probability of being diagnosed with HIV in any three-
month period. This was chosen such that the modelled median CD4 count at diagnosis 
would resemble what is observed in practice (which for MSM in the UK was 410.5 
cells/mm
3
 in 2009)[821]. The ‘low’ rate of diagnosis was defined so that patients were 
diagnosed only if symptomatic (which includes both pre-AIDS symptoms as well as 
AIDS).  
In addition to the ‘high’ and ‘low’ diagnosis rates, I also considered the effect of having a 
‘very high’ (better than currently observed) and ‘medium’ diagnosis rate (a rate between 
‘low’ and ‘high’) (Table 4-1) In all four diagnosis rate scenarios considered, all men were 
also assumed to have a 10% chance of diagnosis during primary infection (defined as 
the first three months after infection). All men also had a 50% chance of being 
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diagnosed in presence of pre-AIDS symptoms, but are diagnosed as HIV-positive 
immediately with development of AIDS. 
Table 4-1: Rates of HIV diagnosis considered 
Diagnosis rate Event 
Probability of 
diagnosis in a three-
month period  
High - 4.5%* 
Low - 0%* 
Very high - 10%* 
Medium - 2.5%* 
All 
Development of AIDS 100% 
Development of pre-AIDS symptoms 50% 
Primary infection 10% 
*probability refers to an asymptomatic individual 
 
4.4.1.4 Sensitivity analyses 
Several sensitivity analyses were performed to explore the effects on projected life 
expectancy of varying other key assumptions, as well as to comprehensively assess the 
robustness of the estimate. I performed both univariable sensitivity analyses and a 
multivariable uncertainty analysis.  
In the univariable sensitivity analyses, only one variable is changed at a time (from the 
model used to simulate the base case scenario). Variables which I modified include the 
probability of interrupting treatment, proportion of lifelong smokers assumed, the overall 
distribution of underlying adherence in the population, rate of ART initiation following 
diagnosis and risk of AIDS-related deaths at diagnosis.   
In the multivariable uncertainty analysis, a total of 10,000 runs of the model were made, 
each time sampling at random values for a number of different key parameters in order 
to generate the distribution of life expectancy. The probability distributions and thus the 
uncertainty bounds for each parameter were chosen such that even at the boundary 
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values (those close to the 5
th
 and 95
th
 percentile of the parameter distribution), the 
parameter was thought to be plausible. Parameters were chosen on the basis that there 
is some uncertainty regarding the assumed value (Appendix X), i.e. some have only 
limited evidence supporting the choice of value for the parameter and some are purely 
best guess estimates as, to my knowledge, there are no good quality supporting data.  
4.4.2 Results 
4.4.2.1 Base case scenario 
Under the assumption of a high diagnosis rate similar to that observed amongst MSM in 
the UK, the median (interquartile range, IQR) CD4 count at diagnosis was 432 (244-593) 
cells/mm
3
 (Table 4-2). The proportion estimated to present with AIDS at diagnosis was 
5.9%. The median time from infection to diagnosis was 2.8 years. After three, five and 
ten years from the time of infection, 56.8%, 78.1% and 96.9% of MSM were diagnosed 
respectively. This led to a projected median life expectancy (age at death) of 75.0 years 
for the 10,000 simulated MSM infected at age 30 in 2010 (Table 4-3).  
Table 4-2: Characteristics of the 10,000 simulated MSM, according to the assumed 
main rates of diagnosis considered 
 Diagnosis rate 
High Low 
Median (IQR) time from infection to diagnosis, years 2.8 (1.0-4.8) 6.8 (3.5-10.3) 
Median (IQR) CD4 count at time of diagnosis, 
cells/mm3 
432 (244-593) 140 (43-307) 
Median (IQR) viral load at time of diagnosis, log 
copies/ml 
4.4 (3.9-4.8) 4.9 (4.4-5.2) 
Proportion of patients with AIDS before or at HIV 
diagnosis 
0.059 0.420 
Probability of death before or at HIV diagnosis, % 1.3 9.4 
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Table 4-3: Estimated life expectancy (median age at death), according to 
diagnosis rate  
Diagnosis rate Median CD4 count at 
diagnosis, cells/mm3 
Median (IQR) life 
expectancy, 
years 
Median years of 
life lost due to 
HIV infection 
High 432 75.0 (62.5-83.3) 7.0 
Low 140 71.5 (51.8-81.8) 10.5 
Very high 509 75.3 (63.5,83.3) 6.7 
Medium 351 74.5 (61.5-83.3) 7.5 
No HIV infection - 82.0 (72.8-89.3) - 
 
The level of detail in Synthesis V5 allows for calculation of additional information on 
these simulated MSM. The mean time from infection to initiating ART was 5.9 years 
(assuming a rate of starting ART of 0.98 per three months in men with CD4 count <350 
cells/mm
3
). On average, 39.1 years were spent after ART initiation in a lifetime. There 
was an 85% chance of interrupting ART at least once in a lifetime and a mean of 7.1 
years were spent off ART after ART initiation. Men were estimated to be over 80% 
adherent during 96% of the time spent on ART. There was a 97% chance of starting 
ART over a lifetime, a 60% chance of starting a second line regimen and a 32% chance 
of starting a third line regimen. Lines of therapy are based on virologic failure and not 
changes due to toxicity. A mean of 18.8, 7.2 and 6.0 years were spent receiving first, 
second and third line regimens (and beyond) respectively.  
Among the scenarios in which the MSM developed AIDS, 16% did so before or at 
diagnosis, a further 4% after diagnosis but whilst ART-naïve, 40% whilst on ART and 
40% whilst interrupting ART. There was a 41% chance of developing at least one AIDS 
disease before death. However, only 14% of deaths were estimated to be from AIDS-
related causes. Of these AIDS-deaths, only 10% of men had resistance to all three 
original drug classes and integrase inhibitors at the time of death.  
A lower rate of diagnosis, such that diagnosis in the absence of any HIV-related 
symptoms was negligibly low, was also considered. In this scenario, median CD4 count 
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at diagnosis was 140 cells/mm
3
 (Table 4-2), and 42% presented with AIDS at diagnosis. 
The proportion of men diagnosed with HIV after three, five and ten years from time of 
infection were 21.7%, 37.4% and 73.6% respectively. The median time from infection to 
diagnosis was 6.8 years (Table 4-2). Here, the projected life expectancy was 71.5 years. 
This low rate of diagnosis resulted in a higher risk of death by 10 years from infection 
(12.6% compared with 5.2% in the high diagnosis rate scenario).  
4.4.2.2 Alternative diagnosis rates 
Alternative estimates for the projected life expectancy according to the other diagnosis 
rates modelled are summarised in Table 4-3. It also includes the estimates assuming 
‘very high and ‘medium’ diagnosis rates, as well as the estimate of life expectancy in 
people not infected by HIV. In the situation where the 10,000 MSM were never infected 
with HIV, life expectancy was estimated to be 82.0 years. This implies that under the 
assumption of the ‘high’ diagnosis rate, 7.0 years of life were lost due to HIV infection 
and 10.5 years of life were lost under the assumption of a ‘low’ diagnosis rate. 
Figure 4-2 shows the Kaplan-Meier estimates of the time to death from time of infection 
by diagnosis rate. The cumulative probability of death starts diverging very early on and 
even by ten years from the time of infection, the cumulative probability of death in 
people diagnosed late with a median CD4 count of 140 cells/mm
3
 is over 10-fold that of 
someone without HIV infection. By 20 years from infection, there is an even greater 
disparity in the probability of death, mainly between those without HIV infection, HIV-
positive people who are diagnosed with CD4 counts between 351 and 509 cells/mm
3
 
and people who are diagnosed much later with a lower CD4 count. Interestingly, when 
restricting to the period up to 20 years from the time of HIV infection, there is not a huge 
difference in the time to death whether someone is diagnosed with a CD4 count of 351, 
432 or 509 cells/mm
3
, thought to be due to the effectiveness of timely ART initiation. 
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Figure 4-2: Kaplan-Meier estimates of time to death (all-cause mortality) from HIV 
infection (age 30) [725] 
 
4.4.2.3 Projected range of outcomes over 80 years 
Figure 4-3a shows the projected range of outcomes in terms of diagnosis status and 
death under the high diagnosis rate assumption over 80 years of follow-up. Figure 4-3b 
demonstrates the same information under the assumption of the low rate of diagnosis 
described previously in Table 4-1 and Table 4-2. As expected, more people remain 
undiagnosed and for longer in the low diagnosis rate scenario. Those diagnosed late 
then spend less time as HIV-diagnosed but ART-naive, given that their CD4 counts are 
lower at HIV diagnosis. Figure 4-3 shows that the majority of an individual’s lifetime from 
age 30 onwards is predicted to be spent on ART.  
The estimated probabilities of current CD4 count category by time since infection are 
given for the high and low diagnosis rate scenarios in Figure 4-4. In the first years 
following infection, more people have CD4 counts in the lower categories as they are 
undiagnosed and therefore untreated. Within five to ten years however this improves as 
a greater number of people are diagnosed and then start ART. The impact of late HIV 
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diagnosis on CD4 count is estimated to be greatest in the first 15 years following 
infection. The CD4 count distribution after this point in time is similar between the two 
scenarios. 
Figure 4-3: Projected range of outcomes over 80 years in terms of mortality and 
diagnosis status for 30-year-old MSM infected in 2010. (a) Top figure, high rate of 
diagnosis. (b) Bottom figure, low rate of diagnosis over. [725] 
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Figure 4-4: Projected range of outcomes over 80 years in terms of mortality status 
and CD4 counts for 30-year-old MSM infected in 2010. (a) Top figure, high rate of 
diagnosis. (b) Bottom figure, low rate of diagnosis. [725] 
 
Regardless of the assumed diagnosis rate, the proportion of deaths which are AIDS-
related, decreases over time (Figure 4-3 and Figure 4-4). However at any point in time, 
there is a higher cumulative probability of death in the low diagnosis rate scenario 
(Figure 4-3b and Figure 4-4b). 
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4.4.2.4 Univariable sensitivity analyses 
In one sensitivity analysis, I looked at the impact on life expectancy of altering the rate of 
ART interruption, again assuming a high rate of diagnosis. If the rate of interruption was 
increased by 10-fold in MSM with low tendency to adhere (those with an average 
tendency to adhere of 0.5) compared with 1.5-fold in the base case scenario, this 
resulted in a median life expectancy of 73.8 years (Table 4-4). If on the other hand, the 
rate of ART interruption was reduced to zero, regardless of adherence level, then this 
resulted in a life expectancy of 76.5 years.  
I also looked at the impact on life expectancy of altering the probability of ART initiation 
under the assumption of a high diagnosis rate. The probability of ART initiation was 
altered such that both a higher rate and a lower rate treatment uptake than that thought 
to be currently in use were modelled. This change however did not alter substantially the 
estimated life expectancy, which remained at 75.0 years (Table 4-4).  
In the base case scenarios (for both the high and low rate diagnosis rate) the risk of 
death for a person with a given AIDS-defining condition was assumed to be the same 
regardless of whether the AIDS event occurred at diagnosis or whilst in care under 
follow-up. In another sensitivity analysis under the assumption of a low diagnosis rate, I 
instead assumed a 3-fold raised risk of AIDS-related deaths occurring at HIV diagnosis, 
on the basis that delays in diagnosis can lead to more serious disease. This reduced the 
life expectancy further from 71.5 years to 68.0 years (Table 4-4).  
The beneficial effect of not smoking on life expectancy was apparent both in people with 
HIV and without HIV. Given the 2-fold risk of mortality associated with lifetime smoking 
assumed in the model, the resulting life expectancy assuming no one was infected with 
HIV was 84.8 and 77.8 years in a population with 0% and 100% smokers respectively 
(Table 4-4). Under the assumption of a high diagnosis rate in MSM with HIV, life 
expectancy increased to 78.0 years from 75.0 if it was assumed that 0% of men were 
lifetime smokers. 
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Table 4-4: Estimated life expectancy (median age at death), according to diagnosis rate and scenario (base case versus alternative 
scenario) 
Diagnosis 
rate* 
Assumption made in base case scenario Assumption made in alternative 
scenario 
Median (IQR) life expectancy in 
years in alternative scenarios 
High 
 
Base case - 75.0 (62.5-83.3) 
1.5-fold increase in ART interruption in those 
with low tendency to adhere 
10-fold increase in ART interruption in 
those with low tendency to adhere 
73.8 (60.3-82.8) 
Rate of ART interruption as described in 
Chapter 3 (dependent on factors such as 
underlying tendency to adhere, viral 
suppression status and presence of toxicity ) 
No ART interruption 
76.5 (65.8-84.8) 
Over 80% adherent during 96% of their time 
spent on ART 
Over 80% adherent for 57% and between 
50-80% adherent for 34% of their time 
spent on ART 
73.5 (58.8-82.8) 
40% of men smokers for life 0% of men smokers for life 78.0 (65.5-86.0) 
No raised risk of HIV-related deaths in people 
with CD4 count >500 cells/mm3 
1.1-fold increased risk of HIV-related 
deaths in people with CD4 count >500 
cells/mm3 
75.3 (63.0-83.5) 
95% chance of ART initiation if CD4 count <350 
cells/mm3 and 2% chance of ART initiation if 
CD4 count ≥350 cells/mm3 
98% chance of ART initiation if CD4 count 
≤500 cells/mm3 75.0 (63.0-83.5) 
95% chance of ART initiation if CD4 count <350 
cells/mm3 and 2% chance of ART initiation if 
CD4 count ≥350 cells/mm3 
80% chance of ART initiation if CD4 count 
<350 cells/mm3 and 2% chance of ART 
initiation if CD4 count ≥350 cells/mm3 
75.0 (62.5-83.5) 
95% chance of ART initiation if CD4 count <350 
cells/mm3 and 2% chance of ART initiation if 
CD4 count ≥350 cells/mm3 
50% chance of ART initiation if CD4 count 
≤500 cells/mm3 74.8 (62.5-83.5) 
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Diagnosis 
rate* 
Assumption made in base case scenario Assumption made in alternative 
scenario 
Median (IQR) life expectancy in 
years in alternative scenarios 
Low Base case - 71.5 (51.8-81.8) 
No raised risk of AIDS-related deaths occurring 
after HIV diagnosis 
3-fold increased risk of AIDS-related 
deaths occurring after HIV diagnosis 
68.0 (43.8-80.5) 
No HIV 
infection 
Base case - 82.0 (72.8-89.3) 
40% of men smokers for life 0% of men smokers for life 84.8 (75.8-91.3) 
40% of men smokers for life 100% of men smokers for life 77.8 (68.8-84.8) 
Very high Base case  - 75.3 (63.5-83.3) 
Medium Base case  - 74.5 (61.5-83.3) 
*The rate of diagnosis was altered such that the median CD4 counts at diagnosis were 140, 351, 432 and 509 cells/mm
3
 respectively for low, medium, high 
and very high diagnosis rates.  
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4.4.2.5 Multivariable uncertainty analyses 
Multivariable uncertainty analyses were performed to attempt to quantify the uncertainty 
associated with the estimates of life expectancy. For each of the 10,000 runs of the 
model, values for a number of different key parameters were sampled to generate a 
distribution of the estimated life expectancy. The median life expectancy from this 
analysis was 73.8 years and the 95% uncertainty bound was (68.0,77.3). These median 
and bounds were derived from the 10,000 runs, i.e. the projected life expectancy was 
between 68.0 and 77.3 years in 95% of these runs.    
4.4.3 Discussion 
In this study, I used the Synthesis V5 model to predict the life expectancy for a 30 year 
old MSM living in a HIC, infected with drug-sensitive virus in 2010. The estimated life 
expectancy of 75.0 years (IQR:62.5-83.3) assumes a 40% chance of being a lifelong 
smoker and no hepatitis co-infection. I also calculated the life expectancy had HIV 
infection not occurred, which was estimated to be 82.0 years. This is consistent with life 
expectancy projections in several Western European countries[793]. Therefore, 7.0 
years of life is estimated to be lost on average due to HIV infection. It is worth noting that 
this excess mortality is similar to that of other chronic illnesses such as diabetes[822].  
In the base case scenario, I found that the impact of later diagnosis on the death rate 
was most pronounced in the first 10 to 20 years from infection (Figure 4-3b and Figure 
4-4b). After this period, the effect on life expectancy was more modest. This is due to 
the durable effects of ART modelled, even in those who start ART with a low CD4 
count[751, 823]. This modest difference in life expectancy between the high and low 
diagnosis rates however, should not deter from the fact that late diagnosis should be 
minimised by increased access and uptake of HIV testing. Not only is the death rate 
higher, particularly in the first 10 years following infection, but also a much higher 
proportion of people are thought to present with AIDS at diagnosis: 42% in the low 
diagnosis rate scenario versus 6% in the high diagnosis rate scenario. Additionally, 
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there is now strong evidence that the probability of HIV transmission is very small if an 
HIV-positive person is on treatment with suppressed viral load, as a result of reduced 
infectiousness[284, 824]. Thus, another advantage of earlier diagnosis is timely initiation 
of ART to prevent onward transmission.  
I have found in this analysis that one consequence of increased life expectancy is that 
the number of deaths resulting from non-AIDS related causes now considerably 
exceeds the number of deaths resulting from AIDS. This has also been observed in 
other HIC where deaths due to non-AIDS malignancies, cardiovascular disease and 
hepatic disease in people with hepatitis condition are now among the leading causes of 
death[825, 826].  
Whilst reviewing the literature on studies estimating life expectancy, I found that a lower 
CD4 count at ART initiation (or similarly at diagnosis) is strongly associated with shorter 
life expectancy[806, 814, 816-819], as is late presentation[818]. Late presentation to 
care, commonly defined as someone presenting for care with a CD4 count <350 
cells/mm
3
 or presenting with an AIDS-defining event regardless of CD4 count[827], has 
consistently been found to be associated with poorer prognosis, including worse 
response to treatment and an increased risk for HIV-related morbidity and mortality[828-
831]. To improve life expectancy further would thus require an improvement in HIV 
testing rates so that people are diagnosed early enough to initiate ART in a timely 
manner. Even assuming a high diagnosis rate in my analysis such that the median CD4 
count at HIV diagnosis was 432 cells/mm
3
, the median CD4 count at ART initiation could 
have dropped considerably below 350 cells/mm
3
 in some MSM by the time they had 
waited for it to fall below this threshold for starting treatment. In reality, MSM may 
actually initiate ART before their CD4 count falls below 350 cells/mm
3
 because of the 
length of time between clinic visits. Also, UK guidelines now recommend use of ART as 
a prevention measure for onward HIV transmission in addition to how it has been 
traditionally used as treatment for the infected individual[194]. Another means to 
increase life expectancy in HIV-positive people is to further improve the overall wellbeing 
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of such individuals. This is because it is generally recognised that HIV-positive people 
have an higher prevalence of lifestyle risk factors compared to the general population, 
such as smoking, alcohol abuse and recreational drug-use, all of which are associated 
with an increased risk of death[289, 743, 832-835]. 
The method employed here uses a simulation model of HIV progression and the effect 
of ART, using estimates of rates of virologic failure and rates of resistance emergence 
from the published literature[288, 751, 836, 837]. This means that I am assuming the 
long-term sustainability of antiretroviral drugs and their consequent impact on CD4 
counts based on the short- to mid-term data currently available. In contrast, other 
analyses which have estimated life expectancy from cohort studies are based on the 
assumption that current death rates will remain unchanged[786, 801, 805]. However, 
such an approach does not allow for improvements in mortality rates over time which 
has been observed in the HIV-positive population[133, 134, 791]. The assumption that 
death rates will remain unchanged is likely to be pessimistic because the risk of death 
declines with increasing CD4 count, which in turn is a result of durable viral load 
suppression[738].  
In this study I did not assume any direct increased risk of death associated with the use 
of any specific antiretroviral drugs. Despite evidence that some antiretrovirals can lead 
to an increased risk of myocardial infarction and possible kidney and liver function 
impairment[738, 833, 838-841], I assumed that the direct effect of antiretroviral drugs on 
mortality would be minimal. This is because the wide choice of antiretroviral drugs now 
available in HIC and the tailoring of ART regimens according to a person’s specific risk 
factors (e.g. ABC would most likely not be used in people with high cardiovascular 
disease risk) means any excess risk is likely well managed. However, a lifelong 1.5-fold 
increased risk of non-AIDS related causes of deaths compared with the general 
population was assumed in the model, to reflect both an excess risk due to the presence 
of HIV infection itself and to reflect any excess risk of using antiretroviral drugs in 
general[737-742]. The assumption is made even in people with viral suppression, 
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although it is probably true to a lesser degree. If the increased risk of non-AIDS deaths 
is not as high as 1.5-fold in all MSM, then the model may have resulted in 
underestimating life expectancy. 
It is difficult to directly compare my estimate of projected life expectancy with estimates 
from other recently published studies (Appendix IX) because none based in HIC give an 
estimate of male life expectancy at age 30. However generally speaking, the life 
expectancy estimated here is somewhat higher than most. It is also higher than an 
estimate calculated using an alternative mathematical model. Sloan et al. found using 
the CEPAC model (using French data on the natural history and treatment 
characteristics to inform model parameters) that the estimated additional years of life 
after entry into healthcare was 26.5 years, assuming mean age and CD4 count at entry 
as 38 years and 372 cells/mm
3
 respectively[818]. The equivalent figure using Synthesis 
V5 was a median of 41.5 years after entry into care. The difference in the estimates 
could be explained by the fact that in this study, mean age at infection is assumed to be 
30 years old (and median time from infection to diagnosis is 2.8 years) and thus 
individuals are younger at the point of entering into care. It could also be due to the 
assumption that all MSM starts treatment with combination therapy and are all assumed 
to be neither co-infected with hepatitis nor do they actively inject drugs.   
There are a number of limitations for this study. Even though Synthesis V5 has been 
shown to closely simulate the key features of HIV disease progression and the effect of 
ART as they are currently understood (Chapter 3), any model is at best an 
approximation to the truth. To estimate life expectancy, the model is simulated over a 
lifetime of an individual, which introduces uncertainty for a large number of years. This 
means that the effects of any potential model misspecification could have been amplified 
over time. 
Several assumptions are also made in the model which may have affected the resulting 
estimates of life expectancy. Testing and treatment guidelines, as well as the current 
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standard of care, are assumed to remain as they are now and any changes which may 
occur in the future are not incorporated. Population-level adherence to ART is assumed 
to remain stable over time, as recent evidence suggests this has been the case for over 
a decade[842]. As mentioned previously already, I have not directly modelled an 
increased risk of death associated with use of some antiretroviral drugs, though such 
risks are likely to be small in any case with the current selection of drugs.  
The all-cause death rates which were used in the model throughout the simulation 
period were fixed at rates calculated in 2009 among the male general population, rather 
than assuming that they will continue to gradually decline over time. Given the death 
rates which were used, the projected life expectancy estimated in this study is not 
generalisable to people with hepatitis co-infection, which is known to be associated with 
a higher risk of mortality[401, 843], and also among HIV-positive females living in the UK. 
In fact, as a substantial proportion of females living with HIV in the UK are not originally 
from the UK, whereas a large proportion of MSM are (or at least from other developed 
countries with similar background death rates), it is uncertain whether UK-based all-
cause death rates would be appropriate.   
In summary, based on the assumption of continuing low rates of virologic failure 
currently observed in individuals treated with ART, projected life expectancy in people 
living with HIV is high in settings with good access to care and antiretroviral drugs. This 
is especially the case amongst people who are diagnosed before ART is indicated. 
Delays in diagnosis pose a large risk of excess mortality for people with HIV. Although 
life expectancy has improved substantially since the introduction of effective treatment 
and is approaching that of HIV-negative individuals, there is still room for improvement. 
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Chapter 5 Development of the HIV 
Synthesis V6 model 
As mentioned in Chapter 3, Synthesis V5 was used as a starting point for developing the 
model to be used for the SSOPHIE project, i.e. Synthesis V6. In this chapter, I describe 
the analyses, mainly using data from the COHERE cohort collaboration, and literature 
reviews, to inform or re-inform parameter values and/or the model structure which I 
conducted to develop this new version of the model. Where suitable, I also compare 
published data to simulated outputs from the Synthesis models. In the final part of this 
chapter, I describe the addition of parameters relating to pregnancy in the model. 
5.1 Background 
The process of developing the new version of the model was, although systematically 
and logically done, also somewhat informal. For each of the sections of the Synthesis 
V5 model that were to be revisited and revised, the literature was first reviewed to 
assess the data already available which could inform the model. The choices of sections 
to be revisited and revised were chosen in conjunction with members in the SSOPHIE 
project working group based on a series of teleconferences.  
5.1.1 Analysis approach 
If there was a lack of evidence or conflicting evidence in the literature about a subject 
then a number of statistical analyses were conducted using data from the COHERE 
cohort collaboration (Section 5.1.2). The same analysis was replicated using simulated 
data generated by Synthesis V5. I chose to use simulate and therefore analyse, a 
similar sized dataset to that of the COHERE dataset so that the standard errors in the 
models would be comparable. The results of both these analyses were compared to 
decide if and how the model should be updated. This was done by assessing the 
magnitude and direction of the effects of estimates in each of the fitted regression 
models. Using the new parameters and assumptions, this new interim model was used 
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to simulate more data, which were then compared to the results from Synthesis V5 and 
from the COHERE analysis. Again, this was done by assessing and comparing the 
effect sizes of the relevant parameters in the fitted regression models. COHERE data 
are collected within Europe, which makes it suitable for Synthesis V6 as it will be used 
within the European context for the purposes of the SSOPHIE project. Analyses 
performed on the COHERE dataset used particular statistical methods, such that the 
resulting outcomes could be used directly to inform model parameters in Synthesis V6, 
which updates variables in three-month intervals. Variables chosen to be added or 
modified in Synthesis V6 were those which I found there was consistent and compelling 
evidence of its impact on HIV disease progression in the literature.  
Where it was thought that enough data was already present in the literature, I 
summarise the findings in the latter half of this Chapter accordingly (Sections 5.5 to 
5.10).  
Finally, I also reviewed the literature relating to pregnancy among people living with HIV, 
which was not explicitly modelled in Synthesis V5. As well as the need to model 
incidence of pregnancy in HIV-positive women, the following factors needed to be 
modelled differently by pregnancy status: probability of diagnosis, progression of HIV 
and the effect of ART, specifically the use of antiretrovirals and adherence. 
5.1.2 COHERE 
COHERE (Collaboration of Observational HIV Epidemiological Research Europe, 
http://www.chip.dk/COHERE) is a collaboration of most HIV observational cohorts in 
Europe[844]. The collaboration was initiated in 2005 with the aim to conduct hypothesis-
driven epidemiological research on the prognosis and outcome of HIV-positive people 
across Europe. The research conducted within COHERE focuses on scientific questions 
and analyses which require a large sample size, and therefore which cannot be 
answered by any individual cohort. It also allows for effects and associations to be 
estimated with as much precision as possible. 
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There are two regional coordinating centres which are responsible for data collection, 
overseeing the adherence to strict quality assurance guidelines and performing data 
checks. The data collected in COHERE is submitted by each cohort using a 
standardised data format known as HICDEP (HIV Collaboration Data Exchange 
Protocol)[845]. Data collected include information on patient demographics, CD4 counts, 
HIV viral loads, AIDS, deaths and use of ART. As of September 2013, there were data 
on approximately 245,000 adults, 6,000 children and 29,000 mother and child pairs.  
5.2 Analysis: Investigating factors associated with 
the initial CD4 count and viral load set point 
5.2.1 Background 
As described in Chapter 1, CD4 count and viral load levels are known to be very 
variable both between and within HIV-positive individuals. However, there are a number 
of factors which have been suggested to be associated with both of these markers soon 
after seroconversion in treatment-naïve individuals. Previous studies have shown that 
higher CD4 count at seroconversion is associated with younger age, female sex, lower 
viral load, non-African race, acquisition of HIV through IDU or haemophilia and subtype 
B (compared to C)[846-852], and that higher viral load set point is associated with older 
age and male sex[108, 853-855]. There is conflicting evidence regarding the effect of 
race on viral load set point[853, 856-858]. 
I described in Chapter 3 that, the viral load set point is sampled from Normal(4,0.5
2
) on 
the log copies/ml scale in Synthesis V5. The initial CD4 count is modelled on the square 
root scale and is determined as, 
√CD4 count  = 32 − (2 × viral load set point)  + Normal(0, 22). 
Thus the CD4 count is higher with lower viral load set point. In Synthesis V5 these 
values do not depend on any other factors. In this analysis, I sought to determine the 
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factors which are strongly associated with these initial levels in a group of people with 
known date of seroconversion in the COHERE cohort collaboration.   
5.2.2 Methods 
In the COHERE dataset, the analysis was restricted to adults (age >14 years at the time 
of seroconversion, seroconversion to occur anytime between 1982 and 2011 inclusive) 
who had both a known date of last negative HIV test and first positive HIV test. The date 
of seroconversion was calculated as the midpoint between the last negative HIV test 
and first positive HIV test. Initial CD4 count and viral load set point was defined as the 
first CD4 count and viral load measurement taken after the first positive HIV test result. 
Individuals were excluded if the date of first CD4 count measurement was either before 
their estimated date of seroconversion or more than one year after the estimated date of 
seroconversion. 
A multivariable linear regression model was fitted to model the initial CD4 count, with 
potential covariates being age at seroconversion, gender, race and viral load set point. 
Although initially the transmission risk group was also considered as a potential 
predictor, it was subsequently excluded on the basis that there is currently no 
compelling evidence or biological rationale for a causal effect on the initial CD4 count or 
viral load set point. As mentioned in Chapter 3, viral subtype is not explicitly modelled in 
Synthesis V5, because it is thought that there is not a significant subtype effect on the 
natural history. Therefore subtype data will not be considered for the same reasons in 
Synthesis V6. A separate multivariable linear regression model was fitted to estimate the 
association of viral load set point with age at seroconversion and gender as potential 
covariates. Race was not considered in this analysis mainly due to the inconsistent 
evidence in the literature.  
CD4 counts were fitted on the square root scale. Viral loads were fitted on the log scale 
and centred around 4 log copies/ml when included as an explanatory variable in the 
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CD4 count model. Age at seroconversion was centred around 35 years. Although all 
races recorded within COHERE were initially modelled (white, black, Hispanic, Asian, 
American, indigenous, mixed, other/unknown/prohibited), given the lack of numbers of 
non-white or non-black individuals, race was fitted using the categories: white, black and 
other/unknown (also includes ‘prohibited’). 
5.2.3 Results: from analysis on COHERE data 
Data on 11,120 individuals were included in this analysis. The estimated date of 
seroconversion ranged from March 1982 to March 2011. The median (IQR) time from 
seroconversion to first CD4 count measurement was 156 (83-239) days. The median 
(IQR) age at seroconversion was 32 (26-39) years and 80% were male. The breakdown 
of mode of transmission was: MSM (56%), heterosexual (28%), PWID (5%) and 
other/unknown (11%). Many people (69%) had other/unknown race, 30% were white 
and 1% were black race. There was a large proportion of people with 
other/prohibited/unknown race because data on race is not collected by one of the 
largest cohorts in COHERE (FHDH). The distribution of initial CD4 count and viral load 
set point stratified by age, gender and race is given in Table 5-1. 
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Table 5-1: Distribution of initial CD4 count and viral load set point 
Variable Group n (%) 
Median (IQR) 
initial CD4 
count, cells/mm3 
Median (IQR) 
viral load set 
point, log 
copies/ml 
Age, years 14-19 281 (2%) 527 (412-727) 3.8 (2.7-4.7) 
20-24 1616(14%) 520 (372-714) 4.0 (2.7-4.7) 
25-29 2418 (22%) 524 (370-706) 4.0 (2.7-4.8) 
30-34 2417 (22%) 510 (360-686) 4.0 (2.7-4.8) 
35-39 1849 (17%) 511 (347-696) 4.2 (2.7-4.9) 
40-44 1138 (10%) 468 (321-654) 4.4 (2.7-5.1) 
45+ 1401 (13%) 455 (300-630) 4.3 (2.7-5.1) 
Gender Male 8849 (80%) 503 (356-678) 4.2 (2.7-4.9) 
Female 2271 (20%) 511 (337-721) 3.8 (2.7-4.6) 
Race White 3337(30%) 501 (332-690) 4.2 (2.7-5.0) 
Black 125 (1%) 391 (267-551) 3.1 (2.7-4.4) 
Other/unknown 7658 (69%) 508 (360-684) 4.1 (2.7-4.9) 
 
Table 5-2 and Table 5-3 show the results of the multivariable linear regression models 
estimating the initial CD4 count and viral load set point respectively, together with 95% 
confidence intervals (CI) and p-values. The model was also adjusted for the time from 
seroconversion to date of first CD4 count, given the effects were statistically significant. 
However, this variable was not a covariate of interest because the high levels of viral 
load seen during primary infection and subsequent declines in the first few months are 
not modelled in the Synthesis model. The intercept in the CD4 model, Table 5-2, can be 
interpreted as the estimated mean CD4 count on the square root scale, for a white male, 
aged 35 years old, with viral load set point of 4 log copies/ml at the time of 
seroconversion. Similarly, the intercept in the viral load model, Table 5-3, can be 
interpreted as the estimated mean log viral load for a white male, aged 35 years old at 
the time of seroconversion. 
 197 
 
Table 5-2: Estimated initial CD4 count (cells/mm
3
, square root scale) in COHERE 
(n=11,120) 
Model parameter Estimate 95% CI p-value 
Intercept* 22.23 22.0,22.5 <.0001 
Viral load set point (per log copies/ml higher) -1.24 -1.34,-1.14 <.0001 
Age at seroconversion (per 10 years older) -0.65 -0.76,-0.53 <.0001 
Male ref - 0.015 
Female -0.36 -0.64,-0.07 
White race ref - <.0001 
Black race -2.56 -3.65,-1.47 
Other/unknown race 0.57 0.32,0.83 
Time from seroconversion to first CD4 count 
measurement (per month longer) 
-0.05 -0.08,-0.01 0.009 
*Intercept applies to a white male, aged 35 years with viral load set point of 4 log copies/ml 
at time of seroconversion. 
 
Table 5-3: Estimated viral load set point (log copies/ml) in COHERE (n=11,120) 
Model parameter Estimate 95% CI p-value 
Intercept* 4.06 4.04,4.09 <.0001 
Age at seroconversion (per 10 years older) 0.10 0.08,0.12 <.0001 
Male ref - <.0001 
Female -0.25 -0.30,-0.19 
Time from seroconversion to first CD4 count 
measurement (per month longer) 
-0.02 -0.03,-0.02 <.0001 
*Intercept applies to a male aged 35 years with viral load set point of 4 log copies/ml at time 
of seroconversion. 
Age at seroconversion, viral load set point and race were all associated with the initial 
CD4 count (Table 5-2). There was little evidence of an effect of gender. The viral load 
set point was strongly associated with the age at seroconversion and gender (Table 5-3. 
Age at seroconversion was also fitted as a categorical variable in both models to confirm 
the linearity of the effect and a linear association was found to be appropriate (results 
not shown). 
5.2.4 Results: comparing COHERE results with Synthesis V5 
Table 5-4 and Table 5-5 show the model estimates using simulated data from Synthesis 
V5. The number of people included in the analysis of this simulated data was 13,228. In 
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Synthesis V5, race is not a variable which is modelled and so it was not possible to 
include in the model to estimate its effect. The models were not adjusted for the time 
between seroconversion to date of first CD4 count measurement because all dates are 
simulated and therefore, there is a CD4 count measurement on the same day as 
seroconversion.  
Table 5-4: Estimated initial CD4 counts (cells/mm
3
, square root scale) in Synthesis 
V5 (n=13,228) 
Model parameter Estimate 95% CI p-value 
Intercept* 23.30 23.2,23.4 <.0001 
Viral load set point (per log copies/ml higher) -2.00 -2.10,-1.90 <.0001 
Age at seroconversion (per 10 years older) -0.03 -0.06,0.00 0.13 
Male ref - 0.87 
Female 0.01 -0.15,0.17 
*Intercept applies to a white male, aged 35 years with viral load set point of 4 log copies/ml. 
 
Table 5-5: Estimated viral load set point (log copies/ml) in Synthesis V5 (n=13,228) 
Model parameter Estimate 95% CI p-value 
Intercept* 4.00 3.99,4.01 <.0001 
Age at seroconversion (per 10 years older) -0.002 -0.010,0.005 0.53 
Male ref - 0.89 
Female -0.002 -0.032,0.028 
*Intercept applies to a male aged 35 years. 
 
The initial CD4 count is only dependent on the viral load set point in Synthesis V5 and 
therefore it follows that the effect of gender is not statistically significant. As the viral load 
set point (and subsequent viral loads) is currently just a randomly chosen, normally 
distributed number with no dependence on age or gender, it thus follows that age at 
seroconversion and gender are not significantly associated with viral load. 
 199 
 
5.2.5 Discussion and changes made 
The initial CD4 count already depends on the viral load set point and the COHERE 
analyses have confirmed that this is appropriate. However, the viral load effect was 
larger (-2.00) in Synthesis V5 than it was in COHERE (-1.24) (Table 5-4), so this implies 
that the viral load effect size may need to be reduced. The COHERE model also 
suggested that a higher initial CD4 count was associated with lower age and white race. 
There was only moderate evidence for a difference in initial CD4 count between genders. 
The COHERE model suggested that there was very good reason to include an age 
effect and gender effect on the viral load set point (Table 5-3). Including a gender effect 
means that there will be a small gender effect on the initial CD4 count also as this will 
act through the viral load. The changes made on the basis of the above analyses are 
summarised in Table 5-6. I decided to model race as a binary variable (white or black) in 
Synthesis V6.  
Table 5-6: Changes made to the Synthesis model [initial CD4 count and viral load 
set point] 
 Synthesis V5 Synthesis V6 
Initial CD4 
count, 
square 
root scale 
32  
– (2 x viral load set point)  
+ Normal(0,22) 
29.5  
– (1.5 x viral load set point) 
– [0.05 x (age at seroconversion - 35)]  
– (2.0 if black race)  
+ Normal(0,22) 
Log viral 
load set 
point 
4  
+ Normal(0,0.52) 
4.075  
+ [(0.005 x (age at seroconversion - 35)]  
– (0.2 if female)  
+ Normal(0,0.52) 
 
5.2.6 Results: comparing COHERE results with Synthesis V6 
Table 5-7 and Table 5-8 show the models fitted for Synthesis V5, COHERE and 
Synthesis V6 data to estimate the initial CD4 count and viral load respectively. Given 
that Synthesis V5 already fits very well to the observed data, all changes which were 
made are rather modest. Nevertheless, there is now a small race effect and a slightly 
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larger effect of age on initial CD4 count, as well as a small age effect on viral load set 
point. Having incorporated the additional changes, Synthesis V6 also fits well to the 
COHERE data and agrees with effects founds in the literature. 
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Table 5-7: Estimated initial CD4 counts (cells/mm
3
, square root scale); comparison between COHERE and simulated data from Synthesis V5 
and V6 
Model Parameter 
Synthesis V5 n=13,228 COHERE* n=11,120 Synthesis V6 n=13,301 
Estimate p-value Estimate p-value Estimate p-value 
Intercept 23.30 <.0001 22.23 <.0001 23.09 <.0001 
Viral load set point, (per log copies/ml higher) -2.00 <.0001 -1.24 <.0001 -1.45 <.0001 
Age at seroconversion (per 10 years older) -0.03 0.13 -0.65 <.0001 -0.06 <.0001 
Male ref 0.87 ref 0.014 ref 0.22 
Female 0.01 -0.36 -0.12 
White race - - ref <.0001 ref <.0001 
Black race - - -2.56 -2.01 
Other/unknown race - - 0.57 - 
*COHERE model is also adjusted for time from seroconversion to first CD4 count measurement (estimate and p-value not shown here) 
 
Table 5-8: Estimated viral load set point (log copies/ml); comparison between COHERE and simulated data from Synthesis V5 and V6 
Model parameter 
Synthesis V5 n=13,228 COHERE* n=11,120 Synthesis V6 n=13,301 
Estimate p-value Estimate p-value Estimate p-value 
Intercept 4.00 <.0001 4.06 <.0001 4.10 <.0001 
Age at seroconversion (per 10 years older) -0.002 0.53 0.10 <.0001 0.0049 <.0001 
Male ref 0.89 ref <.0001 ref <.0001 
Female -0.002 -0.25 -0.18 
*COHERE model is also adjusted for time from seroconversion to first CD4 count measurement (estimate and p-value not shown here). 
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5.3 Analysis: Investigating factors associated with 
the changes in CD4 count and viral load in ART-
naïve individuals 
5.3.1 Background 
HIV infection in treatment-naïve individuals is typically characterised by a rise in HIV 
viral load and a consistent decline in CD4 count, subsequently followed by the 
development of AIDS and death if the individual is not treated with antiretroviral drugs[85, 
101]. One aspect that has been confirmed over different points in the course of infection 
is that the higher the level of viral load measured, the faster the CD4 count 
depletion[123, 735, 859, 860]. In addition, it is known that there is great variability in the 
rate of CD4 count depletion between individuals, but one study has suggested that only 
a very small proportion can be explained by the viral load[860]. Other studies have 
shown conflicting results and suggest that viral load measurements are a good predictor 
of CD4 count decline over time[861, 862]. 
It is important to understand as much as possible about the association between CD4 
counts and viral load, as both are used as prognostic markers of HIV infection, as well 
as predictors of short-term risk of developing AIDS and death[101, 116, 863, 864]. In 
particular, I was interested in quantifying the relationship between viral load and CD4 
counts before ART is initiated, and to investigate the factors which are associated with 
the changes in both these prognostic markers.  
This analysis (on data from COHERE) was published on behalf of the Natural History 
Project Group for COHERE in AIDS[865]. The paper can be seen in Appendix XIII. 
5.3.2 Methods 
All available viral load and CD4 count measurements of HIV-positive individuals 
participating in the COHERE study measured prior to the date of starting ART were 
considered. Pairs of consecutive viral load and CD4 count values measured between 60 
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and 365 days apart were included from the COHERE data. Variables are updated three-
monthly in the Synthesis models so measurements from the simulated data were 
naturally three months apart. The time of the first measurement of the pair is hereafter 
referred to as t0 and the second as t1. In addition, viral load measurements had to be 
available from samples measured within one week of each of the two CD4 count 
measurements. Three consecutive viral load and CD4 count measurements were 
required per individual for study inclusion, so that the one taken prior to the pair (at time 
t-1) could be included as an additional covariate in the model to help minimise biases 
which arise as a result of regression to the mean. The statistical phenomenon of 
regression to the mean is described as, 
‘an expression of the observation that, when we take pairs of related 
measurements, the more extreme values of one variable will, on average, 
be paired with less extreme values of the other variable’[866].  
 
Pairs of measurements were excluded if the difference between consecutive viral load 
measurements were >0.8 log copies/ml (due to suspected data errors related to 
unrecorded ART-use) or if the first CD4 count measurement of the pair was <100 
cells/mm
3
 (because there is less scope for decline). These criteria excluded 12% of the 
COHERE data pairs and less than 2% of the simulated Synthesis data. Individuals 
younger than 16 years old were also excluded.  
In the first part of this analysis, the time-standardised change (per year) in CD4 count 
(on the absolute scale) was defined as 
(CD4 count at 𝑡1 − CD4 count at 𝑡0) × 365
(𝑡1 − 𝑡0)
 , 
and was used to assess how this differed according to the current viral load (at time t0). 
The mean time-standardised change (per year) of the viral load was similarly defined as   
(log viral load at 𝑡1 − log viral load 𝑡0) × 365
(𝑡1 − 𝑡0)
 . 
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Generalised linear models (GLM) were then fitted to evaluate the factors which are 
associated with the short-term changes in viral load and CD4 count measurements. 
Each individual could contribute more than one pair of measurements, so an 
autoregressive correlation structure and robust standard errors were used in order to 
take into account repeated measurements. The response variable in each of the GLMs 
was the annualised change in viral load (viral load model) and the annualised change in 
CD4 count (CD4 model). The main covariates of interest were viral load at t0 (included 
only in CD4 model), CD4 count at t0 (included only in viral load model), age at t0, gender, 
race and whether transmission was by IDU. The covariate included to adjust for mode of 
transmission was included to act as a proxy for hepatitis co-infection, given that most 
individuals who acquired HIV through IDU would also be co-infected with hepatitis virus.   
In a sub-analysis, the effect of baseline viral load on the CD4 count changes was 
assessed to compare with the effect of current viral load. Current was defined as time t0. 
In the COHERE data, baseline for each patient was defined as the first date on which 
both viral load and CD4 count were available. In the Synthesis data, baseline was 
defined to be the date of HIV diagnosis. In this analysis, pairs of CD4 count 
measurements were included only if viral load at t0 was measured at least one year from 
baseline. 
The sensitivity of results was assessed by fitting mixed models instead. In another 
sensitivity analysis, calendar year was fitted as an extra covariate, as both a linear and 
categorical covariate (1984-1989, 1990-1994, 1995-1999, 2000-2004, and 2005-2010). 
The CD4 model used the absolute scale for CD4 count for ease of interpretation, but 
additional models were fitting using CD4 count transformed to the square root scale (on 
which the assumption of Normality is more likely to closely hold) to ensure that my 
conclusions did not alter. As the inclusion criteria would exclude individuals with faster 
progression who are started on ART more quickly, a further sensitivity analysis was 
carried out where only the first measured pair for each person was included in the 
models.  
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5.3.3 Results: from analysis on COHERE data 
34,384 individuals who contributed a total of 158,385 pairs of viral load and 
corresponding CD4 count measurements between 1984 and 2010 were included from 
the COHERE data. The median number of pairs of observations per person was three 
(IQR:2-7). The median time between consecutive viral load and CD4 measurements 
was four months (IQR:3-5). At baseline, the median age was 34 years (IQR:28-40), 
median viral load was 4.0 log copies/ml (IQR:2.7-4.7) and median CD4 count was 477 
cells/mm
3
 (IQR:362-625). 73% of patients were male and the breakdown of mode of HIV 
transmission was: MSM (47%), heterosexual (34%), IDU (12%), other/unknown (7%). 
Five percent, 34% and 61% of patients were black, white and other/unknown race 
respectively. 
The median viral load and CD4 count at t0 across all pairs were 4.1 log copies/ml and 
463 cells/mm
3
 respectively. The mean (95% CI) annual change in viral load and CD4 
count were 0.091 (0.086-0.096) log copies/ml per year and -78.0 (-80.1 to -76.0) 
cells/mm
3
 per year respectively (Table 5-9). There was strong evidence that both of 
these changes were non-zero (p<0.001). 
Table 5-9: Average annual changes in viral load and CD4 count in COHERE 
(n=158,385) 
 Mean (95% CI) Median (IQR) 
Annual change in viral load, log copies/ml 0.091 (0.086-0.096) 0 (-0.41 to +0.64) 
Annual change in CD4 count, cells/mm3 -78.0 (-80.1 to -76.0) -73.1 (-273 to +114) 
 
The univariable association between the mean annual CD4 count change and the 
current viral load was visually assessed (Figure 5-1). The mean (95% CI) change in 
CD4 count varied from -5 (-23 to 13) cells/mm
3
 when the viral load was < 200 copies/ml, 
to -225 (-301 to -150) cells/mm
3
 per year when it was above one million copies/ml. 
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Figure 5-1: Estimated CD4 count decline per year by viral load category at t0 
 
Table 5-10 and Table 5-11 show the multivariable models fitted to estimate the factors 
associated with the change in viral load and CD4 count respectively. The intercept in 
Table 5-10 can be interpreted as the annual change in viral load for a white male, aged 
35 years, who did not acquire their HIV through IDU, with viral load at t-1=4 log copies/ml 
and CD4 count at t0=500 cells/mm
3
. Similarly for Table 5-11, the intercept can be 
interpreted as the annual change in CD4 count for a white male, aged 35 years, who did 
not acquire HIV through IDU, with viral load at t0=4 log copies/ml and CD4 count at t-
1=500 cells/mm
3
.  
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Table 5-10: Multivariable model results for factors associated with the annualised 
change in log viral load in COHERE (n=158,385) 
Model parameter Estimate 95% CI p-value 
Intercept* 0.093 0.086, 0.10 <0.001 
Viral load at t-1 (per log copies/ml higher) -0.026 -0.031,-0.021 <0.001 
CD4 count at t0 (per 100 cells/mm
3 higher) -0.004 -0.007,-0.002 <0.001 
Age at t0 (per 10 years older) 0.022 0.017,0.027 <0.001 
Male ref - 0.42 
Female 0.004 -0.006,0.014 
White race ref - - 
Black race -0.019 -0.04,0.002 0.07 
Other/unknown race -0.020 -0.030,-0.011 <.0001 
Transmission not by IDU ref - 0.12 
Transmission by IDU -0.011 -0.024,0.003 
*Intercept applies to a white male, aged 35 years, not infected by IDU with viral load at t-1 of 
4 log copies/ml and CD4 count at t0 of 500 cells/mm
3
.  
 
Table 5-11: Multivariable model results for factors associated with the annualised 
change in CD4 count (absolute scale) in COHERE (n=158,385) 
Model parameter Estimate 95% CI p-value 
Intercept* -69.0 -71.8,-66.2 <0.001 
CD4 count at t-1 (per 100 cells/mm
3 higher) -17.0 -18.1,-15.9 <0.001 
Viral load at t0 (per log copies/ml higher) -37.6 -39.6,-35.7 <0.001 
Age at t0 (per 10 years older) -1.7 -3.3,-0.03 0.046 
Male ref - 0.67 
Female -0.8 -4.2,2.7 
White race ref - - 
Black race 2.3 -3.8,8.3 0.48 
Other/unknown race -6.0 -9.3,-2.7 0.0004 
Transmission not by IDU ref - 0.80 
Transmission by IDU 0.7 -4.6,6.0 
*Intercept applies to a white male, aged 35 years, not infected by IDU with viral load at t0 of 4 
log copies/ml and CD4 count at t-1 of 500 cells/mm
3
.   
 
Estimated increases in viral load were significantly greater in people who were older 
(p<0.001) such that the viral load change was an additional 0.022 (95% CI:0.017-0.027) 
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log copies/ml per year greater per 10 years older (Table 5-10). In contrast, the viral load 
change was 0.026 (95% CI: -0.031 to -0.021) log copies/ml smaller per year for every 
one log copies/ml higher the viral load at t-1. There was no evidence of an association 
with gender, race (white compared to black) or transmission by IDU. However, there 
was some evidence of an interaction between age and gender (p=0.03) with a greater 
rise in viral load in older females than in older males. For women aged over 55 years, 
the mean viral load increase was 0.16 (95% CI:0.12-0.20) log copies/ml per year, 
whereas for men in the same age group, it was 0.11 (95% CI:0.09-0.14) log copies/ml.  
The current viral load (measured at t0) was the strongest predictor of CD4 count decline 
(p<0.001); for every one log copies/ml higher viral load, the CD4 count declined on 
average by a further -37.6 (95% CI: -39.6 to -35.7) cells/mm
3
 per year (Table 5-11). 
There was some evidence of a small age effect where for a 10-year increase in age, the 
CD4 count declined by a further -1.7 cells/mm
3
 per year (p=0.05). This effect was found 
to be even stronger (3.3 cells/mm
3
 per year decline per 10-year increase, p<0.001) if 
viral load was removed from the statistical model. Gender, race (white compared to 
black) or transmission by IDU were not associated with CD4 count decline, nor was 
there any evidence of an interaction between these effects.  
For those pairs where t0 was more than one year from baseline, the effects of adjusting 
for the baseline viral load in addition to the current viral load was also assessed. When 
the model included only baseline viral load, there was a strong effect (p<0.001) where 
for every one log copies/ml increase in baseline viral load, the estimated CD4 count 
decline was greater by an estimated -14 cells/mm
3
 per year. However, when including 
both baseline and current viral load, the effect of baseline viral load was not as 
influential as the current viral load, which was more statistically significant. 
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5.3.4 Sensitivity analyses 
Similar estimate sizes resulted for both the viral load model and the CD4 model after 
using a mixed model approach, as well as adjusting for calendar year (results not 
shown).  
An additional model was fitted with CD4 count measurements considered on the square 
root-scale. This model estimated the annual change in CD4 count (square root scale) to 
be -1.83 (95% CI: -1.76 to -1.89) and it was found that higher viral load at t0 (p<0.001), 
and also white race (p=0.01) was associated with a steeper CD4 count decline. There 
was no evidence of an effect of age (p=0.1) or gender (p=0.8) in this model. 
In another sensitivity analysis including only the first measured pair for each person, 
CD4 count depletion was estimated to be -76.1 cells/mm
3
 per year (a steeper decline 
than in the main analysis where those with faster progression were probably under-
represented, which therefore meant the decline was underestimated). The viral load rise 
was however less and now estimated to be 0.064 log copies/ml per year.   
5.3.5 Results: comparing COHERE results with Synthesis V5 
Table 5-12, Table 5-13 and Table 5-14 show the model estimates using simulated data 
from Synthesis V5. The number of observations included in the analysis of this 
simulated data was 193,313. Note that the proportion of different genders and ages 
were not exactly the same in the COHERE data and in the Synthesis V5 data (the 
population simulated using Synthesis V5 reflects the distribution seen in the UK). 
Therefore, the mean annual changes seen in Table 5-12 were not expected to 
correspond exactly.  
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Table 5-12: Average annual changes in viral load and CD4 count in Synthesis V5 
(n=193,313) 
Variable Mean (95% CI) Median (IQR) 
Annual change in viral load, log copies/ml 0.087 (0.082-0.093) 0 (-0.8 to +0.8) 
Annual change in CD4 count, cells/mm
3
 -55.7 (-58.8 to -53.2) -66 (-424 to +304) 
 
Table 5-13: Multivariable model results for factors associated with the annualised 
change in log viral load in Synthesis V5 (n=193,313) 
Model parameter Estimate 95% CI p-value 
Intercept* 0.129 0.12,0.14 <0.001 
Viral load at t-1 (per log copies/ml higher) -0.129 -0.14,-0.12 <0.001 
CD4 count at t0 (per 100 cells/mm
3
 higher) -0.007 -0.009,-0.004 <0.001 
Age at t0 (per 10 years older) 0.038 -0.017,0.093 0.18 
Male ref - 0.12 
Female 0.010 -0.003,0.022 
Transmission not by IDU ref - 0.53 
Transmission by IDU -0.001 -0.04,0.02 
*Intercept applies to a male, aged 35 years, not infected by IDU with viral load at t-1 of 4 log 
copies/ml and CD4 count at t0 of 500 cells/mm
3
.  
 
Table 5-14: Multivariable model results for factors associated with the annualised 
change in CD4 count (absolute scale) in Synthesis V5 (n=193,313) 
Model parameter Estimate 95% CI p-value 
Intercept* -24.8 -29.6,-20.1 <0.001 
CD4 count at t-1 (per 100 cells/mm
3
 higher) -11.8 -13.8,-9.8 <0.001 
Viral load at t0 (per log copies/ml higher) -78.6 -85.6,-71.7 <0.001 
Age at t0 (per 10 years older) -11.4 -14.8,-8.04 <0.001 
Male ref - 0.3 
Female 4.1 -4.1,12.3 
Transmission not by IDU ref - 0.03 
Transmission by IDU 21.0 2.08,40.0 
*Intercept applies to a male, aged 35 years, not infected by IDU with viral load at t0 of 4 log 
copies/ml and CD4 count at t-1 of 500 cells/mm
3
.   
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5.3.6 Discussion and changes made 
Despite differences in the demographics of the populations, the annual changes in viral 
load and CD4 counts calculated using the simulated data (Table 5-12) were comparable 
to that of the COHERE dataset (Table 5-9). Further, these were also consistent with 
those published in previous studies[95, 108, 859].  
Age was found to be a strong predictor of the change in viral load in the COHERE data, 
which is an effect not modelled in Synthesis V5. On the contrary, although the effect of 
age on CD4 count is modelled in Synthesis V5, only a modest effect with borderline 
statistical significance was found in the COHERE data. Although a statistically significant 
effect of transmission by IDU in the CD4 model was observed in the Synthesis data, this 
effect was actually not modelled directly. This observation may have been a result of 
random chance and/or residual confounding which was not fully taken care of. Race was 
not found to be strongly associated with the change in CD4 count in the COHERE 
dataset, perhaps due to a lack of power or residual confounding. However, I found many 
studies demonstrating strong evidence for a slower decline in people of black race in the 
literature[849, 853, 867-870], and so after some deliberation decided to put a small 
effect in Synthesis V6. The changes made on the basis of the above analyses are 
summarised in Table 5-15. 
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Table 5-15: Changes made to the Synthesis model [changes in viral load and CD4 count in the absence of treatment] 
 Synthesis V5 Synthesis V6 
Change in log viral load 
from (t-1) to t 
0.02275+Normal(0,0.052) 0.0225+Normal(0,0.052) 
+ [0.0005 x (current age - 35)] 
Effect of viral load (VL) 
at (t-1) on change in 
CD4 count from (t-1) to 
t, square root scale 
 
If (VL at t-1)<3 then change = -0.027+Normal(0,1.22) 
If 3≤(VL at t-1)<3.5 then change = -0.072+Normal(0,1.22)  
If 3.5≤(VL at t-1)<4 then change = -0.135+Normal(0,1.22)  
If 4≤(VL at t-1)<4.5 then change = -0.18+Normal(0,1.22)  
If 4.5≤(VL at t-1)<5 then change = -0.45+Normal(0,1.22)  
If 5 ≤(VL at t-1)<5.5 then change = -0.9+Normal(0,1.22)  
If 5.5≤(VL at t-1)<6 then change = -1.8+Normal(0,1.22)  
If (VL at t-1)≥6 then change = -2.25+Normal(0,1.22)  
If (VL at t-1)<2.5 then change = 0 
If 2.5≤(VL at t-1)<3 then change = -0.05+Normal(0,1.22) 
If 3≤(VL at t-1)<3.5 then change = -0.15+Normal(0,1.22)  
If 3.5≤(VL at t-1)<4 then change = -0.25+Normal(0,1.22)  
If 4≤(VL at t-1)<4.5 then change = -0.30+Normal(0,1.22)  
If 4.5≤(VL at t-1)<5 then change = -0.45+Normal(0,1.22)  
If 5≤(VL at t-1)<5.5 then change = -0.95+Normal(0,1.22)  
If 5.5≤(VL at t-1)<6 then change = -1.55+Normal(0,1.22)  
If (VL at t-1)≥6 then change = -1.75+Normal(0,1.22)  
Additional effect of age 
at t on change in CD4 
count from (t-1) to t, 
square root scale 
If (age at t)<20 then add further +0.15 
If 20≤(age at t)<25 then add further +0.09 
If 25≤(age at t)<30 then add further +0.06 
If 30≤(age at t)<40 then no further change 
If 40≤(age at t)< 45 then add further +0.06 
If 45≤(age at t)<50 then add further -0.06 
If 50≤(age at t)<55 then add further -0.09 
If 55≤(age at t)<60 then add further -0.15 
If (age at t)≥60 then add further -0.20 
None 
Additional effect of race 
on change in CD4 
count from (t-1) to t, 
square root scale 
None If black race then add further +0.05 
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5.3.7 Results: comparing COHERE results with Synthesis V6 
Table 5-16 shows the annual change in viral load and CD4 count respectively for 
Synthesis V5, COHERE and Synthesis V6. Table 5-17 and Table 5-18 show the models 
fitted for Synthesis V5, COHERE and Synthesis V6 data to estimate the factors 
associated with the change in viral load and CD4 count respectively. Given that the 
changes in viral load directly affect the changes in CD4 count, I found it hard to 
incorporate some of the newfound effects without it impacting both outcomes. 
Table 5-16: Annual changes in viral load and CD4 count; comparison between 
COHERE data and simulated data from Synthesis V5 and V6 
Variable Synthesis V5 
n=193,313 
COHERE 
n=158,385 
Synthesis V6 
n=160,471 
Median (IQR) Median (IQR) Median (IQR) 
Annual change in viral load, log 
copies/ml 
0 
(-0.8 to +0.8) 
0 
(-0.41 to +0.64) 
0 
(-0.8 to +0.8) 
Annual change in CD4 count, 
cells/mm
3
 
-66 
(-424 to +304) 
-73.1 
(-273 to +114) 
-56  
(-340 to +236) 
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Table 5-17: Multivariable model results for factors associated with the annualised change in log viral load; comparison between COHERE 
data and simulated data from Synthesis V5 and V6 
Model parameter Synthesis V5 n=193,313 COHERE n=158,385 Synthesis V6 n=160,471 
Estimate p-value Estimate p-value Estimate p-value 
Intercept* 0.129 <0.001 0.093 <0.001 0.108 <0.001 
Viral load at t-1 (per log copies/ml higher) -0.129 <0.001 -0.026 <0.001 -0.135 <0.001 
CD4 count at t0 (per 100 cells/mm
3
 higher) -0.007 <0.001 -0.004 <0.001 -0.008 <0.001 
Age at t0 (per 10 years older) 0.038 0.18 0.022 <0.001 0.033 <0.001 
Male ref 0.12 ref 0.42 ref 0.03 
Female 0.010 0.004 -0.010 
White race - - ref - ref 0.76 
Black race - - -0.019 0.07 -0.014 
Other/unknown race - - -0.020 <.0001 - 
Transmission not by IDU ref 0.53 ref 0.12 ref 0.04 
Transmission by IDU -0.001 -0.011 0.022 
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Table 5-18: Multivariable model results for factors associated with the annualised change in CD4 count (absolute scale); a comparison 
between COHERE data and simulated data from Synthesis V5 and V6 
Model parameter Synthesis V5, n=193,313 COHERE, n=158,385 Synthesis V6 n=160,471 
Estimate p-value Estimate p-value Estimate p-value 
Intercept* -24.8 <0.001 -69.0 <0.001 -50.1 <0.001 
CD4 count at t0 (Per 100 cells/mm
3
 higher) -11.8 <0.001 -17.0 <0.001 -12.0 <0.001 
Viral load at t-1 (Per log copies/ml higher) -78.6 <0.001 -37.6 <0.001 -49.7 <0.001 
Age at t0 (Per 10 years older) -11.4 <0.001 -1.7 0.046 -0.92 0.38 
Male ref 0.3 ref 0.67 ref 0.50 
Female 4.1 -0.8 1.4 
White race - - ref - ref 0.002 
Black race - - 2.3 0.48 6.7 
Other/unknown race - - -6.0 0.0004 - 
Transmission not by IDU ref 0.03 ref 0.80 ref 0.75 
Transmission by IDU 21.0 0.7 1.67 
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As a result of the changes there are some effect sizes which fit better to the COHERE 
data and some which fit worse. Both the intercept values, i.e. the average annual 
changes, are much closer to the observed data. In Synthesis V6 there is now an 
adequately sized age effect on both the viral load and CD4 count change. I also 
introduced a small race effect on the change in CD4 count, though the magnitude of the 
effect is somewhat larger than preferred. The effect of viral load on the CD4 count 
change is now much closer to the observed data than it was previously (-37.6 in 
COHERE, -78.6 in Synthesis V5 and -49.7 in Synthesis V6). Overall, these results 
indicated that Synthesis V6 fits to the COHERE data and also agrees with effects found 
in the literature. 
5.4 Analysis: Determination of changes in CD4 count 
whilst on ART 
5.4.1 Background 
The SSOPHIE working group agreed that there were three components in the model 
which should be investigated further using data from COHERE on people on ART: 
predictors of the changes in CD4 count whilst on ART, the change in the rate of CD4 
count rise over time and whether there is evidence for a sub-normal plateau beyond 
which the CD4 increases stop completely.  
The rise in CD4 count whilst on ART varies hugely among people with HIV and many 
studies have looked into factors associated with this rise. Successful viral suppression, 
younger age, taking a boosted PI-based regimen and lower CD4 count at ART initiation 
have all been found to be strong predictors of a larger rise in CD4 count[159, 165, 844, 
871-875]. The CD4 count rise in Synthesis V5 depends on the person’s current ‘effective 
adherence’, current number of active drugs, time on current antiretroviral regimen and 
viral load in the previous three month period (whether < or ≥4 log copies/ml). Each 
person also has a different propensity for CD4 count rise whilst on ART. There is an 
additional effect such that the rate of CD4 count rise depends on time on current 
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continuous period of ART, with a change at two years; i.e. if a patient has been on their 
current regimen for longer than two years, their underlying propensity for CD4 count rise 
reduces 4-fold, to reflect the fact that the rate of CD4 count increase decreases over 
time. I will reconsider by analysing the COHERE dataset whether this step function is 
reasonable. The literature is somewhat conflicting on whether there is evidence for a 
sub-normal plateau beyond which CD4 increases stop completely. Some studies 
suggest that there may be a plateau[159-161] whilst others suggest that there is no 
evidence of a plateau[162-165]. 
5.4.2 Methods 
Similarly to the natural history analysis in Section 5.3, in the COHERE data, pairs of 
CD4 counts were included from patients whilst taking ART. Pairs of CD4 counts were 
included if they were measured between 60 and 365 days apart and in addition, any 
pairs of values in which the absolute annual change in CD4 count was greater than 
2000 cells/mm
3
 were considered as data errors and thus excluded. Each CD4 count 
measurement contributed only to one pair, unlike the analysis in Section 5.3 as there 
were a lot more CD4 count and viral load data post-ART initiation. Only CD4 count pairs 
measured whilst the person was virologically suppressed (defined as <500 copies/ml) 
were considered, in order to evaluate the effect of CD4 count rise whilst on virally 
suppressive treatment. This meant excluding the effects of any factors which may have 
an impact on the viral loads measurements, such as inconsistent adherence to 
treatment, interruption of therapy and virologic failure. Pairs were excluded if the patient 
interrupted treatment or changed regimen type between the two measurements. 
Likewise in the simulated Synthesis data, pairs of CD4 counts which were taken whilst 
patients were on ART were included in the analysis. As in the previous analysis, 
variables are updated three-monthly in the Synthesis models so measurements from the 
simulated data were naturally three months apart. Similarly, pairs were excluded if the 
patient interrupted treatment or changed regimen type between the two measurements. 
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GLMs, adjusted for correlation within patients using an autoregressive correlation 
structure were then fitted to both datasets. Variables considered for inclusion in these 
multivariable models (including factors which have previously been shown to be 
associated with a change in CD4 count in patients on treatment) were: CD4 count 
previous to the pair (to reduce effects of regression to the mean), age, regimen type, 
gender and race. The time on current regimen was also fitted as a covariate to 
determine how to model the change in rate of CD4 count rise and to give an indication of 
whether the CD4 count rise eventually plateaus at a sub-normal level or otherwise. 
Further analyses were performed to check the sensitivity of the results. Firstly, only pairs 
of CD4 counts which had an annual change of less than 1000 cells/mm
3
 were included. 
An additional GLM was fitted in another sensitivity analysis, but this time restricted only 
to people who contributed at least five pairs of CD4 counts and viral load measurements. 
I also refitted the models using the definition of viral load <50 copies/ml to define viral 
suppression.  
5.4.3 Results: from analysis on COHERE data 
149,693 people contributed 823,325 pairs of observations in this analysis. The median 
number of pairs of observations per person was seven (IQR:3-13). At baseline (first CD4 
count or viral load date after when ART is started), the median (IQR) age, viral load and 
CD4 count were 39 (33-45) years, 2.7 (2.4-4.4) and 284 (160-430) respectively. 
Seventy-four percent of patients were male and the breakdown of mode of HIV 
transmission was: MSM (41%), heterosexual (36%), IDU (14%), other/unknown (9%). 
Six percent, 32% and 62% of patients were black, white and other/unknown race 
respectively. Median (IQR) time since start of ART across all pairs of observations was 
four (2-8) years. The distribution of regimen type was as follows: 2 NRTI + 1 NNRTI 
(36%), 2 NRTI + 1 PI/r (24%), 2 NRTI + 1 PI (13%), 3 NRTI (8%), a combination of 3 
drugs from the original classes, NRTI, NNRTI or PI (17%) and three drugs from any 
class (2%).  
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The mean (95% CI) annual change in CD4 count was 49.1 (48.1 to 50.1) cells/mm
3
 per 
year (Table 5-19). As demonstrated by the IQR, in more than half the observations, 
there was no change in viral load over the year (as most people had undetectable levels 
throughout).  
Table 5-19: Average annual changes in viral load and CD4 count whilst on ART in 
COHERE (n=823,325) 
 Mean (95% CI) Median (IQR) 
Annual change in viral load, log copies/ml -0.083  
(-0.084 to -0.081) 
0  
(0 to 0) 
Annual change in CD4 count, cells/mm3 49.1  
(48.1 to 50.1) 
40.8  
(-167.4 to 266.0) 
 
Table 5-20 shows the univariable and multivariable models fitted to estimate the factors 
associated with the change in CD4 count among people with viral suppression. Although 
the effect of race was significant (p<.0001) in the univariable analyses, I did not find it to 
be significant in the multivariable model and therefore it was not adjusted for this. 
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Table 5-20: Estimated annual change in CD4 count (cells/mm
3
) by previous CD4 count, current age, regimen type, gender and time on 
current regimen in COHERE (n=823,325) 
Model parameter Univariable Multivariable 
Estimate 95% CI p-value Estimate 95% CI p-value 
Intercept - - - 77.1 74.1,80.1 <.0001 
Previous CD4 count, 
cells/mm
3
 
0–100 34.3 29.9,38.7 <.0001 17.8 14.3,21.3 <.0001 
101–200 5.4 1.4,9.5 1.07 -1.5,3.6 
201–350  ref - ref - 
351–500 -10.2 -13.1,-7.2 -5.93 -8.3,-3.5 
501–700   -19.2 -22.2,-16.3 -12.5 -15.3,-9.7 
701–900  -27.6 -31.2,-24.0 -19.5 -23.6,-15.4 
901+ -46.3 -50.4,-42.2 -37.6 -43.2,-31.9 
Age, years 16–25  34.8 26.9,42.3 <.0001 23.0 14.2,31.7 <.0001 
26–35 16.6 13.9,19.3 10.1 7.3,12.9 
36–45  ref - ref - 
46–55  -10.3 -12.7,-7.9 -7.5 -10.0,-5.0 
56–65  -17.3 -20.8,-13.8 -13.5 -16.8,-10.1 
65+ -29.4 -35.1,-23.7 -25.6 -30.8,-20.5 
Regimen type 2 NRTI + 1 NNRTI ref - <.0001 ref - <.0001 
2 NRTI + 1 PI/r 16.1 13.6,18.9 10.3 7.8,12.8 
2 NRTI + 1 PI 21.5 18.4,24.6 14.7 11.5,17.9 
3 NRTI -6.9 -10.8,-3.0 -2.3 -6.5,1.9 
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3 NRTI/NNRTI/PI* -6.1 -9.0,-3.3 -12.2 -15.1,-9.4 
3 other ARVs
#
 15.0 7.5,22.5 7.3 0.0,14.7 
Gender Male ref - <.0001 ref - <.0001 
Female 9.7 7.4,11.9 5.70 3.4,8.0 
Time on current regimen, 
years 
0–0.5 ref - <.0001 ref - <.0001 
0.6–1.0 -20.3 -23.3,-17.3 -15.5 -18.5,-12.5 
1.1–2.0 -35.0 -37.8,-32.3 -27.4 -30.2,-24.6 
2.1–3.0 -45.0 -48.3,-41.7 -34.6 -38.0,-31.1 
3.1–4.0 -53.9 -57.9,-50.0 -41.3 -45.5,-37.2 
4.1–5.0 -57.5 -62.4,-52.8 -43.1 -48.2,-38.0 
5.1–6.0 -62.3 -68.8,-57.2 -46.8 -53.1,-40.6 
6.1–7.0 -61.1 -68.2,-54.1 -43.6 -51.2,-36.1 
7.1–8.0 -63.6 -72.2,-55.0 -45.0 -54.0,-36.0 
8.1–9.0 -58.8 -69.4,-48.2 -39.5 -50.5,-28.6 
9.1+ -66.9 -76.0,-57.8 -47.5 -57.0,-38.0 
*3 NRTI/NNRTI/PI is any regimen other than those specifically listed already, involving drugs only from the original three classes.  
#
3 other ARVs is any regimen including drugs from the ‘newer’ classes of antiretrovirals (i.e. integrase inhibitors, fusion inhibitors and CCR5 antagonists). 
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I found that the time on current regimen was a significant predictor of the CD4 count 
change, independent of the previous CD4 count. I also re-fitted the multivariable model 
using a different reference group (4.1-5.0 years instead of 0-0.5 years) for the time on 
current regimen variable (Table 5-21) to see if there was any evidence for a sub-normal 
plateau beyond which the CD4 increases stop completely. After controlling for CD4 
count, age, regimen type and gender, the new intercept value was 34.0 (95% CI:28.8-
39.1). There seems to be evidence that the CD4 count increases are significantly 
greater in the first two years after starting a given regimen, but then the rise remains 
roughly the same for the next five to six years. The CD4 count rise perhaps slows down 
even further after that, although there is less certainty due to less data. 
Table 5-21: The effect of time on current regimen (years) on CD4 count rise 
(adjusting for previous CD4 count, current age, regimen type and gender) 
Time on current regimen, years Estimate 95% CI p-value 
0–0.5 43.1 38.0,48.2 <.0001 
0.5–1.0 27.6 22.4,32.8 <.0001 
1.1–2.0 15.7 10.6,20.8 <.0001 
2.1–3.0 8.6 3.2,13.9 0.0018 
3.1–4.0 1.8 -4.0,7.6 0.55 
4.1–5.0 ref - - 
5.1–6.0 -3.7 -11.2,3.7 0.33 
6.1–7.0 -0.5 -9.1,8.0 0.91 
7.1–8.0 -1.9 -11.7,8.0 0.71 
8.1–9.0 3.6 -8.1,15.3 0.55 
9.1+ -4.4 -14.7,5.9 0.40 
 
In the first of the two sensitivity analyses performed I re-analysed the data, restricting 
only to pairs of CD4 counts which had an annual change of less than 1000 cells/mm
3
. 
This excluded 39,434 (5%) pairs of data. In the second sensitivity analysis, which 
restricted only to people who contributed at least five pairs of CD4 counts and viral load 
measurements, 94,362 (11%) pairs of observations were excluded. In both these 
sensitivity analyses, results were similar to the primary analysis (data not shown). The 
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overall results of the analysis also did not change much when defining viral suppression 
as a viral load <50 copies/ml (570,055 pairs of observations in the analysis contributed 
by 122,089 people).  
5.4.4 Results: comparing COHERE results with Synthesis V5 
Table 5-22 shows the multivariable model estimates using simulated data from 
Synthesis V5. Viral suppression was defined as a viral load <500 copies/ml. The change 
in CD4 count in Synthesis V5 was associated with the previous CD4 count, regimen 
type and time on current regimen.  
Table 5-22: Estimated annual change in CD4 count (cells/mm
3
) by previous CD4 
count, current age, regimen type, gender and time spent on current regimen in 
Synthesis V5 (n=680,976) 
Model parameter Estimate 95% CI p-value 
Intercept 140.3 135.5,145.1 <.0001 
Previous CD4 count, 
cells/mm
3
 
0–100 -44.8 -48.8,-40.8 <.0001 
101–200 -8.1 -12.3,-3.8 
201–350  ref - 
351–500 -4.2 -8.0,-0.4 
501–700   -29.8 -33.8,-25.8 
701–900  -61.4 -66.3,-56.4 
901+ -89.4 -96.8,-82.0 
Current age, years 16–25  -2.9 -12.4,6.7 0.42 
26–35 -2.8 -0.9,6.4 
36–45  ref  
46–55  -0.6 -4.1,2.9 
56–65  2.8 -2.0,7.5 
65+ -0.1 -7.0,6.9 
Regimen type 
 
2 NRTI & 1 NNRTI ref - <.0001 
2 NRTI & 1 PI/r -0.2 -3.4,3.0 
2 NRTI & 1 PI -6.5 -13.4,0.4 
3 NRTI 6.6 -7.2,20.4 
3 NRTI/NNRTI/PI* -8.0 -14.2,-1.9 
3 other ARVs
#
 -19.0 -31.1,-6.9 
Gender Male ref - 0.13 
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Model parameter Estimate 95% CI p-value 
Female 2.29 -0.65,5.23 
Time on current 
regimen, years 
0–0.5 ref - <.0001 
0.5–1.0 -20.3 -25.5,-15.2 
1.1–2.0 -27.9 -32.8,-23.0 
2.1–3.0 -81.1 -86.5,-75.8 
3.1–4.0 -82.6 -88.4,-76.9 
4.1–5.0 -82.9 -89.1,-76.7 
5.1–6.0 -85.3 -91.7,-78.4 
6.1–7.0 -88.1 -95.4,-80.8 
7.1–8.0 -85.6 -93.5,-77.7 
8.1–9.0 -90.8 -99.5,-82.1 
9.1+ -93.9 -100.0,-87.9 
*3 NRTI/NNRTI/PI is any regimen other than those specifically listed already, involving drugs 
only from the original 3 classes.  
#
3 other ARVs is any regimen including drugs from the ‘newer’ classes of antiretrovirals (i.e. 
integrase inhibitors, fusion inhibitors and CCR5 antagonists). 
 
5.4.5 Discussion and changes made 
There were some marked differences between the model estimates for the observed 
COHERE data and the modelled Synthesis V5 data. In particular, the intercept (which is 
the annual CD4 count change for a male with previous CD4 count 201-350 cells/mm
3
, 
aged 36-45, on an NNRTI-based regimen who has been on the regimen for less than 6 
months) was 140.3 in the modelled Synthesis data but only 77.1 in the observed 
COHERE data. I think that this difference is partly due to a different selection of patients 
in each of the models and confounders that have not been taken into account. As there 
are so many factors in which the change in CD4 count can depend on, it is perhaps 
unsurprising that the two intercept values are not very similar. Given the Synthesis V5 
estimates of the intercept and effect of previous CD4 count, I thought that the model 
would be improved if an additional effect is included, such that CD4 count rise is lower if 
previous CD4 count >100 cells/mm
3
 and lower still if it is >200 cells/mm
3
. Further, I also 
decided to revise the distribution of the maximum CD4 count which can be achieved 
whilst a patient is on ART, so that the mean value is lower and the overall distribution 
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more skewed to the right. As the intercept value in the COHERE data was quite a lot 
lower, I think that this will better reflect what is observed in the cohort data.  
Although previous CD4 count was a strong predictor of the change in CD4 count in the 
observed COHERE data, a similar trend in the higher CD4 count range was also seen in 
the simulated data, even though this effect is not explicitly included in Synthesis V5. I 
think that this may have occurred due to effects from regression to the mean, as once 
someone has a high CD4 count, then the CD4 count is unlikely to continue increasing. 
As mentioned in Chapter 3, in Synthesis V5, the maximum CD4 count potentially 
attainable for each individual whilst on ART is sampled from Normal(800,150
2
).  
Data from COHERE showed that larger CD4 count rises were associated with younger 
age, being on a PI-based regimen, female gender and lesser time on the current 
regimen. Age had a linear relationship with CD4 count change, with greater increases 
seen in younger people. Compared to being on an NNRTI-based regimen, there was 
strong evidence of the CD4 count rising faster on a boosted or non-boosted PI-based 
regimen. CD4 count rises in the first few years of starting a new regimen is much greater 
than in subsequent years. I think that these results support to modify the way in which 
the relative propensity for CD4 count rise whilst on ART is modelled. The changes made 
on the basis of the above analyses are summarised in Table 5-23. 
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Table 5-23: Changes made to the Synthesis model [CD4 count changes whilst on 
ART on absolute scale (cells/mm
3
)] 
 Synthesis V5 Synthesis V6 
CD4 count 
change 
(three-
monthly) 
Change in CD4 count =  
[depends on the effective 
adherence and number of active 
drugs]* 
Change in CD4 count =  
[depends on the effective 
adherence and number of active 
drugs]* 
+ (-0.3x(age–40))   if 16≤age≤70  
+ 2 if female 
+ 3 if regimen contains a PI 
Additional 
effect on 
CD4 count 
rise 
 lower by a factor of 0.85 if 100< 
current CD4 count ≤200 cells/mm3 
lower by a factor of 0.7 if current 
CD4 count >200 cells/mm3 
Relative 
propensity 
for CD4 
count rise 
whilst on 
ART 
Each person is given a value for 
their propensity, which is sampled 
from lnNormal(ln1,0.52)), i.e. 
approximately 95% of people will 
have a value between 0.43 and 
2.29 
step function after 2 years, such 
that if a patient has been on their 
current regimen for longer than 2 
years and their underlying 
propensity for CD4 count rise is 
<1, their underlying propensity for 
CD4 count rise reduces 4-fold 
Each person is given a value for 
their propensity, which is sampled 
from lnNormal(ln1,0.22), i.e. 
approximately 95% of people will 
have a value between 0.72 and 
1.39 
step function after 1 year, such that 
if a patient has been on their 
current regimen for longer than 1 
year and their underlying propensity 
for CD4 count rise is <1, their 
underlying propensity for CD4 count 
rise reduces 1.5-fold 
another step function after 3 years, 
such that if a patient has been on 
their current regimen for longer than 
3 years and their underlying 
propensity for CD4 count rise is <1, 
their underlying propensity for CD4 
count rise reduces 2-fold (not in 
addition to the previous 1.5-fold 
reduction) 
Maximum 
CD4 count 
achievable 
on ART 
Sampled for each person from 
Normal(800,1502)  
(i.e. approximately 95% of 
maximum CD4 counts lie 
between 500 and 1100 cells/mm3) 
Sampled for each person from 
lnNormal(ln6.6,0.252)  
(i.e. approximately 95% of 
maximum CD4 counts lie between 
491 and 1112 cells/mm3) 
ART:antiretroviral therapy; PI:protease inhibitor. 
*the change in CD4 count from t-1 to t, determined by the effective adherence and number of 
active drugs, is shown in Appendix VII. 
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5.4.6 Results: Comparing COHERE results with Synthesis V6 
Table 5-24 shows the estimated annual change in CD4 count respectively for Synthesis 
V5, COHERE and Synthesis V6. The overall fit of the model using the simulated 
Synthesis V6 data is considerably closer to the COHERE data than the simulated 
Synthesis V5 data. The additional effects that have been included in Synthesis V6 which 
seem to have improved the model estimates are the previous CD4 count effect on CD4 
count rise, age effect on CD4 count rise, gender effect on CD4 count rise and the 
revised effect of the time on current regimen to the propensity of CD4 count rise. 
Although I incorporated a 3 cells/mm
3
 change per three-month period in CD4 count rise 
if an individual is on a PI-based regimen, the size of the effect is perhaps not as large in 
the Synthesis V6 model. However, I don’t think there is any further evidence in addition 
to the COHERE results to justify including a larger effect so I have decided to not 
change this further for Synthesis V6.   
Table 5-24: Estimated annual change in CD4 count (cells/mm
3
) by previous CD4 
count, current age, regimen type, gender and time spent on current regimen; 
comparison between COHERE data and simulated data from Synthesis V5 and V6 
Model parameter 
Synthesis V5 
n=680,976 
COHERE 
n=823,394 
Synthesis V6 
n=695,953 
Estimate p-value Estimate p-value Estimate p-value 
Intercept 140.3 <.0001 77.13 <.0001 93.91 <.0001 
Previous CD4 count, cells/mm
3
 
0–100 -44.8 <.0001 17.79 <.0001 13.82 0.0003 
101–200 -8.1 0.002 1.06 0.61 6.53 0.003 
201–350  ref - ref - ref - 
351–500 -4.2 0.03 -5.94 <.0001 -13.09 <.0001 
501–700   -29.8 <.0001 -12.47 <.0001 -39.58 <.0001 
701–900  -61.4 <.0001 -19.47 <.0001 -62.73 <.0001 
901+ -89.4 <.0001 -37.54 <.0001 -81.96 <.0001 
Current age, years 
16–25  -2.9 0.55 22.96 <.0001 17.97 <.0001 
26–35 -2.8 0.14 10.07 <.0001 4.73 0.0014 
36–45  ref - ref - ref - 
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46–55  -0.6 0.74 -7.50 <.0001 -0.93 0.53 
55–65  2.8 0.25 -13.47 <.0001 -4.70 0.03 
65+ -0.1 0.99 -25.65 <.0001 -6.29 0.04 
Regimen type 
2 NRTI + 1 NNRTI ref - ref - ref - 
2 NRTI + 1 PI/r -0.2 0.91 10.30 <.0001 2.71 0.04 
2 NRTI + 1 PI -6.5 0.067 14.70 <.0001 -0.11 0.98 
3 NRTI 6.6 0.35 -2.33 0.25 -3.44 0.54 
3 NRTI/NNRTI/PI* -8.0 0.011 -12.23 <.0001 -2.72 0.30 
3 other ARVs
#
 -19.0 0.0021 7.31 0.058 -14.69 0.0015 
Gender 
Male ref - ref - ref - 
Female 2.29 0.13 5.67 <.0001 5.79 <.0001 
Time on current regimen, years 
0–0.5 ref - ref - ref - 
0.5–1.0 -20.3 <.0001 -15.51 <.0001 -5.09 0.053 
1.1–2.0 -27.9 <.0001 -27.44 <.0001 -22.77 <.0001 
2.1–3.0 -81.1 <.0001 -34.62 <.0001 -21.70 <.0001 
3.1–4.0  -82.6 <.0001 -41.34 <.0001 -32.36 <.0001 
4.1–5.0 -82.9 <.0001 -43.12 <.0001 -36.46 <.0001 
5.1–6.0 -85.3 <.0001 -46.86 <.0001 -37.95 <.0001 
6.1–7.0 -88.1 <.0001 -43.65 <.0001 -41.54 <.0001 
7.1–8.0 -85.6 <.0001 -44.94 <.0001 -45.53 <.0001 
8.1–9.0 -90.8 <.0001 -39.53 <.0001 -41.44 <.0001 
9.1+ -93.9 <.0001 -47.53 <.0001 -51.98 <.0001 
*3 NRTI/NNRTI/PI is any regimen other than those specifically listed already, involving drugs 
only from the original three classes.  
#
3 other ARVs is any regimen including drugs from the ‘newer’ classes of antiretrovirals (i.e. 
integrase inhibitors, fusion inhibitors and CCR5 antagonists). 
 
As a further comparison between the observed and new simulated data, the average 
CD4 count over time was visually assessed. The change in mean and median CD4 
count from time of ART initiation calculated using data from COHERE and data from 
Synthesis V6 are shown in Figure 5-2. These changes were calculated in individuals 
who achieved virologic suppression (again defined as viral load <500 copies/ml) within 
six months of starting ART and who have also never experienced virologic failure. The 
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figure indicates that the average changes in CD4 count over time in suppressed 
individuals on ART simulated in Synthesis V6, fit closely to the observed data. 
Figure 5-2: Mean and median CD4 count change (and 95% confidence intervals for 
the mean) from start of ART in stably suppressed (viral load <500 copies/ml) 
individuals 
 
5.5 Review: Effect of Effect of age and acquiring HIV 
through IDU on treatment adherence 
5.5.1 Background 
Synthesis V5 does not account for any effects of either age or acquisition of HIV through 
IDU on adherence. In both observational studies and trial settings, adherence to 
treatment is often poorly measured and no gold standard method yet exists[876]. In 
cases where data on adherence are not available, virologic outcomes are often used as 
a surrogate measure, due to the fact that a virologic response (suppressed or low viral 
load) can only be attained in cases where good adherence is achieved[877-879]. In this 
section, I first summarise the findings of studies which investigated the effect of age and 
having acquired HIV through IDU on adherence and virologic outcomes. I then looked at 
the existing data from COHERE on factors associated with a virologic response. Finally, 
I specifically reviewed data collected within the SMART study to supplement my findings. 
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5.5.2 Adherence and virologic outcomes by age 
The effect of age on adherence seems to be well established now in HIV literature. 
Numerous studies have consistently found that older age is associated with better ART 
adherence[842, 880-882].  
Long-term data on adherence (covering a period up to 13 years from start of ART) 
measured using prescription data was available in the Royal Free Clinic Cohort from the 
UK, which showed that for every ten year older in age, the odds of achieving adherence 
greater than 95% was 1.12-fold higher[842].  
An observational study in women only, which measured adherence using MEMS caps 
(Medication Event Monitoring System caps, often considered to be a more accurate 
method of measuring adherence) over a six month period, also found that younger age 
was significantly (p=0.047) associated with lower adherence[880].    
A recently published meta-analysis concluded that older age reduced the risk for non-
adherence by 28% (relative risk, RR:0.72, 95% CI:0.64-0.82) among people living with 
HIV[881]. This effect was seen both in studies assessing the short-term and long-term 
adherence (RR:0.75, 95% CI:0.64–0.87 and RR:0.65, 95% CI:0.50–0.85, respectively). 
In this meta-analysis, the authors defined ‘older age’ to be at least 45 years of age and 
non-adherence to be <80% of prescribed doses of ART.    
Adherence may only improve up to a certain age however[883]. Often there are a 
number challenges associated with older age, such as more complex medicine 
regimens (in addition to ART), more co-morbidities, as well as reduced social and 
economic security. In a small US study which investigated adherence in 84 older adults 
taking ART (aged 47 to 69 years), the researchers found that 31% of patients skipped at 
least one medication dose during the past seven days[884]. However, these data may 
be too pessimistic to apply directly to a European setting, given that adherence among 
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Americans has been found to be significantly worse than all other areas of the 
world[885]. 
5.5.3 Adherence and virologic outcomes in people who acquired HIV 
through IDU 
The progression of HIV disease and the factors which affect treatment response are 
thought to vary between PWID and others for several reasons. Compared to people who 
did not acquire HIV through IDU, PWID are thought to have lower adherence to 
ART[886, 887], lower uptake of ART[888, 889], worse rates of treatment response[887, 
890], and increased rates of mortality and morbidity[887, 891]. Further, interactions 
between antiretroviral drugs, opioids and opioid substitutes provide a further risk to 
PWID[892]. However, although this group of people classified as ‘PWID’ may have once 
acquired their HIV infection through IDU, it can be inappropriate to consider them as a 
homogenous population. Clearly it is possible for someone’s behaviour of drug use and 
treatment status (whether on opioid substitution treatment or not) to change over 
time[893]. There are only a handful of studies which look at the uptake and outcomes of 
ART within the sub-populations of people who acquired HIV through IDU (those which 
compare outcomes between for example, active drug users and former drug users).  
A Canadian study compared the virologic response among participants in an HIV 
treatment centre by IDU status, which was categorised as current PWID, former PWID, 
or non-injecting drug users[890]. They did not find a significant difference in the odds of 
viral suppression (outcome defined as two consecutive viral loads <500 copies/ml) 
between non-injecting drug users and former PWID, however current PWID were 
significantly less likely to achieve viral suppression compared to non-injecting drug users 
(odds ratio OR:0.37, 95% CI:0.16–0.82). Consistent with previous studies, they also 
found that virologic outcomes were independently associated with adherence among 
non-injecting drug users and former PWID[261, 264, 894, 895]. This was not the case in 
current PWID. Adherence was measured by pharmacy refill compliance data, which was 
found to be unreliable among current PWID.  
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An observational study conducted in Switzerland looked into the uptake of and virologic 
response to antiretroviral therapy, partitioning the cohort into four groups: abstinent 
former PWID, persons in OST programmes without concomitant IDU, persons in OST 
programmes with concomitant IDU, and current PWID[896]. They found that uptake of 
ART was significantly lower in current PWID and persons in OST programmes with 
concomitant IDU, compared to non-IDUs, abstinent former PWID and persons in OST 
programmes without concomitant IDU. Adherence to HIV treatment was less among 
people who continued to inject drugs and was correlated with virologic response rates. 
The odds of viral suppression were similar among non-IDUs, abstinent former PWID and 
persons in OST programmes without concomitant IDU, but were much lower among 
current PWID and persons in OST programmes with concomitant IDU. 
A systematic review has also been recently conducted to review the factors associated 
with HIV progression among PWID[897]. The endpoints which were considered included 
the following: an AIDS diagnosis, death, changes in CD4 counts and viral load levels. 
The review did not identify any studies among PWID which assessed the direct effect of 
access and adherence to ART on time to AIDS. Further, studies have shown that PWID 
who were engaged in OST programmes had better survival and better virologic 
outcomes compared to those not engaged in OST programmes[898-900]. The overall 
results from the review suggest that there is only weak evidence of a direct association 
between IDU and HIV disease progression. The authors also concluded that there is still 
a lack of studies which incorporate the individual-level effects of social and structural 
factors on disease progression among PWID and that therefore, it is still difficult to draw 
solid conclusions based on the current literature.  
5.5.4 Virologic response to ART in COHERE 
Although data on adherence is not collected in COHERE, it is still valuable to look at the 
data on virologic outcomes. A previous study using COHERE data did indeed find that 
older age is associated with better virologic response to treatment[844]. In this study, 
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virologic response was defined to be the achievement of two consecutive viral load 
measurements <50 copies/ml. By 12 months after starting ART, 54% of all patients had 
experienced a virologic response. The best responses were observed in those aged 50-
54 (61.4%), 55-59 (60.3%) and >60 years (61.8%). Factors which were also associated 
with a good virologic response were later calendar periods, lower pre-ART CD4 count 
and viral load, unknown/non-European origin and receipt of an NNRTI-based regimen. 
The authors were not able to adjust for route of HIV acquisition owing to the high 
colinearity with age and so an effect size was not given. 
5.5.5 Factors associated with adherence in the SMART study 
Self-reported adherence data were collected routinely within the SMART study, which 
was conducted across 33 countries globally[259]. Although self-reported adherence is 
more likely to show higher adherence than the true levels, I thought it was important to 
consider the data from SMART given it is thought to provide the largest set of 
prospectively collected data on adherence[885]. Adherence in SMART was collected 
every four months whilst receiving ART. Participants used a self-report form to rate their 
adherence to every single drug in their regimen, reporting whether they had taken ‘all’, 
‘most’, ‘about one-half’, ‘very few’, or ‘none’ of their pills during the previous week. ‘High’ 
adherence was defined as those who reported taking ‘all’ their pills. All other categories 
fulfilled the criteria for “suboptimal adherence”.  
Factors found to be independently associated with high adherence included higher latest 
CD4 count, being prescribed concomitant drugs in the year preceding the visit, being in 
the drug conservation arm of the trial and having received a higher level of education. 
The odds of having a higher adherence increased with older age (OR per 10 year 
increase, 0.90; 95% CI:0.85-0.96, p=0.0004, where an OR of >1 indicates an increased 
odds of suboptimal adherence). The global p-value for the multivariable OR for risk 
group was not significant, however compared to the group of people who acquired HIV 
through MSM transmission, PWID seemed to have lower adherence (OR:0.88, 95% 
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CI:0.73-1.07). Although this was not significant, this is believed to be due to the 
considerably small sample size of PWID within the trial population. Further, PWID who 
join trials are known to be a selected subgroup of particularly stable people. 
5.5.6 Discussion and changes made 
Having reviewed the literature, together with observations from the COHERE cohort 
collaboration and SMART study, I can conclude that there is sufficient evidence that 
older age is associated with both better adherence and virologic response and that 
people who acquired HIV through IDU have both worse adherence and virologic 
response compared to people who did not acquire HIV through IDU. The following 
paragraphs together with Table 5-25 summarise the changes made to Synthesis V5. 
For Synthesis V6, I decided to include a fixed person-specific effect to inform levels of 
effective adherence for people who became HIV-positive via IDU which would be 
uniformly distributed between -0.1 and 0. This would then assume that a proportion of 
such people would have worse lifelong adherence compared to people who acquired 
HIV in other ways. A person for whom this fixed person-specific effect is sampled to be 0 
means that their adherence is the same as someone who did not acquire HIV through 
IDU. This distribution thus assumes that people who acquired HIV through IDU will 
never have better adherence than those who did not acquire HIV through IDU. I decided 
to model this effect in this way because of the lack of observed data on current IDU 
status. Most cohorts, to my knowledge, do not routinely collect data on whether 
someone is currently actively injecting drugs or whether someone is enrolled in OST. 
This makes informing such model parameters impossible.   
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Table 5-25: Changes made to the Synthesis model [factors associated with 
adherence] 
 Synthesis V5 Synthesis V6 
Effective  
adherence 
0.95 + ε if very high adherence* 
  or 0.9 + ε if high adherence*  
  or 0.79 + ε if moderate adherence* 
  or 0.49 + ε if low adherence* 
 
- 0.12 if year<1996 
- (2006 - year)x0.01 if 
1996≤year<2006 
 
- 0.25 + Normal(0,0.12) if person has  
current CD4 count <200 cells/mm3 
and has experienced triple-class 
failure 
 
+ 0.05 if on NNRTI-based regimen 
(increases effective adherence due 
to long half-life) 
0.95 + ε if very high adherence* 
  or 0.9 + ε if high adherence*  
  or 0.79 + ε if moderate adherence* 
  or 0.49 + ε if low adherence* 
 
- 0.12 if year <1996 
- (2006 - year)x0.01 if 
1996≤year<2006 
 
- 0.25 + Normal(0,0.12) if person has  
current CD4 count <200 cells/mm3 
and has experienced triple-class 
failure 
 
+ 0.05 if on NNRTI-based regimen 
(increases effective adherence due 
to long half-life) 
 
+ (0.002 x (age - 40))  if 16≤age≤70 
+ 0.01 if age>70 
 
– Uniform(0,0.1) if acquired HIV 
through IDU 
NNRTI:non-nucleoside reverse transcriptase inhibitor 
*Very high, high, moderate and low adherence indicates the individual’s underlying tendency 
to adhere and ε is the period-to-period variability in the person’s underlying tendency to 
adhere (described in Chapter 3 and Appendix VII).  
 
I have also included a linear effect of current age on adherence in Synthesis V6, such 
that effective adherence increases with older age. A linear effect was thought to be more 
suitable than a stepwise function for the majority of ages, however I decided that the 
linearity should be restricted up to the age of 70 years. The reason for this is that there 
is currently a lack of data to inform whether the positive effect of older age on adherence 
would continue beyond this cut-off[844, 881]. Individuals in the model over the age of 70 
are modelled to have the same ‘effective adherence’ as those who are 70. 
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5.6 Review: Changes to resistance mutations 
modelled 
5.6.1 Background 
The resistance mutations which are considered in Synthesis V5 are listed in Table 3-7 
(Chapter 3). All drug resistance mutation databases are updated on a regular basis. The 
revision from Synthesis V5 to V6 was based on the Stanford University HIV Drug 
Resistance Database[901, 902], March 2013 revision of the IAS-USA drug resistance 
mutations update[903] and the September 2012 French ANRS AC11 Resistance group 
algorithm[904]. 
5.6.2 Results and changes made 
In consultation with virology experts within the SSOPHIE group, I narrowed down the list 
of antiretroviral-mutation relationships to consider in revising the model to V6. I made 
the final decision on which mutations to model following a review of the available 
literature. Table 5-26 summarises the resistance mutations considered, the literature 
identified that relates to the mutations and the changes which were made following this 
review.  
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Table 5-26: Changes made to the Synthesis model [resistance mutations modelled] 
Drug/mutation Evidence in the literature Decision for Synthesis V6 Additional 
references 
ABC/Y115F 
 
 Y115F reduces susceptibility to ABC 
 Acquisition of Y115F mutation from ABC-use is very rare 
 Y115F does not affect susceptibility to other NRTIs 
Y115 (mutation not modelled in 
Synthesis V5) will not be modelled. 
[905, 906] 
DRV/V32I, I47V 
 
 Both V32I and I47V reduce susceptibility to DRV. Susceptibility 
further reduced if V32I or I47V present in combination with other PI 
mutations 
 Acquisition of PI mutations is rare and V32I and I47V seem no 
different 
 V32I may be the most commonly occurring mutation in patients who 
have virologically failed DRV-containing regimen 
 Presence of I47V has been associated with a lower rate of virologic 
response to RTV-boosted DRV at month 3 
V32I and I47V will be modelled 
such that drug susceptibility is 
reduced when present alongside 
use of a DRV -containing regimen. 
[907-909] 
LPV/L76V 
 
 L76V reduces susceptibility to LPV/r 
 L76V seems to occur rarely on its own and is seen more commonly 
in conjunction with other mutations such as M46, I54, V82, I84 and 
L90 
L76V will be modelled such that 
drug susceptibility is reduced when 
present alongside use of a LPV/r-
containing regimen. 
[910] 
TPV/L33F, I47V, 
Q58E, T74P 
 
 Some evidence that L33F, I47V, Q58E and T74 reduce TPV 
susceptibility 
 L33F thought to be one of four key mutations which reduce 
susceptibility to TPV, others being V82A/F/S/T, I84V and L90M 
 One study showed that having at least 5 of 8 mutations present at 
baseline (out of I13V, V32I, M36I, I47V, Q58E, D60E, V82A/F/S/T 
and I84V) was associated with a worse virologic response rate after 
24 weeks, however the most common mutations which emerged at 
Remove TPV from Synthesis V6 
based on general low-use of TPV 
across Europe since introduction. 
[911-914] 
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Drug/mutation Evidence in the literature Decision for Synthesis V6 Additional 
references 
virologic failure were L33F, V82A/F/S/T and I84V  
3TC, 
FTC/K65R, 
Q151M 
 K65R acquired when ABC, ddC, ddI, d4T or TDF used 
 Q151M acquired when AZT, d4T, ABC or ddI is used  
 There is evidence that both K65R and Q151M confers some 
resistance to 3TC and FTC too (resistance to other NRTIs already 
modelled in Synthesis V5) 
K65R and Q151M will be modelled 
such that drug susceptibility is 
reduced when present alongside 
use of a 3TC- or FTC-containing 
regimen. 
[915] 
RPV/K101E, 
E138K, Y181C 
 K101E, E138K and Y181C most often acquired in patients 
virologically failing RPV-containing regimen  
 K101E, E138K and Y181C reduce susceptibility to RPV 
At the time of developing Synthesis 
V6, RPV was still a new drug and 
not commonly used. The effect of 
RPV and its mutations to be 
included in future revision. 
[916]  
Mutations 
associated with 
NNRTIs 
 K103N, Y181C and G190A seen most often (prevalence >10%) in 
people who have virologically failed an NNRTI-containing regimen 
Model the three most common 
NNRTI mutations separately, given 
that RPV will most likely be added 
in the next model revision, which 
similarly to ETV has a different 
resistance profile to NVP and EFV. 
[320, 332, 
917, 918] 
Mutations 
associated with 
INIs 
 Mutations associated with INIs commonly categorised as either a 
primary/signature/major mutation or secondary/accessory/minor 
mutation, where primary mutations confer high-level resistance on its 
own and secondary mutations contribute only a modest resistance 
but lead to substantial further decreases in susceptibility when 
present with one of the primary mutations 
 The three primary mutations are Y143, Q148 and N155 
 Secondary mutations include E92 and G140 
Model two variables to represent 
resistance to INIs, one to represent 
the primary mutations and the 
other to represent secondary 
mutations. 
[919]  
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5.7 Review: Determination of acquisition of new 
resistance mutations  
5.7.1 Background 
In addition to reviewing which resistance mutations were to be modelled in Synthesis V6 
(as summarised Section 5.6), I also revised the probabilities of mutations arising to a 
particular antiretroviral drug based on findings in the literature. I summarise below 
results from a number of studies and randomised controlled trials which aided in the 
choice of the probabilities of acquiring specific mutations. The prevalence of resistance 
mutations were then compared between the simulated data and various data from 
observational studies to assess the model fit. 
The drugs considered in this section, 3TC, T-20, RAL, MVC, NVP, EFV and ETV were 
chosen in consultation with the SSOPHIE working group and reflect those which were in 
need of review and possible modification. The list of antiretroviral drugs modelled in 
Synthesis V5 (which have not been changed for Synthesis V6 except for exclusion of 
TPV) is shown in Chapter 3 Section 3.6.2. Drugs which are modelled are those which 
have been licensed for at least three years in Europe at the time of development of 
Synthesis V6.   
5.7.2 Resistance to 3TC 
Unless the viral load is suppressed, therapy with 3TC is known to rapidly result in 
mutations at the M184 codon position[315, 920]. In one analysis where two 3TC mono-
therapy studies were evaluated, they found that almost all subjects had resistance to 
3TC by eight to 20 weeks. In another study which involved 20 patients all taking 3TC 
mono-therapy, the researchers observed that all patients had an M184 mutation by 
three months from starting therapy[315]. However, they note that 11 of these patients 
were antiretroviral-experienced prior to taking 3TC and that antiretroviral treatment was 
discontinued in all patients at least 28 days before the start of the 3TC regimen.  
   
240 
 
5.7.3 Resistance to RAL 
Data from the combined BENCHMRK trials showed that by week 48 (of starting a 
treatment regimen containing RAL), a total of 105 out of 462 patients had virologic 
failure[236]. 94 of these 105 patients had integrase genotyping performed both at 
baseline and after virologic failure, and of those 94, 64 (68%) were found to have 
genotypic evidence of resistance to RAL. Virologic failure was found to be generally 
associated with a mutation at one of these codon positions Y143, Q148 or N155, and 
was usually in combination with at least one other mutation. In another study, which 
included only 11 heavily pre-treated patients starting a RAL-containing regimen, they 
found that four patients developed resistance mutations associated with RAL 
resistance[921]. Resistance to RAL developed within 12 weeks of treatment amongst 
three of these four patients. The authors commented that the discrepancy in the timing 
of emergence of integrase resistant strains (compared to the study results at week 48 of 
the BENCHMRK trials) may be explained by the tighter monitoring schedule adopted in 
this study. Whether the same rates of resistance acquisition is seen with use of other 
INIs is not fully known given the lack of data as yet, however it seems like DTG has 
higher a genetic barrier compared to RAL and EVG[241, 327].   
5.7.4 Resistance to T-20 
Data on the emergence of resistance mutations to T-20 suggest that development of 
mutations is quicker than that modelled in Synthesis V5. Firstly, data from the phase I 
trial of T-20 mono-therapy suggested that selection for the resistant virus was occurring 
by week 2 (conclusion based on viral load measurements initially declining over the first 
10 days but then rising)[922]. Another study has also demonstrated that T-20 resistance 
emerges rapidly; in 10 patients who had virologically failed a T-20-containing regimen 
(and in which cloning and sequencing of gp41 was successful), mutations associated 
with T-20 resistance were detected in 8 of them after only 2 weeks[923]. A long-term 
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prospective study including only patients who were treated with T-20 also showed high 
rates of resistance (7 out of 12) after at least one year on the drug[924]. 
5.7.5 Resistance to MVC 
Resistance to MVC can occur in one of two pathways: a change in tropism (which allows 
the virus to use the CXCR4 co-receptors), or through emergence of mutations (multiple 
mutations within different regions of HIV gp120 molecule) which allows the virus to 
continue using the CCR5 co-receptors[925, 926]. As yet, there isn’t much data on rates 
of emergence of resistance to MVC. One study found that 50% of people who had 
virologically failed an MVC-containing regimen had X4- or dual-tropic virus (i.e. a mixture 
of the two tropisms) present[927]. 
5.7.6 Resistance to NVP, EFV and ETV 
NNRTIs have a low genetic barrier to resistance and resistance mutations emerge 
rapidly when given as part of treatment regimen which is failing to suppress the viral 
load. The three most prevalent mutations observed in people failing NNRTIs are K103N, 
Y181C and G190A[320, 332, 917, 918]. K103N is most prevalent among people failing 
EFV and Y181C is most prevalent among people failing NVP[917, 918]. It is well-
established that there is high-level cross-resistance between NVP and EFV. In a study 
of 104 patients failing an NNRTI-containing regimen, all patients failing an EFV-
containing regimen had mutations conferring cross-resistance to NVP and 80% of 
patients failing an NVP-containing regimen had mutations conferring cross-resistance to 
EFV[332]. ETV seems to have a higher genetic barrier compared to NVP and EFV and 
there seems to be less cross-resistance with them too[320]. The higher genetic barrier is 
a result of the need for multiple ETV resistance associated mutations to be acquired 
before resistance is conferred to ETV and for the drug susceptibility to be greatly 
reduced[928]. Of the mutations associated with ETV resistance, Y181C is the most 
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prevalent and requires attention given that it also confers resistance to NVP and 
EFV[928, 929].   
5.7.7 Results and changes made 
Table 5-27 summarises the changes made to the probabilities of acquiring a new 
resistance mutation (in a given three-month period), based on the literature review 
described above. Note that in order for these probabilities to take effect, a number of 
conditions must be satisfied (determined by the number of active drugs in the current 
regimen, individual’s viral load, adherence and current length of time on continuous 
ART). Details on how the risk of resistance emergence is modelled in the Synthesis 
model are given in Appendices VII and VIII. 
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Table 5-27: Changes made to the Synthesis model [probability of resistance 
mutations arising when on a particular drug-containing regimen (given they 
satisfy the ‘new mutation risk’ factor)] 
Current regimen 
contains 
Resistance mutation Probability of mutation arising 
in a given three-month period 
Synthesis V5 Synthesis V6 
3TC M184 30% 50% 
RAL Integrase inhibitor mutations 7% - 
Primary RAL mutations* - 20% 
Secondary RAL mutations* - 20% 
T-20 Fusion inhibitor mutations 8% 20% 
MVC CCR5 inhibitor mutations 7% 7% 
NVP  Mutations associated with NVP 80% - 
K103 - 20% 
G190 - 20% 
Y181 - 40% 
EFV Mutations associated with EFV 80% - 
K103 - 60% 
G190 - 10% 
Y181 - 10% 
ETV Mutations associated with ETV 30% - 
Y181 - 30% 
Accessory ETV mutations - 10% 
*Resistance to RAL is modelled using two variables; one to represent the primary mutations 
and the other to represent secondary mutations (as outlined in Table 5-26). Similar to all 
other mutation variables, these RAL-associated mutation variables will also be modelled to 
be binary (presence/absence of given mutation). 
 
5.7.8 Comparison of modelled data with observed data 
To assess how well Synthesis V6 simulates data on resistance, I compared the 
prevalence of resistance mutations in the published literature with data simulated using 
Synthesis V5 and Synthesis V6. In the simulated data analyses, virologic failure was 
defined as one viral load measurement >500 copies/ml.    
For the first comparison I replicated an analysis (using both Synthesis V5 and V6) done 
using UK data to estimate the long-term risk of development of resistance mutations 
(Figure 5-3). The outcomes of interest were the cumulative proportion of patients with 
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virologic failure and with resistance mutations amongst people who started an NNRTI- 
or PI/r-based regimen. In the observed data (Figure 5-4), virologic failure was defined as 
two consecutive viral load measurements >400 copies/ml at least six months after 
starting therapy while patients were still receiving at least one antiretroviral. Resistance 
mutations were defined using the IAS-USA list (December 2008 update) [836]. After 
seven years from start of ART, resistance mutations were seen in 27% of simulated 
patients in Synthesis V6 data but only 17% in the observed data. As explained in 
Chapter 3, the presence or absence of individual resistance mutations is modelled for 
each simulated individual at each time point in the Synthesis model. Therefore, at any 
time during follow-up it is possible to assess their specific resistance profiles. However 
in reality, resistance tests are not always performed at virologic failure or soon after. 
Therefore the prevalence of resistance mutations was expected to be higher in the 
simulated data compared to the observed data.  
Figure 5-3: Cumulative proportion of patients with resistance mutations (and 
virologic failure) after start of ART in patients starting with NNRTI or boosted-PI 
based regimen 
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Figure 5-4: Cumulative proportion of patients with virologic failure (black line) and 
with at least one detected resistance mutation (dashed line) after starting ART 
[836] 
 
The cumulative risk of triple class resistance was also compared between the observed 
and simulated datasets (Table 5-28). The outcome of interest was the cumulative 
proportion of people with resistance mutations from all three main drug classes (NRTIs, 
NNRTIs and PIs) after start of ART. The observed data defined virologic failure as two 
consecutive viral load values >1000 copies/mL at least six months after starting 
treatment, or one value followed by the starting of at least one new drug, with their list of 
resistance mutations based broadly on the IAS-USA list. The fit to the data on triple 
class resistance has slightly improved from Synthesis V5 to V6. 
Table 5-28: Proportion (%) with at least one resistance mutation for all three main 
classes (and virologic failure) [837] 
Years from start of ART Observed Synthesis V5 Synthesis V6 
2 1.0% 0.5% 0.5% 
4 2.7% 1.6% 2.0% 
6 4.1% 2.9% 3.8% 
 
In the final comparison, I looked at the cumulative risk of resistance mutation 
accumulation by drug class from the start of ART (Table 5-29). The same definition of 
 
Figure not available due to copyright restrictions 
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virologic failure was used as for the previous analysis (Table 5-28). Overall, Synthesis 
V6 still fits fairly closely to the observed data.   
Table 5-29: Risk of resistance mutations after start of ART [837] 
Years from start of  
ART 
Proportion (%) with at least one resistance mutation 
(and virologic failure) 
2 4 6 
Obs. V5 V6 Obs. V5 V6 Obs. V5 V6 
M184V mutation  
(in those starting with  
3TC or FTC) 
6 10 15 13 16 20 18 20 24 
TAMS 
(in those starting with  
AZT or d4T) 
4 7 8 9 11 12 13 14 14 
PI mutation  
(in those starting with  
boosted-PI regimen) 
3 4 7 7 6 9 - 6 10 
NNRTI mutation  
(in those starting with  
NNRTI regimen) 
8 16 14 14 21 20 21 25 23 
3TC:lamivudine; ART:antiretroviral therapy; AZT:zidovudine; d4T:stavudine; 
FTC:emtricitabine; NNRTI:non-nucleoside reverse transcriptase inhibitor; obs:observed; 
PI:protease inhibitor; TAMS:thymidine analogue mutations. 
 
5.8 Study: Antiretroviral drug activity 
5.8.1 Background 
As described in Chapter 3, the activity of a drug is modelled such that it takes a value 
between 0 and 1, where 0 means no activity and 1 means full activity, depending on the 
presence of any resistance mutations. In Synthesis V5 it is assumed that all drugs have 
the same potency and that no drug can currently have an activity greater than 1. 
However, despite the substantial benefits of ART in suppressing HIV infection, studies 
have shown that different triple therapy regimens have varying levels of potency, as 
measured by the level of decay in HIV viral load from the start of a regimen being 
initiated[930, 931]. This is particularly the case for RTV-boosted PIs, which are known to 
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be highly effective on their own, so much so that they have been investigated as an 
option for mono-therapy regimens[213, 217]. 
5.8.2 Results and changes made 
In Synthesis V6, I decided (after discussion among the SSOPHIE working group) that 
the drug activity level for RTV-boosted PIs should be two rather than one, i.e. a 2-fold 
increase. I did not find any evidence in the literature to make changes to drug activity 
levels for other antiretroviral drugs. However, due to minor changes made in terms of 
the mutations which are modelled and the risk of acquiring these (as in Sections 5.6 and 
5.7), I decided that it would be useful to visually compare, between the outputs of 
Synthesis V5 and V6, the predicted virologic outcomes and the proportion of people who 
develop resistance when using a number of different antiretroviral drugs. These 
comparisons are displayed in Figure 5-5 to Figure 5-10. 
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Figure 5-5: Mean viral load change (left) and proportion with ≥1 NNRTI mutation (right) following NVP mono-therapy in Synthesis models 
 
Figure 5-6: Mean viral load change (left) and proportion with ≥1 PI mutation (right) following LPV/r mono-therapy in Synthesis models 
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Figure 5-7: Mean viral load change (left) and proportion with ≥1 PI mutation (right) following DRV/r mono-therapy in Synthesis models 
 
Figure 5-8: Mean viral load change (left) and proportion with ≥1 NRTI mutation (right) following AZT mono-therapy in Synthesis models 
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Figure 5-9: Mean viral load change (left) and proportion with ≥1 NRTI mutation (right) following 3TC mono-therapy in Synthesis models 
 
Figure 5-10: Mean viral load change (left) and proportion with ≥1 NRTI mutation (right) following AZT/3TC dual-therapy in Synthesis models 
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Figure 5-5 shows that the viral load declines in the first few weeks after starting 
treatment with NVP mono-therapy but rebounds to its original level soon after, 
accompanied by a rapid rate of NNRTI mutation acquisition. These trajectories were 
based on results from early trials in participants on NVP[221, 932, 933].  
Figure 5-6 and Figure 5-7 on the other hand show that when the potency of RTV-
boosted-PIs are doubled (from Synthesis V5 to V6), as PIs are known to have high 
genetic barrier to resistance, the viral load still remains at levels which are such that the 
viral load level will be around the level of detectability or below[934-937].   
Figure 5-8 and Figure 5-9 demonstrate that NRTI mono-therapy is not effective and in 
particular, that therapy with 3TC leads to a very quick acquisition of M184 mutation (the 
probability of acquiring it has been increased in V6; see Table 5-27). Figure 5-10 shows 
the extent of the modelled virologic response whilst on dual-therapy being better than 
mono-therapy and that resistance mutations accumulate somewhat slower. These 
trends are in line with observed data from trials and studies in people treated with AZT 
and 3TC separately and in combination[176, 938, 939]. 
Where the change in viral load is concerned, the model does not currently (either in 
Synthesis V5 of V6) differentiate within drug classes. However, the NRTI and PI 
mutations have always been modelled separately and now the NNRTI mutations are 
modelled separately too (following the changes as described in Section 5.6), so there 
will inevitably be some small variation in these figures if done separately within a drug 
class (e.g. plotting the change in viral load for TDF rather than AZT in Figure 5-8), 
though large differences are not expected. 
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5.9 Review and analysis: Risk of treatment 
interruption 
5.9.1 Background 
The risk of treatment interruption in Synthesis V5 depends on the person’s current viral 
load and CD4 count, underlying adherence and presence of side effects. The risk of 
interruption is greater in people with higher viral load, higher CD4 count, low ‘underlying 
tendency to adhere’, and if they have currently have any side effects present. A review 
of the literature was carried out, firstly to investigate the predictors of unstructured 
treatment interruption, secondly to decide whether to incorporate an additional gender 
and calendar time effect or not, and thirdly to choose whether to re-parameterise the 
CD4 count effect (which is linear in Synthesis V5). I also compared the rates of 
interruption in the COHERE cohort collaboration and in the simulated cohorts by looking 
at the proportion of ART-experienced people who are currently not on ART.  
5.9.2 Review of the literature 
Touloumi et al. found that among patients in the CASCADE study, women had 
significantly higher probabilities of treatment interruption than men among both PWID 
and heterosexuals, with the gender difference being similar within both[940]. Higher risk 
of treatment interruptions was also associated with not responding to treatment 
virologically (500 copies/ml or higher throughout follow-up), higher viral load at ART 
initiation and higher CD4 count nadir pre-ART. The last CD4 count measured during 
treatment was also significantly associated with the risk of treatment interruption, where 
the hazard of interrupting was modified by a factor of 0.93 for every 100 cells/mm
3
 it was 
higher. 
An Italian online study where 359 people completed a questionnaire found that people 
who asked their clinician to discontinue their current regimen for a period were more 
likely to have higher CD4 counts, higher viral loads, more symptoms and also self-
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reported suboptimal adherence[941]. Similarly, people who reported having 
discontinued their regimen for at least one day were more likely to have higher viral 
loads, be smokers, self-report suboptimal adherence and seek more information on 
HIV/AIDS, but were less likely to take NNRTI-based regimens.  
Since the results of the SMART trial which were published in 2006, it has been found 
that the frequency of treatment interruptions has decreased[942]. The CASCADE 
collaboration has also done a series of analyses on their cohort of seroconverters and 
found that relative to the year 2000, the rate of interruption was lower in the years 
preceding and following 2000[943]. In addition, they also found that the following factors 
were associated with a higher risk of treatment interruption: higher CD4 counts, female 
gender, younger age, treated with a PI-based regimen and individuals treated in early 
infection compared with in chronic infection.  
A systematic review published in 2011 identified 16 studies of relevance which 
described the frequency, reasons, risk factors and consequences of unstructured 
treatment interruptions[944]. The study authors found that treatment interruptions were 
more commonly reported amongst people of younger age and those who inject drugs. 
However, they found that the effect of gender was inconsistent across studies. Similarly, 
some reported that a high CD4 count (baseline or current) was associated with an 
increased risk of interruptions whilst others reported this association was with lower CD4 
counts.  
5.9.3 Analysis: proportion of ART-experienced people currently not on 
ART 
To assess how well Synthesis V5 was modelling rates of treatment interruption, I 
outputted some simulated data on the ART-experienced population to compare against 
available observed data. I looked at the proportion of people who are ART-experienced 
and under follow-up that are currently not on ART, by both years from starting ART 
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(Figure 5-11) and by calendar year (Figure 5-12) in the COHERE dataset and in the 
simulated dataset.  
Figure 5-11: Of the ART-experienced people under follow-up, proportion who are 
currently not on ART by years from ART initiation 
 
Figure 5-12: Of the ART-experienced people under follow-up, proportion who are 
currently not on ART by calendar year 
 
5.9.4 Discussion and changes made 
Findings from studies identified in the review suggested that the strongest risk factors for 
treatment interruption are younger age, acquiring HIV through IDU and earlier calendar 
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year. The changes made on the basis of the review conducted and the above analyses 
are summarised in Table 5-30. 
Table 5-30: Changes made to the Synthesis model [Risk of treatment interruption] 
 Synthesis V5 Synthesis V6 
Risk of 
treatment 
interruption  
Probability of treatment 
interruption (in any three-month 
period whilst on ART) depends on: 
 
current viral load (whether < or 
≥500 copies/ml) 
underlying tendency to adhere 
(whether < or ≥0.8) 
presence of any current side 
effects 
current CD4 count 
 
Probability of treatment 
interruption (in any three-month 
period whilst on ART) depends on: 
 
current viral load (whether < or 
≥500 copies/ml) 
underlying tendency to adhere 
(whether < or ≥0.8) 
presence of any current side 
effects 
current CD4 count but after 2006, 
effect is reduced 5-fold in people 
with current CD4 count >350 
cells/mm3 (i.e. those with higher 
CD4 counts are 5 times less likely 
to interrupt after 2006 compared to 
before 2006) 
current age, where risk of 
interrupting is 0.9 times more likely 
per 10 year increase, centred 
around age 40 (i.e. probability of 
interruption is the same as in V5 
for someone aged 40, but is 1.1-
fold for some aged 30, and 0.9-
fold for someone aged 50) 
 
There was conflicting evidence in the literature about the effect of CD4 count on 
interruption. Although traditionally, higher CD4 count may have been associated with a 
higher rate of interruption, due to the structured treatment interruption strategies being 
offered only to those with higher CD4 count, once the results of the SMART trial were 
available this was probably no longer the case. For Synthesis V6, I chose to model a 
lower risk of treatment interruption following 2006 and in those with CD4 count >350 
cells/mm
3
 to reflect the period of the SMART trial and the ART initiation threshold at that 
time. 
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IDU is already implicitly associated with the risk of treatment interruption in Synthesis V5 
because those who acquire HIV through IDU are modelled to have worse underlying 
adherence and are therefore more likely to interrupt. The effect of age on adherence 
however is not attained through the underlying adherence, but instead through the 
current adherence mechanism. Therefore I decided to include an additional effect of age 
on the probability of interruption in Synthesis V6. Based on the studies included in the 
systematic review[944], an effect of 0.9 times increased risk of treatment interruption per 
10 years increase in age was introduced.  
5.9.5 Results: comparing COHERE results with Synthesis V6 
Figure 5-13 and Figure 5-14 show that the proportion of ART-experienced people 
currently not under follow-up fits well to the COHERE data with Synthesis V6. 
Figure 5-13: Of the ART-experienced people under follow-up, proportion who are 
currently not on ART by years from ART initiation 
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Figure 5-14: Of the ART-experienced people under follow-up, proportion who are 
currently not on ART by calendar year 
 
5.10 Review: Side effects of antiretroviral drugs 
5.10.1 Background 
All side effects modelled in Synthesis V5 are binary variables, i.e. if the individual 
develops a certain side effect in a given three-month period, it takes the value 1, 
otherwise 0. Side effects are modelled in two steps: firstly there is a probability of 
developing a new side effect (the incidence) in a three-month period, and secondly there 
is a probability of retaining an existing side effect in a three-month period. Additionally, 
there is a probability of switching drugs due to a side effect in a three-month period.  
The changes made to the probability of developing side effects and the probability of 
switching a regimen once a side effect has developed, were reviewed and revised in 
collaboration with clinicians and other experts within the SSOPHIE working group and 
were therefore based on expert opinion. These can be seen in Appendix XI. In Section 
5.10.2 I summarise some reasons on why other changes were not made to the 
Synthesis model.  
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I also made two comparisons between observed data and simulated data relating to side 
effects. First, I compared the prevalence of side effects at a given point in time. In the 
second comparison, I looked at the probability of treatment discontinuation, which is 
often the result of developing side effects. 
5.10.2 Discussion and changes not made 
ATV and IDV are both independently associated with hyperbilirubinaemia (elevations in 
bilirubin)[945-947]. A patient may discontinue for cosmetic reasons because of effects 
caused by hyperbilirubinaemia (such as scleral icterus or jaundice). However, as most 
side effects modelled in Synthesis V6 are mainly treatment-limiting, I decided to not 
model incidence of hyperbilirubinaemia despite it occasionally resulting in 
discontinuation.  
Use of NVP in adult females with CD4 count >250 cells/mm
3
 and adult males with CD4 
count >400 cells/mm
3
 is strongly associated with a higher risk of hepatotoxicity and skin 
reactions[948], but this is not modelled in Synthesis V6. This is largely because NVP is 
assumed to be used infrequently as a first line regimen in people in these CD4 count 
ranges in Europe. 
The risk of developing ddI-associated pancreatitis is associated with a lower CD4 count, 
but also with higher levels of ddI[949, 950]. Although it is a serious side effect, it is quite 
uncommon when on ddI and hence I decided to not model this relationship in Synthesis 
V6, although it may be of interest for future updates.  
The possibility of modelling an elevated risk of coronary heart disease as a result of 
ABC usage[838, 951] has been excluded for the moment. This is because in order to do 
so it will be necessary to model the underlying cardiovascular disease risk, which is 
currently not included.  
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Use of PIs are known to raise the lipid profile of a patient, notably cholesterol and 
triglycerides[952]. Therefore some patients switch from a PI-containing regimen, 
especially if they are at high risk of cardiovascular disease for other reasons. This is also 
the case in patients on ABC who have high cardiovascular disease risk although the 
association was only found in 2008. However, as noted above, it is difficult at this stage 
to model the acquisition of these side effects and the resulting switch of regimen unless 
the underlying risk of cardiovascular disease is modelled. The alternative option is to 
include an increased risk of all-cause mortality as a result of using certain antiretroviral 
drugs, as opposed to modelling cardiovascular disease risk for each patient. This is 
something to consider for inclusion in the model in the next revision.  
Finally, it was also considered that some side effects may be better modelled as 
continuous variables rather than binary variables. One example would be to model 
eGFR (estimated glomerular filtration rate) values to determine the risk of developing 
renal dysfunction. This would also be something to consider in the next revision of the 
model.  
5.10.3 Comparing observed data with Synthesis V5 and V6 
To assess how well Synthesis V6 simulates data relating to side effects, I compared the 
prevalence of side effects and incidence of treatment discontinuation in the published 
literature and also for data simulated using Synthesis V5 and Synthesis V6. 
First, I compared the prevalence of side effects amongst the population at a given point 
in time, i.e. a cross-sectional analysis (Table 5-31). The observed data was based on an 
estimate from the Swiss HIV Cohort Study, which used standard clinical methods 
(physicians explicitly asked patients if symptoms listed in a questionnaire had arisen 
within the 30 days preceding the visit), to calculate the prevalence of adverse events in 
1160 adult patients receiving ART[358]. The prevalence in the simulated data was also 
from 1999 and included all modelled side effects.   
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Table 5-31: Prevalence of side effects in 1999 (clinical only and not laboratory side 
effects) that are probably or definitely attributed to use of antiretrovirals [358] 
Observed Synthesis V5 Synthesis V6 
47% 48% 45% 
 
The cumulative risk of discontinuing at least one antiretroviral drug in the initial ART 
regimen was also compared between the observed and simulated datasets. The 
observed data (Figure 5-15) comes from the EuroSIDA study, and calculated at each 
month after starting treatment, the number of patients who remained on their original 
regimen, the number who were off all treatment and the number who had made some 
change (stop, switch or intensification of ≥1 drug)[953]. I similarly outputted using both 
Synthesis V5 and V6 (Table 5-32), the cumulative risk of discontinuation of at least one 
drug in the initial regimen (discontinuation for any reason) from the time of ART 
initiation.  
Figure 5-15: Proportion of people on their initial ART regimen over time [953] 
 
 
Figure not available due to copyright restrictions 
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Table 5-32: Time from start of ART to discontinuation (for any reason) of at least 
one drug in the initial regimen. Synthesis data for 1996-2001 inclusive. 
Years from start of ART % which discontinued at least one drug 
Synthesis V5 Synthesis V6 
1 30% 24% 
2 43% 35% 
3 52% 44% 
4 61% 50% 
 
Although it still fits fairly closely to the observed data, the incidence of discontinuation is 
a little lower using the Synthesis V6 data than when using Synthesis V5 data. I think that 
the discontinuation rates have decreased since inception of Synthesis V5 due to a 
combination of the small decreases in rates of acquiring side effects (lipodystrophy, 
peripheral neuropathy and hepatotoxicity) and switching (after occurrence of nausea, 
diarrhoea and renal dysfunction). Given the extensive review process that was 
undertaken, I have chosen to use the new parameter values for Synthesis V6 
henceforth, but a further revision may at some point be necessary. 
5.11 Review: pregnancy in women with HIV 
5.11.1 Background 
When estimating the characteristics of an HIV-positive population, one outcome of 
interest is the number of women who are pregnant at a given point in time. This is not 
modelled in Synthesis V5. As antiretroviral use and adherence are different in pregnant 
women compared to non-pregnant women and men, the explicit modelling of this is 
critical, as they are likely to affect the outcomes that are of interest in the SSOPHIE 
project. As the aim was to model only the incidence of births, MTCT was not considered 
and I decided to not model the infant being born either in Synthesis V6. 
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5.11.2 Incidence rate of pregnancy 
First I decided that the incidence rate of pregnancy modelled in Synthesis V6 should 
relate to the incidence of births. Miscarriages and terminations were not considered 
because data on fertility is usually measured by the number of full-term births[954]. The 
proportion of pregnancies resulting in delivery is thought to have increased considerably 
in women living with HIV, from around 50-60% in the pre- and early cART era to 87% in 
2002-2009[955-957]. Consistent with the literature, child bearing years were taken to be 
between the ages of 16 and 48[958]. Factors found to be associated with the incidence 
of pregnancy include the woman’s age, race, country of origin, calendar year (and 
whether cART was available), knowledge of HIV status and maternal wellbeing[955-957, 
959, 960]. 
5.11.2.1 Underlying incidence rate of pregnancy resulting in live birth 
The rate of pregnancy resulting in live birth was the main underlying parameter relating 
to incidence of pregnancy in the model. This was modelled as a probability in a given 3 
month period, given the model structure of Synthesis V6. I included the restriction that 
no more than one pregnancy in a 12 month period was possible.  
The relationship between age and rate of pregnancy takes the form of an inverted U-
shape, wherein women aged approximately 25 to 34 years have the highest rates and 
those who are younger and older have lower rates[955-957, 959]. According to UK data, 
women of white ethnicity are less likely to have a pregnancy compared to women of 
black-African ethnicity[956].  
The underlying rate of pregnancy was based on age-specific fertility data for the general 
population from UNdata, which is a statistical database handled by the United Nations 
Statistics Division[954]. There is data available on birth rates by country and by five year 
age groups (15-19, 20-24, 25-29, 30-34, 35-39, 40-44 and 45-49). The rate is given as 
the number of births per 1,000 women-years (person-years in women) per calendar 
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year. For example, in the case of the UK, separate age-specific rates are given for two 
calendar year periods (Appendix XII). The appropriate rate (by country, age and 
calendar year) could therefore be used directly in the model, converted into a rate per 
three months. This would imply that the live birth rate in the general population is the 
same as in the HIV-positive population, which in some settings may be an incorrect 
assumption. However, it may not be appropriate to use birth rates from the migrant’s 
country of origin either as this may overestimate, so for now I have chosen to use 
country-specific rates for all races, as those are representative for the population.    
5.11.2.2 Effect of calendar year, availability of cART and knowledge of HIV status 
The effect of calendar year on incidence of pregnancy needed further consideration 
because trends differ between HIV-negative and HIV-positive women. In HIV-positive 
women, similar to the trend in proportion of pregnancies resulting in live births as 
described above, the absolute number as well as the rate of pregnancy has increased 
over time[957, 959, 960]. There is therefore a further interaction of effects between 
calendar year (which also determines availability of cART) and knowledge of HIV status.  
Studies have shown that knowledge of HIV status is associated with a lower incidence 
of pregnancy, especially in the pre-cART era[957, 961]. The rate has been estimated to 
decrease 1.4-fold from pre- to post-diagnosis. Since the availability of cART however, 
fertility rates have gradually increased over time[955, 957, 959] because of the 
improvements in management of HIV care in pregnancy and the reduction of MTCT 
rates[485, 955]. If used correctly, alongside other methods of preventing transmission 
such as elective caesarean sections (although some guidelines now recommend vaginal 
delivery in women with suppressed viral load[82, 962]) and formula feeding, cART has 
lowered rates of transmission to as low as 1 to 2 per 100 births[955, 963-965].   
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5.11.2.3 Effect of maternal wellbeing 
Maternal wellbeing is strongly associated with the rate of pregnancy; many studies have 
found that women are less likely to become pregnant if they have had a history of AIDS 
or opportunistic infections, or if they have lower CD4 counts (typically <200 
cells/mm
3
)[955, 956, 959, 960]. Blair et al. reported a 0.4-fold reduction in the rates of 
pregnancy in women with a history of AIDS and a 0.6-fold reduction in women with CD4 
count <200 cells/mm
3
 but without opportunistic infections[959]. Huntington et al. found 
that women with CD4 count <200 cells/mm
3
 were 0.65 times less likely than women with 
CD4 count 200-350 cells/mm
3
 to have a pregnancy[956]. Myer et al. also reported 
similar reductions for women in SSA: 0.7-fold reduction for women with CD4 count <200 
cells/mm
3
 compared to >500 cells/mm
3
 and 0.75-fold reduction if WHO stage 3&4 
compared to WHO stage 1[960].   
5.11.2.4 Effect of repeat pregnancies 
Repeat pregnancies are pregnancies for women who have already had at least one 
pregnancy. Factors associated with an increased rate of repeat pregnancy are similar to 
that of a first reported pregnancy[966, 967]. I have not modelled a separate rate of 
second pregnancy, i.e. it is assumed that the rate of a second pregnancy is the same as 
a first pregnancy (except the rate is zero for the first three month period after birth 
because only one pregnancy is allowed within a 12 month period). Similarly, the rate of 
a third pregnancy is the same as the first and second pregnancy and so on. 
5.11.2.5 Summary of modelled effects on incidence rate of pregnancies 
Based on the above data and the literature, the modelled effects of diagnosis, calendar 
year and maternal wellbeing on the incidence of pregnancy are summarised in Table 
5-33 for pregnant women in European settings. In SSA, ART was not widely available 
until the mid-2000s, but since then the same trends in incidence of pregnancy have 
been observed (higher incidence post-cART)[968]. The post-cART era is therefore 
defined as 2004 onwards for pregnant women in SSA.  
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Table 5-33: Modelled effects in Synthesis V6 of knowing one’s HIV status on 
incidence rate of pregnancy leading to live births for pregnant women in Europe 
Knowledge 
of HIV 
status 
Calendar 
year 
Maternal wellbeing Fold change in incidence rate 
of pregnancy leading to live 
births 
 
Undiagnosed All years All women 1 (same as underlying rate*) 
Diagnosed All years Experience of AIDS or 
HIV-related symptoms  
2.5-fold reduction in incidence 
compared to underlying rate* 
 CD4≤200 cells/mm3 
but no experience of 
HIV-related symptoms 
or AIDS 
1.5-fold reduction in incidence 
compared to underlying rate* 
Pre-cART  
(1980-1996) 
All women 1.4-fold reduction in incidence 
compared to underlying rate* 
Post-cART  
(1997-2000) 
CD4 count >200 
cells/mm
3
 and no 
experience of HIV-
related symptoms or 
AIDS 
1.3-fold reduction in incidence 
compared to underlying rate* 
Post-cART  
(2001-2003) 
1.2-fold reduction in incidence 
compared to underlying rate* 
Post-cART  
(2004 
onwards) 
1 (same as underlying rate*) 
*underlying rate is the rate seen in the general population 
 
5.11.3 Probability of diagnosis 
Some women will know their HIV status before pregnancy, whereas others will be 
diagnosed during pregnancy. In women who are not pregnant or not yet pregnant, the 
rate of being diagnosed was assumed to be the same as a woman not currently 
pregnant. This rate depends on the country, age, race, mode of HIV acquisition and 
clinical status as for all other HIV-positive people. 
In women who are pregnant, the rate of being diagnosed depends on the setting’s 
antenatal HIV testing policy. In Europe, access to antenatal HIV testing for every 
pregnant woman in Europe has been recommended since the mid-1990s, however 
there are great differences in who is offered one (everyone, or just people at high risk of 
contracting HIV), whether it is mandatory to offer one (opt-in versus opt-out) and in the 
rate of uptake when offered a test[969, 970]. Where routine antenatal screening is in 
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place, the probability of diagnosis within the whole pregnancy period is the same as the 
proportion of women who accept an HIV test. Where testing acceptance rates are high, 
this means that most women will be diagnosed by the third trimester[955]. In the UK the 
probability of a woman being diagnosed before delivery was around 30% in the mid-
1990s, and since 2008 has been >95%[971]. If the woman chooses to opt-out of the 
screening test, then it is assumed that the rate of diagnosis is again the same as for a 
woman who is not pregnant. 
5.11.4 Progression of disease in the absence of treatment 
There is limited evidence to suggest that pregnancy affects the progression of HIV, in 
terms of changes in CD4 count, viral load or risk of AIDS or death[972-976]. The 
progression of HIV in women during and after pregnancy was therefore modelled to be 
exactly the same as in someone who has never been pregnant, given the antiretroviral 
regimen prescribed during pregnancy. 
5.11.5 Effect of treatment 
5.11.5.1 Treatment regimens specific to pregnancy 
In women who do not need to initiate ART for their own health, but need to initiate in 
order to prevent MTCT, commonly used regimens in the past included AZT mono-
therapy, AZT+3TC dual-therapy, and a variety of cART regimens[977]. AZT mono-
therapy and AZT+3TC dual-therapy are already modelled as a first line option for all 
individuals initiating treatment in 1994-1995 in Synthesis V5. cART regimens are also 
modelled in Synthesis V5, but there are no pregnancy-specific regimens. 
In ART-naïve women, use of ART during pregnancy depends on whether the pregnant 
woman requires treatment for their own health or not, as defined by the standard adult 
treatment recommendations using CD4 count thresholds. In pregnant women who do 
require ART for their own health, the difference in regimen compared to people not 
pregnant is the avoidance of EFV due to its teratogenic properties. Pregnant women 
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who do not require ART for their own health are given treatment usually by the 24
th
 
week of pregnancy and may continue up to or during the breast-feeding period or may 
carry on taking ART even after this period. Data from one UK study showed 
approximately a quarter of women discontinued ART after delivery[978]. For some time 
in Europe the recommendation has been to start women on a cART regimen, which 
would typically be a PI/r-based regimen[82, 962]. AZT mono-therapy was commonly 
used in the past as a short-course of treatment to prevent MTCT[979, 980], and rates of 
resistance accumulation were quite low if maternal viral loads were also low[981, 982]. 
Single-dose NVP which does select resistant viruses at high rates[977] has not been 
commonly used in Europe at any point in time. 
In SSA, use of ART for preventing MTCT has only been slowly rolled out since 2000. 
Until the mid-2000s, most programs relied on the use of single-dose NVP to mothers 
(and babies, although this is not modelled in Synthesis V6) and countries have gradually 
been transitioning to using cART regimens (the current recommendation)[983-985]. 
Prevalence of resistance to NVP following single-dose exposure has been estimated as 
35.7% (95% CI:23.0-50.6) in a meta-analysis[986]. Recommended cART regimens for 
use in women are AZT+3TC or TDF+3TC backbones with NVP, EFV or LPV/r. More 
recent safety data on use of EFV in pregnant women suggest that the risk of birth 
defects is quite low and it is therefore recommended in LMIC due to the programmatic 
advantages (it is available as an FDC, it is the preferred first-line regimen in all adults, 
costs have been reduced and it is efficacious against HBV) and the clinical benefit of 
EFV in preventing MTCT[254, 987]. 
The proposed ART regimens modelled for pregnant women, separately for Europe and 
SSA, in Synthesis V6 are summarised in Table 5-34. Although the focus of my thesis is 
on populations in Europe, in Chapter 7, I explain that in order to model the progression 
of HIV among migrants from SSA, I simulate a group of people to be infected in SSA 
(and who would thus be subject to different ART regimens). I chose not to model AZT 
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mono-therapy because it is only given short-term and rates of resistance accumulation 
are low so would not impact future long-term outcomes of the mother. 
Table 5-34: ART regimens for pregnant women modelled in Synthesis V6 
Setting ART 
experience 
Health of 
pregnant 
woman 
ART regimen 
Europe Naïve Doesn’t require 
ART for her own 
health 
Start cART (one which does not include 
EFV) at 2
nd
 trimester. 75% continue 
after delivery.  
Does require 
ART for her own 
health 
Start cART (one which does not include 
EFV) immediately and continue after 
delivery. 
Experienced - Continue on current regimen, but switch 
if on EFV. 
SSA Naïve  Doesn’t require 
ART for her own 
health 
Until 2006, half of women given single-
dose NVP only, half given cART at 2
nd
 
trimester and stopped after a year. After 
2006, all women given cART at 2
nd
 
trimester and stopped after a year. 
Does require 
ART for her own 
health 
Start cART immediately and continue 
after delivery. 
Experienced - Continue on current regimen. 
 
5.11.6 Adherence 
There is a substantial body of evidence that suggests postnatal adherence is 
significantly worse than pre-pregnancy and during pregnancy[988-991]. One meta-
analysis showed that across 51 studies, the proportion adherent were 75.7% (95% 
CI:71.5-79.7) and 53.0% (95% CI:32.8-72.7) in the antepartum and postpartum periods 
respectively[989]. Another study which collected adherence data using MEMS 
(medication event monitoring system) reported mean pre-natal adherence of 50% and 
mean post-natal adherence of 34%[991].   
I decided to model a somewhat conservative effect of adherence in Synthesis V6 such 
that in the three months following birth (and only in this one three-month period) 
effective adherence is temporarily modified by a random factor, which will be selected 
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from Beta(20,1) for each woman post-birth, shown in Figure 5-16. This means that most 
(approximately 80%) women will experience no drop in adherence but some will 
experience a drop between 0-20%.   
Figure 5-16: Probability density function for Beta(20,1) distribution 
 
 
Solid line indicates the probability (y-axis) of a random variable distributed ~Beta(α,β) taking 
the value shown along the x-axis. 
 
5.11.7 Comparing observed data with Synthesis V6 
To assess how well the Synthesis model simulates data on pregnancy, I investigated the 
incidence rate of pregnancy and the rate of virologic failure in pregnant women in the 
published literature and generated these figures from the simulated data using 
Synthesis V6.  
First, I compared the incidence of pregnancy among HIV-positive women in the UK over 
time (Table 5-35). The observed incidence was based on data obtained through the 
linkage of two studies, the UK CHIC study and the National Study of HIV in Pregnancy 
and Childhood (NSHPC)[956]. The incidence rates in the simulated data were expected 
to be fairly consistent with the observed data, because the general trend over time in 
number of reported pregnancies in the UK modelled were based on data from the 
NSHPC. 
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Table 5-35: Incidence of pregnancy over time. Observed data [956] 
Calendar year Observed 
(95% CI) 
Synthesis V6 
2000 3.4% (2.9-4.0) 3.4% 
2001 4.1% 
2002 3.9% (3.5-4.4) 4.2% 
2003 4.0% 
2004 4.4% (3.9-4.8) 4.2% 
2005 4.2% 
2006 4.6% (4.2-5.1) 4.5% 
2007 4.1% 
2008 4.5% (4.1-4.9) 4.7% 
2009 4.7% 
 
Unfortunately, I found that there was limited data in the literature regarding the effect of 
pregnancy on virologic outcomes and definitions of failure and the time to failure also 
varied markedly. Data from the SHCS and cohort data from France, which would have 
similar population demographics as the UK, did not report significant differences in 
virologic response rates after initiation of cART in pregnant and non-pregnant 
women[992, 993]. A study from the US found that of the women with a viral load 
measurement at 24 weeks postpartum, 28.6% (95% CI:17.9–41.4) met the criteria for 
viral load rebound (defined as an increase of ≥0.7 log (5-fold) from the average of the 
weeks 34 and 36 gestation viral loads to week 24 postpartum, or an absolute increase to 
>500 copies/mL for those with viral load <50 copies/ml)[994]. A larger study conducted 
in SSA found 81 out of 541 (15%) pregnancies resulted in virologic failure, which was a 
proportion similar to non-pregnant women. It also found that the rate of time to virologic 
failure was 7.0 and 8.2 per person year for pregnant and non-pregnant women 
respectively. Virologic failure was defined as either a failure to achieve viral load <400 
copies/ml within six months of cART initiation or a viral rebound to >400 copies/ml at 
any time after initial suppression[995]. Together, the evidence suggests that virologic 
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response rates among women in pregnancy are similar, and perhaps potentially worse 
than for women who are not pregnant. 
I also outputted the rate of virologic failure (defined as one viral load measurement >500 
copies/ml within the first six months following the birth, after at least six months on ART) 
using the simulated data from Synthesis V6. I found that 16% of women experienced a 
viral rebound within six months of pregnancy and the rate of viral rebound was 6.9 per 
person year. Although these figures are not directly comparable to the estimates 
described above, they still demonstrate that the modelled rates of virologic failure are 
within the expected ranges.   
5.12 Conclusion 
In this chapter, I have described all the statistical analyses which were undertaken and 
summarised all the findings from reviewing the literature, in order to explain the changes 
which were made to develop Synthesis V6. I have also demonstrated that Synthesis V6 
calibrates well, and in most cases slightly better than Synthesis V5, to a range of 
observed data. This newly developed model satisfies the first objective of the SSOPHIE 
project which was to ‘build a stochastic simulation model of HIV infection and the effect 
of ART that can be used to reconstruct and project the status of HIV-positive individuals 
in a given country’ (Chapter 3). In the following chapters, I use Synthesis V6 to 
reconstruct the HIV-positive population in a given setting by fitting to the available 
surveillance data, in order to estimate the size and characteristics of the population.    
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Chapter 6 Development of the model 
calibration method to countries 
with HIV surveillance data 
In Chapter 5, I described the process of how the model was formulated within the 
context of the SSOPHIE project, in that I started with an existing model (Synthesis V5), 
and revised the model parameters and assumptions in order to formulate a new version 
of the model (Synthesis V6). I then decided to investigate how best to calibrate the 
model to country-specific HIV surveillance data in order to estimate HIV incidence and 
the rate of diagnosis, as well as other parameters likely to differ by country. The outputs 
generated from the calibrated model can then be used to reconstruct the HIV-positive 
population of interest, from which I can calculate estimates and plausibility ranges. 
In this Chapter I first describe the approach I used to calibrate the model. This is 
followed by a description of the calibration method which was developed, including the 
choice of parameter distributions from which to sample values. I then present how the fit 
of the model was assessed using a ‘calibration score’. The final method which was 
developed to calibrate the model to any setting or population where the infections 
primarily occur within that setting is then described, as well as the process to derive 
plausibility ranges for the estimates. Finally, I present results from applying the method 
to surveillance data on MSM in the UK and to pseudo data to assess the impact of 
different levels of availability of data. 
6.1 Statistical methods used in simulation modelling 
As mentioned in Chapter 3, stochastic simulation models are commonly run multiple 
times in order to pool results for the outcomes of interest to provide a distribution. When 
model parameters are unknown or cannot be informed by data, the outcomes from such 
simulations can be used to infer the approximate distribution of model parameters by 
making comparisons with the observed data. In other words, the modelled outcomes 
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and observed data are compared and then one works backwards to see what values the 
model parameters had to take in order to end up with such an outcome. This process of 
starting with observed data and then using a model to estimate the parameter values is 
known as parameter estimation (and also calibration, inverse-problem and Bayesian 
inference).   
A number of methods for parameter estimation have been developed for statistical 
inference of detailed implicit models (usually stochastic simulation models) for which 
usual likelihood estimation of parameters is inappropriate[712]. Synthesis V6 naturally 
lends itself to working in a Bayesian framework to account for multiple parameter 
combinations providing outputs that correspond well to observed data, instead of 
converging to a single set of parameter values as would be the case in maximum 
likelihood estimation. The approach I have used to calibrate the model is based on 
Approximate Bayesian Computation methods[996]. These methods involve running the 
model multiple times, with each run of the model considered to be one simulation. 
6.2 Approximate Bayesian Computation 
6.2.1 Overview  
Approximate Bayesian Computation is a method of statistical inference, which does 
without the need to evaluate the likelihood function[997, 998]. They are a group of 
methods in which parameter estimation is performed within a Bayesian framework. They 
use prior distributions (reflecting the uncertainty regarding parameter values) in an 
assumed model together with observed data, in order to estimate the posterior 
distributions. The outcome of Approximate Bayesian Computation is thus a range of 
values of the parameters of interest, which are distributed approximately according to 
this posterior distribution. The general underlying principle is summarised in Figure 6-1.  
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Figure 6-1: General principle of Approximate Bayesian Computation [996]   
 
6.2.2 Approximate Bayesian Computation rejection algorithm 
One type of algorithm used in Approximate Bayesian Computation is the rejection 
algorithm. For a given model, the rejection algorithm firstly involves sampling a set of 
parameters from the prior distribution for each simulation. A dataset ?̂? is then simulated 
under the model, given the sampled parameters and then compared to the observed 
data 𝐷. If the generated dataset ?̂? is considered to be too different to the observed data 
𝐷, as measured by a summary statistic and tolerance threshold (also known as the 
acceptance threshold), then the sampled parameter values are rejected[996].  
 
Figure not available due to copyright restrictions 
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6.2.3 Sampling of parameters 
The simplest approach to sampling the parameters from the prior distribution is to use 
simple random sampling (SRS), where parameters are sampled at random for each 
simulation. The advantage of SRS is that it is free of bias and also requires the least 
amount of prior knowledge about the parameter space sampled. However, as it samples 
from the entire parameter space in each simulation, it is also the most inefficient method. 
Other methods which have been proposed are to combine the Metropolis-Hastings 
algorithm with Approximate Bayesian Computation, or to use other Markov Chain Monte 
Carlo based algorithms, but these are not without limitations either (such as the 
correlation between samples, difficulty for assessing convergence and the requirement 
of a burn-in period)[1000].  
Another approach to improve the efficiency of SRS is to use stratified sampling methods 
such as Latin hypercube sampling (LHS). The LHS algorithm ensures that the 
probability distribution function for each parameter is sampled evenly by partitioning the 
cumulative distribution function into segments[1001]. The number of segments is equal 
to the number of simulations to be performed. In each simulation, a sample is randomly 
chosen from each segment, and is then transformed to a value from the variable’s actual 
distribution (Figure 6-2). Each segment is sampled only once and therefore the resulting 
sample of parameter values is uniformly distributed across the cumulative distribution 
function. To generate five samples from a given probability distribution for example, the 
cumulative distribution function is partitioned as 0-0.2, 0.21-0.4, 0.41-0.6, 0.61-0.8 and 
0.8-1.0. A sample is then chosen randomly within each of these segments and the 
variable value which has this cumulative probability is calculated. 
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Figure 6-2: Example of partitioning the cumulative distribution function into 20 
segments for a normal distribution [1002] 
 
6.2.4 Summary statistics 
Summary statistics are used to describe the combined characteristics of a dataset. 
Ideally, a summary statistic would contain the same information as the original data for 
the purpose of parameter estimation, be sensitive to changes in the prior distributions, 
but also be robust to stochastic variability in the observed dataset 𝐷[996]. However, the 
choice of summary statistic is not always straightforward, particularly in cases where the 
model being used is not a standard statistical model and the decision may be somewhat 
arbitrary. The choice of summary statistic will largely depend on the research question 
and may have to be tested to see if it is appropriate. One approach in choosing a 
summary statistic is to attach weights to components within the statistic by their degree 
of importance[1003].  
 
Figure not available due to copyright restrictions 
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6.2.5 Model calibration 
Once summary statistics have been calculated for each simulation performed, the final 
step is to assess the fit of the model, which is referred to as model validation or 
calibration. I use the term calibration hereafter in this thesis. It is also of interest to be 
able to quantify the differences in fit between simulations. One approach to calibration is 
to compare the value of the summary statistic against some theoretical expected value 
(which could be the summary statistic calculated for the observed data)[1004]. The aim 
is to select those set of parameters which calibrate well to the observed data. This 
therefore depends on the tolerance threshold, which, similarly to the summary statistic, 
is chosen in an arbitrary but logical manner. Usually, it is selected such that a certain 
proportion of parameters are accepted, where this proportion chosen is quite small[996].  
6.2.6 Advantages and limitations of Approximate Bayesian 
Computation methods 
Approximate Bayesian Computation methods are suitable for calibrating simulation 
models to multiple data sets within tolerance thresholds and are thus an ideal method to 
use with the HIV Synthesis model. Further, they have the added advantage that 
parameter uncertainty can be directly taken into account and that prior distributions 
covering a large parameter space can be used. This allows for consideration of as many 
parameter sets as possible which are adequately consistent with the data, rather than 
focusing on finding a single parameter set that is most consistent. As well as the fact 
that the likelihood function does not need to be estimated, another advantage of these 
methods is that the simulations are generated independently, therefore allowing cluster 
computation to be used. This can increase the speed of the overall simulation procedure, 
as well as having the advantage of simpler implementation and programming.  
However, due to the nature of having to run multiple simulations, Approximate Bayesian 
Computation methods are computationally intensive. Another disadvantage, as 
mentioned above, is that in order to implement such methods, the user needs some 
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prior understanding or intuition of the set of summary statistics to be outputted in order 
to define the tolerance threshold. Further limitations include the difficulty of choosing 
how to define the summary statistic and choosing how many simulations to run.  
6.3 Developing the calibration method 
In this Section, I will describe the terms and definitions used in developing and finalising 
the calibration method in the SSOPHIE project. The calibration method will be applied 
by country, as opposed to Europe as whole, but could also be applied to specific sub-
populations within a country.  
6.3.1 How ‘calibration’ is defined 
As illustrated in previous Chapters, outcomes from Synthesis V6 take the form of a 
longitudinal dataset for a hypothetical population with a range of variables that describes 
the course of disease progression for each individual, which can then be analysed to 
calculate outcomes of interest. Simulated populations can have different characteristics 
and therefore different outcomes, depending on the values of the input (prior) parameter 
distributions used (parameterisation is described in more detail in Section 6.3.3).  
As described in Chapter 2, national-level surveillance of HIV/AIDS is conducted in most 
European countries although there is large variability in the type of data collected and 
methods of collecting and reporting. Data on HIV and AIDS case-reports (individual-level 
and aggregate-level data) and number of HIV tests conducted are routinely submitted to 
ECDC through the TESSy system (Chapter 2 Section 2.5.4). Some countries also 
collect a range of other data which are not collected at the European-level.   
Calibration refers to the process of finding the set of input parameter values for the 
Synthesis model (the posterior values of input parameters into the model) which 
generates a set of modelled outcomes similar to those actually observed in the 
appropriate surveillance or observational data. Unlike likelihood-based estimation 
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methods, the aim of the Synthesis model calibration method is not to estimate a specific 
set of curves. Instead, the aim is to find multiple sets of curves (i.e. sets of parameter 
values) which all calibrate well to the observed data, in order to make inferences about 
the modelled population, which would have similar characteristics to the population of 
interest.  
6.3.2 Population to calibrate model to 
In order to calibrate the model to a particular population, the parameters sampled are 
those thought to differ between populations or which have a large degree of uncertainty 
and should not be fixed in each simulation. This differs to the model parameters 
described in Chapters 3 and 5, as these were factors which are unlikely to differ in 
different situations and which are reliably estimated in the published literature. This 
means it is necessary to decide and consider which population or sub-population to 
calibrate the model to. The choice of whether to calibrate a model to an entire population, 
or to a specific sub-population, will predominantly depend on whether there are 
substantial differences in the incidence of new infections and probability of diagnosis by 
sub-population. As I will explain later in this chapter, the main parameters for which 
values are sampled are those which describe the incidence and diagnosis rate. Sub-
populations may be defined based on their mode of HIV transmission, or perhaps a 
regional population. In this thesis I consider sub-populations by mode of transmission 
only. The choices to be made here are:  
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 Whether to calibrate to data on the total HIV-positive population 
 Whether to break down the whole HIV-positive population into groups defined by 
mode of transmission (e.g. MSM, PWID, heterosexually-acquired infections) and 
thus, 
o calibrate the model to one specific transmission risk group only 
o calibrate the model to the total HIV-positive population, but also to data 
by transmission risk groups 
 
One notable issue to consider is that the calibration method will take longer if the model 
is calibrated to a number of sub-populations simultaneously, as opposed to the 
population as a whole. This is because of an increased number of parameters to 
estimate and is discussed further in Chapter 7. 
If calibrating to data on heterosexuals separately, then there is an additional 
consideration to be made: whether there are appreciable numbers of HIV-positive 
people who originate from outside Europe (primarily countries in SSA) and were 
therefore likely to have been infected outside Europe. If there are indeed large numbers 
of people infected heterosexually in SSA who then subsequently immigrate to the 
European country of interest, these infections need to be modelled separately and the 
modelling approach described in this chapter is not appropriate. 
There are countries that do not collect data on mode of HIV acquisition or have limited 
data. Reasons include it being a newly collected variable, patients not disclosing for fear 
of stigma, or questionable data quality. Similarly, there may be risk groups in a country 
which are small in size and may not have sufficiently reliable data to warrant calibration 
separately. In order to accommodate for individuals with such ‘unknown’ or ‘other’ risk 
groups, one choice is to add these people with unknown/other risk groups proportionally 
to the rest of the population. Alternatively, the whole of the unknown/risk group sub-
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population could be combined with another particular risk group(s) based on expert 
opinion.  
6.3.3 Parameterisation 
6.3.3.1 Types of parameters 
In the Synthesis V6 model, parameters can either be fixed (fixed parameter) or varied 
(varied parameter) per simulation. A fixed parameter is one in which the value does not 
change from simulation to simulation. A varied parameter is one in which the value is 
sampled from a probability distribution and therefore changes from simulation to 
simulation. 
6.3.3.2 Parameter values reflecting the intrinsic effects of HIV and ART 
As explained in Chapters 3 and 5, the Synthesis model and the updates made have 
been shown to provide a close fit to observed data relating to the natural progression of 
HIV and ART outcomes[723-725]. Therefore, for the purpose of calibrating the model to 
a given HIV-positive population, parameter values reflecting the intrinsic effects of HIV 
and ART are held fixed. These parameter values are effectively part of the stochastic 
model structure.  
6.3.3.3 Parameters which are varied per simulation 
In order to calibrate the model to a particular population, the parameters for which 
values are sampled are those thought to potentially differ between populations or which 
have a large degree of uncertainty and should not be fixed in each simulation.  
The two main sets of parameters for which values are sampled are those which 
parameterise the HIV incidence (number of new infections per year) and diagnosis rate 
(probability of diagnosis in any three-month period in people without symptoms or AIDS). 
These parameters are described further in Section 6.3.4. The reason I focus on these 
parameters specifically is because it is impossible to ascertain estimates for these 
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parameters directly from observed data. Although the number of diagnoses can be 
captured, it is not possible to capture the number of infections which take place. 
Similarly, although testing rates do capture some underlying levels of diagnosis, they do 
not fully reflect the likelihood of an HIV-positive individual getting diagnosed. Therefore, 
as there is no direct information to inform these parameters in particular, I recognised 
early on that the parameter space to be sampled needs to be chosen such that it would 
be large enough to allow for extreme values and that the parameterisation is sufficiently 
non-informative and flexible, but is also small enough to limit computation time.  
In addition, other parameter values that may be specific for a given population and 
which could also be varied across simulations are as follows: proportion of people 
resistant to testing for HIV; probability of not being linked to care within three months of 
diagnosis; rate of being lost to follow-up whilst ART-naïve; rate of being lost to follow-up 
whilst on ART; rate of re-entry into care after being lost to follow-up; probability of 
starting ART when eligible; population distribution of underlying levels of ART 
adherence; rate of ART interruption; rate of re-starting ART after interruption; and rate of 
emigration. These parameters are described in further detail in Section 6.3.5. 
6.3.4 Parameters which determine HIV incidence and diagnosis rate 
The parameters in Synthesis V6 which determine the incidence and diagnosis rate are 
given in Table 6-1. The incidence denotes the number of new HIV infections per year. 
The diagnosis rate denotes the probability of diagnosis in any three-month period in 
people without symptoms or AIDS (the probability of diagnosis in people with symptoms 
is 5-fold the underlying rate of diagnosis in asymptomatic people, and people who have 
developed AIDS are assumed to be always diagnosed within three months). The 
process in which I decided the parameterisation for these curves is described later in 
Section 6.4.1. The prior distributions presented are examples, with values to be 
amended per setting being calibrated. The suggested probability distributions, Beta(2,4), 
Beta(1,5) and Beta(1,50) are shown in Figure 6-3. The Beta distribution is proposed for 
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describing the prior distributions because of the great flexibility offered. Specific values 
are discussed within the relevant population simulated (e.g. Section 6.5 for MSM in the 
UK, Section 6.6 for the hypothetical epidemic). Such crude parameterisation for both the 
incidence and diagnosis rate parameters are used in order to limit the number of 
parameters and also to sample from a wide parameter space so that any parameter 
values which may calibrate well to the data are not excluded. Also, as explained 
previously, the primary aim of the calibration method is to not estimate these curves per 
se, but rather to find sets of parameter values which generate a modelled population 
with characteristics similar to those of the surveillance and/or observational data.  
Table 6-1: Parameters and their prior distributions which determine HIV incidence 
and diagnosis rate per simulation in Synthesis V6 
Name Description of parameter Prior distribution 
i1 Number of infections per year during 1980-1984 Beta(2,4)*max1 
i2 Number of infections per year during 1985-1989 Beta(2,4)*max1 
i3 Number of infections per year during 1990-1994 Beta(2,4)*max1 
i4 Number of infections per year during 1995-1999 Beta(2,4)*max1 
i5 Number of infections per year during 2000-2004 Beta(2,4)*max1 
i6 Number of infections per year during 2005-2009 Beta(2,4)*max1 
i7 Number of infections per year during 2010-2013 Beta(2,4)*max1 
d1 Diagnosis rate per three-month period during 1984-
1991 
Beta(1,5)*max2 
d2 Additional change in diagnosis rate from 1984-1991  
(i.e. diagnosis rate during 1992-1999 is d1+d2) 
Beta(1,50) 
d3 Additional change in diagnosis rate from 1992-1999  
(i.e. diagnosis rate during 2000-2008 is d1+d2+d3) 
Beta(1,50) 
d4 Additional change in diagnosis rate from 2000-2008  
(i.e. diagnosis rate during 2009-2013 is 
d1+d2+d3+d4) 
Beta(1,50) 
Parameters i1,i2,…,i7, d1,d2,…,d4, max1 and max2 are defined later in this Section.  
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Figure 6-3: Probability density functions for Beta(2,4) distribution (top left), 
Beta(1,5) distribution (top right) and Beta(1,50) distribution (bottom centre) 
 
 
Solid line indicates the probability (y-axis) of a random variable distributed ~Beta(α,β) taking 
the value shown along the x-axis. 
 
Parameters i1,i2,…,i7 determine the absolute number of HIV infections per year 
(incidence) for a given five-year period. These parameters inform a piecewise constant 
curve for the HIV incidence. As i1,i2,…,i7 are sampled randomly in each simulation, the 
curve is also randomly generated in each simulation (Figure 6-4). Model variables are 
updated every three months and each infection is sampled to occur at one of four time 
points in a year (25% probability they will be infected in January-March, April-June, July-
September and October-December). Beta(2,4) was chosen to reflect the fact that the 
true incidence is more likely to lie in the range of the lower numbers, but that it is 
plausible for it to be considerably higher.  
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Figure 6-4: Example of a randomly sampled incidence curve (left) and diagnosis 
rate curve (right) for one simulation 
 
Similarly, parameters d1,d2,…,d4 each determine the diagnosis rate for a given 8 year 
period. These parameters inform a piecewise constant curve for the HIV diagnosis rate. 
Given that all individuals in the Synthesis model are HIV-positive, the diagnosis rate 
denotes the probability with which an HIV-positive individual gets diagnosed with HIV in 
a given 3-month period, given that they are not in the primary infection phase, not 
symptomatic and do not have AIDS. As d1,d2,…,d4 are all sampled randomly in each 
simulation, the curve is also randomly generated in each simulation (Figure 6-4). 
Beta(1,5) was chosen for parameter d1, as initial rates of diagnosis are expected to be 
much lower than in later years. For parameters d2, d3 and d4, the change in diagnosis 
rate from one 8-year period to another is sampled from the Beta(1,50) distribution, rather 
than the absolute diagnosis rate. I hypothesised that in most settings, the diagnosis rate 
is unlikely to change hugely from one period to the next and if it does then it will be 
monotonically increasing, i.e. the diagnosis rate will either stay the same, or rise, but not 
fall. This is thought to be a reasonable choice of prior because in general, increased 
rates of testing have been observed[1005, 1006]. If there are data that suggest a decline 
in the rate of diagnosis is possible, then the parameterisation must be changed 
accordingly to allow a decrease as well as an increase over time. 
I assume that the minimum value for both the incidence and change in diagnosis rate is 
0 in a given period over which the values are constant (5 years for incidence and 8 for 
diagnosis rate). The maximum value which can be sampled for the incidence per period 
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of time is given by max1 in the example situation. Likewise, the maximum value which 
can be sampled for the diagnosis rate parameter d1, is given by max2 in the example 
situation. In order to define the prior distributions for parameters i1,i2,…,i7 and d1 (as 
listed in Table 6-1), I developed the following formulae to select values for max1 and 
max2:  
𝑚𝑎𝑥1 = 𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐻𝐼𝑉 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛𝑠 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 
= 𝐻𝑖𝑔ℎ𝑒𝑠𝑡 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐻𝐼𝑉 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑒𝑠 𝑒𝑣𝑒𝑟 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑖𝑛 𝑜𝑛𝑒 𝑦𝑒𝑎𝑟 × 3 
𝑚𝑎𝑥2 = 𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑟𝑎𝑡𝑒 𝑝𝑒𝑟 3 𝑚𝑜𝑛𝑡ℎ𝑠 
=  
𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑜𝑚𝑝𝑡 𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑛 𝑚𝑜𝑠𝑡 𝑟𝑒𝑐𝑒𝑛𝑡 𝑦𝑒𝑎𝑟 
4
 
These formulae provide a simple and objective method to decide on the initial prior 
distributions, so that the calibration method can be applied to any given setting. I 
suggest that max1 should take the value of 3-fold the highest number of HIV diagnoses 
ever observed during one year as observed in the surveillance system. For example, if 
the highest number of diagnoses in one year is 3,000 then max1=3000*3. I suggest that 
max2 should take the value of 0.25-fold the proportion of prompt presentations of all 
diagnosed cases in the most recent year of surveillance. A prompt presentation is 
defined as when the person has a CD4 count >350 cells/mm
3
 at the time of diagnosis 
(or within six months of diagnosis). For example, if in the most recent year of 
surveillance 50% of HIV diagnoses were in people with CD4 count >350 cells/mm
3
, then 
max2=0.5/4. Although both formulae were somewhat arbitrarily devised, I wanted to 
decide on a formula that could be used in any setting. The main aim was to decide on a 
range that is wide enough to capture unlikely but plausibly high incidence or diagnosis 
rates.  
If the above formulae do not seem appropriate for a given setting, the initial parameter 
distributions for both the incidence curve and diagnosis rate curve could be modified 
using a combination of surveillance/observational data and expert opinion. The true 
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incidence and diagnosis rate curves are unknown and for most epidemics there will be a 
lack of data to inform the prior distributions for these parameters. If there are no or little 
data to inform the prior distributions, then wide distributions can be selected to 
incorporate a large range of plausible curves.  
6.3.5 Other parameter values that may be specific for a given HIV 
exposure group and country 
As mentioned above, there are a number of other parameters which are varied per 
simulation. These are parameters which are likely to vary by sub-population, or for which 
there are few data sources to inform them precisely. These parameters are listed in 
Table 6-2.  
In addition to the parameters describing the incidence and diagnosis rate curve, the 
parameters in Table 6-2 are also sampled from various distributions in each simulation. 
In most settings, it should be possible for the prior distributions for these parameters to 
be largely informed by relevant surveillance data or observational studies carried out in 
the country of interest or from other similar European studies. The sample space for 
these parameters will thus be much narrower compared to the prior distributions for the 
incidence and diagnosis rate parameters. Therefore for these nine parameters the aim is 
make sure that the results from the model reflect the uncertainty associated with the 
priors chosen. 
 
   
 
 
2
8
9
 
Table 6-2: Other parameters which are sampled per simulation in Synthesis V6 
Name Description of parameter Notes 
prop_avoid_testing Proportion of people resistant 
to testing for HIV 
These people are 10-fold less likely to be diagnosed with HIV (unless they have HIV 
related symptoms or AIDS) 
prob_loss_at_diag Probability of not being linked 
to care within three months of 
diagnosis 
This is the probability per 3-month period. These people are then classified as being 
lost to follow-up.  
prob_lost Probability of being lost to 
follow-up (for those not on 
ART) 
This is the base probability per three-month period for those with average adherence 
≥0.8. Those with average adherence 0.5-0.8 and <0.5 are 1.5-fold and 2-fold more 
likely to being lost to follow-up respectively. 
prob_lost_art Probability of being lost to 
follow-up given that ART has 
been interrupted 
This is the base probability per three-month period for those with average adherence 
≥0.8. Those with average adherence 0.5-0.8 and <0.5 are 2-fold and 3-fold more likely 
to being lost to follow-up respectively. 
rate_return Rate of re-entry into care This is the base rate per three-month for those with average adherence ≥0.8. Those 
with average adherence 0.5-0.8 and <0.5 are 2-fold and 3-fold less likely to re-enter 
into care respectively. If the person has an AIDS-defining condition however, they 
consistently have 80% probability every three-months of re-entry into care. 
prob_art Probability of starting ART 
when eligible 
This is the base probability per three-month for people with eligible CD4 count. If the 
person has AIDS, then there is a 90% probability of starting ART in any three-month 
time period. 
adh_pattern Population distribution of 
underlying levels of ART 
adherence 
This is a categorical variable. The value of this variable is sampled from (1,2,3,4,5), 
each representing a different distribution of the adherence levels in a population 
(Appendix VII). 1 represents a very good population level of adherence (around 95% of 
people on treatment with suppressed viral load) and 5 represents a poor population 
level of adherence (around 60% of people on treatment with suppressed viral load).  
rate_inter Rate of ART interruption This is the base rate per three-month period, for those with average adherence ≥0.8. 
Those with average adherence 0.5-0.8 and <0.5 are 1.5-fold and 2-fold more likely to 
interrupt respectively. If the person has an ART-related side effect, this rate is further 
   
 
 
2
9
0
 
Name Description of parameter Notes 
multiplied by a factor of 2. The rate of interruption is further modified by age, such that 
the younger the person, the more likely they are to interrupt. 
rate_restart Rate of re-starting ART after 
interruption (for people still in 
clinical care) 
This is the base rate per three-month period. If symptomatic or an AIDS-defining 
condition has developed then the person is more likely to restart by a factor of 2 and 3-
fold respectively. 
rate_emig Rate of emigration This is the rate of emigration per three-month period. 
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There are a number of other parameters which may also be varied (instead of being 
fixed), such as the proportion of people with HBV co-infection, proportion of people with 
HCV co-infection and prevalence of smoking. Whether these parameters are sampled or 
not will depend on the setting and availability and reliability of data to inform these 
parameters. 
6.3.6 Outline of calibration method 
There are three stages to the calibration method (Figure 6-5). In brief, for each 
simulation, unknown parameter values (which describe the incidence and diagnosis rate 
curves, i.e. those listed in Table 6-1) are sampled from suitable distributions, the model 
is run, and outcomes of the simulation are compared with a range of observed 
surveillance data. The next stage is to quantify how well the model outputs match the 
surveillance data, i.e. assessing the goodness-of-fit, by calculating a summary statistic 
(which I refer to as the ‘calibration-score’). If the calibration-score is sufficiently low (the 
lower it is, the better the fit), then the set of parameter values used for that simulation 
are accepted. This process is repeated over multiple simulations. The parameter values 
that give sufficiently low calibration-scores are then used to simulate an additional 
number of HIV populations to ensure that the parameter sets used to calculate the final 
modelled outcomes represent those which repeatedly calibrate well. These simulations 
will be used to calculate the point estimates and plausibility ranges for the model 
outcomes. At every stage and for each simulation, the parameters previously listed in 
Table 6-2 are also sampled to reflect the uncertainty reflected in the chosen priors. The 
multi-stage calibration method is described in full in Section 6.4.2.  
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Figure 6-5: Main steps of the calibration method 
Note that ①, ② and ③ refer to the first, second and third stage of the multi-stage 
calibration method respectively (Section 6.4.2).  
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6.3.7 Assessment of goodness-of-fit using a derived calibration-score 
6.3.7.1 The basic principle  
As described previously in Section 6.2.4, a summary statistic is required to quantify the 
combined characteristics of any given dataset. For the purposes of this calibration 
method, I refer to the summary statistic as the ‘calibration-score’. In order to assess how 
well the model outputs match the surveillance data, the calibration-score is calculated 
for each simulation. If the calibration-score for a simulation is within a defined tolerance 
threshold, then the set of parameter values used for that simulation is accepted. 
6.3.7.2 Quantification of the deviance  
The calibration-score was derived based on the chi-square test statistic, which is a 
measure of how close observed values are to expected values. If 𝐷 is the surveillance 
(and/or observational) data point and 𝑀 is the corresponding output of Synthesis V6 for 
the same data point, then the deviance for that data point is simply quantified by  
|𝐷 − 𝑀|
𝐷
 . 
This definition was chosen because it succinctly and simply captures the magnitude of 
the difference between the surveillance data and modelled outputs. 
6.3.7.3 Data items 
I define a ‘data item’ to be a type of data which is directly used to calibrate the Synthesis 
V6 model. A list of data items which can be considered for a given calibration-score is 
given in Table 6-3. Other data items can be considered so long as they are modelled 
within Synthesis V6. This flexibility of being able to calibrate to almost any data, gained 
from the fact that the model captures the majority of aspects with regards to the 
progression of HIV in an individual, differentiates itself from other mathematical models 
and methods of back-calculation. 
   
294 
 
Table 6-3: Data items which may be considered for a given calibration-score 
Data item Notes 
Number of HIV diagnoses Annual and/or cumulative. May be stratified by age 
group 
Number of AIDS diagnoses Annual and/or cumulative. 
Number of simultaneous 
HIV/AIDS diagnoses 
Annual and/or cumulative. These are diagnoses in 
which HIV is diagnosed within 3-6 months of an AIDS 
diagnosis 
Number of deaths Annual and/or cumulative. 
CD4 count at HIV diagnosis Annual median. 
Proportion of HIV 
diagnoses with advanced 
HIV disease  
Annual proportion. Advanced HIV disease is defined 
as a CD4 count <200 cells/mm3 at HIV diagnosis. 
Proportion of HIV 
diagnoses which are 
prompt  
Annual proportion. Prompt diagnosis is defined as a 
CD4 count >350 cells/mm3 at HIV diagnosis. 
Proportion of HIV 
diagnoses which are recent 
infections 
Annual proportion. A recent infection is one within 
three or six months of a HIV diagnosis (as determined 
by an assay measure) 
Number of people seen in 
care 
Total per year (could be estimated at the end of each 
calendar year, for example) 
Number of people seen in 
care and on ART 
Total per year 
 
6.3.7.4 Calculation of the calibration-score 
The deviance (between the surveillance data and modelled output) is calculated for 
each data point, at calendar year, i, for each data item, j. For example, one data point 
could be the number of HIV diagnoses reported in 2005 (so i=2005 and j=number of 
reported HIV diagnoses). For each of the nd data items, the sum of the deviances is then 
averaged over the number of years, rj, that data were available. The un-weighted 
calibration-score per data item j is then summarised by 
un­weighted calibration­score, 𝑆𝑗  = 
1
𝑟𝑗
∑
|𝐷𝑖𝑗 − 𝑀𝑖𝑗|
𝐷𝑖𝑗
 , 
𝑦𝑟
𝑖=𝑦1
 
where i=[y1,…,yr] represents the calendar year and j=[1,…,nd] represents the data item.  
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The calibration-score can be further weighted by factors which describe the relative 
confidence of the accuracy of a data point in the measured surveillance/observational 
data. Specifically, 
weighted calibration­score = 
∑ 𝑤𝑗𝑆𝑗
𝑛𝑑
𝑗=1
∑ 𝑤𝑗
𝑛𝑑
𝑗=1
 
The weights, wj, should ideally be chosen a priori to reflect the confidence, quality or 
conversely, uncertainty associated with data items. A larger weight would be used for 
data items for which it is believed that the model should calibrate better to. This ensures 
that these data items contribute more towards the calibration-score. The potential range 
of weights used was decided to be [0.5, 5], although note that the actual values are 
arbitrary and it is the relative importance within the calibration-score that matters. Any 
data item deemed to have a very low weight because of the lack of certainty or quality 
should not be included in the calibration-score.  
Given the formula shown above, the property of the calibration-score means that the 
lower the calibration-score, the smaller the deviance between the modelled data and 
observed data and thus the better the model calibrates to the data. The aim of the 
calibration method is therefore to find sets of parameter values which achieve low 
calibration-scores. 
The calibration-score is calculated in a way that it is standardised by the quantity of 
observed data and the weights used, and therefore the calibration-score for one setting 
(with a certain range of data items with associated confidence in quality) can be directly 
compared to that of another setting with a different range of data items and associated 
confidence in quality. Note that a simulation with calibration-score <0.2 can be 
interpreted as saying that the weighted average deviation of the modelled outcomes 
from the observed data across all data items is <20%, i.e. the modelled outputs have 
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less than 20% error on average compared to the observed data. The main limitation is 
that the weights chosen will be subjective, and so should be chosen a priori. 
6.4 Method used to calibrate model to data for 
settings where infections primarily occur within the 
country of interest 
This section outlines how I reached and decided on the final calibration method that was 
going to be used to apply the Synthesis V6 model to any given European country where 
the infections primarily occur within the country.  
6.4.1 Preliminary work to decide on the parameterisation  
6.4.1.1 Parameterisation of incidence and diagnosis rate curve 
The choice of parameterisation for the incidence and diagnosis rate curves (i.e. choice 
of keeping the incidence constant over five years; examples in Table 6-1) was 
influenced by my preliminary work using a simple regression approach. The main factors 
I chose to consider for the parameterisation were the number of parameters and shape 
of the resulting curve.  
For the incidence curve, I considered between five, seven and 11 parameters and for 
the diagnosis rate curve I considered between four, five and six parameters. I 
considered using a higher number of parameters for the incidence curve because this is 
more likely to change greatly over time compared to the diagnosis rate.  
For the shape of the curve, I only considered using a piecewise constant curve for the 
incidence curve, but for the diagnosis rate curve I decided to investigate the possibility of 
using a piecewise linear curve instead. A piecewise constant curve would involve 
sampling the absolute value for each parameter, meaning that the incidence (or 
diagnosis rate) would stay constant for a given period of time. In contrast, the piecewise 
linear curve would involve sampling parameters to define two slopes, e.g. sampling the 
intercept value at 1984, a date of change in slope between 1984 and 2010, and 
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sampling the gradient of the two slopes. I kept the parameterisation simple because the 
aim was not to identify and estimate exactly what the two curves look like, but to find 
sets of parameter values which calibrate well enough to the observed data.  
I also decided to investigate the effects of changing the type of sampling method used: 
whether to use only SRS, or to use LHS.  
6.4.1.2 Statistical analysis performed 
Using UK data on MSM provided by PHE, a statistical analysis was performed to decide 
which parameterisation and sampling method was optimal. I compared 15 combinations 
of parameterisation and sampling approaches, shown in Table 6-4. Three thousand 
simulations were run for each of the 15 combinations, each time sampling the 
parameters at random from the chosen incidence and diagnosis rate parameter 
distributions. For each simulation, an un-weighted calibration-score was calculated by 
comparing the observed number of HIV diagnoses, AIDS diagnoses, deaths and 
number of people seen in care in each year to the modelled equivalents. Based on all 
the 45,000 (=15x3000) simulations performed, three different calibration-score 
thresholds were defined at 1%, 5% and 20% (t1, t5 and t20). For each simulation, a binary 
variable was then defined for each threshold; for example, the variable took the value 1 
if a calibration-score for a particular simulation was ≤t1 and 0 if >t1.  
I next fitted logistic regression models. For each simulation I outputted whether the 
calibration-score was below or above the three thresholds (which were the independent 
variables), and outputted five further variables to describe parameterisation and 
sampling approach used for that simulation (which were the dependent variables). The 
dataset used to fit the regression models therefore has 45,000 rows (15 approaches 
each with 3,000 simulations) with five and three columns representing the dependent 
and independent variables respectively, described in Table 6-5.  
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Table 6-4: Combinations of parameterisation and sampling approaches 
considered  
 Incidence curve Diagnosis rate curve 
Number of 
parameters 
Sampling 
method 
Number of 
parameters 
Sampling 
method 
Type of 
parameterisation 
1 7 LHS 5 LHS Constant 
2 5 LHS 5 LHS Constant 
3 11 LHS 5 LHS Constant 
4 7 SRS 5 SRS Constant 
5 5 SRS 5 SRS Constant 
6 11 SRS 5 SRS Constant 
7 7 SRS 4 SRS Slope 
8 5 SRS 4 SRS Slope 
9 11 SRS 4 SRS Slope 
10 7 SRS 6 SRS Slope 
11 5 SRS 6 SRS Slope 
12 11 SRS 6 SRS Slope 
13 7 LHS 4 SRS Slope 
14 5 LHS 4 SRS Slope 
15 11 LHS 4 SRS Slope 
 
Table 6-5: Variables in the logistic regression model to determine sampling 
method 
Variable 
type 
Variable description Categories 
Dependent Number of parameters used to parameterise 
incidence curve  
5, 7, 11 
Number of parameters used to parameterise 
diagnosis rate curve 
4, 5, 6 
Sampling method for incidence curve SRS, LHS 
Sampling method for diagnosis rate curve SRS, LHS 
Type of parameterisation for diagnosis rate curve Constant, slope 
Independent 1% cut-off ≤ t1, > t1 
5% cut-off ≤ t5, > t5 
20% cut-off ≤ t20, > t20 
SRS:simple random sampling; LHS:Latin hypercube sampling; t1:1
st
 percentile; t5:5
th
 
percentile; t20:20
th
 percentile. 
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Three multivariable logistic regression models were fit; one for each independent 
variable. The odds ratios in each of the models represent the odds of getting a 
calibration-score ≤ t1, t5 or t20. The results (Table 6-6) suggest that a smaller calibration-
score is more likely to be achieved with seven or 11 parameters for the incidence, using 
LHS to sample the incidence parameters, using SRS to sample the diagnosis rate 
parameters and using piecewise constant parameters instead of sampling gradients and 
an intercept for the diagnosis rate parameters. The number of parameters used to 
describe the diagnosis rate curve did not seem to affect the calibration-score achieved. 
Table 6-6: Results from the logistic regression models (odds ratio of getting a 
calibration score ≤1st, 5th and 20th percentiles) 
Parameter Odds ratio (p-value)  
1% model 5% model 20% model 
Number of parameters 
used to parameterise 
incidence curve  
5 1.26 (0.26) 0.95 (0.22) 0.93 (0.0012) 
7 ref ref ref 
11 1.53 (0.33) 1.45 (0.05) 1.36 (0.03) 
Number of parameters 
used to parameterise 
diagnosis rate curve 
4 1.33 (0.34) 1.00 (0.99) 0.96 (0.16) 
5 ref ref ref 
6 1.27 (0.42) 1.00 (0.99) 0.97 (0.28) 
Type of 
parameterisation for 
incidence curve 
SRS ref ref ref 
LHS 1.06 (0.82) 1.13 (0.01) 1.08 (0.005) 
Type of 
parameterisation for 
diagnosis rate curve 
SRS ref ref ref 
LHS 1.19 (0.47) 0.82 (<.0001) 0.86 (<.0001) 
Type of 
parameterisation for 
diagnosis rate curve 
Constant ref ref ref 
Slope 1.15 (0.57) 0.73 (<.0001) 0.76 (<.0001) 
SRS:simple random sampling; LHS:Latin hypercube sampling; 
 
There was no obvious choice for the number of parameters to use to parameterise the 
incidence curve. However, I decided to use seven parameters to describe the incidence 
curve, where each year the number of infections is fixed for a period of time (assuming 
the HIV epidemic begins in 1980 in a given setting, this would mean a constant 
incidence rate for each five-year period). This decision also took consideration of the 
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fact that there would be ten further parameters to be sampled in addition to the 
incidence and diagnosis rate parameters (those listed in Table 6-2). I also decided to 
use four parameters to describe the diagnosis rate curve, where each rate is fixed for a 
period of time (assuming HIV testing & diagnosis is available in a setting from 1984 
onwards, this would mean a constant diagnosis rate over an eight-year period). Given 
the opposing results regarding the sampling method to use, I decided to use a hybrid 
approach in the calibration method by using both types of sampling method. This would 
involve first using LHS to sample both the incidence and diagnosis rate parameters, 
then using SRS. Details of this multi-stage calibration method are described in further 
detail below. 
6.4.2 Multi-stage calibration method 
This multi-stage approach, using Approximate Bayesian Computation to calibrate the 
Synthesis model to the available surveillance data, described below is a novel method 
within the HIV field to my knowledge.  
6.4.2.1 Stage 1 
In the first stage, 10,000 sets of parameter values (those listed in Table 6-1, i.e. seven 
for incidence and four for diagnosis rate) are sampled using LHS[1001]. As explained 
earlier, LHS is used to ensure maximum and even coverage of the entire plausible 
parameter space. This type of sampling approach is ideal here because it ensures that a 
sufficient sample space can be covered efficiently. The simulation model is then run 
10,000 times, each time using one of these sampled sets of parameter values. A 
different population of HIV-positive people until 2013 is constructed in each simulation. 
Outcomes of the model are then compared with a range of surveillance (and/or 
observational) data. I quantify how well the model outputs match the surveillance data, 
i.e. assessing the goodness-of-fit, by calculating the ‘calibration-score’. If the calibration-
score deems it a close fit (i.e. within the tolerance threshold), then the parameter values 
are accepted. The parameters listed in Table 6-2 are not sampled in this stage because 
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the main objective of this first stage is to narrow the widths of the prior distributions (i.e. 
reduce the sample space) which describe the incidence and diagnosis rate. The 
incidence and diagnosis rate parameters have greater uncertainty than the parameters 
listed in Table 6-2, which can be approximated from observational data (best guess 
estimates are used as fixed values in this stage).     
6.4.2.2 Stage 2 
The second stage is similar to the first, but the parameters are sampled using SRS. 
Here, the distribution of all simulations ran in the first stage that resulted in calibration-
scores less than the selected threshold for each separate parameter (i.e. each of 
i1,i2,…,i7 and d1,d2,…,d4) obtained in stage 1 is examined. The minimum and maximum 
values of each value are then used as the limits for each parameter to be sampled from, 
thus refining the prior distributions and improving the efficiency of the calibration method. 
One remains in this second stage until ‘enough’ sets of parameters values calibrate well 
to the observed data. The parameters listed in Table 6-2 are sampled in this stage to 
reflect the uncertainty in the chosen prior distributions.  
6.4.2.3 Stage 3 
In the third stage, further simulations are run using the parameter values which 
calibrated well in the second set. Due to the stochastic nature of the model, a set of 
parameter values may calibrate well to the data in one simulation but not another. 
Therefore, only simulations which again calibrate well to the observed data are used to 
determine the final model outputs. For a particular output, the point estimate is 
calculated as the median value of the modelled outcomes which calibrated well in this 
third stage. Hence if in this third stage, 100 sets of parameter values which calibrate well 
are identified, then the point estimate is calculated as the median across these 100 
simulations.  
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6.4.3 Plausibility range 
In addition to the point estimate, it is useful to have a range in which the underlying 
parameter value is likely to lie. I define this as the ‘plausibility range’ (PR). The range 
should reflect the uncertainty associated with the point estimates, which will be 
determined by the data used to calibrate the model. If there are little data to calibrate the 
model and therefore inform the posterior distributions, then the ensuing PR would be 
wide and not much narrower than the prior distribution. On the contrary, if there are 
many good quality data items, which are consistent with one another, then the ensuing 
PR would be relatively narrow.  
Given that the calibration method is based on multiple simulations using different 
parameter sets, the plausible range is determined quite naturally within this framework. 
Similarly to the point estimate, the PR for the point estimates is determined using the 
outcomes from the third stage of the calibration method. The 5
th
 and 95
th
 percentiles of 
the distribution of these model outputs are considered the 90% PR limits.  
6.4.4 Calibration-score threshold 
In the process of developing this calibration method, I judged that a simulation with a 
calibration-score <0.25 demonstrated that the modelled data were sufficiently 
comparable to the observed data. This was assessed by visually comparing plots of the 
both the observed data and modelled outputs. Simulations with a calibration-score <0.2 
therefore demonstrated an even closer comparison. In the following application of the 
method detailed in Section 6.5, I therefore specify that the threshold of a well-calibrated 
model should have a calibration-score of <0.2. Recall that a simulation with calibration-
score <0.2 can be taken to mean that the weighted average deviation of the modelled 
outcomes from the observed data across all data items is <20%. In a setting with large 
quantities of data to calibrate to, it would be rare to observe a calibration-score <0.1 
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because it would be difficult to simultaneously calibrate to all sources of data, because 
sometimes the data themselves are inconsistent with each other.  
The threshold used in stage 1 of the multi-stage calibration method is likely to be greater 
than 0.2, because from experience it has been very unlikely to achieve parameter sets 
which calibrate well purely from 10,000 samples despite using LHS. Also, the aim is to 
narrow the prior distribution without risking exclusion of parameter values that could be 
part of low calibration-score parameter sets. The threshold chosen here will therefore 
vary by setting. The threshold could alternatively be chosen based on the distribution of 
parameters which contributed, for example, the 20
th
 or 50
th
 percentile of runs with the 
smallest calibration-scores, which will still result in a narrowing of the prior distributions. 
In stage 2 of the calibration process, simulations are continuously performed until a 
sufficient number of simulations are completed with calibration-score <0.2. If this does 
not happen within a reasonable number of simulations, then it is likely that there are 
inconsistencies between the data items, or that the model is incorrectly specified. In this 
event, the calibration-score can be re-defined. This could be done by selecting different 
data items, altering weights for data which are inconsistent with each other, removing 
data items if there are possible reasons why the model might not calibrate due to biases 
in the surveillance data, or increasing the tolerance threshold to a larger value.  
The parameter sets selected to be used in stage 3 are those which achieved a 
calibration-score<0.2 in the second stage. The final model outputs are then based on 
the simulations from stage 3 which again achieve a calibration-score<0.2. 
6.4.5 Improving the efficiency of the calibration method 
6.4.5.1 Simulating a subset of the population 
As Synthesis V6 is an individual-based model, in theory it is possible to simulate every 
single individual in a given epidemic, as long as time and resources allow. However, re-
   
304 
 
construction of a whole HIV-positive population in a setting with a large HIV epidemic 
with an individual-based model means prohibitively large computing resources and time 
may be required.  
Simulating a smaller proportion of the infected population is one way of improving the 
efficiency of the calibration method. For settings with more than 10,000 individuals 
thought to be HIV-positive in 2013, a random sample of these people could be chosen 
such that only 10% of the total population will be individually simulated. The modelled 
outcomes are then multiplied back up to represent the full population. The calibration-
score is calculated from this full population data. For some smaller epidemics, it may not 
be necessary to simulate only a random sample of the population. For larger epidemics 
though this will substantially reduce computing burden, yet ensure a representative 
distribution of the full population. 
6.4.5.2 Terminating simulations prematurely 
During each simulation, the calibration-score will be calculated in five year intervals. If it 
becomes clear during the simulation that it is unlikely, based on the current calibration-
score, to calibrate well to all the observed data, then the simulation could be terminated 
prematurely. The criteria may differ by setting, but an example could be that a simulation 
is terminated in situations where the calibration-score, calculated after each five-year 
period, is ever >0.5, i.e. the modelled outputs are more than 50% away from the 
observed data on average. This has the advantage that computing resources can be 
saved and used for further simulations. 
6.5 Applying the calibration method to data on MSM 
in the UK 
6.5.1 Methods and assumptions 
This calibration method was initially applied to data on the MSM population in the UK, as 
this was the population with which I was most familiar and to which I had access to 
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observed data. The aim was to generate estimates of various characteristics of the UK 
HIV-positive MSM population for 2013. Surveillance data used to calibrate the model 
were obtained from PHE databases. This includes the number of reported HIV and AIDS 
cases from HARS, number of people seen in care with diagnosed HIV from SOPHID, 
number of patients who recently acquired HIV at the time of diagnosis (using RITA) and 
data on CD4 counts from the CD4 surveillance scheme. Behavioural and other clinical 
data were obtained from a range of sources, described in references[725, 729]. The HIV 
epidemic in MSM in the UK has also been studied extensively using other methods[1007, 
1008], which meant that there were other estimates with which comparisons could be 
made. 
I assumed that the first infections occurred in 1980. Diagnosis of HIV (i.e. testing for 
HIV) was available from 1984 onwards[1009]. The diagnosis rate was assumed to 
monotonically increase over time. This was based on data showing an increase over 
time in median CD4 count at diagnosis[1010]. ART use was based on information from 
clinical cohorts on use of specific drugs[1011]. 
To apply this method to the HIV epidemic among MSM in the UK, the model was 
calibrated to surveillance data, which were available until 2012. The same incidence and 
diagnosis rate were assumed for 2012 and 2013 to generate HIV estimates for 2013. To 
reconstruct the HIV-positive MSM population in the UK, a random 1/10
th
 of the infections 
which took place were simulated, predominantly to make the simulations more 
manageable. Although this depended on the actual incidence sampled, this 
corresponded to approximately 8,500 people (1/10
th
 of 85,000 infections thought to have 
occurred in total). The distributions of the sampled parameters are summarised in Table 
6-7. To further improve the efficiency of the calibration method, simulations were 
terminated prematurely by calculating the calibration-score at five year intervals during 
the simulation. Simulations were terminated prematurely if the total number of AIDS 
case reports in 1986-1990 or 1991-1995 were 50% greater than actually observed. 
Similarly, simulations were also terminated prematurely if the total number of HIV case 
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reports in 1996-2000, 2001-2005 or 2006-2011 were also 50% greater than actually 
observed. 
   
 
 
3
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Table 6-7: Parameters and prior distributions used for calibrating the model to data on MSM in the UK 
Parameter Prior distribution 
[mode/mean] 
Data source used to inform choice of 
prior distribution 
i1 Number of infections per year during 1980-1984 Beta(2,4)*9750 
[mode=2438] 
Max incidence per year=Highest number of 
HIV diagnoses ever observed in one year ×3 
i2 Number of infections per year during 1985-1989 Beta(2,4)*9750 
[mode=2438] 
As for i1 
i3 Number of infections per year during 1990-1994 Beta(2,4)*9750 
[mode=2438] 
As for i1 
i4 Number of infections per year during 1995-1999 Beta(2,4)*9750 
[mode=2438] 
As for i1 
i5 Number of infections per year during 2000-2004 Beta(2,4)*9750 
[mode=2438] 
As for i1 
i6 Number of infections per year during 2005-2009 Beta(2,4)*9750 
[mode=2438] 
As for i1 
i7 Number of infections per year during 2010-2013 Beta(1,5)*0.16 
[mode=2438] 
As for i1 
d1 Diagnosis rate per three-month period during 1984-1991 Beta(1,50) [mode=0] Max rate of diagnosis per three 
months=(Proportion of prompt presentations 
in most recent year)/4, [1012] 
d2 Additional change in diagnosis rate from 1984-1991  
(i.e. diagnosis rate during 1992-1999 is d1+d2) 
Beta(1,50) [mode=0] [1012] 
d3 Additional change in diagnosis rate from 1992-1999  
(i.e. diagnosis rate during 2000-2008 is d1+d2+d3) 
Beta(1,50) [mode=0] [1012] 
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Parameter Prior distribution 
[mode/mean] 
Data source used to inform choice of 
prior distribution 
d4 Additional change in diagnosis rate from 2000-2008  
(i.e. diagnosis rate during 2009-2013 is d1+d2+d3+d4) 
Beta(1,50) [mode=0] [1012] 
p1 Proportion of people resistant to testing for HIV  Beta(9,91) 
[mode=0.08] 
[1013] 
p2 Probability of not being linked to care within three months of 
diagnosis 
Beta(2.5,49.5) 
[mode=0.03] 
[1012] 
p3 Rate (three-monthly) of loss to follow-up for those not yet on ART lnNormal(ln0.02,0.5
2) 
[mean=0.02] 
[1012] 
p4 Rate (three-monthly) of loss to follow-up for those who started but 
interrupted ART 
Beta(2,10) 
[mode=0.1] 
[1012] 
p5 Rate (three-monthly) of re-entry into care lnNormal(ln0.4,0.1
2) 
[mean=0.4] 
[1014] 
p6 Probability of starting ART when eligible (per three-month period) Beta(41,11) 
[mode=0.8] 
[888] 
p7 Population distribution of underlying levels of ART adherence 1: 50%, 2: 50% [N/A] [1012] 
p8 Rate (three-monthly) of ART interruption lnNormal(ln0.01,0.2
2) 
[mean=0.01] 
[942] 
p9 Rate (three-monthly) of re-starting (after interrupting) ART lnNormal(ln0.8,0.1
2) 
[mean=0.8] 
[1014] 
p10 Rate (three-monthly) of emigration lnNormal(ln0.002,1
2) 
[mode=0.002] 
[1015, 1016] 
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The data items and corresponding weights used to calibrate the model are shown in 
Table 6-8. Note that although there are more data available on MSM in the UK, the table 
shows only the data which were used as part of the calibration-score definition. 
Table 6-8: Data items and the range of calendar years for which data were used to 
calibrate the model to data on MSM in the UK (weights used in calibration-score 
given in brackets) 
Data item, per calendar year Years (weight) 
Number of HIV diagnoses 1997-2012 (1) 
Number of first AIDS diagnoses 1985-1996 (1) 
Median CD4 count at diagnosis 1985-1996 (0.5), 
1997-2012 (1) 
Proportion of diagnoses which were in recently 
acquired infections 
2009-2013 (0.5) 
Number seen for care 1998-2012 (0.5) 
Number seen for care and on ART 1998-2012 (0.5) 
 
6.5.2 Results 
6.5.2.1 Simulation details 
A total of 10,000 simulations were run during the first stage of the calibration method. In 
the second stage, a further 2,000 simulations were required to obtain at least 100 
parameter sets with a calibration-score <0.2 (i.e. parameters were accepted only if the 
calibration-score was within the tolerance threshold of 0.2). 12,000 simulations of the 
epidemic were therefore generated in total in the first two stages of the calibration 
process, corresponding to over 5,000 computer hours. 121 out of 12,000 simulations 
were within the 0.2 calibration-score tolerance threshold. In the third stage, a further 300 
simulations were performed by resampling these 121 parameter sets. The following 
results presented are those generated using the 224 runs (based on the 121 parameter 
sets) where the calibration-score was <0.2 (median:0.18, min:0.144, max:0.199) among 
the 300 resampled simulations. The posterior distributions (after the third stage) for the 
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sampled parameters i1,…,i7,d1,…,d4,p1,…,p10 are given in Table 6-9 and can also be 
seen in Figure 6-6. 
Table 6-9: Prior and posterior distributions for parameters sampled 
Parameter Prior 
distribution 
[90% range]
a
 
Posterior 
distribution 
[90% PR] 
i1 Number of infections per year during 
1980-1984 
[736,6394] [822,2205] 
i2 Number of infections per year during 
1985-1989 
[736,6394] [951,3275] 
i3 Number of infections per year during 
1990-1994 
[736,6394] [706,2600] 
i4 Number of infections per year during 
1995-1999 
[736,6394] [596,2257] 
i5 Number of infections per year during 
2000-2004 
[736,6394] [1394,3942] 
i6 Number of infections per year during 
2005-2009 
[736,6394] [1960,4567] 
i7 Number of infections per year during 
2010-2013 
[736,6394] [2324,5438] 
d1 Diagnosis rate per three-month period 
during 1984-1991 
[0.002,0.072] [0.003,0.027] 
d2 Additional change in diagnosis rate from 
1984-1991 (i.e. diagnosis rate during 
1992-1999 is d1+d2) 
[0.001,0.058] [0.013,0.038]
b
 
d3 Additional change in diagnosis rate from 
1992-1999 (i.e. diagnosis rate during 
2000-2008 is d1+d2+d3) 
[0.001,0.058] [0.020,0.056]
b
 
d4 Additional change in diagnosis rate from 
2000-2008 (i.e. diagnosis rate during 
2009-2013 is d1+d2+d3+d4) 
[0.001,0.058] [0.026,0.061]
b
 
p1 Proportion of people resistant to testing for 
HIV 
[0.048,0.141] [0.039,0.136] 
p2 Probability of not being linked to care 
within three months of diagnosis 
[0.011,0.104] [0.011,0.105] 
p3 Rate (three-monthly) of loss to follow-up 
for those not yet on ART 
[0.009,0.046] [0.009,0.026] 
p4 Rate (three-monthly) of loss to follow-up 
for those who started but interrupted ART 
[0.033,0.364] [0.025,0.406] 
p5 Rate (three-monthly) of re-entry into care [0.339,0.471] [0.300,0.530] 
p6 Probability of starting ART when eligible 
(per three month period) 
[0.690,0.874] [0.695,0.873] 
p7 Population distribution of underlying levels 1:50%, 2:50%
c
 1:44%, 2:56%
c
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Parameter Prior 
distribution 
[90% range]
a
 
Posterior 
distribution 
[90% PR] 
of ART adherence 
p8 Rate (three-monthly) of ART interruption [0.007,0.014] [0.007,0.014] 
p9 Rate (three-monthly) of re-starting (after 
interrupting) ART 
[0.678,0.943] [0.701,0.801] 
p10 Rate (three-monthly) of emigration [0.000,0.010] [0.0004,0.007] 
a.90% range limits are given by the 5th and 95th percentiles, which are estimated from 
100,000 sampled values for each prior distribution.   
b.Posterior distributions refer to the absolute diagnosis rate for that time period, as opposed 
to the additional change. 
c.1 and 2 refer to adherence patterns (Appendix VII) 
 
Figure 6-6: Estimated incidence and diagnosis rate amongst MSM in the UK 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range.  
Incidence:number of new HIV infections in a year. Diagnosis rate:probability with which an 
HIV-positive individual gets diagnosed with HIV in a three-month period, given they are not in 
the primary infection phase, not symptomatic and do not have AIDS. 
 
6.5.2.2 Main results 
Figure 6-7 shows that the final chosen simulations generally calibrate well to the 
surveillance data that were used for the calibration-score. The surveillance data in 2012 
compared to the median across the simulations, respectively, were as follows: number 
of HIV diagnoses (3,250 vs. 3,080), number of AIDS diagnoses (138 vs. 530), number of 
deaths (161 vs. 380), proportion of diagnoses with CD4 <350 cells/mm
3
 (39% vs. 40%), 
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number seen for care (33,969 vs. 36,530) and number seen for care and currently on 
ART (28,526 vs. 31,070).  
Figure 6-7: Calibrating the model to surveillance data on HIV-positive MSM in the 
UK 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range; diamonds: surveillance data until 2012 supplied by Public Health England (filled 
diamonds show data used to calibrate the model, open diamonds show data not used to 
calibrate the model). 
A recent infection is defined here as an infection which took place within six months of an 
HIV diagnosis. 
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The distribution of incidence and diagnosis rate parameters are shown in Figure 6-6. 
This shows a steady increase in incidence from 1980, followed by a slightly lower level 
in the early 1990s and then a gradual increase again from then onwards. An estimated 
3,270 (90% PR:2,310-5,380) infections per year on average are thought to have 
occurred since 2010. The cumulative number of HIV infections that had taken place by 
end of 2012 totalled 71,960 (90% PR:59,800-84,600). The diagnosis rate (in people 
without symptoms or AIDS) has steadily increased over time but still remains low at 
0.041 (90% PR:0.026-0.061) per three months in recent years. 
By 2013, an estimated 51,000 (90% PR:41,400-61,000) MSM were living with HIV in the 
UK (Figure 6-8), and 3,400, 7,200, 12,700 and 27,700 individuals had CD4 count ≤200, 
201-350, 351-500 and >500 cells/mm
3
 respectively. The estimated number of MSM 
living with undiagnosed HIV (Figure 6-8) was 11,500 (90% PR:7,500-16,700), which 
means the undiagnosed proportion is estimated as 23% (90% PR:15%-33%). In the 
undiagnosed population, 800, 2100, 3,500 and 5,100 individuals had CD4 count ≤200, 
201-350, 351-500 and >500 cells/mm
3
 respectively.  
Figure 6-9 shows the HIV care cascade in 2013 and a further detailed breakdown of the 
population characteristics. Of all MSM living with HIV in the UK, 24% were not retained 
in care and 60% of all those who are HIV-positive (both diagnosed and undiagnosed) 
were receiving ART. Over half (56%) of all HIV-positive MSM had suppressed viral load 
(<500 copies/ml). Of the 42,000 MSM in need of treatment (defined as people on ART 
and people ART-naïve with CD4 count <500 cells/mm
3
, as per the new WHO 
guidelines) 80% were actually receiving it. Current national UK guidelines recommend 
ART to be initiated when CD4 count drops below 350 cells/mm
3
. 
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Figure 6-8: Estimates of the total number of MSM living with HIV and total number 
of MSM living with undiagnosed HIV in the UK 
 
Diamonds: model median; Bars: model 90% plausibility range. 
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Fourteen percent of all HIV-positive MSM, equating to 7,200 (90% PR:5,700-8,800) 
individuals, were estimated to have at least one major resistance mutation in majority 
virus where the source includes both transmitted and acquired drug resistance in 2013 
(Figure 6-9). Of those with at least one mutation, most (71%) MSM had NRTI resistance 
mutations, whereas NNRTI (55%) and PI (51%) resistance mutations were still 
frequently seen, but less common. Two percent of all HIV-positive MSM had triple class 
resistance. The number of MSM with viral load >50 copies/ml and at least one major 
resistance mutation in majority virus (i.e. a group with potential to transmit drug-resistant 
virus) was 3,510 (90% PR:2,500-4,700). The number of MSM with triple class drug 
failure was 830 (90% PR:570-1,200). This low estimate is likely a result of low rates of 
viral failure, which in turn is a result of the high population levels of adherence assumed 
in the model based on observed data (of all MSM on ART for at least six months, 96% 
have undetectable viral load)[1017]. 
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Figure 6-9: Estimated treatment cascade and population characteristics of MSM 
living with HIV in the UK in 2013  
 
Columns: model median; error bars: model 90% plausibility range. 
‘Resistance’ is defined as at least one resistance mutation in majority virus. ‘In need of ART’ 
includes people who are on ART and those who are ART-naïve with CD4 count <500 
cells/mm
3
. 
 
6.5.2.3 Sensitivity analysis 
One limitation of the method is the choice to use piecewise constant curves to 
parameterise the incidence and diagnosis rate. In other words, I have assumed that 
neither the incidence nor the diagnosis rate changes over a given time period. This can 
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alternatively be interpreted as the average value (of incidence or rate of diagnosis) over 
the given time period. Figure 6-7 for example, illustrates some mis-fitting to the AIDS 
case-report data in the early phase of the epidemic, but this may also be a consequence 
of keeping the incidence constant over an extended period. Other back-calculation 
studies on MSM epidemics in Western Europe have found a peak in incidence in the 
early to mid-1980s[510, 556, 1018]. Although this means the resulting incidence curve 
may not be an accurate reflection of infections in the past, the resulting estimates are 
unlikely to be severely biased, as the incidence is just an average over a given time 
period.  
To explore whether this method has indeed mis-specified this peak by calculating 
average incidence rates over five-year periods, I implemented the calibration method 
again, but parameterised the incidence curve slightly differently. For the results below, I 
used exactly the same calibration method, but instead split the first period into 1980-1 
and 1982-4 (i.e. inclusion of one additional parameter). 
Figure 6-10 shows the re-parameterised incidence curve and corresponding diagnosis 
rate curve. The peak in incidence, seen using other back-calculation type models, is not 
obvious from looking at the median value, although the 90% PR suggests that it is 
plausible. Some of the infections which make up the peak in incidence in the mid-1980s 
may actually be an artefact of an increase in the number of tests conducted in this 
period, given that HIV testing was available from 1984 onwards. However, it is difficult to 
disentangle exactly how much was a due to the rise in the number of infections and how 
much due to an increase in testing.  
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Figure 6-10: Re-parameterised estimated incidence and diagnosis rate amongst 
MSM in the UK 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range. 
 
The main outcomes of interest, total number living with HIV and number living with 
undiagnosed HIV, are shown in Figure 6-11. For the most recent decade in particular, 
the estimates are similar to the main results. I consider this sensitivity analysis to also 
demonstrate the repeatability of the calibration method, since similar results were 
attained after repeating the entire process described, with only one minor alteration to 
the parameterisation.  
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Figure 6-11: Estimates of the total number of MSM living with HIV in the UK and 
total number of MSM living with undiagnosed HIV, using re-parameterised 
incidence parameters 
 
Diamonds: model median; Bars: model 90% plausibility range. 
 
6.6 Applying the calibration method to pseudo data  
6.6.1 Methods and assumptions 
The calibration method was also applied to pseudo data to assess how well the method 
would work in multiple settings with varying availability of data. The pseudo data was 
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simulated using one run of the Synthesis model, for a given incidence and diagnosis 
rate (all other parameters were fixed). The simulated outcomes were used as if they 
were real data and the method is applied to model the hypothetical epidemic (assuming 
reasonable priors for the incidence and diagnosis rate as would be used in the situation 
where the true values are unknown). Various amounts of data for the epidemic were 
then assumed to be ‘unknown’, allowing me to use the method described above to see 
how well it is able to reconstruct the true epidemic in scenarios with different data 
availability. Three scenarios of data availability were conceived: high, medium and low 
(Table 6-10). The method was applied under each scenario and the resulting HIV 
estimates compared. Although this approach is somewhat circular in that the same 
model is used to generate and analyse the epidemic, it provides a useful means to 
compare the calibration method with differing levels of data availability.  
Table 6-10: Data items and the range of calendar years for which data were used 
to calibrate the model to pseudo data (weights used in calibration-score given in 
brackets) 
Data item, per calendar year Data assumed available (weight) 
High Medium Low 
Number of HIV diagnoses 1985-2012 (1) 1996-2012 (1) 2011-2012 (1) 
Number of first AIDS diagnoses 1985-2012 (1) 1996-2012 (1)  
Number of deaths 1985-2012 (1)   
Median CD4 count at diagnosis 1990-2012 (1)  2011-2012 (1) 
Proportion of diagnoses where CD4 
count <200 cells/mm
3
 
1990-2012 (1)   
Proportion of diagnoses which were 
in recently acquired infections 
2009-2012 (1)   
Number seen for care 1998-2012 (1)   
Number seen for care and on ART 1998-2012 (1) 2000-2012 (1)  
Data were assumed available on a per calendar year basis, i.e. there are 28 data points 
(1985 to 2012 inclusive) to calibrate for the number of HIV diagnoses in the high data 
availability scenario. 
 
The hypothetical epidemic is loosely based on that thought to have occurred in MSM in 
Western Europe. The incidence curve (Figure 6-12) depicts the number of infections 
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over calendar time. In Western European countries, there is thought to have been an 
early peak in incidence in the mid-1980s, which plateaued in the mid-1990s and 
gradually increased again after that. The total number of infections from 1980 to 2014 
was 10,000. Diagnoses of HIV start from 1985 onwards. Again I assume that the 
diagnosis rate is monotonically increasing (Figure 6-13). 
Figure 6-12: Number of infections per year in hypothetical epidemic 
 
Figure 6-13: Rate of diagnosis per three months in hypothetical epidemic 
 
The prior distributions for the incidence and diagnosis rate parameters used are shown 
in Table 6-11. As the epidemic I am trying to reconstruct has a single incidence and 
diagnosis rate, the priors used for all three data availability scenarios (high, medium and 
   
322 
 
low) are also the same. In this example using pseudo data, I chose not to sample the 
other parameters listed in Table 6-2. 
Table 6-11: Parameters used for calibrating the model to pseudo data 
Parameter Prior distribution 
i1 Number of infections per year during 1980-1984 Beta(2,4)*1350 
i2 Number of infections per year during 1985-1989 Beta(2,4)*1350 
i3 Number of infections per year during 1990-1994 Beta(2,4)*1350 
i4 Number of infections per year during 1995-1999 Beta(2,4)*1350 
i5 Number of infections per year during 2000-2004 Beta(2,4)*1350 
i6 Number of infections per year during 2005-2009 Beta(2,4)*1350 
i7 Number of infections per year during 2010-2013 Beta(2,4)*1350 
d1 Diagnosis rate per three-month period during 
1984-1991 
Beta(1,5)*0.16 
d2 Additional change in diagnosis rate from 1984-
1991 (i.e. diagnosis rate during 1992-1999 is 
d1+d2) 
Beta(1,100) 
d3 Additional change in diagnosis rate from 1992-
1999 (i.e. diagnosis rate during 2000-2008 is 
d1+d2+d3) 
Beta(1,100) 
d4 Additional change in diagnosis rate from 2000-
2008 (i.e. diagnosis rate during 2009-2013 is 
d1+d2+d3+d4) 
Beta(1,100) 
 
6.6.2 Results 
6.6.2.1 Simulation details 
The number of simulations in the first stage of the calibration process was 10,000. 
Similarly to the example using MSM data from the UK, it was decided to aim for at least 
100 parameter sets with calibration-score <0.2 for each data availability scenario in the 
second stage of the calibration method. For this illustrative example, the third stage of 
the calibration was not implemented, nor were any simulations terminated prematurely. 
The three different data availability scenarios required a different number of simulations 
to achieve 100 parameter sets with calibration-score<0.2. The number of simulations 
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required depended on how quickly 100 such parameter sets can be found. The results 
which follow are based on 100 simulations with calibration-scores <0.2 for each of the 
three data availability scenarios. Where there were more than 100 simulations with 
calibration-score <0.2, the 100 parameter sets leading to the 100 smallest calibration-
scores were used. The smallest calibration-scores which were achieved amongst these 
100 simulations were 0.153, 0.138 and 0.001 for ‘high’, ‘medium’ and ‘low’ data 
availability respectively. 
6.6.2.2 Main results 
Figure 6-14 shows the estimated number of people living with HIV and living with 
undiagnosed HIV in 2013 by data availability. The category, ‘based on prior distributions’, 
refers to the median and 90% PR of the estimates based on the full parameter 
distributions, including the outcomes which did not get accepted based on the tolerance 
threshold. Therefore, the PR for this category shows how wide it could have been if 
there were no data to calibrate the model, compared to the other three scenarios. 
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Figure 6-14: Estimates of the number of people living with HIV in a hypothetical 
epidemic by data availability 
 
Diamonds: model median; Bars: model 90% plausibility range. Dotted line: refers to the 
actual number of people living with HIV in the hypothetical epidemic. 
‘Based on prior distributions’ refers to the outcomes when all parameter sets (none excluded 
by calibration-score criteria) are taken into account.  
 
Figure 6-15 depicts how well each data availability scenario was able to recapture the 
‘true’ incidence and diagnosis rate curves. Comparing with the incidence curve firstly, 
only the ‘high’ scenario was able to obtain the approximate trend of an initial rise in 
incidence, followed by dip, then a gradual increase, although some of the observations 
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are outside the 90% PR. All three scenarios estimate approximately the same number of 
infections which took place from 2010 onwards, although the widths of the PRs differ 
greatly. Comparing with the diagnosis rate curve, all three scenarios were able to obtain 
a diagnosis rate of approximately 0.06 per three months in the most recent years of the 
epidemic. The differences however, lie in the widths of the PRs, especially in the early 
years of the epidemic. 
Figure 6-15: Resulting incidence and diagnosis rate curves as determined 
using the calibration method to the high (top row), medium (middle row) and 
low (bottom row) data availability scenarios 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range. Diamonds: ‘true’ values of incidence and diagnosis rate for simulated epidemic. 
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6.7 Discussion 
In this chapter, I have described an approach to estimate the size and characteristics of 
HIV-positive populations using a stochastic computer simulation model of HIV 
progression and the effects of ART. As the model reconstructs the population 
characteristics in great detail, at a level corresponding to data which are collected as 
part of clinical care, it provides an approach to describe and understand HIV-positive 
populations in detail. I have shown here that it is possible to generate estimates of 
numbers of people living with HIV and their characteristics, albeit with different levels of 
uncertainty, with various quality and availability of surveillance data. It is important to 
bear in mind that the overall method used to calibrate the model to country data would 
need to be generalizable to many different settings with various quantities and qualities 
of data. Together with other available information about the epidemic, epidemiological 
and clinical estimates and PRs generated using the Synthesis V6 could be used to 
further inform decisions and policies[701, 1019]. Although the HIV care cascade can be 
ascertained using alternative estimates of the undiagnosed population together with 
available surveillance data about the diagnosed population, I have demonstrated that it 
is possible to estimate the full cascade using this approach too (Figure 6-9). 
The number of MSM living with HIV in the UK has gradually been increasing and is now 
estimated to be 51,000 (90% PR:41,400-61,000) in 2013. I estimated that there were 
approximately 3,270 new infections per year between 2010 and 2013, which was slightly 
higher than the average for 2005-2009. I also found that the total number of 
undiagnosed HIV infections to have remained reasonably stable over the last five or six 
years at over 10,000. Due to data being available only until 2012 at the time this work 
was conducted, these figures have considerable uncertainty as demonstrated by the 
width of the PR in the most recent calendar years (Figure 6-8). It was encouraging to 
see that these results were consistent with other UK estimates. Official UK estimates 
(using the MPES method[467, 469]) presented that 43,500 (95% credible 
interval:40,200-48,200) MSM were estimated to be living with HIV in the UK[501]. Using 
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the same method, Birrell and colleagues previously modelled incidence in MSM (limited 
to England and Wales) and found that the number of new infections between 2001 and 
2010 oscillated between 2,200 and 2,800 per year[1007]. They also estimated the 
number of MSM living with undiagnosed HIV (Figure 6-16) in 2010 to be 7,690 (95% 
credible interval:5,460-10,580).  
Figure 6-16: Number of undiagnosed HIV infections among MSM in England and 
Wales as estimated using a back-calculation model [1007]   
 
Results from the pseudo data example, which compared estimates when calibrating the 
model with varying amounts of data availability, show the difference in estimates and 
ranges for three different scenarios. The presented results indicate that more reliable 
estimates are made with a wide range of surveillance data, and that having historical 
data also helps. The width of the PR increases with less data available to calibrate the 
model. The differences between the three different scenarios show that having data 
about the current population in care, such as data on the numbers of people on ART 
and case reporting based data on the number of diagnoses in a year, vastly help inform 
estimates of the total numbers living with HIV (Figure 6-14). 
The smallest calibration-scores which were achieved amongst the 100 simulations were 
0.153, 0.138 and 0.001 for ‘high’, ‘medium’ and ‘low’ data availability respectively. These 
results illustrate that the more data there are to calibrate the model to, the harder it is to 
find a smaller calibration-score. Although the ‘low’ data availability situation led to the 
 
Figure not available due to copyright restrictions 
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smallest calibration-score, looking at the PR presented in Figure 6-14, it can be deduced 
that a small calibration-score does not necessarily mean that it captures the underlying 
epidemic well, but in fact just calibrates very closely to the small amount of data 
available. So in other words, while the calibration scores are in some sense comparable 
between situations with a large amount of data to fit to or little, it is important to bear in 
mind that a calibration-score of 0.18, say, based on a large amount of data is more likely 
to be accurately capturing an underlying epidemic than a simulation with a calibration-
score of 0.07 based on little data. Although this means that the calibration-score itself is 
somewhat hard to interpret, it is still a useful concept because it indicates that the model 
was calibrated to the observed data with a given error margin and has an intuitively 
simple interpretation. In the most ideal situation, the model will be calibrated to a range 
of observed data with the smallest calibration-score possible. This will vary by setting 
however, as if the data within the surveillance system are inconsistent with each other 
given the model, then this indicates either bias in one or both observed data sources or 
model misspecification. If these cannot be resolved (and the basic underlying model 
cannot be changed just to calibrate to one set of country data and it should only be done 
if model-specification is consistently indicated over multiple country data calibrations), 
such a conflict would mean that the calibration-score threshold may have to be larger 
than desired. 
This calibration method has a number of advantages. Synthesis V6 is an individual-
based stochastic simulation model which means it models each individual’s life course 
and therefore reconstructs detailed characteristics of populations infected with HIV[703]. 
This means that it is possible to calibrate the model to a wide range of observed data 
simultaneously. This is beneficial because for some countries there may not be much 
HIV case-reporting data whereas data on the numbers of people on ART for example 
might be very accurate. In fact, only recently have most countries in Western Europe 
had a national-level surveillance system in place to collect and report data on the 
number of new HIV diagnoses[1020]. In addition, by calibrating the model to a number 
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of different types and sources of data, data triangulation can also be carried out because 
the outputs of the model can be used to cross-validate across these data sources. 
The results from applying the method to pseudo data illustrated that the more data there 
are to calibrate the model to, the harder it is to find a smaller calibration-score[996]. The 
model could always be calibrated to less data however, in which case the width of the 
PR would become greater. The calibration method is thus a very flexible approach which 
can utilise the data available, including but not limited to case-report data. Using an 
individual-based model means that it is possible to estimate not only the size of the 
undiagnosed population, but it is also possible to simultaneously describe the population 
in terms of whether they are in care, ART coverage, immunological status and 
population viral load. The model is also able to take account of specific drug-use if data 
on regimens used are available, and hence can output estimates of drug resistance 
mutations and drug side-effects, which may further help to inform national 
recommendations and policies. 
A major limitation of any modelling approach is that the validity of model estimates is 
highly dependent on the quality of available data used to calibrate the model. This 
means that the more reliable and accurate the data used to calibrate the model, the 
more likely estimates will be useful. In particular, it is essential to know the 
characteristics of the data and the mechanisms of surveillance systems so that these 
can also inform the model calibration process. For instance, most countries will be 
aware of data issues such as under-ascertainment, double-counting and 
misclassification bias amongst others, so efforts to reduce these errors or otherwise 
adjust the surveillance data accordingly is of importance. In the case of applying the 
method to data on MSM in the UK specifically, I think that the discrepancy between the 
observed data and modelled outcomes on AIDS case reports in particular (Figure 6-7) is 
most likely due to under-reporting of such data in the UK in the era of effective 
ART[1021].  
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There are also a number of other limitations specific to this approach. Firstly, even 
though the simulations are run on a computing cluster, this method is time-consuming. 
Also, the iterative calibration method is not automatically implemented, so needs 
considerable attention throughout. However, once the plausible ranges of the historic 
incidence and diagnosis rate curves have been estimated, updating the estimates in 
future years will not require the same intensive calibration process. One other limitation 
is that the definition of a ‘good’ calibration-score is somewhat arbitrary, which is an 
inherent problem of using Approximate Bayesian Computation.  
In summary, in this Chapter I have shown an approach using an individual-based model 
of HIV progression and effect of ART which can generate HIV estimates for populations 
where infections mainly occur within these settings (and few infections amongst 
migrants who were infected in their country of origin). This novel method also naturally 
produces PRs, which describe the uncertainty surrounding the estimates. By extending 
the duration of the simulated epidemic and projecting into the future (e.g. assuming 
incidence and diagnosis rate remain as in 2012), the method can also potentially be 
used for making short-term projections. Such projections however, will be based heavily 
on the assumptions made regarding the incidence and diagnosis rate in the future and 
all resulting estimates will only be as reliable as the information put into the model. 
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Chapter 7 Development of the model 
calibration method at a national 
level 
In Chapter 6, I presented an approach to calibrate an individual-based stochastic 
simulation model to data from countries where infections primarily occur within the 
country of interest, using the example of MSM data in the UK. In this Chapter, I present 
a modification to this calibration method which can be used at a national level, which 
explicitly accounts for infections which occur abroad. Specifically, these infections refer 
to those heterosexually transmitted in countries with generalised HIV epidemics. The 
method is then applied to data from the UK to estimate the size and characteristics of 
the HIV-positive population in the UK, stratified by the main routes of HIV acquisition. 
The estimates generated using my method are compared with other modelling estimates 
and then discussed. 
7.1 Developing the calibration method 
7.1.1 Differences from the calibration method presented in Chapter 6 
The method presented in this chapter involves simultaneously estimating the size and 
characteristics of the entire population of HIV-positive people who have ever lived in a 
country of interest. The main new development compared to the calibration approach 
presented in Chapter 6 concerns the modelling of additional sub-populations, specifically, 
the heterosexual population with HIV. This is because many infections which occur in 
countries with a generalised HIV epidemic occur in the heterosexual population. I 
developed a method using heterosexuals who live in the UK as an illustration of the 
approach and present my choices and considerations here. I start by describing the key 
differences, such as how the infections acquired abroad are modelled. I then explain 
how the calibration method incorporates more than one sub-population in order to make 
national-level estimates for a given setting. 
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7.1.2 Infections which occur in sub-Saharan Africa 
Many European countries have historical links with countries in SSA, the region where 
the largest proportion of the world’s new HIV infections occur[1022]. This means that 
there are individuals who acquire HIV in SSA who then subsequently immigrate to a 
European country. As a result of the ease of international travel in the last few decades, 
alongside the development of effective treatment for HIV, there are many HIV-positive 
people who settled in countries other than their country of origin or infection. In order to 
model the size and characteristics of an HIV-positive population currently residing in a 
European country, it is therefore necessary to include such people who acquired their 
infection abroad but who now live in that country.  
I assume for the case of the UK, that all infections which did not take place in the UK 
must have taken place in SSA. This is likely to be a reasonable assumption for the UK 
given that the vast majority of non-UK acquired infections are in people of African 
origin[501, 1023]. Although many migrants with HIV are often originally from countries in 
SSA, this is not always the case. For example, Sweden has a large number of migrants 
from South East Asia who arrive in Sweden already infected with HIV[535]. Infections 
which take place in other European countries are not explicitly modelled due to limited 
data on migration patterns among HIV-positive people within Europe. In any case, the 
net effect of migration within Europe is assumed to cancel out the movements of 
migrants with HIV to some extent.  
7.1.3 Parameters which determine HIV incidence and arrival in the UK 
For the purposes of this calibration method, people living in the UK who acquired their 
infections through heterosexual contact are categorised into one of the following two 
groups:  
 people who acquired their infection in the UK 
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 people who acquired their infection in SSA.  
The make-up of the total number of people living with HIV in the UK at any point in time 
is summarised in Figure 7-1. As such, I decided to parameterise the number of new 
infections using two curves: 
1. Number of new infections (incidence) amongst those infected in the UK. This is 
analogous to the incidence curve used in the example illustrated with MSM in the 
UK in Chapter 6. 
2. Rate of arrival (probability per three months) in the UK of HIV-positive people 
infected in SSA. 
 
Figure 7-1: The make-up of the total HIV-positive population in the UK 
 
7.1.3.1 Incidence among people infected in the UK 
The number of infections which occur in the UK is parameterised in the same way as in 
Chapter 6. The incidence curve is thus parameterised using 7 parameters, each fixed for 
a period of time (assuming the HIV epidemic begins in 1980 in a given setting, this 
would mean a constant incidence rate over a five-year period). 
 
HIV-positive people in the UK= 
People 
infected in 
the UK 
People 
infected in 
sub-Saharan 
Africa 
HIV-positive people 
in sub-Saharan 
Africa 
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7.1.3.2 Incidence among people infected in SSA 
The incidence of HIV outside the UK is based on the incidence curve for SSA outputted 
by the UNAIDS EPP/Spectrum programs (Section 2.3.1.1)[1024]. Mr John Stover 
(UNAIDS Reference Group on Estimates, Models and Projections) kindly provided me 
with region-specific incidence curves for SSA (Figure 7-2)[1025]. By assuming an 
incidence curve, I wanted to capture the process by which people who were infected in 
SSA then migrate, or in other words ‘arrive’ in the UK.  
Figure 7-2: New adult HIV infections in SSA by region, based on the UNAIDS 
Spectrum model [1025] 
 
Given former colonial links, the majority of migrants to the UK are from eastern and 
southern SSA countries. Nonetheless there are still appreciable numbers of migrants 
with HIV coming from other areas of SSA[506]. For this reason, I have chosen to 
emulate the shape of the incidence curve for the total SSA region as shown in the light 
blue colour in Figure 7-2. Such people are simulated in the model from the date of 
infection and follow-up is generated for these individuals as for individuals who were 
infected in the UK.  
   
335 
 
7.1.3.3 Simulating a subset of the population in SSA 
According to the incidence estimates derived using the UNAIDS EPP/Spectrum 
programs (Figure 7-2), there are estimated to have been over 47 million infections in 
SSA until 2013. It is therefore necessary to simulate a fraction of the incidence in SSA in 
order to limit the overall number of individuals with HIV simulated in the model. The 
choice of fraction therefore impacts on the magnitude of the rate of arrival. In other 
words, as the absolute level of arrival is arbitrary (as determined by the size of the pool 
of the people simulated in SSA), the rate of arrival depends on the relative size of the 
fraction simulated. For a given number of people to arrive in the UK with HIV, the greater 
the group of infected people in SSA there is (the greater the simulated fraction), the 
lower the rate of arriving must be and vice versa.  
As a result of trial and error, I decided to simulate 1% of all infections which occurred in 
the total SSA region, which amounts to approximately 470,000 infections between 1980 
and 2013. In deciding this proportion, it was necessary to compromise between 
modelling enough infections so that even with a high rate of arrival, the group of people 
in SSA would not be appreciably depleted whilst ensuring that the model still ran within a 
reasonable length of time when simulating such a large number of individuals.  
7.1.3.4 Rate of arrival in the UK among people infected in SSA 
Similarly to all other rate parameters in Synthesis V6, the rate of arrival in the UK will be 
modelled as a probability per three-month period. I decided that the trends in the rate of 
arrival should be comparable to immigration trends seen in the general population. This 
implicitly assumes that the rate of arrival in people with HIV is no different to that seen in 
the general population. I used data from the Office of National Statistics on long-term 
international migration to inform the trends in the rate of arrival[1026]. Figure 7-3 shows 
the trends in number of people entering the UK who have listed country of birth as 
‘South Africa’ or ‘Other African Commonwealth’. The figure shows a stable flow of 
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migrants from the region until the late 1990s, followed by a large increase over the next 
seven to eight years which has since declined.   
Figure 7-3: Immigration estimates for people with country of birth as South Africa 
or other African commonwealth countries [1026] 
 
To model the rate of arrival, I therefore mimic the trends seen in the general population 
by assuming the same shape. As mentioned above, the absolute level of arrival is 
strictly arbitrary, as it is dependent on the fact that only 1% of all infections which 
occurred in the total SSA region are simulated. As the shape of the arrival curve is 
assumed to be known, I therefore use only one parameter rate_arrival, (Table 7-1) to 
model the arrival rate curve in the model. This parameter is then modified by fixed 
values (which do not change in each simulation) at certain calendar years in order to 
depict the trends over time, i.e. the shape of the curve does not change from one 
simulation to another, but the rate may be x-fold higher or lower. Based on 1% of the 
SSA HIV-positive population being simulated, I chose the prior distribution for 
rate_arrival in the UK to be given by lnNormal(ln0.01,0.25
2
). This was chosen from 
preliminary calibration results and is sampled in each of the simulations to reflect the 
uncertainty associated with the parameter. This rate converts to approximately 5000 
HIV-positive people arriving in the UK from SSA at the migration peak in the mid-2000s 
in one year (with lower numbers during other years). 
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One external factor which I incorporated to impact on the probability of a person 
migrating to the UK was the presence of a pre-AIDS symptom or an AIDS-defining 
condition. If either was present in the previous three-months in a person, then this 
reduced the person’s probability of migration to 0 for a given three-month period given 
that they would be too ill to travel.  
In the UK, the number of HIV diagnoses among black Africans has always been slightly 
higher in females than in males[506, 1010]. This may have arisen due to a higher rate of 
arrival of female migrants from SSA, rather than just due to a higher rate of HIV infection 
and HIV diagnosis in females compared to males. Although many migrants came to the 
UK because of political or economic pressures in their home countries, this difference by 
sex could also have resulted because the UK has in the past actively recruited 
healthcare professionals from countries in SSA, who were perhaps more likely to be 
female[1027, 1028]. For this reason, I also incorporated another parameter into the 
model, arrivex (Table 7-1), which describes the fold-decrease in rate of arrival in males 
compared to females. For this UK example, the value for arrivex is sampled from 
lnNormal(ln0.6,0.05
2
) per simulation.  
7.1.4 Modelling sub-populations within a country 
7.1.4.1 Defining sub-populations in the UK 
For the purposes of calibrating to UK data, the HIV-positive population is considered to 
consist of infections among MSM and heterosexuals only, as these are the two main 
routes through which HIV is acquired[501]. Other less common routes of transmission 
including via IDU and MTCT, although not explicitly modelled separately, are included in 
the estimated total population by calibrating to data on the total population (in addition to 
sub-population level data). They would thus not be ascribed to a specific risk group. 
The decision regarding which sub-populations to model is determined by the data 
collection practices within the surveillance system to some degree. Surveillance systems 
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will differ in the type of data collected and how variables are defined. Examples of such 
variables, associated with the heterosexual population in particular, include race, 
ethnicity, nationality, country of birth, country of origin and country of probable infection.  
Due to the way in which infections in SSA are to be modelled (with the assumed 
UNAIDS curve), I model the following sub-populations for the UK (with the exception of 
PWID due to low numbers): 
 MSM (all assumed to acquire HIV in the UK) 
 Non-black African heterosexual men (all assumed to acquire HIV in the UK) 
 Non-black African heterosexual women (all assumed to acquire HIV in the 
UK) 
 Black African heterosexual men (a proportion acquire HIV in SSA, the rest in 
the UK) 
 Black African heterosexual women (a proportion acquire HIV in SSA, the 
rest in the UK) 
For the first three exposure groups, all are assumed to acquire HIV in the UK, or that the 
number of immigrants matches the number of emigrants and therefore cancels out in 
effect. The last two exposure groups take into account that there are some 
heterosexuals of black African race who, having emigrated from SSA and immigrated 
into the UK at some point, then acquire HIV infection in the UK. For black African 
individuals who are born in SSA but acquire HIV in the UK, the incidence is estimated 
(as for MSM and other non-black African heterosexuals), and a year of arrival (also 
based on the immigration curve as in Figure 7-3), is randomly allocated. This is a 
resourceful way to model the arrival of SSA-born individuals because there are data 
available for migrants on the year of arrival (in the UK), which would be a good source of 
data to calibrate model outcomes to. However, the data on year of arrival is not able to 
tell where the infection was likely to be acquired, so it is important to calibrate the data 
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on year of arrival to the modelled year of arrival in SSA-born individuals, regardless of 
where HIV was acquired.  
7.1.4.2 Parameters to model sub-populations 
The parameters which are used to model the sub-populations are given in Table 7-1. 
The prior distributions presented are chosen as an example for the UK situation. Firstly, 
as I am modelling the entire UK epidemic I need to model which proportion of all 
infections occur in each of the main exposure groups (which in the UK are 
heterosexuals and MSM). Parameters j1,j2,…,j7 determine the proportion of all UK-
acquired infections that have occurred in MSM for a given 5 year period. These 5 year 
periods are defined the same as for the method presented in Chapter 6. Each of 
j1,j2,…,j7 are sampled randomly in each simulation from Beta distributions. The prior 
distributions (i.e. values for the shape parameters α and β) chosen are based upon the 
exposure group distributions seen in the number of new HIV diagnoses in the UK[501]. 
The value 1-j1 therefore equates to the proportion of all UK-acquired heterosexual 
infections (because only these two exposure groups are modelled in this instance). 
Parameters k1,k2,…,k7 determine the proportion of all UK-acquired heterosexual 
infections that have occurred among black Africans for a given 5 year period. The value 
(1-j1)-k1 therefore equates to the proportion of all UK-acquired heterosexual infections 
that have occurred among non-black Africans. 
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Table 7-1: List of additional parameters and its prior distributions (as for the UK 
example) modelled to calibrate to national-level data by sub-population 
Parameter Prior distribution 
[mode/mean] 
j1 Proportion of all UK-acquired infections which 
occurred in MSM during 1980-1984 
Beta(9,3) [mode=0.8] 
j2 Proportion of all UK-acquired infections which 
occurred in MSM during 1985-1989 
Beta(8,4) [mode=0.7] 
j3 Proportion of all UK-acquired infections which 
occurred in MSM during 1990-1994 
Beta(7.5,4.5) 
[mode=0.65] 
j4 Proportion of all UK-acquired infections which 
occurred in MSM during 1995-1999 
Beta(2,2) [mode=0.5] 
j5 Proportion of all UK-acquired infections which 
occurred in MSM during 2000-2004 
Beta(4,8) [mod=0.3] 
j6 Proportion of all UK-acquired infections which 
occurred in MSM during 2005-2009 
Beta(5,7) [mode=0.4] 
j7 Proportion of all UK-acquired infections which 
occurred in MSM during 2010-2013 
Beta(5.5,6.5) 
[mode=0.45] 
k1 Proportion of UK-acquired heterosexual infections in 
black Africans during 1980-1984 
Beta(2.5,4.5) 
[mode=0.3] 
k2 Proportion of UK-acquired heterosexual infections in 
black Africans during 1985-1989 
Beta(2.5,4.5) 
[mode=0.3] 
k3 Proportion of UK-acquired heterosexual infections in 
black Africans during 1990-1994 
Beta(6,6) [mode=0.5] 
k4 Proportion of UK-acquired heterosexual infections in 
black Africans during 1995-1999 
Beta(5.5,6.5) 
[mode=0.45] 
k5 Proportion of UK-acquired heterosexual infections in 
black Africans during 2000-2004 
Beta(5,7) [mode=0.4] 
k6 Proportion of UK-acquired heterosexual infections in 
black Africans during 2005-2009 
Beta(4.5,7.5) 
[mode=0.35] 
k7 Proportion of UK-acquired heterosexual infections in 
black Africans during 2010-2013 
Beta(4,8) [mode=0.3] 
dx1 Fold-change in diagnosis rate in people who acquire 
HIV through heterosexual transmission (regardless 
of race) in the UK compared to MSM 
lnNormal(ln0.8,0.12) 
[mean=0.8] 
dx2 Fold-change in diagnosis rate in males compared to 
females (both UK-acquired and SSA-acquired 
infections) 
lnNormal(ln0.8,0.12) 
[mean=0.8] 
rate_arr
ival 
Base rate of arrival in the UK amongst those who 
acquired HIV in SSA for males 
lnNormal(ln0.02,0.12) 
[mean=0.02] 
arrivex Fold-change in arrival rate for males compared to 
females 
lnNormal(ln0.6,0.052) 
[mean=0.6] 
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Parameters dx1 and dx2 are intended to differentiate between the differences in the 
probability of someone being diagnosed depending on their route of HIV acquisition. As I 
did not have access to any testing data, parameters dx1 and dx2 are informed by data on 
CD4 count at diagnosis (the lower the CD4 count at diagnosis for an exposure group, 
the lower the probability of getting diagnosed must have been). dx1 is sampled from 
lnNormal(ln0.8,0.1
2
) initially and represents the multiplicative factor decrease used to 
calculate the diagnosis rate in heterosexuals (with HIV acquired in the UK), compared 
with MSM. In other words, the probability of being diagnosed if someone acquired their 
HIV heterosexually in the UK is on average 0.8-fold that of the probability of an MSM 
being diagnosed. Similarly, dx2 is also sampled from lnNormal(ln0.8,0.1
2
) and 
represents the multiplicative factor rise used to calculate the diagnosis rate in females 
compared to males (regardless of whether HIV was acquired in UK or SSA). In other 
words, the probability of a heterosexual female being diagnosed is on average 
1/0.8=1.25-fold that of a heterosexual male.  
Note that although parameters j1,j2,…,j7, k1,k2,…,k7,dx1 and dx2 are not directly informed 
by any observed data, I have chosen suitable distributions as opposed to fixing these 
parameters to a single value for all simulations. Moreover, if anything I am 
overestimating the uncertainty associated with these parameters by choosing wide 
distributions (i.e. fairly flat distributions with lower kurtosis). 
7.2 Characteristics of people infected abroad 
In Synthesis V5, people who were infected abroad could only arrive in the UK if they had 
not yet developed AIDS. If they had developed AIDS after 1997, there was a 0.5% 
probability of arrival in a three-month period. All individuals were assumed to be 
undiagnosed and untreated at the point of arrival in the UK. 
However, with the expansion of ART roll-out in SSA countries[800, 1029], it is no longer 
the case that people who acquire their infections in those countries arrive in the UK 
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undiagnosed and untreated. I have therefore included in Synthesis V6 the probability 
that someone is diagnosed and treated before coming to the UK. This allows people 
who have recovered from AIDS to experience the same probability of arrival as those 
who has not developed AIDS. 
7.2.1.1 Diagnosis status  
In asymptomatic people, I have modelled the rate of diagnosis in people outside Europe 
to be linearly increasing with time from when testing was available, before levelling off. 
HIV testing is assumed to have been in use from 1996 as there was very little testing 
before 2000, so the probability of being diagnosed is set to 0 until 1996[1030, 1031]. 
The probability of being diagnosed then linearly increases each year until 2012 at which 
point it reaches 0.19 per three-month period. The probability then remains at 0.19 
beyond 2012. This equates to a cumulative probability of 0.57 per year for 2012 (0.19 + 
0.81*0.19 + 0.81
2
*0.19 + 0.81
3
*0.19). I have based these figures on data on the 
proportion of people who have ever tested and the proportion of people who have tested 
in the last year from surveys conducted in South Africa and Kenya[444, 1032]. For 
example in South Africa, of people who had ever tested, 66.2% had tested within the 
past year according to the 2012 survey. The increasing trend in testing levels over time 
is also based on findings from the African Health and Sex Survey[1033]. 
Similarly to the situation in Europe, if HIV-positive individuals in SSA develop AIDS, they 
will be diagnosed immediately. If they develop HIV-related symptoms (but not AIDS), 
then they have a 5-fold raised risk of diagnosis compared to asymptomatic people at 
any time. I have also modelled a proportion of people (same proportion as people 
infected in the UK, determined by the parameter prop_avoid_testing) who are resistant 
to testing and are 10-fold less likely to get diagnosed.    
If individuals are diagnosed outside the UK and are ART-naïve, then I assume they have 
a 30% probability of being re-diagnosed (so that they can be linked to care) as soon as 
they arrive in the UK. As there are no data to directly inform this probability to my 
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knowledge, I sample this value of 30% from a distribution (Beta(10,22) which has modal 
value 0.3) in each simulation. If they remain undiagnosed after this point in time, they 
have the same probability of being re-diagnosed as people who acquire their infection in 
the UK.  
If individuals have already started ART outside the UK, they then have a 90% probability 
of being re-diagnosed as soon as they arrive in the UK. This value is also sampled in 
each simulation from a distribution (Beta(28,4) which has modal value 0.9) to reflect the 
uncertainty of the estimate. If they remain undiagnosed after this point in time, then they 
have the same probability of being re-diagnosed as people who acquire their infection in 
the UK (and are assumed to discontinue their ART at this time).   
7.2.1.2 Treatment status whilst living outside the UK 
ART is assumed to be available from 2000 onwards. As per WHO guidelines[1034, 
1035], individuals are modelled to be eligible for ART initiation between 2000 and 2010 if 
they have a CD4 count measurement within the last six months ≤200 cells/mm3 or have 
AIDS. After 2010, they are eligible if they have a CD4 count measurement ≤350 
cells/mm
3
 or have AIDS. I model the three-month probability of someone starting ART in 
SSA to increase accordingly over calendar time; it is 0.005 before 2004, 0.03 between 
2004 and 2006 and 0.075 beyond 2006. This is in line with data from WHO on ART 
coverage shown in Figure 7-4.  
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Figure 7-4: Antiretroviral therapy coverage in sub-Saharan Africa, 2003-2007  
 
If someone is eligible to start treatment, then they start with the combination of 
AZT+3TC+NVP immediately. Only one regimen type is usually recommended in SSA 
because they use a public health approach for access to ART. No second line treatment 
is assumed to be available due to observed restricted availability and low switching 
rates[1036]. Thus, even if the person experiences virological failure on that regimen, 
they will remain on that triple combination whilst living in SSA. TDR in this instance is 
also not modelled as levels to now have generally been low[1037].  
When HIV-positive individuals who have already started treatment in SSA arrive in the 
UK, they temporarily stop all drugs in the ART regimen to reflect the change in 
circumstances. As mentioned in Section 7.2.1.1, people who were already on treatment 
before arriving in the UK have a 90% chance of being diagnosed in the UK immediately. 
As long as they are then not lost to follow-up following diagnosis, they are modelled to 
continue on the AZT+3TC+NVP regimen. If and when individuals experience virologic 
failure to this regimen whilst in the UK, the same switching procedures as for infections 
which occurred in the UK are assumed. 
 
Figure not available due to copyright restrictions 
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7.3 Method used to calibrate model to national-level 
data 
The principles of the calibration method in this scenario are identical to those presented 
in Chapter 6. This means that a method based on Approximate Bayesian Computation, 
which involves running the simulation model multiple times and comparing a summary 
statistic (the calibration-score) to the observed data each time, is used to calibrate the 
model to the data. 
The main difference, compared to the calibration method applicable only to situations 
where the majority of infections occur in the European country of interest, is that all 
exposure groups (sub-populations) are jointly modelled and calibrated. The calibration 
method thus needs to calibrate to exposure group-specific data as well as national-level 
data.   
 
7.3.1 Multi-stage calibration method 
7.3.1.1 Stage 1 
In the first stage, 10,000 sets of parameter values are sampled using LHS. The 
parameters which are sampled include the seven parameters for incidence in the UK 
and four for the diagnosis rate (Table 6-1), as well as the 18 additional ones (Table 7-1) 
regarding the proportion of infections that took place in the different transmission groups, 
relative diagnosis rates according to risk of transmission group and the rate of arrival in 
the UK. The simulation model is then run 10,000 times, each time using one of those 
sampled sets of parameter values. The calibration-score is calculated for each of these 
simulations.  
To calculate the calibration-score in this initial stage, the modelled outcomes are 
compared only to data on the whole population, i.e. at the national level. This means the 
   
346 
 
model is not calibrated to exposure group-specific data at this stage. I thought that it was 
most important for the model to calibrate to the entire population first and foremost. 
Once it does, then estimates of the cumulative number of infections that must have 
taken place in the country and the basic probability of diagnosis per three-month period 
in asymptomatic people can be obtained from the resulting incidence and diagnosis rate 
curves. As the aim is to narrow the widths of prior distributions which describe the 
incidence and diagnosis rate to a more likely range, the parameters listed in Table 6-2 
such as the rate of loss to follow-up and interruption, are not sampled in this stage either.   
7.3.1.2 Stage 2 
The distribution of all accepted values for each separate parameter from the first stage 
is used to refine the prior distributions to be used in this second stage. This is to reduce 
the sampling space to improve efficiency of the calibration method. SRS is then used to 
sample from the newly refined distributions. All parameters listed in Table 6-2 are also 
sampled in this stage to reflect the uncertainty in the chosen prior distributions.  
One remains in this second stage until ‘enough’ sets of parameter values calibrate well 
to the observed data. The modelled outcomes will be compared, to both data on the 
whole population and exposure group-specific data. The calibration-score calculated in 
this second stage therefore includes information on how well the modelled outcomes 
calibrate to each of the modelled sub-populations. 
7.3.1.3 Stage 3 
The purpose of the third stage is the same as for the calibration method described in 
Chapter 6. That is, to determine the simulations which calibrate well for a second time to 
the observed data. To do so in this third stage, further simulations are run using the 
parameter values which calibrated well in the second stage. Only the outcomes from 
parameter sets which repeatedly calibrate well to the observed data (both to data on the 
whole population and by sub-population) are used to determine the final model outputs. 
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For a particular output, the point estimate is calculated as the median value of the 
modelled outcomes which calibrated well in this third stage.  
7.3.2 Plausibility range and calibration-score threshold 
The PR is calculated in the same way as the point estimate and so also uses the 
modelled outcomes which calibrated well in the third stage. The 5
th
 and 95
th
 percentiles 
of the distribution of these outcomes are considered the 90% PR limits. 
As described in Chapter 6, I judged that a simulation with a calibration-score <0.25 
demonstrated that the modelled data were fairly comparable with the observed data. 
The calibration-score threshold used in the first stage of the calibration method will likely 
be >0.25 as all parameters are sampled from very wide prior distributions. The actual 
threshold used therefore cannot be determined until the range of scores is calculated for 
all 10,000 simulations.  
Simulations are to be continuously performed until a sufficient number with calibration-
score <0.2 are attained. The parameter sets used in the third stage will be those which 
achieved a calibration-score <0.2 in the second stage. The final model outputs are 
based on the simulations from this final stage which again achieved a score <0.2.   
7.4 Applying the calibration method to UK data 
7.4.1 Methods and assumptions 
As mentioned previously, the calibration method was applied to data on the HIV-positive 
population in the UK, stratified by the five main routes of HIV acquisition as listed in 
Section 7.1.4.1. As for estimating the UK MSM population in Chapter 6, surveillance 
data used to calibrate the model were obtained from PHE databases.  
The first HIV infections both in the UK and SSA were assumed to have occurred in 1980. 
Diagnosis of HIV was assumed to be possible from 1984 in the UK and from 1996 in 
   
348 
 
SSA[1009, 1030, 1031]. I assumed that the rate of diagnosis in people living in the UK 
monotonically increases in a stepwise manner over time. The shape of the diagnosis 
rate curve is the same in all exposure groups, but with a multiplicative difference 
(parameterised by dx1 and dx2).  
The model was calibrated to UK surveillance data, which were available until 2013. The 
same incidence and diagnosis rate were assumed for 2012 and 2013 to generate HIV 
estimates for 2013. As explained in Section 7.1.3, I assumed that there are two 
incidence curves: one describing the number of new HIV infections in the UK and 
another which describes the number of new HIV infections in SSA. There was also an 
assumed arrival curve describing the rate of migrants arriving from SSA. Following the 
results from the sensitivity analysis in Chapter 6 Section 6.5.2.3 which suggested that 
the incidence between 1980-81 and 1982-84 are different, I used eight parameters 
(i1,i2,…,i8) to describe the incidence in the total population. Age-specific fertility data from 
UNdata (Appendix XII) were used to model the number of pregnancies in women living 
with HIV in the UK. 
To reconstruct the HIV-positive population in the UK, I simulated a random 1/10
th
 
(approximately 14,000) of the infections which took place in the UK and 1/100
th
 
(approximately 470,000) of the infections which took place in SSA. The distributions of 
the sampled parameters are summarised in Table 7-2. Simulations were terminated 
prematurely, by calculating the calibration-score at five year intervals during the 
simulation, if the total number of AIDS case reports in 1986-1990 or 1991-1995 were 
100% greater than actually observed. Similarly, simulations were also terminated 
prematurely if the total number of HIV case reports in 1996-2000, 2001-2005 or 2006-
2011 were 100% greater than actually observed. 
 
   
 
 
3
4
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Table 7-2: Model parameters used for calibrating the model to HIV data in the UK 
Parameter Prior distribution 
[mode/mean] 
Data source used to inform choice of 
prior distribution 
i1 Number of UK-acquired infections
a per year for 1980-1981 Beta(2,4)*24000 
[mode=6000] 
Max incidence per year=Highest number 
of HIV diagnoses ever observed in one 
year ×3 
i2 Number of UK-acquired infections
a per year for 1982-1984 Beta(2,4)*24000 
[mode=6000] 
As for i1 
i3 Number of UK-acquired infections
a per year for 1985-1989 Beta(2,4)*24000 
[mode=6000] 
As for i1 
i4 Number of UK-acquired infections
a per year for 1990-1994 Beta(2,4)*24000 
[mode=6000] 
As for i1 
i5 Number of UK-acquired infections
a per year for 1995-1999 Beta(2,4)*24000 
[mode=6000] 
As for i1 
i6 Number of UK-acquired infections
a per year for 2000-2004 Beta(2,4)*24000 
[mode=6000] 
As for i1 
i7 Number of UK-acquired infections
a per year for 2005-2009 Beta(2,4)*24000 
[mode=6000] 
As for i1 
i8 Number of UK-acquired infections
a per year for 2010-2013 Beta(2,4)*24000 
[mode=6000] 
As for i1 
d1 Diagnosis rate per three-month period during 1984-1991 Beta(1,5)*0.15 
[mode=0]b 
Max rate of diagnosis per three 
months=(Proportion of prompt 
presentations in most recent year)/4, 
[1012] 
d2 Additional change in diagnosis rate from 1984-1991 (i.e. diagnosis 
rate during 1992-1999 is d1+d2) 
Beta(1,50) [mode=0]b [1012] 
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Parameter Prior distribution 
[mode/mean] 
Data source used to inform choice of 
prior distribution 
d3 Additional change in diagnosis rate from 1992-99 (i.e. diagnosis rate 
during 2000-2008 is d1+d2+d3) 
Beta(1,50) [mode=0]b [1012] 
d4 Additional change in diagnosis rate from 2000-2008 (i.e. diagnosis 
rate during 2009-2013 is d1+d2+d3+d4) 
Beta(1,50) [mode=0]b [1012] 
j1 Proportion of all UK-acquired infections in MSM during 1980-1984 Beta(9,3) 
[mode=0.8] 
[501, 506, 1038] 
j2 Proportion of all UK-acquired infections in MSM during 1985-1989 Beta(8,4) 
[mode=0.7] 
[501, 506, 1038] 
j3 Proportion of all UK-acquired infections in MSM during 1990-1994 Beta(7.5,4.5) 
[mode=0.65] 
[501, 506, 1038] 
j4 Proportion of all UK-acquired infections in MSM during 1995-1999 Beta(2,2) 
[mode=0.5] 
[501, 506, 1038] 
j5 Proportion of all UK-acquired infections in MSM during 2000-2004 Beta(4,8) 
[mode=0.3] 
[501, 506, 1038] 
j6 Proportion of all UK-acquired infections in MSM during 2005-2009 Beta(5,7) 
[mode=0.4] 
[501, 506, 1038] 
j7 Proportion of all UK-acquired infections in MSM during 2010-2013 Beta(5.5,6.5) 
[mode=0.45] 
[501, 506, 1038] 
k1 Proportion of UK-acquired heterosexual infections in black Africans 
during 1980-1984 
Beta(2.5,4.5) 
[mode=0.3] 
[501, 506, 1038] 
k2 Proportion of UK-acquired heterosexual infections in black Africans 
during 1985-1989 
Beta(2.5,4.5) 
[mode=0.3] 
[501, 506, 1038] 
k3 Proportion of UK-acquired heterosexual infections in black Africans Beta(6,6) [mode=0.5] [501, 506, 1038] 
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Parameter Prior distribution 
[mode/mean] 
Data source used to inform choice of 
prior distribution 
during 1990-1994 
k4 Proportion of UK-acquired heterosexual infections in black Africans 
during 1995-1999 
Beta(5.5,6.5) 
[mode=0.45] 
[501, 506, 1038] 
k5 Proportion of UK-acquired heterosexual infections in black Africans 
during 2000-2004 
Beta(5,7) [mode=0.4] [501, 506, 1038] 
k6 Proportion of UK-acquired heterosexual infections in black Africans 
during 2005-2009 
Beta(4.5,7.5) 
[mode=0.35] 
[501, 506, 1038] 
k7 Proportion of UK-acquired heterosexual infections in black Africans 
during 2010-2013 
Beta(4,8) [mode=0.3] [501, 506, 1038] 
dx1 Fold-change in diagnosis rate in people who acquire HIV through 
heterosexual transmission (regardless of race) in the UK compared 
to MSM 
lnNormal(ln0.8,0.12) 
[mean=0.8] 
[501] 
dx2 Fold-change in diagnosis rate in males compared to females (both 
UK-acquired and SSA-acquired infections) 
lnNormal(ln0.8,0.12) 
[mean=0.8] 
[501] 
rate_arr
ival 
Base rate of arrival in the UK amongst those who acquired HIV in 
SSA for males 
lnNormal(ln0.02,0.12) 
[mean=0.02] 
Based on 1% of the SSA HIV-positive 
population being simulated 
arrivex Fold-change in arrival rate for males compared to females lnNormal(ln0.6,0.052) 
[mean=0.6] 
[1027, 1028] 
p1 Proportion of people resistant to testing for HIV Beta(9,91) 
[mode=0.08] 
[1013] 
p2 Probability of not being linked to care within three months of 
diagnosis 
Beta(2.5,49.5) 
[mode=0.03] 
[1012] 
p3 Rate (three-monthly) of loss to follow-up for those not yet on ART lnNormal(ln0.02,0.5
2) 
[mean=0.02] 
[1012] 
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Parameter Prior distribution 
[mode/mean] 
Data source used to inform choice of 
prior distribution 
p4 Rate (three-monthly) of loss to follow-up for those who started but 
interrupted ART 
Beta(2,10) 
[mode=0.2] 
[1012] 
p5 Rate (three-monthly) of re-entry into care lnNormal(ln0.4,0.1
2) 
[mean=0.4] 
[1014] 
p6 Probability of starting ART when eligible (per three month period) Beta(41,11) 
[mode=0.8] 
[888] 
p7 Population distribution of underlying levels of ART adherence  1:50%, 2:50% [N/A] [1012] 
p8 Rate (three-monthly) of ART interruption lnNormal(ln0.01,0.2
2) 
[mean=0.01] 
[942] 
p9 Rate (three-monthly) of re-starting (after interrupting) ART lnNormal(ln0.8,0.1
2) 
[mean=0.8] 
[1014] 
p10 Rate (three-monthly) of emigration (for people who acquire HIV in the 
UK)c 
lnNormal(ln0.002,12) 
[mean=0.002] 
[1015, 1016] 
a.Includes both MSM and heterosexual transmissions  
b.Probability density functions for Beta(1,5) and (1,50) are given in Figure 6-3. 
c.in people who acquire HIV in SSA, then this rate is increased by 5-fold in men and 8-fold in women. 
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The data items and corresponding weights used to calibrate the model are shown in 
Table 7-3. The calibration-score in the first stage of the calibration method only used 
aggregate data for the whole HIV population (i.e. not stratified by exposure group).  
Table 7-3: Data items and the range of calendar years for which data were used to 
calibrate the model to data in the UK (weights used in calibration-score given in 
brackets) 
Data item, per calendar year (population) Years (weight) 
Used in 
first and 
second 
stage of 
calibration 
method 
Number of HIV diagnoses (All) 1997-2013 (2) 
Cumulative number of deaths (All) 1996-2013 (2) 
Number seen for care (All) 2003-2013 (2) 
Number seen for care and on ART (All) 2004-2013 (2) 
Proportion of diagnoses which were prompt, i.e. 
CD4 >350 cells/mm3 (All) 
2003-2013 (2) 
Used only 
in second 
stage of 
calibration 
method 
Proportion of diagnosed cases of HIV (MSM) 1985-2012 (1) 
Number seen for care (MSM) 1998-2012 (1) 
Proportion of diagnosed cases of HIV (black 
Africans) 
1998-2012 (1) 
Number seen for care (black Africans) 2003-2012 (1) 
Proportion of diagnosed cases of HIV which were 
within two years of arriving in the UK (black 
Africans)  
1999-2013 (1) 
Proportion of diagnosed cases of HIV which were 
beyond five years of arriving in the UK (black 
Africans) 
1999-2013 (1) 
 
7.4.2 Results 
7.4.2.1 Simulation details 
A total of 10,000 simulations were run during the first stage of the calibration method. An 
additional 30,000 simulations were run during the second stage, which resulted in 302 
simulations which had a calibration-score <0.2. In the third stage, a further 1,000 
simulations were performed by resampling these 302 parameter sets. The following 
results presented are those generated using the 240 runs (based on the 302 parameter 
sets) where the calibration-score was <0.2 (median:0.174, min:0.116, max:0.199) 
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among the 1,000 resampled simulations. The posterior distributions (after the third 
stage) of the sampled parameters are shown in Table 7-4 and can also be seen in 
Figure 7-5 for the incidence and diagnosis rate parameters. 
Table 7-4: Prior and posterior distributions of model parameters used for 
calibrating the model to UK data 
Parameter Prior 
distribution 
[90% range]
a
 
Posterior 
distribution 
[90% PR] 
i1 
Number of infections per year during 
1980-1981 
[1844,15794] [1468,8215] 
i2 
Number of infections per year during 
1982-1984 
[1844,15794] [949,8001] 
i3 
Number of infections per year during 
1985-1989 
[1844,15794] [785,5796] 
i4 Number of infections per year during 
1990-1994 
[1844,15794] [672,3842] 
i5 Number of infections per year during 
1995-1999 
[1844,15794] [979,4907] 
i6 Number of infections per year during 
2000-2004 
[1844,15794] [2154,8234] 
i7 Number of infections per year during 
2005-2009 
[1844,15794] [1846,7367] 
i8 Number of infections per year during 
2010-2013 
[1844,15794] [1277,9552] 
d1 
Diagnosis rate per three-month period 
during 1984-1991 
[0.002,0.067] [0.000,0.015] 
d2 
Additional change in diagnosis rate from 
1984-1991 (i.e. diagnosis rate during 
1992-1999 is d1+d2) 
[0.001,0.059] [0.007,0.040]
b
 
d3 
Additional change in diagnosis rate from 
1992-1999 (i.e. diagnosis rate during 
2000-2008 is d1+d2+d3) 
[0.001,0.059] [0.020,0.070]
b
 
d4 
Additional change in diagnosis rate from 
2000-2008 (i.e. diagnosis rate during 
2009-2013 is d1+d2+d3+d4) 
[0.001,0.059] [0.028,0.101]
b
 
j1 Proportion of all UK-acquired infections 
which occurred in MSM during 1980-
1984 
[0.531,0.921] [0.556,0.931] 
j2 Proportion of all UK-acquired infections 
which occurred in MSM during 1985-
1989 
[0.435,0.866] [0.405,0.858] 
j3 Proportion of all UK-acquired infections 
which occurred in MSM during 1990-
[0.392,0.834] [0.436,0.795] 
   
355 
 
Parameter Prior 
distribution 
[90% range]
a
 
Posterior 
distribution 
[90% PR] 
1994 
j4 Proportion of all UK-acquired infections 
which occurred in MSM during 1995-
1999 
[0.135,0.866] [0.330,0.819] 
j5 Proportion of all UK-acquired infections 
which occurred in MSM during 2000-
2004 
[0.135,0.566] [0.194,0.662] 
j6 Proportion of all UK-acquired infections 
which occurred in MSM during 2005-
2009 
[0.200,0.651] [0.245,0.740] 
j7 Proportion of all UK-acquired infections 
which occurred in MSM during 2010-
2013 
[0.235,0.688] [0.299,0.777] 
k1 Proportion of UK-acquired heterosexual 
infections in black Africans during 1980-
1984 
[0.105,0.659] [0.173,0.604] 
k2 Proportion of UK-acquired heterosexual 
infections in black Africans during 1985-
1989 
[0.105,0.659] [0.121,0.570] 
k3 Proportion of UK-acquired heterosexual 
infections in black Africans during 1990-
1994 
[0.271,0.729] [0.223,0.736] 
k4 Proportion of UK-acquired heterosexual 
infections in black Africans during 1995-
1999 
[0.235,0.688] [0.241,0.634] 
k5 Proportion of UK-acquired heterosexual 
infections in black Africans during 2000-
2004 
[0.200,0.651] [0.212,0.653] 
k6 Proportion of UK-acquired heterosexual 
infections in black Africans during 2005-
2009 
[0.166,0.608] [0.163,0.606] 
k7 Proportion of UK-acquired heterosexual 
infections in black Africans during 2010-
2013 
[0.135,0.566] [0.172,0.531] 
dx1 Fold-change in diagnosis rate in people 
who acquire HIV through heterosexual 
transmission (regardless of race) in the 
UK compared to MSM 
[0.678,0.943] [0.649,0.945] 
dx2 Fold-change in diagnosis rate in males 
compared to females (both UK-acquired 
and SSA-acquired infections) 
[0.678,0.943] [0.681,0.898] 
rate
_arr
ival 
Base rate of arrival in the UK amongst 
those who acquired HIV in SSA for males 
 [0.017,0.024] [0.006,0.022] 
arriv Fold-change in arrival rate for males [0.553,0.652] [0.545,0.645] 
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Parameter Prior 
distribution 
[90% range]
a
 
Posterior 
distribution 
[90% PR] 
ex compared to females 
p1 
Proportion of people resistant to testing 
for HIV 
[0.048,0.141] [0.047,0.127] 
p2 
Probability of not being linked to care 
within three months of diagnosis 
[0.011,0.104] [0.014,0.097] 
p3 
Rate (three-monthly) of loss to follow-up 
for those not yet on ART 
[0.009,0.046] [0.011,0.052] 
p4 
Rate (three-monthly) of loss to follow-up 
for those who started but interrupted ART 
[0.033,0.364] [0.030,0.347] 
p5 Rate (three-monthly) of re-entry into care [0.339,0.471] [0.300,0.550] 
p6 
Probability of starting ART when eligible 
(per three-month period) 
[0.690,0.874] [0.705,0.864] 
p7 
Population distribution of underlying 
levels of ART adherence  
1:90%, 2:10%
c
 1:95%, 2:5%
c
 
p8 Rate (three-monthly) of ART interruption [0.007,0.014] [0.007,0.014] 
p9 
Rate (three-monthly) of re-starting (after 
interrupting) ART 
[0.678,0.943] [0.683,0.910] 
p10 
Rate (three-monthly) of emigration (for 
people who acquire HIV in the UK)
d
 
[0.000,0.010] [0.0014,0.0038] 
a.90% range limits are given by the 5
th
 and 95
th
 percentiles, which are estimated from 
100,000 sampled values for each prior distribution.   
b.Posterior distributions refer to the absolute diagnosis rate for that time period, as opposed 
to the additional change. 
c.1 and 2 refer to adherence patterns (Appendix VII) 
d.In people who acquire HIV in SSA, then this rate is increased by 5-fold in men and 8-fold in 
women 
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Figure 7-5: Estimated incidence and diagnosis rate amongst all HIV-positive 
people in the UK 
 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range.  
Incidence:number of new HIV infections in a year. Diagnosis rate:probability with which an 
HIV-positive individual gets diagnosed with HIV in a three-month period, given they are not in 
the primary infection phase, not symptomatic and do not have AIDS. 
 
7.4.2.2 Main results 
Figure 7-6 shows visually how well the modelled outcomes from the 240 chosen 
simulations calibrate to the observed UK data for the total HIV-positive population. The 
surveillance data in 2013 compared to the median across the simulations, respectively, 
were as follows: number of HIV diagnoses (6,000 vs. 6,320), number of AIDS diagnoses 
(319 vs. 1,470), number of deaths (527 vs. 890), number seen for care (81,500 vs. 
84,200), number seen for care and currently on ART (73,290 vs. 69,440), proportion of 
diagnoses with CD4 <350 cells/mm
3
 (42% vs. 49%) and proportion with recently 
acquired infections (22% vs. 12%). The model is also calibrated to data on year of 
arrival for migrants born in SSA, by assessing the probability of being diagnosed within 
two years or greater than five years after arriving in the UK. Overall, the model calibrates 
well to most data items. However, similarly to the example on UK MSM presented in 
chapter 6, there is likely to be some under-reporting of AIDS case reports in the post-
cART period and therefore it is not so concerning that the observed and modelled 
values differ. 
   
358 
 
Figure 7-6: Calibrating the model to national-level HIV surveillance data for the UK 
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Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range; diamonds: surveillance data until 2013 supplied by Public Health England (filled 
diamonds show data used to calibrate the model, open diamonds show data not used to 
calibrate the model). 
A recent infection is defined here as an infection which took place within six months of an 
HIV diagnosis. 
 
 
The incidence of HIV, defined as the number of new infections per year, for UK-acquired 
infections is shown in Figure 7-5. Results generated using Synthesis V6 suggest that the 
incidence of HIV in the UK started off reasonably high at an average of 5,000 infections 
per year in 1980 and 1981. In the early 1990s, the modelled results suggest that 
incidence dropped to less than 2,000 infections per year in the UK. In the last ten years, 
the incidence averaged at approximately 5,000 infections per year in the UK, although 
the PR is fairly wide.  
Figure 7-7 shows the year of arrival from SSA. The number of people arriving includes 
both those who acquired HIV in SSA and those who subsequently acquire HIV in the UK 
(but who are originally born in SSA). As expected, the trend in year of arrival is modelled 
to mimic the trends seen in the general population (shown earlier in Figure 7-3), where it 
was low in the 1980s and early 1990s followed by a sudden increase. The modelled 
results suggest that there may have been upwards of 7,000 people per year from SSA 
arriving in the mid-2000s. The number of people arriving has since fallen in recent years. 
This may be the reason for the observed fall in number of HIV diagnoses among people 
born in Africa seen this decade in the UK[501].  
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Figure 7-7: Year of arrival in the UK from SSA for HIV-positive people 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range.  
Number arriving includes people who acquired HIV in SSA, and those who acquired HIV in 
the UK after arriving. 
 
Figure 7-5 shows the probability of an asymptomatic MSM being diagnosed per 3 month 
period. The diagnosis rate has steadily increased over time but still remains low at 0.053 
(90% PR: 0.028-0.101) per 3 months in recent years. According to the modelled results 
(i.e. the posterior estimates of dx1 and dx2), the diagnosis rate in female heterosexuals 
and male heterosexuals, regardless of country of HIV acquisition, is thought to be 0.80-
fold and 0.78-fold that of MSM respectively. For all HIV-positive people in the UK 
(regardless of exposure group and development of HIV-related symptoms/AIDS), the 
probability of being diagnosed within one year from infection is shown in Figure 7-8. This 
probability has gradually risen over time from 10% in 1985, to 15% in 1995 and 23% in 
2012 (though recall that the rate of diagnosis in asymptomatic individuals was assumed 
to be monotonically increasing over time). 
 
   
361 
 
Figure 7-8: Probability of diagnosis within one year for all HIV-positive people in 
the UK 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range. 
 
By 2013, an estimated 109,840 (90% PR:88,440-126,500) people were thought to be 
living with HIV in the UK (Figure 7-9). The equivalent figures for 1983, 1993 and 2003 
were 17,500 (90% PR:7,500-25,600), 32,800 (90% PR:23,300-43,000) and 67,000 (90% 
PR:55,300-77,900) respectively. As expected, there has been a steady rise in the 
number of people living with HIV in the cART era. The estimated number of people living 
with undiagnosed HIV (Figure 7-9) in 2013 was 24,200 (90% PR:14,200-36,000). The 
size of the undiagnosed population is thought to have remained around this size for the 
last ten years.  
The estimated treatment cascade for people living with HIV in the UK for 2013 is shown 
in Figure 7-10. The undiagnosed proportion is estimated to be 22%. The absolute 
numbers relating to the rest of the cascade (retained in care, on ART and viral load 
<500 copies/mL) are expected to be fairly similar to the observed data because the 
model has been calibrated to this exact data. However, the proportions depend on the 
estimated number living with HIV and are thus novel findings obtained from using this 
calibration method. 
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Figure 7-9: Estimates of the total number of people living with HIV and total 
number of people living with undiagnosed HIV in the UK 
 
Diamonds: model median; Bars: model 90% plausibility range. 
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Figure 7-10: Estimated treatment cascade and population characteristics of all 
individuals living with HIV in the UK in 2013  
 
Columns: model median; error bars: model 90% plausibility range. 
 
Figure 7-11 shows the number of people living with HIV in the UK, separately by HIV 
exposure group. As expected from the un-stratified estimates (Figure 7-9), the numbers 
of people living with HIV in each of these groups have increased over time. The total 
number of MSM and non-black African heterosexuals living with HIV has gradually 
increased over time, even in the last ten years. However, the number of black African 
heterosexuals living with HIV is not estimated to have risen as substantially.   
The estimated numbers of people living with HIV in 2013 by exposure group, as well as 
the total for the UK, are summarised in Table 7-5. MSM comprise the largest share of 
the HIV-positive population in the UK. The remaining modelled population is comprised 
of people who acquired HIV heterosexually. Of the people who acquired HIV 
heterosexually, the model estimates that there are higher numbers of black African 
individuals compared to non-black African individuals. Among both black African and 
non-black African heterosexuals, there are more women than men living with HIV. The 
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size of the undiagnosed proportion ranges from 17% in MSM to 26% in black African 
individuals. 
Figure 7-11: Estimates of the total number of people living with HIV by calendar 
year in MSM, non-black African heterosexual men and women, and black African 
heterosexual men and women 
 
 
Columns: model median; error bars: model 90% plausibility range. 
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Table 7-5: Median (90% plausibility range) number of people living with HIV and the size of the undiagnosed portion in the UK in 2013 by HIV 
exposure group 
 MSM Non-black 
African 
heterosexual 
men 
Non-black 
African 
heterosexual 
women 
Black African 
heterosexual 
men 
Black African 
heterosexual 
women 
Total population 
Total number living 
with HIV 
42,400 
(28,700-54,300) 
11,200 
(7,400-17,300) 
14,300 
(9,600-21,400) 
16,700 
(13,300-20,300) 
23,300 
(17,400-30,700) 
109,800 
(88,400-126,500) 
Number living with 
diagnosed HIV 
34,900 
(25,100-43,900) 
8,600 
(5,700-13,000) 
11,100 
(7,500-16,800) 
12,200 
(9,600-14,800) 
17,400 
(13,000-23,000) 
85,000 
(71,900-95,200) 
Number living with 
undiagnosed HIV 
7,100 
(2,700-15,300) 
2,700 
(1,100-6,200) 
3,000 
(1,200-6,900) 
4,400 
(3,100-6,100) 
6,000 
(4,000-8,000) 
24,200 
(14,200-36,000) 
Proportion 
undiagnosed 
17% 24% 21% 26% 26% 22% 
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7.4.2.3 Number of pregnancies leading to live births 
The number of pregnancies which led to a live birth in women living with HIV in the UK 
was also estimated in the model, stratified by the woman’s race and whether she was 
diagnosed with HIV before the pregnancy (Table 7-6). These figures do not include 
pregnancies which are modelled to have occurred in SSA. The number of pregnancies 
has increased over time with increasing numbers of women living with HIV, although it 
seems to have plateaued since the mid-2000s.   
Table 7-6: Modelled number of pregnancies (which led to a live birth) in women 
living with HIV in the UK for selected calendar years 
Year Number of pregnancies 
Total Diagnosed 
with HIV 
before 
pregnancy 
Non-black 
African 
women 
Black African 
women 
1990 430 (260-630) 40 (20-120) 210 (120-350) 220 (120-340) 
1995 450 (290-620) 80 (20-160) 150 (70-290) 280 (180-430) 
2000 710 (520-980) 120 (50-250) 180 (80-360) 520 (350-710) 
2001 840 (630-1,100) 130 (50-270) 210 (110-390) 620 (440-830) 
2002 980 (720-1,290) 180 (70-310) 240 (110-450) 720 (500-1,240) 
2003 1,130 (850-1,430) 220 (90-400) 280 (140-500) 840 (600-1,130) 
2004 1,320 (940-1,680) 260 (120-460) 320 (160-580) 980 (680-1,300) 
2005 1,440 (1,070-1,840) 330 (160-600) 370 (180-660) 1,060 (740-1,450) 
2006 1,500 (1,100-1,940) 380 (190-910) 390 (200-670) 1,100 (780-1,520) 
2010 1,530 (1,140-1,970) 530 (280-870) 450 (240-800) 1,050 (730-1,420) 
2013 1,500 (1,130-2,020) 590 (320-950) 530 (290-890) 950 (660-1,320) 
 
7.5 Discussion 
In this chapter, I have presented the adapted calibration method which can be used at a 
national level, which explicitly accounts for infections which occur abroad, thus allowing 
for separate routes of HIV exposure. The route by which someone acquires HIV is one 
suitable way to group people. This is because prevention efforts are often targeted to a 
specific group and it serves as a proxy for a number of characteristics that are shared, 
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which may have an effect on how likely it is for someone with HIV to be diagnosed. To 
my knowledge, the method presented here is one of very few where migration of HIV-
positive people are considered in order to estimate the number of people currently living 
with HIV in a country.  
In this initial attempt, I implemented the method to data from the UK. The model is 
calibrated to data on the number of new HIV diagnoses among people of black African 
ethnicity and the year of arrival of migrants from SSA. Ideally, in addition there would be 
reliable data available on the probable country of HIV acquisition for migrants, which 
could also be used as a source of data to calibrate the model against. In the UK, data on 
likely country of HIV acquisition is often filled in by the patient’s clinician or healthcare 
advisor at the time of HIV diagnosis based on sexual history. In 2012, Rice and 
colleagues from PHE published a paper which showed that estimating the country of 
acquisition is more likely to be accurate by applying an estimated rate of CD4 count 
decline between an individual’s CD4 count at diagnosis and estimates of CD4 count at 
infection[1039]. The year of arrival into the country is also required in their method such 
that if the estimated year of infection is after the year of arrival, then the transmission of 
HIV is thought to have occurred in the UK. For this thesis, I chose not to use the 
probable country of infection as estimated using the PHE method because I wanted the 
data items to be solid forms of observed data.   
I have shown in this chapter that it is possible to characterize HIV-positive populations 
with a high proportion of migrants, if there are some data available regarding infections 
that occurred outside the country of interest. However, even in European countries, 
where on the whole HIV/AIDS surveillance systems have long been established, only 
few countries have data available on the year of arrival and probable country of infection. 
If a country wishes to use this adapted method, it is necessary to have information on 
the arrival year of migrants and a CD4 count measurement within one to three months of 
HIV diagnosis. With these two pieces of information, it is possible to estimate the 
probable country of infection using the PHE method[1039]. 
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The results in this chapter for the MSM population are slightly different to those 
presented in Chapter 6. In particular, the size and proportion of the undiagnosed 
population was estimated to be 11,500 and 23% in Chapter 6, and 7,100 and 17% 
respectively, in this Chapter. These differences could be due to mis-specification of 
parameters j1,j2,…,j7 (proportion of all UK-acquired infections which occurred in MSM by 
five-year periods), or because the calibration-score did not incorporate any data items 
associated with the CD4 count at diagnosis among MSM. I decided not to calibrate the 
model to data on CD4 count at diagnosis (such as the median CD4 count at diagnosis, 
or proportion of people diagnosed late) specifically by risk group in the second stage of 
the calibration method because I only had such stratified data for the MSM group and 
not for the black African or non-black African groups.  
It is also noteworthy that in the HIV-positive MSM population, 56% were estimated to 
have suppressed viral load (Figure 6-9), whilst the equivalent figure for the total HIV-
positive population presented in this chapter was 64%. This implies that the proportion 
suppressed could be higher for heterosexuals than for MSM. Surveillance data from 
PHE suggest that this proportion does not differ substantially by ethnicity or HIV 
exposure group[501]. There are little differences modelled between the MSM and non-
black African heterosexuals in Synthesis V6, so if anything, I may have overestimated 
the number of people in whom HIV is already diagnosed or are already on ART in SSA 
(as these are the main differences between the two populations). Else, it could be that 
the population distribution of adherence has been overestimated in the whole population.  
The MPES method[467, 469] has also been used to estimate the total number of people 
living with diagnosed and undiagnosed HIV in the UK. In Figure 7-12, I present my 
modelled estimates of the number of people living with HIV in the UK in 2013, alongside 
the MPES estimates. It is reassuring to see that my estimates are compatible with the 
MPES estimates on the whole. This is the case for the population overall but also by HIV 
exposure group. The one large difference is in the widths of the PRs. Despite the range 
from MPES estimates being 95% credible intervals rather than 90%, they are 
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considerably narrower than the 90% PR generated using my method. The PR generated 
using the adapted calibration method presented in this chapter, takes into account all 
the uncertainty associated with parameters not directly informed, as well as the beliefs 
held with regards to certain data items (as quantified using the different weights in the 
calibration-score). On a separate note, given that the estimates generated using the 
MPES method rely on a different set of data sources, mainly prevalence survey data 
(see Section 2.3.1.2), then the MPES estimates could also be potentially used as an 
additional source of data to calibrate the Synthesis model outputs to.  
Figure 7-12: Estimated number of people living HIV in the UK in 2013 with 90% 
plausibility ranges (for Synthesis estimates) and 95% credible intervals (for MPES 
estimates [501]) 
 
Figure 7-13 shows the observed number of pregnancies (for all outcomes, not just live 
births although the number of pregnancies ending in terminations has declined from 
27% in 1990-94 to 2% beyond 2010) in the UK and Ireland for 1998 to 2014[1040]. The 
numbers of pregnancies predicted in the model (Table 7-6) are comparable overall, 
however the number of women diagnosed with HIV before pregnancy is overestimated 
after 2010 to some extent. The incidence of pregnancies is not modelled directly using 
   
370 
 
this data (parameterisation detailed in Chapter 5) and so these results can be 
considered to be independently generated. 
Figure 7-13: Number of pregnancies reported in UK & Ireland [1040] 
 
The number of pregnancies is for all outcomes. 2014 data subject to reporting delay.  
 
According to the modelled results, the number of people living with HIV in the UK in 
2013 is thought to have surpassed 100,000 and around a fifth of the HIV-positive 
population are unaware that they are HIV-positive. Although there is great uncertainty 
about the average number of new infections per year which have taken place in the last 
few years, there is a distinct possibility that such numbers are higher than even the high 
levels seen at the beginning of the epidemic in the early 1980s. This is despite the fact 
that over half (64%) the infected population are thought to be virally suppressed and at 
low risk of transmitting the virus. It is worth noting that not all people in care are eligible 
to receive ART in the UK because the CD4 count threshold for starting treatment is still 
<350 cells/mm
3
 as of 2014, unless individuals are in sero-discordant relationships and 
wish to reduce the risk of transmission to their partner (although anecdotally, increasing 
numbers of people are starting before their CD4 counts drop below 350 cells/mm
3
)[194]. 
However, even if this threshold were to be raised, studies have shown that HIV 
transmission in the UK is largely driven by the undiagnosed population and that testing 
rates need to be higher in order to limit further increases in incidence[729, 1017].  
 
Figure not available due to copyright restrictions 
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In 2013, PHE figures stated that 4.3% of new HIV diagnoses were through IDU or other 
routes of transmission (not including sexual transmission) and 11.5% of new diagnoses 
did not have a probable exposure category reported in the UK[501]. One limitation with 
this modelling study therefore was that I did not explicitly model people infected with HIV 
through IDU, MTCT or other less common routes of transmission. These infections are 
not overlooked but considered as part of the total population, as the model is also 
calibrated to data such as the total number of people diagnosed per year and seen in 
care. This means however, that I have not estimated separately the size of this sub-
population of people infected through IDU, MTCT or other routes. One approximate 
estimate would be to take the total number of people living with HIV in the UK and 
subtract the number of MSM and heterosexuals, which for 2013 would give 1,900 
(=109,800-42,400-65,500).  
If this method were to be applied to another setting with a greater number of sub-
populations to be modelled, then a greater number of parameters will be required to 
model the different proportions of infections being attributed to each of the sub-
populations (per time period modelled, which was in five year intervals here). This will 
then likely mean that the calibration method will take longer because of an increased 
number of parameters to estimate. 
Another limitation is that I inherently assumed that the available data on route of HIV 
transmission is correct for each individual, although this is thought to be only a minor 
concern as the model is still calibrated to data on the total HIV-positive population. 
Nevertheless, a recent phylogenetic analysis in the UK has shown that actually, 
between 1% and 11% of self-reported heterosexual men diagnosed with HIV could have 
been infected through sex with other men and that between 1% and 21% of black 
African heterosexual men chose not to disclose sex with men at HIV diagnosis and 
preferred to be identified as heterosexual[1041]. The UK is an example of a country 
where there is relatively less stigma regarding homosexuality and HIV compared to 
other countries in Europe[1042]. If there is misclassification to this extent in the UK, it 
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may mean that this method is not suitable for many other settings where the quality of 
data on likely route of HIV acquisition is not as good as the UK because of a more 
prevalent fear of disclosure.    
One other limitation is the use of the incidence curve for the total SSA region as 
generated using the UNAIDS EPP/Spectrum programs, in order to model HIV incidence 
in SSA (among people who then migrate to the UK). First, it must be assumed that the 
incidence curves generated using the UNAIDS EPP/Spectrum programs are accurate 
and representative. EPP relies on country-specific prevalence survey data to estimate 
national levels of prevalence and incidence. Second, it is assumed that the trend in 
number of new infections for the whole of SSA is applicable to migrants to the UK, even 
though the majority of migrants are from eastern and southern SSA countries. Looking 
at the region-specific trends in Figure 7-2, this is probably also a reasonable assumption, 
given that South Africa constitutes the greatest number of infections in these two regions, 
which have historically collected population-level data through demographic health 
surveys and sentinel surveillance in antenatal clinics. However, no method is without 
fault and if the estimates of incidence in SSA were erroneous (even if only a little, due to 
the large numbers of infections in consideration) then this will also impact on the results 
presented here.  
In this application of the calibration method, the incidence of pregnancies was also 
estimated, as a result of adding pregnancy-related parameters into Synthesis V6. 
Specifically, I incorporated pregnancies that took place in the UK and which led to live 
births into the model in order to estimate the number of pregnancies among HIV-positive 
women. However, only the pregnancy itself is modelled and neither the transmission of 
HIV to the baby, nor the characteristics of the baby are then subsequently tracked in the 
model. To do so would require a dynamic transmission model, where the transmission 
probabilities through the different stages of pregnancy and birth are also modelled.  
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In this Chapter, I have shown a method to calibrate an individual-based simulation 
model to national-level data, in order to estimate the size and characteristics of the HIV-
positive population stratified by route of HIV acquisition. Using Synthesis V6, the 
calibration method compares the modelled outcomes to a diverse range of surveillance 
and observational data, which otherwise may not be possible with other estimation 
methods currently available. The method has the potential to be more efficient providing 
there is good data to inform model parameters and a sound understanding of the HIV-
positive population to be estimated.  
The method also allows for infections to occur outside the European country of interest, 
specifically in countries with generalised HIV epidemics, so that the resulting estimates 
can include those of migrant heterosexuals who acquired HIV abroad. To calibrate the 
model to data for populations which have large numbers of such migrants, I found that it 
is important to be able to approximate as well as possible, the likely characteristics of 
the migrants, including the likelihood of being diagnosed and treated prior to immigrating. 
The method presented here provides a useful approach to generate national-level 
estimates about the size and characteristics of HIV-positive populations. In settings 
where many infections occurred abroad, it is important to know how many of the people 
living with HIV now actually acquired their infection abroad, in order to target prevention 
interventions most effectively.  
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Chapter 8 Application of the calibration 
method to three countries 
In this Chapter, I present the results from applying the calibration method to a number of 
other European countries. I chose the Netherlands, Spain and Estonia as these three 
countries have distinctly different HIV epidemics and varying amounts of surveillance 
data. Thus, the aim was to evaluate how well the calibration method works in each 
setting and to evaluate whether there are any possible complications or limitations which 
may arise when applying the method in other settings.  
8.1 Netherlands 
8.1.1 Background and rationale 
I chose to apply the calibration method to the Netherlands as a first example, because 
the characteristics of the epidemic are very similar to that of the UK, albeit on a smaller 
scale, and the surveillance system is also very comprehensive. There has also been a 
lot of modelling work done using the Dutch data to which I will be able to compare my 
results[468, 480, 510, 1043, 1044].  
8.1.2 Methods and assumptions 
I decided to focus on one risk group initially, using the method described in Chapter 6. 
The calibration method was applied to data on the MSM population in the Netherlands. 
The data used to calibrate the model were from the ATHENA cohort and the National 
Institute of Public Health and Environment in the Netherlands (RIVM) and were obtained 
from Dr Ard van Sighem of SHM[518, 1045].  
As for the UK, the first infections were assumed to have occurred in 1980, with 
diagnosis possible from 1984 onwards. The incidence for 1980-81 and 1982-84 is 
modelled separately. The diagnosis rate was assumed to monotonically increase over 
time, based on data showing an increase in both the proportion of recent infections and 
   
376 
 
CD4 counts at diagnosis over time[1045]. However the data on CD4 count at diagnosis 
suggested that MSM in the Netherlands were more likely to be diagnosed earlier than 
MSM in the UK[1045]. Also, according to data from EMIS (European MSM Internet 
survey), the proportion of men ever tested was 79.5%, one of the highest proportions in 
Europe[8]. For these reasons, I allowed greater increases in the diagnosis rate between 
each time period (so the prior distribution chosen for parameters d2, d3 and d4 were 
Beta(1,25), rather than Beta(1,50) for the UK MSM situation). The ART eligibility criteria 
for ART-naïve patients in the model were also changed to reflect practices carried out in 
the Netherlands (e.g. of all patients started ART in 2013, 24% and 30% had CD4 counts 
>500 and 350-499 cells/mm
3
 respectively).  
To apply this method to the HIV epidemic among MSM in the Netherlands, the model 
was calibrated to surveillance data, which were available until 2012. The same 
incidence and diagnosis rate were assumed for 2012 and 2013 to generate HIV 
estimates for 2013. To reconstruct the HIV-positive MSM population, a random 1/5
th
 of 
the infections (thought to have occurred in total) were simulated, corresponding to 
approximately 4,000 people. I was able to simulate a larger proportion of the number of 
infections and still keep the simulations manageable because the total number of 
infections thought to have occurred in MSM in the Netherlands was approximately 4-fold 
lower than in the UK. The distributions of the sampled parameters are summarised in 
Table 8-1. Where estimates were not available from the ATHENA cohort to inform some 
of the parameters, I used the same prior distributions as for the MSM UK example. 
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Table 8-1: Model parameters and prior distributions used for calibrating the model to HIV data on MSM in the Netherlands 
Parameter Prior distribution 
[mode/mean] 
Data used to inform choice of prior distribution 
i1 Number of infections per year during 1980-1981 Beta(2,4)*2500 
[mode=625] 
Max incidence per year=Highest number of HIV 
diagnoses ever observed in one year ×3 
i2 Number of infections per year during 1982-1984 Beta(2,4)*2500 
[mode=625] 
As for i1 
i3 Number of infections per year during 1985-1989 Beta(2,4)*2500 
[mode=625] 
As for i1 
i4 Number of infections per year during 1990-1994 Beta(2,4)*2500 
[mode=625] 
As for i1 
i5 Number of infections per year during 1995-1999 Beta(2,4)*2500 
[mode=625] 
As for i1 
i6 Number of infections per year during 2000-2004 Beta(2,4)*2500 
[mode=625] 
As for i1 
i7 Number of infections per year during 2005-2009 Beta(2,4)*2500 
[mode=625] 
As for i1 
i8 Number of infections per year during 2010-2013 Beta(2,4)*2500 
[mode=625] 
As for i1 
d1 Diagnosis rate per three-month period during 1984-
1991 
Beta(1,5)*0.18 
[mode=0] 
Max rate of diagnosis per three 
months=(Proportion of prompt presentations in 
most recent year)/4, [515] 
d2 Additional change in diagnosis rate from 1984-1991 
(i.e. diagnosis rate during 1992-1999 is d1+d2) 
Beta(1,25) [mode=0] ATHENA cohort (2000-2010), [515, 1046] 
d3 Additional change in diagnosis rate from 1992-1999 
(i.e. diagnosis rate during 2000-2008 is d1+d2+d3) 
Beta(1,25) [mode=0] ATHENA cohort (2000-2010), [515, 1046] 
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Parameter Prior distribution 
[mode/mean] 
Data used to inform choice of prior distribution 
d4 Additional change in diagnosis rate from 2000-2008 
(i.e. diagnosis rate during 2009-2013 is d1+d2+d3+d4) 
Beta(1,25) [mode=0] ATHENA cohort (2000-2010), [515, 1046] 
p1 Proportion of people resistant to testing for HIV Beta(9,91) 
[mode=0.08] 
Schorer Monitor (2011), [1046] 
p2 Probability of not being linked to care within three 
months of diagnosis 
Beta(2.5,49.5) 
[mode=0.03] 
ATHENA cohort (2000-2010), [1046] 
p3 Rate (three-monthly) of loss to follow-up for those not 
yet on ART  
lnNormal(ln0.02,0.5
2
) 
[mean=0.02] 
ATHENA cohort (2000-2010), [1046] 
p4 Rate (three-monthly) of loss to follow-up for those 
who started but interrupted ART 
Beta(2,10) 
[mode=0.1] 
ATHENA cohort (2000-2010), [1046] 
p5 Rate (three-monthly) of re-entry into care lnNormal(ln0.4,0.1
2
) 
[mean=0.4] 
No available information, so based on rate for UK 
p6 Probability of starting ART when eligible (per three-
month period) 
Beta(41,11) 
[mode=0.8] 
No available information, so based on probability 
for UK 
p7 Population distribution of underlying levels of ART 
adherence 
1:50%, 2:50% No available information, so based on distribution 
for UK 
p8 Rate (three-monthly) of ART interruption lnNormal(ln0.01,0.2
2
) 
[mean=0.01] 
No available information, so based on rate for UK 
p9 Rate (three-monthly) of re-starting (after interrupting) 
ART 
lnNormal(ln0.8,0.1
2
) 
[mean=0.8] 
No available information, so based on rate for UK 
p10 Rate (three-monthly) of emigration lnNormal(ln0.002,1
2
) 
[mean=0.002] 
No available information, so based on rate for UK 
ATHENA:AIDS Therapy Evaluation in the Netherlands 
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As the ATHENA cohort only started in 1998 with retrospective inclusion of patients from 
1996 onwards, patients who died before 1996 are not included in the database. So 
although data completeness in the ATHENA cohort is very high, this is only the case for 
1996 onwards. The number of AIDS cases registered before 1996 is available from 
RIVM instead. The data on the number of HIV and simultaneous HIV/AIDS cases for 
2011 and 2012 were already corrected for reporting delay by adding 3% and 11% 
respectively to the number of cases observed so far[1045]. I did not have access to data 
on the number of deaths in people with HIV (although these data are collected as part of 
routine surveillance). Based on these known data features, the data items and 
corresponding weights used to calibrate the model are shown in Table 8-2. I assigned a 
smaller weight for the proportion of HIV diagnoses which were recently acquired, 
because these data from Dutch surveillance systems were limited only to people with a 
previous negative HIV test result and so may be less reliable. Simulations were 
terminated prematurely if the total number of AIDS case reports in 1986-1990 or 1991-
1995 were 100% greater than actually observed. Similarly, simulations were also 
terminated prematurely if the total number of HIV case reports in 1996-2000, 2001-2005 
or 2006-2011 were 100% greater than actually observed. 
Table 8-2: Data items and the range of calendar years for which data were used to 
calibrate the model to data on MSM in the Netherlands (weights used in 
calibration-score given in brackets) 
Data item, per calendar year Years (weight) 
Number of HIV diagnoses 1997-2012 (1) 
Number of first AIDS diagnoses 1985-1996 (1) 
Median CD4 count at diagnosis  1996-2012 (1) 
Proportion of diagnoses which were in 
recently acquired infections 
1996-2012 (0.5) 
Number seen for care 2000-2012 (2) 
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8.1.3 Results 
8.1.3.1 Simulation details 
The total number of complete simulations in the first and second stage of the calibration 
process was 13,035, based on 10,000 runs in the first stage and 10,000 in the second 
stage. There were 477 simulations of these 13,035 in which the calibration-score was 
within the tolerance threshold of 0.2. In the third stage, a further 300 simulations were 
performed by resampling from the 100 parameter sets with the smallest calibration-
score in the previous stages (the other 377 parameter sets were not carried forward). 
The following results presented are those generated using the 244 runs (based on the 
100 parameter sets) where the calibration-score was <0.2 (median:0.183, min:0.129, 
max:0.199). The final posterior distributions (after the third stage) of the sampled 
parameters are given in Table 8-3 and can also be seen in Figure 8-1. 
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Table 8-3: Prior and posterior distributions of model parameters used for 
calibrating the model to data on MSM in the Netherlands 
Parameter Prior distribution 
[90% range]
a
 
Posterior distribution 
[90% PR] 
i1 [190,1644] [174,909] 
i2 [190,1644] [265,909] 
i3 [190,1644] [141,676] 
i4 [190,1644] [386,817] 
i5 [190,1644] [126,313] 
i6 [190,1644] [398,671] 
i7 [190,1644] [580,1110] 
i8 [190,1644] [268,984] 
d1 [0.001,0.081] [0.001,0.038] 
d2 [0.002,0.112] [0.015,0.056]
b
 
d3 [0.002,0.112] [0.047,0.110]
b
 
d4 [0.002,0.112] [0.081,0.205]
b
 
p1 [0.048,0.141] [0.053,0.161] 
p2 [0.011,0.104] [0.012,0.116] 
p3 [0.009,0.046] [0.007,0.040] 
p4 [0.033,0.364] [0.028,0.385] 
p5 [0.339,0.471] [0.290,0.540] 
p6 [0.690,0.874] [0.705,0.872] 
p7 1:50%, 2:50%
c
 1:46%, 2:54%
c
 
p8 [0.007,0.014] [0.007,0.014] 
p9 [0.678,0.943] [0.685,0.915] 
p10 [0.000,0.010] [0.0003,0.0040] 
a.90% range limits are given by the 5th and 95th percentiles, which are estimated from 
100,000 sampled values for each prior distribution.   
b.Posterior distributions refer to the absolute diagnosis rate for that time period, as opposed 
to the additional change. 
c.1 and 2 refer to adherence patterns (Appendix VII) 
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Figure 8-1: Estimated incidence and diagnosis rate amongst MSM in the 
Netherlands 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range.  
Incidence:number of new HIV infections in a year. Diagnosis rate:probability with which an 
HIV-positive individual gets diagnosed with HIV in a three-month period, given they are not in 
the primary infection phase, not symptomatic and do not have AIDS. 
 
 
8.1.3.2 Main results 
Figure 8-2 shows that the final chosen simulations generally calibrate well to the 
surveillance data. The Dutch national surveillance data in 2012 compared to the median 
across simulations, respectively, were as follows: number of HIV diagnoses (704 vs. 
725), number of AIDS diagnoses (98 vs. 125), proportion of diagnoses with CD4 <350 
cells/mm
3
 (40% vs. 40%), number seen for care (9,717 vs. 9,217) and number seen for 
care and on ART (8,989 vs. 7,850). The modelled number of AIDS cases in the cART 
era appears to fit better to the observed data overall (the observed number of AIDS 
cases according to the ATHENA data are well within the modelled 90% plausibility 
limits) compared to the UK case presented in Chapters 6 and 7. However, the model 
underestimates the number of people on ART and the proportion of Dutch MSM 
diagnosed with recent infections in the last few years in particular.  
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Figure 8-2: Calibrating the model to surveillance data on HIV-positive MSM in the 
Netherlands 
 
 
 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range; diamonds: surveillance data until 2012 supplied by Stichting HIV Monitoring 
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(filled diamonds show data used to calibrate the model, open diamonds show data not used 
to calibrate the model). 
A recent infection is defined here as an infection which took place within six months of an 
HIV diagnosis. 
 
The estimated distribution of incidence and diagnosis of HIV-positive MSM in the 
Netherlands are shown in Figure 8-1. Since 1980, there have been between 200 and 
1000 infections on average per year in MSM in the Netherlands. The incidence was high 
in the early 1980s, which then declined until 2000, followed by a gradual increase from 
then onwards reaching levels higher than those observed in the early 1980s. An 
average of 640 (90% PR:270-980) infections per year are predicted to have occurred 
between 2010 and 2013. The model estimates that average HIV incidence in 2010-13 
was lower than in 2005-09, although the PR suggests that the incidence could actually 
be higher. The rate of diagnosis (in asymptomatic people) has steadily increased over 
time and is estimated to be as high as 0.14 (90% PR:0.08-0.21) per three months after 
2009.  
The estimated number of MSM thought to be living with HIV in 2013 in the Netherlands 
is 12,100 (90% PR:10,600-13,900). This number has steadily increased since the 
availability of effective treatment (Figure 8-3). 2,100 (90% PR:1,200-3,300) are thought 
to be undiagnosed, a number which has not changed largely over the course of the 
epidemic and has maintained a level between 2,000 and 3,000 every year. This equates 
to 82% of the infected population knowing that they are HIV-positive. There were 130, 
390, 630 and 950 undiagnosed MSM with a CD4 count ≤200, 201-350, 351-500 and 
>500 cells/mm
3
 respectively. This means that nearly half (45%) of the undiagnosed 
population are already eligible for ART initiation at a CD4 count threshold of 500 
cells/mm
3
. 
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Figure 8-3: Estimates of the total number of MSM living with HIV in the 
Netherlands and total number of MSM living with undiagnosed HIV  
 
Diamonds: model median; Bars: model 90% plausibility range. 
 
The HIV care cascade in 2013 is shown in Figure 8-4. Once MSM are diagnosed, the 
majority are linked and retained in care. Of all MSM living with HIV, 81% are retained in 
care and 78% of those retained in care are on treatment, equating to 63% of all people 
living with HIV. 60% of the infected population have a suppressed viral load (<500 
copies/mL). 
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Figure 8-4: Estimated treatment cascade of all MSM living with HIV in the 
Netherlands in 2013 
 
Columns: model median; error bars: model 90% plausibility range. 
 
8.1.4 Discussion 
Using the same approach as in Chapter 6, I have shown that it is possible to estimate 
the size and characteristics of a different HIV-positive MSM population. Both the UK and 
the Netherlands have experienced an HIV epidemic where MSMs have been 
disproportionately affected and both have a high standard of HIV care services.  
Figure 8-5 shows estimates of the total number of MSM living with diagnosed and 
undiagnosed HIV from a separate study which used a multi-state back-calculation model 
(the model was fit to data on number of new HIV diagnoses by CD4 count stratum 
number of new AIDS cases and number of concurrent HIV and AIDS diagnoses)[1044]. 
Figure 8-6 shows an estimate of the total number of MSM living with HIV using the 
UNAIDS EPP/Spectrum approach[1046] (which was calculated by multiplying the 
estimated total number of HIV-positive people in the Netherlands, which is 25,000, by 
the proportion of HIV-positive people thought to be MSM), together with other observed 
data from the ATHENA cohort to make up the full treatment cascade[1043].  
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Figure 8-5: Estimate of the total number of MSM living with diagnosed and 
undiagnosed HIV in the Netherlands using a back-calculation method [1044] 
 
Figure 8-6: Estimate of the treatment cascade for HIV-positive MSM living with HIV 
in the Netherlands in 2013 based on UNAIDS estimate and ATHENA data [1046] 
 
My estimate of 12,100 for the total number living with HIV in 2013 is similar to both 
estimates presented in Figure 8-5 and Figure 8-6, but with wider PRs. The PR estimated 
using this calibration method, as explained previously, takes into account much of the 
uncertainty associated with the model parameters. The estimated number of MSM living 
with HIV in earlier calendar years is also comparable with Figure 8-5, similarly predicting 
that the rise has been quickest in the last ten years.   
 
Figure not available due to copyright restrictions 
 
Figure not available due to copyright restrictions 
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The total number of MSM living with undiagnosed HIV has remained between 2000 and 
3000 throughout the course of the epidemic, despite high levels of HIV testing being 
observed[8]. This is line with other modelling estimates, such as those shown in Figure 
8-5 and Figure 8-6 amongst others[510, 1044].   
Although the model was calibrated to data on the number of people seen in care, the 
modelled estimate of the number of people on ART is somewhat lower than that 
observed in the ATHENA cohort for 2012. The modelled estimate was 7,850 compared 
to 8,989 in ATHENA (although in Figure 8-6 it is 8,726). This discrepancy could have 
resulted from a difference in how ‘on ART’ was defined. The modelled estimate includes 
only people who were taking ART during that calendar year. There is the possibility that 
the ATHENA cohort may have overestimated the number of people on ART by not 
excluding people who had interrupted or were lost to follow-up, due to the difficulties in 
capturing this information.  
8.2 Spain 
8.2.1 Background and rationale 
At the time of developing the calibration method for the UK, our modelling group was 
approached by Dr Mercedes Diez of ISCIII (Centro Nacional de Epidemiología, Instituto 
de Salud Carlos III). She wanted to collaborate in order to estimate HIV prevalence and 
the size of the undiagnosed fraction in Spain, as there had been no attempts to make 
estimates for the HIV-positive population other than those carried out by UNAIDS using 
the EPP/Spectrum approach. This was also a good opportunity to investigate the 
application of my calibration approach to a situation with a different epidemic to that 
typically seen in Western European countries.  
8.2.2 Methods and assumptions 
Most infections in the Spanish HIV-positive population are thought to have occurred in 
Spain, rather than amongst migrants. Among the diagnosed population, the number of 
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affected migrants is still low, although it has been increasing slowly over time[1047]. 
Migration from SSA is thus not modelled and all individuals are assumed to have been 
infected in Spain. Therefore, I use the method described in chapter 6 for estimating the 
total number of HIV-positive people living in Spain. The model was calibrated to several 
data sources collected and managed by the ISCIII, including the New HIV Diagnoses 
Information System (SINIVIH), National AIDS Registry, and CoRIS (Cohort of the 
Spanish HIV Research Network). CoRIS is a multi-centre, hospital-based prospective 
cohort of ART-naïve individuals in Spain[1048].  
There are only a few differences in the progression of HIV modelled in Synthesis V6 by 
route of HIV exposure. These include different assumed prevalence of HBV co-infection, 
HCV co-infection and smoking (which would all be informed by national data in any 
case) and assumed prevalence of TDR. In addition, persons who acquire HIV through 
IDU are modelled to have a slightly lower level of adherence and a 4-fold higher risk of 
all-cause death.  
To account for the differences without formally calibrating to data by exposure group, I 
made a simple assumption about the exposure group distribution based on the 
distribution of HIV cases reported and incorporated this into the model: if before the year 
2000, then the route of HIV acquisition is distributed as 25% MSM, 60% PWID and 15% 
heterosexual and if after 2000, then 40% MSM, 25% PWID and 35% heterosexual. As 
noted in Chapter 5, active IDU is not modelled in Synthesis V6. However given that such 
a large proportion of Spanish HIV-positive individuals are assumed to be PWID, after 
discussions with Dr Diez who informed me that approximately 5% of PWID are thought 
to be actively injecting at any point in time[1049], I decided that the 4-fold higher risk of 
all-cause death should only apply to the same proportion of PWID. This was modelled 
such that in any three-month period, 5% of PWID are randomly simulated to be actively 
injecting and thus incur the higher risk of death. 
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As for the UK and the Netherlands, the first infections were assumed to have occurred in 
1980, with diagnosis possible from 1984 onwards. I decided to again use a 
monotonically increasing rate of HIV diagnosis (probability per 3-month in asymptomatic 
HIV-positive individuals), based on testing data which has showed that the rate of 
testing per 1,000 population has increased from 24.8 in 2004 to 38.2 in 2009[1049]. For 
simplicity it was assumed that the probability of HIV diagnosis would not differ by route 
of HIV exposure.  
To apply this method to the HIV epidemic in Spain, the model was calibrated to 
surveillance data, which were available until 2012. The same incidence and diagnosis 
rate were assumed for 2012 and 2013 to generate HIV estimates for 2013. To 
reconstruct the HIV-positive population, a random 1/20
th
 of the infections (thought to 
have occurred in total) were simulated, corresponding to approximately 15,000 people. 
The distributions of the sampled parameters are summarised in Table 8-4. The ART 
eligibility criteria for ART-naïve patients in the model were changed to reflect practices in 
Spain as follows: CD4 count <200 cell/mm
3
 before 2007, <350 cell/mm
3
 between 2007 
and 2010, and <500 cell/mm
3
 after 2010. In addition, I also modelled a small chance 
(50% of parameter p7 in Table 8-4) of starting before these criteria based on anecdotal 
information from country experts. 
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Table 8-4: Model parameters and prior distributions used for calibrating the model to HIV data in Spain 
Parameter Prior distribution 
[mode/mean] 
Data used to inform choice of prior distribution 
i1 Number of infections per year during 1980-1981 Beta(2,4)*30000 
[mode=7500] 
Max incidence per year=Highest number of HIV 
diagnoses ever observed in one year×3 (SINIVIH) 
i2 Number of infections per year during 1982-1984 Beta(2,4)*30000 
[mode=7500] 
As for i1 
i3 Number of infections per year during 1985-1989 Beta(2,4)*30000 
[mode=7500] 
As for i1 
i4 Number of infections per year during 1990-1994 Beta(2,4)*30000 
[mode=7500] 
As for i1 
i5 Number of infections per year during 1995-1999 Beta(2,4)*30000 
[mode=7500] 
As for i1 
i6 Number of infections per year during 2000-2004 Beta(2,4)*30000 
[mode=7500] 
As for i1 
i7 Number of infections per year during 2005-2009 Beta(2,4)*30000 
[mode=7500] 
As for i1 
i8 Number of infections per year during 2010-2013 Beta(2,4)*30000 
[mode=7500] 
As for i1 
d1 Diagnosis rate per three-month period during 1984-
1991 
Beta(1,5)*0.13 [mode=0] Max rate of diagnosis per three months=(Proportion of 
prompt presentations in most recent year)/4, SINIVIH, 
[1049] 
d2 Additional change in diagnosis rate from 1984-1991 
(i.e. diagnosis rate during 1992-1999 is d1+d2) 
Beta(1,100) [mode=0] SINIVIH, [1049] 
d3 Additional change in diagnosis rate from 1992-1999 
(i.e. diagnosis rate during 2000-2008 is d1+d2+d3) 
Beta(1,100) [mode=0] SINIVIH, [1049] 
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Parameter Prior distribution 
[mode/mean] 
Data used to inform choice of prior distribution 
d4 Additional change in diagnosis rate from 2000-2008 
(i.e. diagnosis rate during 2009-2013 is d1+d2+d3+d4) 
Beta(1,100) [mode=0] SINIVIH, [1049] 
p1 Proportion of people resistant to testing for HIV Beta(9,91) [mode=0.08] 2003 Survey on Health and Sexual Habits, EMIS, [1049] 
p2 Probability of not being linked to care within three 
months of diagnosis 
Beta(3.5,48.5) 
[mode=0.05] 
CoRIS, SINIVIH, [1049] 
p3 Rate (three-monthly) of loss to follow-up for those not 
yet on ART  
lnNormal(ln0.05,0.5
2
) 
[mean=0.02] 
CoRIS, [1050] [1049] 
p4 Rate (three-monthly) of loss to follow-up for those 
who started but interrupted ART 
Beta(2.5,9.5) [mode=0.15] CoRIS, [1049] 
p5 Rate (three-monthly) of re-entry into care lnNormal(ln0.4,0.2
2
) 
[mean=0.4] 
CoRIS, [1049] 
p6 Probability of starting ART when eligible (per three 
month period) 
Beta(41,11) [mode=0.8] CoRIS, [1051] [1049] 
p7 Population distribution of underlying levels of ART 
adherence 
1:90%, 2:10% CoRIS, [1049] 
p8 Rate (three-monthly) of ART interruption lnNormal(ln0.03,0.2
2
) 
[mean=0.03] 
CoRIS, [1049] 
p9 Rate (three-monthly) of re-starting (after interrupting) 
ART 
lnNormal(ln0.8,0.1
2
) 
[mean=0.8] 
CoRIS, [1049] 
p10 Rate (three-monthly) of emigration lnNormal(ln0.005,1
2
) 
[mean=0.005] 
Instituto Nacional de Estadística 
ART:antiretroviral therapy; CoRIS:Cohort of the Spanish HIV Research Network; MSM:men-who-have-sex-with-men; SINIVIH:Sistema de Información sobre 
Nuevos Diagnósticos de VIH (New HIV Diagnoses Information System).  
Data on new HIV diagnoses is collected at the level of the autonomous region then collated to make national figures. Coverage only reached 100% in 2012. 
The maximum value to be sampled for parameter i1 was selected assuming that regional coverage of HIV diagnoses was evenly distributed across the country. 
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There were a number of data issues which I had to consider when deciding on the data 
items to include for the calibration-score. Firstly, data on new HIV diagnoses is collected 
at regional level then collated to make national figures. However, coverage of this 
variable only reached 100% (i.e. 19 out of 19 autonomous regions) in 2012. Data from 
the CoRIS cohort suggested that 79% of ART-experienced people are still currently on 
ART[1049]. This would imply that there is a high rate of treatment interruption, a high 
rate of loss to follow-up, or both. However, separate data from the one-day hospital 
survey showed that 88% of patients in care were on ART in 2011 (which has increased 
from 76% in 2002)[1047]. I was subsequently informed that most ART-experienced 
people recorded as not currently on ART were thought to be lost to follow-up and most 
likely had transferred to another clinic[1049]. As it is not possible to link these cases, the 
true extent of loss to follow-up may not be as high as 21% (100%-79%). Based on these 
known data features, the data items and corresponding weights used to calibrate the 
model are shown in Table 8-5.  
Table 8-5: Data items and the range of calendar years for which data were used to 
calibrate the model to data in Spain (weights used in calibration-score given in 
brackets) 
Data item, per calendar year Years (weight) 
Number of simultaneous HIV/AIDS diagnoses* 1985-2012 (1) 
Number of first AIDS diagnoses 1985-1997 (1), 
1998-2012 (0.5) 
Median CD4 count at diagnosis  2003-2012 (1) 
Number seen for care 2009-2012 (1) 
Number seen for care and on ART 2009-2012 (1) 
*Defined as an AIDS diagnosis within three months of an HIV diagnosis. 
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8.2.3 Results 
8.2.3.1 Simulation details 
The total number of complete simulations in the first and second stage of the calibration 
process was 7,278. This results from 10,000 runs in the first stage and another 30,000 
in the second stage. There were 795 of these 7,278 simulations with a calibration-score 
within the tolerance threshold of 0.2 (only 51 simulations were within a tolerance 
threshold of 0.15). A further 1,000 simulations were performed by resampling from the 
300 parameter sets with the smallest calibration-score (out of 795) in the third stage. 
The following results presented are those generated using the 841 runs (based on the 
300 parameter sets) where the calibration-score was <0.2 (median:0.169, min:0.094, 
max:0.199). The posterior distributions (after the third stage) of the sampled parameters 
are given in Table 8-6 and can also be seen in Figure 8-7.  
Table 8-6: Prior and posterior distributions of model parameters used for 
calibrating the model to data in Spain 
Parameter Prior distribution 
[90% range]
a
 
Posterior distribution 
[90% PR] 
i1 [2275,19672] [986,4447] 
i2 [2275,19672] [1308,6196] 
i3 [2275,19672] [12149,21571] 
i4 [2275,19672] [4831,16320] 
i5 [2275,19672] [3567,13502] 
i6 [2275,19672] [4097,13153] 
i7 [2275,19672] [4028,12365] 
i8 [2275,19672] [5192,19536] 
d1 [0.001,0.059] [0.001,0.030] 
d2 [0.001,0.029] [0.009,0.047]
b
 
d3 [0.001,0.029] [0.018,0.056]
b
 
d4 [0.001,0.029] [0.027,0.084]
b
 
p1 [0.048,0.141] [0.048,0.148] 
p2 [0.022,0.131] [0.012,0.119] 
p3 [0.022,0.114] [0.023,0.128] 
p4 [0.055,0.417] [0.040,0.383] 
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Parameter Prior distribution 
[90% range]
a
 
Posterior distribution 
[90% PR] 
p5 [0.288,0.556] [0.290,0.535] 
p6 [0.690,0.874] [0.686,0.872] 
p7 1:90%, 2:10%
c
 1:85%, 2:15%
c
 
p8 [0.022,0.042] [0.023,0.052] 
p9 [0.678,0.943] [0.675,0.924] 
p10 [0.001,0.026] [0.001,0.029] 
a.90% range limits are given by the 5
th
 and 95
th
 percentiles, which are estimated from 
100,000 sampled values for each prior distribution.   
b.Posterior distributions refer to the absolute diagnosis rate for that time period, as opposed 
to additional change. 
c.1 and 2 refer to adherence patterns (Appendix VII) 
 
 
Figure 8-7: Estimated incidence and diagnosis rate amongst HIV-positive people 
in Spain 
  
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range.  
Incidence:number of new HIV infections in a year. Diagnosis rate:probability with which an 
HIV-positive individual gets diagnosed with HIV in a three-month period, given they are not in 
the primary infection phase, not symptomatic and do not have AIDS. 
 
8.2.3.2 Main results 
Figure 8-8 shows that the final chosen simulations calibrate well to the surveillance data 
used in the calibration-score. The surveillance data in 2012 compared to the median 
across simulations respectively, were as follows: number of AIDS diagnoses (1021 vs. 
1320), number of simultaneous HIV/AIDS diagnoses (429 vs. 540), median CD4 count 
at diagnosis (370 vs. 400), number seen for care (107,823 vs. 106,460) and number 
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seen for care and on ART (98,011 vs. 97,060). The number of reported HIV diagnoses 
in 2013 was 3,278[486], however the modelled equivalent was estimated to be 7,120 
(90% PR: 4,660-10,740), which is substantially higher. 
Figure 8-8: Calibrating the model to surveillance data on HIV-positive individuals 
in Spain 
 
 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range; diamonds: surveillance data until 2012 supplied by Centro Nacional de 
Epidemiología, Instituto de Salud Carlos III (ISCIII) (filled diamonds show data used to 
calibrate the model, open diamonds show data not used to calibrate the model). 
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The distribution of incidence and diagnosis rate parameters are shown in Figure 8-7. In 
the first five years of the epidemic, the incidence was relatively low, with approximately 
2,300 and 3,600 infections per year for the periods 1980-1981 and 1982-1984 
respectively. Between 1985 and 1989 however, the average yearly number of infections 
rose dramatically to 16,300. The incidence has since declined but the model estimates it 
still to be around 10,000 new infections per year. The probability of being diagnosed is 
thought to have gradually increased over time, with a probability of 0.05 (90% PR:0.03-
0.08) per three months after 2009.  
The modelled results suggest there were an estimated 135,600 (90% PR:103,200-
169,600) people living with HIV in Spain in 2013 (Figure 8-9). The number is estimated 
to have increased by approximately 35,000 people since 2003. This has been a slow 
rise, compared to the pre-cART era when it is thought to have increased from 0 to 
80,600 people in the same duration of time between 1980 and 1990. The size of the 
undiagnosed population is thought to have peaked around 1990, when over 55,000 
people were thought to be living with undiagnosed HIV. In 2013, the estimated total 
number of people living with undiagnosed HIV was 24,300 (90% PR:14,200-41,600).  
   
398 
 
Figure 8-9: Estimates of the total number of people living with HIV in Spain and 
total number of people living with undiagnosed HIV 
 
Diamonds: model median; Bars: model 90% plausibility range. 
 
The estimated treatment cascade for people living with HIV in Spain for 2013 is shown 
in Figure 8-10. Most people diagnosed with HIV are retained in care, and 95% of people 
on ART have viral load <500 copies/ml. It is interesting to note that 71% of the total 
infected population are estimated to have viral load <500 copies/ml, which is higher than 
for the MSM population in the UK or the Netherlands, and the total HIV-positive 
population in the UK as seen in previous sections of this thesis.  
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Figure 8-10: Estimated treatment cascade of individuals living with HIV in Spain in 
2013 
 
Columns: model median; error bars: model 90% plausibility range. 
 
8.2.4 Discussion 
In this section, having made some crude assumptions about the proportions of infections 
attributed to different HIV exposure groups, I have presented some results estimating 
the size and characteristics of the Spanish HIV-positive population. Specifically, I 
modelled the distribution of HIV exposure group as 25% MSM, 60% PWID and 15% 
heterosexual before the year 2000 and as 40% MSM, 25% PWID and 35% heterosexual 
after 2000 respectively.  
Published estimates (with low and high estimates) of the number of adults living with 
HIV obtained using the UNAIDS EPP/Spectrum method are 130,000 (66,000-220,000) 
for 2003 and 150,000 (130,000-160,000) for 2013[1052, 1053]. Figure 8-11 shows the 
estimated number of people living with HIV (although it uses the term ‘AIDS’ in the figure 
instead of ‘HIV’), together with the number of new infections and number of HIV-related 
deaths for the period 1982 to 2000[1054], also thought to be derived using the 
EPP/Spectrum method. The shape of the incidence curve (‘persons newly infected with 
HIV’) is somewhat different compared to what was modelled here; in Figure 8-11, the 
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incidence has declined gradually over time since the initial peak in 1985, whereas in 
Figure 8-7, the modelled results show that there has not been much of a decline in the 
cART era. 
Figure 8-11: Alternative estimate of the number of people living with HIV, number 
of new infections and number of HIV-related deaths in Spain for 1982-2000 [1054] 
 
Estimate is assumed to have been calculated using UNAIDS EPP/Spectrum approach. 
‘Persons living with AIDS’ presumed to indicate the number of people living with HIV. 
 
My results estimated that 135,600 (90% PR:103,200-169,600) people were thought to 
be living with HIV in Spain in 2013. The size of the infected population has increased by 
34% since 2003. On the other hand, the size of the undiagnosed population is estimated 
to have stayed stable over the last 5 years. My estimate for 2013 for the total number 
living with HIV, including those undiagnosed, is similar to that using the UNAIDS method, 
but their 2003 estimate is higher and with a much larger uncertainty range. Seventy-one 
percent of people living with HIV in 2013 were estimated to be virally suppressed. This is 
probably due to the high rates of retention, adherence and ART uptake assumed in the 
model.   
As Spain did not have national-level data on the number of HIV diagnoses until 2012, I 
did not calibrate the model to this one data point. This probably explains at least partly 
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why the 90% PRs are quite wide not only for the incidence and diagnosis rate curves 
(Figure 8-7), but also for the total number of undiagnosed people (Figure 8-9). The 
model is instead calibrated to the number of simultaneous HIV/AIDS diagnoses and 
AIDS diagnoses. The modelled number of these diagnoses underestimated the 
observed number in the mid-1990s, but otherwise fits well beyond this point. In contrast, 
the number of deaths during the mid-1990s was slightly overestimated by the model 
(although I did not use this data item in the calibration-score).  
8.3 Estonia 
8.3.1 Background and rationale 
The HIV epidemic in Estonia is typical of those seen in Eastern European countries; a 
fast rise in the number of incident cases which peaked in the early 2000s, mainly 
concentrated within PWID, followed by a rise in the number of heterosexual 
transmissions[540]. I chose to apply the calibration method to Estonia for two reasons: 
firstly, because of the difference in the evolution of the epidemic compared to Western 
European countries, and secondly, because I thought it would be important to try the 
approach to model a country where the surveillance system is not as comprehensive as 
the UK and the Netherlands to see the impact, if any, it would have on the modelling 
results. In addition, I had previously gained some further knowledge about the 
surveillance system in Estonia through a WHO country mission[9].  
8.3.2 Methods and assumptions 
For Estonia, I decided to model the entire HIV-positive population using four sub-
populations. The total population was stratified by HIV exposure group, PWID and non-
PWID (the two main routes of HIV exposure in Estonia), and by gender. To do so, I used 
the adapted calibration method presented in Chapter 7, with additional model 
parameters representing the proportion of infections attributed to each exposure group, 
but without the extra incidence curve for migrants from generalised epidemics. 
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According to data from 2009, 31% of the general population in Estonia were not of 
Estonian ethnicity; the majority (82%) were Russian ethnicity[540]. However, unlike the 
situation in the UK, where large numbers of HIV-positive people were infected in SSA 
and then emigrated, the majority of people living with HIV in Estonia are thought to have 
acquired their HIV in Estonia[535, 1055]. Therefore I assumed that all infections are 
Estonia-acquired and thus only one incidence curve, representing the infections which 
occurred in Estonia was modelled.  
Unlike for the UK, Netherlands and Spain, I did not have a country contact person to 
directly access any surveillance data. I therefore extracted data on the number of HIV 
diagnoses, number of AIDS diagnoses and CD4 count at HIV diagnosis from the ECDC 
TESSy (Chapter 2 Section 2.5.4) database to calibrate the model. I found that the 
submitted data in TESSy for Estonia was aggregated until 2007 and case-based from 
then onwards. Data on likely mode of HIV transmission was scarce, although it has 
improved gradually in recent years. This was particularly the case for people not infected 
through IDU, which is why I decided to model only two exposure groups, PWID and non-
PWID. There are little data on the number of infections among MSM in Estonia so I 
decided not to model these infections explicitly as a separate group. Although data from 
small prevalence surveys have estimated HIV prevalence among MSM to be in the 
region of 2%[1056, 1057], where the size of the MSM population is thought to be around 
18,000[546], in the ECDC surveillance report, there have only been 94 cases reported 
cumulatively in MSM[1020]. There were also data available on the number of people on 
ART and two years’ worth of data on the number of people seen in care, in national 
reports compiled by the Estonian Institute for Health Development[545]. 
HIV testing in Estonia was available from 1987 and the first case of HIV was reported in 
1988[1058]. I assumed that the first infections could have occurred anytime from 1980 
onwards. I modified the prior distributions sampled for parameters i1 and i2 (Table 8-7) 
from Beta(2,4) to Beta (2,10) because I decided that it was highly unlikely from the data 
on number of HIV cases diagnoses that the true incidence was going to lie in the higher 
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ranges towards the maximum of 4428 infections per year. The total number of HIV tests 
performed according to the Estonian Health Board is shown in Figure 8-12. Rather than 
the change in diagnosis rate from one period to the next, I thought it would be more 
appropriate to sample the absolute probability of diagnosis in this instance. This is 
because although Figure 8-12 shows some indication of a small trend in increasing 
testing over time, there is no data on immunological status or CD4 counts at diagnosis 
to support the testing data. I also chose to use only three parameters to describe the 
diagnosis rate (d1, d2 and d3, Table 8-7) because even though testing has been 
available since 1987, there had only been 100 diagnoses made cumulatively until the 
year 2000. 
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Table 8-7: Model parameters used for calibrating the model to HIV data for Estonia 
Parameter Prior distribution 
[mode/mean] 
Data used to inform choice of prior 
distribution 
i1 Number of infections per year during 1980-1984 Beta(2,10)*4428 
[mode=443] 
Max incidence per year=Highest number of HIV 
diagnoses ever observed in one year ×3 
i2 Number of infections per year during 1985-1989 Beta(2,10)*4428 
[mode=443] 
As for i1 
i3 Number of infections per year during 1990-1994 Beta(2,4)*4428 
[mode=1107] 
As for i1 
i4 Number of infections per year during 1995-1999 Beta(2,4)*4428 
[mode=1107] 
As for i1 
i5 Number of infections per year during 2000-2004 Beta(2,4)*4428 
[mode=1107] 
As for i1 
i6 Number of infections per year during 2005-2009 Beta(2,4)*4428 
[mode=1107] 
As for i1 
i7 Number of infections per year during 2010-2013 Beta(2,4)*4428 
[mode=1107] 
As for i1 
d1 Diagnosis rate per three-month period during 1987-1994 Beta(1,25) [mode=0] Max rate of diagnosis per three 
months=(Proportion of prompt presentations in 
most recent year)/4 
d2 Diagnosis rate per three-month period during 1995-2001  Beta(1,25) [mode=0] As for d1 
d3 Diagnosis rate per three-month period during 2002-2013 Beta(1,25) [mode=0] As for d1 
j1 Proportion of infections in PWID during 1984-1999 Beta(20,2) 
[mode=0.95] 
[545] 
j2 Proportion of infections in PWID during 2000-2004 Beta(2,2) [mode=0.5] [545] 
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Parameter Prior distribution 
[mode/mean] 
Data used to inform choice of prior 
distribution 
j3 Proportion of infections in PWID during 2005-2013 Beta(3,9)  
[mode=0.2] 
[545] 
p1 Proportion of people resistant to testing for HIV Beta(3.5,48.5) 
[mode=0.05] 
Assumption (no data)* 
p2 Probability of not being linked to care within three months of 
diagnosis 
Beta(7,15) 
[mode=0.3] 
[544] 
p3 Rate (three-monthly) of loss to follow-up for those not yet on 
ART  
lnNormal(ln0.05,0.5
2
) 
[mean=0.05] 
[544] 
p4 Rate (three-monthly) of loss to follow-up for those who started 
but interrupted ART 
Beta(3,19) 
[mode=0.1] 
Assumption (no data)* 
p5 Rate (three-monthly) of re-entry into care lnNormal(ln0.01,0.2
2
) 
[mean=0.01] 
[544] 
p6 Probability of starting ART when eligible (per three-month 
period) 
Beta(11,41) 
[mode=0.2] 
Assumption (no data)* 
p7 Population distribution of underlying levels of ART adherence 2:4%, 3:32%, 4:32%, 
5:32% 
[540, 543] 
p8 Rate (three-monthly) of ART interruption lnNormal(ln0.02,0.2
2
) 
[mean=0.02] 
Assumption (no data)* 
p9 Rate (three-monthly) of re-starting (after interrupting) ART lnNormal(ln0.5,0.1
2
) 
[mean=0.01] 
[544, 1059] 
p10 Rate (three-monthly) of emigration lnNormal(ln0.002,1
2
) 
[mean=0.002] 
Assumption (no data)* 
*Where there were no direct data to inform parameter values, I used wide prior distributions to allow for large uncertainty. 
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Figure 8-12: HIV tests performed and number of people tested in Estonia, 1987–
2010 [543] 
 
Data on CD4 count at HIV diagnosis has only been available for 2013 and even then, 
this was collected only for 38% of all cases of HIV diagnosed. Given the limited data on 
CD4 count at diagnosis, which to some extent should inform the rate of diagnosis, I 
decided to assume that the rate of diagnosis was the same in PWID and non-PWID. 
Therefore parameters dx1 and dx2, which were used in the example for the UK (Table 
7-2), are not sampled. 
Despite there being a high prevalence of IDU in Estonia[1060], OST is not widely 
available[545]. There is some evidence in the literature which shows that OST can 
improve treatment adherence in PWID within a comprehensive care model[1061]. As 
mentioned in Chapter 5, I incorporated a fixed person-specific effect on the effective 
adherence for all people infected via IDU. The effect size, which is distributed 
Uniform(0,0.1), took into account that some PWID would have worse lifelong adherence. 
These are the people who would not have had access to OST. In Estonia, as OST is 
provided only to a minority of PWID with HIV, I also added an extra effect (80% of PWID 
have a further reduced adherence average of the size Uniform(0,0.5)) to account for 
such PWID without access to OST. Having worse adherence also implies higher loss to 
follow-up, less chance of returning to care after loss to follow-up and more likely to 
interrupt treatment in Synthesis V6. Data from the EuroSIDA study have shown that 
Eastern European countries have the lowest odds of achieving virologic response to 
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ART and highest incidence of loss to follow-up compared to all other regions of 
Europe[758, 1062].  
The ART eligibility criteria for ART-naïve patients in the model were changed to reflect 
the EACS treatment guidelines. However, as there have been reports that uptake of 
ART is particularly low among PWID regardless of whether on OST[544], I also modified 
the probability of ART initiation when eligible among PWID to be 5-fold lower than for 
non-PWID. This may have been a very conservative assumption given that one study 
reported that only two PWID receive ART out of 100 PWID living with HIV in 
Estonia[1063].   
To apply this method to the HIV epidemic in Estonia, the model was calibrated to 
surveillance data, which were available until 2013 in TESSy, to generate HIV estimates 
for 2013. To reconstruct the HIV-positive population, a random 50% of infections 
(thought to have occurred in total) were simulated, corresponding to approximately 
7,000 people. The distributions of the sampled parameters are summarised in Table 8-7. 
Most prior distributions were chosen based on data from various reports summarising 
the situation in Estonia[540, 543-545, 1059]. Whilst there was data on the losses of 
people at various stages of the HIV care and treatment structure, it was difficult to 
disentangle how much was due to people not being linked and how much was due to 
people being lost to care. Here I assumed that the majority of the losses were due to 
loss to follow-up based on the observed high incidence of loss to follow-up seen across 
Eastern Europe countries in general[1062].  
Surveillance systems for HIV and AIDS cases were revised in 2008, where previously 
case reports were anonymous, which may have led to multiple records per person[545]. 
The numbers of people on ART are thought to be reasonably accurate (or at least reflect 
the number of people being prescribed ART), because all drugs are procured and 
distributed by one centre (Ministry of Social Affairs)[544]. Based on these known data 
features, the data items and corresponding weights used to calibrate the model are 
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shown in Table 8-8. Simulations were terminated prematurely only if the total number of 
HIV case reports in 1986-1990 or 1991-1995 exceeded 500 cases in total, or if the total 
number of HIV case-reports in 2006-2011 were 100% greater than actually observed.  
Table 8-8: Data items and the range of calendar years for which data were used to 
calibrate the model to data in Estonia (weights used in calibration-score given in 
brackets) 
 Data item (population) Years (weight) 
Used in first and 
second stage of 
calibration method 
Number of HIV diagnoses (All) 2000-2008 (0.5), 
2009-2013 (2) 
Number seen for care and on ART (All) 2008-2013 (2) 
Used only in second 
stage of calibration 
method 
Number of HIV diagnoses (PWID) 2009-2013 (0.5) 
 
8.3.3 Results 
8.3.3.1 Simulation details 
The total number of complete simulations in the first and second stage of the calibration 
process was 4,353. This includes the 10,000 run in the first stage and another 20,000 in 
the second stage. There were 136 simulations out of the 4,353 where the calibration-
score was within the tolerance threshold of 0.4 (only 26 were within the tolerance 
threshold of 0.3). A further 500 simulations were performed by resampling from the 136 
parameter sets. The following results presented are those generated using the 460 runs 
(based on the 136 parameter sets) where the calibration-score was <0.4 (median: 0.302, 
min: 0.138, max: 0.399). The posterior distributions (after the third stage) of the sampled 
parameters are shown in Table 8-9 and can also be seen in Figure 8-13 for the 
incidence and diagnosis rate parameters. 
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Table 8-9: Prior and posterior distributions of model parameters used for 
calibrating the model to data in Estonia 
Parameter Prior distribution 
[90% range]
a
 
Posterior distribution 
[90% PR] 
i1 [146,1609] [8,85] 
i2 [146,1609] [19,174] 
i3 [340,2918] [30,262] 
i4 [340,2918] [273,1012] 
i5 [340,2918] [282,1187] 
i6 [340,2918] [292,823] 
i7 [340,2918] [333,1614] 
d1 [0.002,0.113] [0.005,0.017] 
d2 [0.002,0.113] [0.011,0.033] 
d3 [0.002,0.113] [0.009,0.031] 
j1 [0.792,0.983] [0.739,0.959] 
j2 [0.135,0.866] [0.169,0.838] 
j3 [0.079,0.471] [0.096,0.400] 
p1 [0.022,0.132] [0.025,0.154] 
p2 [0.168,0.489] [0.162,0.515] 
p3 [0.022,0.114] [0.021,0.094] 
p4 [0.040,0.270] [0.046,0.275] 
p5 [0.007,0.014] [0.000,0.040] 
p6 [0.126,0.310] [0.123,0.326] 
p7 2:4%, 3:32%, 
4:32%, 5:32%
b
 
2:5%, 3:31%, 
4:23%, 5:41%
b
 
p8 [0.017,0.024] [0.013,0.027] 
p9 [0.424,0.589] [0.419,0.635] 
p10 [0.000,0.010] [0.0007,0.0232] 
a.90% range limits are given by the 5
th
 and 95
th
 percentiles, which are estimated from 
100,000 sampled values for each prior distribution.  
b.1 and 2 refer to adherence patterns (Appendix VII)  
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Figure 8-13: Estimated incidence and diagnosis rate amongst HIV-positive people 
in Estonia 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range.  
Incidence:number of new HIV infections in a year. Diagnosis rate:probability with which an 
HIV-positive individual gets diagnosed with HIV in a three-month period, given they are not in 
the primary infection phase, not symptomatic and do not have AIDS. 
 
8.3.3.2 Main results 
Figure 8-14 shows the extent of the model calibration. I present the results from applying 
the method before discussing below the outstanding issues. The surveillance data 
across all risk groups in 2013 compared to the median across simulations respectively 
were as follows: number of HIV diagnoses (325 vs. 486), number of AIDS diagnoses (24 
vs. 264), number seen for care and on ART (2,691 vs. 2,190) and number seen for care 
(3,276 vs. 3,055, for 2012). The number of HIV diagnoses in PWID in 2013 reported to 
ECDC was 72, whereas the modelled number of diagnoses was 120. The results of the 
calibration show that with such a sudden increase in the number of HIV diagnoses in 
2001, the assumed parameterisation (keeping the incidence and diagnosis rate constant 
for a fixed number of years) does not perform particularly well. Before 2001, the number 
of HIV cases diagnosed and reported in the Estonian population ranged from 1 in 1988, 
to 12 in 1999 and 390 in 2000. It should be kept in mind that the modelled estimates 
which follow are based on the parameter sets which generated these figures, which do 
not necessarily fit well with all the available surveillance data, as discussed further below. 
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Figure 8-14: Calibrating the model to surveillance data on HIV-positive individuals 
in Estonia 
 
 
 
Solid line: model median; dotted line: model 90% plausibility range; shaded band: model 
100% range; diamonds: surveillance data until 2012 from ECDC TESSy database and 
Estonian Institute for Health Development (EHID) (filled diamonds show data used to 
calibrate the model, open diamonds show data not used to calibrate the model). 
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The distributions of the incidence and diagnosis rate parameters are shown in Figure 
8-13. Although it gradually increased over time, the number of infections in Estonia was 
estimated to be very low until the mid-1990s. In the period 1985-1989 however, the 
average yearly number of infections rose to 622 (90% PR:270-970) according to the 
model. It has been estimated to have since remained at over 500 infections per year. 
The probability of being diagnosed has not changed much over the years; around 1% of 
HIV-positive people are thought to be diagnosed if asymptomatic in a given 3-month 
period. 
The model estimates that in 2013 there were 7,700 (90% PR:5,200-11,700) people 
living with HIV in Estonia (Figure 8-15). The number has risen by over 4-fold in less than 
20 years. Although the PRs are wide, particularly in the last few years, the modelled 
results suggest that this figure is increasing. The number of people living with 
undiagnosed HIV has also steadily increased since 1995. In 2013, there were estimated 
to be 3,900 (90% PR:2,000-7,700) undiagnosed HIV-positive people.  
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Figure 8-15: Estimates of the total number of people living with HIV in Estonia and 
total number of people living with undiagnosed HIV  
 
Diamonds: model median; Bars: model 90% plausibility range. 
 
A substantial proportion of the HIV-positive population are thought to have acquired HIV 
through IDU, although this has been exceeded by the number of non-PWID after 2000 
(Figure 8-16). There was a steady rise in the number of HIV-positive PWID until 2000, 
but this is estimated to have plateaued since then. The modelled results suggest that 
there are higher numbers of non-PWID living with HIV in 2013 compared to PWID. 
These modelled results are based on calibrating to the data included in the calibration-
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score, but also reflect to some extent the prior distributions which were used (listed in 
Table 8-7, which are also based on observed data).   
Figure 8-16: Estimates of the total number of PWID and non-PWID living with HIV 
and living with undiagnosed HIV 
 
 
Diamonds: model median; Bars: model 90% plausibility range. 
 
The estimated treatment cascade for people living with HIV in Estonia in 2013 is shown 
in Figure 8-17. Half the population are thought to be living with undiagnosed HIV. There 
is a gradual loss in the number of people throughout the rest of the cascade. The model 
was calibrated to data on the number of people receiving ART (Figure 8-14). Only 24% 
of the HIV-positive population are thought to have viral load <500 copies/ml.  
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Figure 8-17: Estimated treatment cascade of individuals living with HIV in Estonia 
in 2013 
 
Columns: model median; error bars: model 90% plausibility range. 
 
8.3.4 Discussion 
In this section, I have demonstrated the use of the calibration method to estimate the 
size and characteristics of the HIV-positive population in Estonia, separately by people 
who were infected by IDU and people not infected by IDU. Unlike the applications for the 
UK, Netherlands and Spain, there were less data available to calibrate the model, which 
is reflected in the wide PRs for all modelled estimates. 
No other modelling estimates for Estonia are available except for those generated using 
the UNAIDS method. The number of people estimated to be living with HIV in 2013 
according to the EPP/Spectrum approach was 8,600 (lower and upper estimates: 6,900-
11,000)[1064]. In 2001, the estimated range was 3,500-5,300 (point estimate 
unavailable)[1065]. Based on the 2013 UNAIDS estimate, the treatment cascade for 
Estonia is shown in Figure 8-18.  
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Figure 8-18: Estimated treatment cascade for Estonia in 2013 [544] 
 
The number of people estimated to be living with HIV in Estonia in 2013 was 7,700 (90% 
PR:5,200-11,700) using my developed calibration method, so the ranges do overlap with 
the UNAIDS approach. However, I estimated the undiagnosed fraction to be 50% which 
is substantially higher than the 13% seen in Figure 8-18. In contrast, the proportion of 
people estimated to have suppressed viral load is similar for the two approaches. In 
Synthesis V6, rates of viral suppression are mainly driven by adherence to ART. 
Figure 8-14 shows that the calibration method was not able to reconstruct the high 
number of HIV diagnoses in 2001. Testing data (Figure 8-12) show that the number of 
HIV tests performed that year was no higher compared to the few years either side. 
Assuming that this peak in HIV diagnoses was not an artefact of testing rates (and thus 
diagnosis rates) and it was a result of a surge in incidence, then the number of AIDS 
cases for the early 2000s would be expected to be lower than modelled. However, 
without this historical data it is difficult to establish what the likely numbers of infections 
were in those years, resulting in substantial uncertainty for the estimated incidence 
curve. The calibration method could be applied again, using different parameterisation of 
the incidence and diagnosis rate curve (for example, more flexibility around the time of 
the peak in HIV diagnoses) to see if the model could be calibrated any closer.   
The wide PRs are most likely a result of having to use a calibration-score threshold of 
0.4. Despite the 30,000 simulations run in the first and second stage of the calibration 
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method, there were only 136 simulations which had a calibration-score <0.4. In the 
application of the calibration method using the pseudo data (Chapter 6 Section 6.6), I 
showed that the ‘low’ data availability situation led to the smallest calibration-score. 
However, this was not the case here as there were few simulations which were within 
the tolerance threshold. The high scores attained could be due to under-reporting and/or 
under-ascertainment of case-reports in the surveillance data, or due to inconsistencies 
between data items. Insights from epidemiologists or people in charge of HIV 
surveillance in Estonia would provide valuable information which would help to calibrate 
the model to the most appropriate data sources. For example, as only 38% of all HIV-
positive people are thought to be on ART, then one may expect higher numbers of AIDS 
cases than reported. Although most observed data points were within the 90% PRs, the 
numbers of AIDS cases outputted by the model were considerably larger than the 
number reported. The wide PRs are also partially a result of the prior distributions used, 
which for most parameters were quite wide due to lack of prior information to inform 
them. 
Although the calibration method did not provide a close calibration to historical data on 
HIV diagnosis case-reports, it was still able to calibrate reasonably well to the number of 
people in care and numbers receiving ART within the last decade. Data on the number 
of deaths among HIV-positive people (if available) would help refine estimates of the 
current status of the population, as the PRs estimated here were rather wide. However, 
the uncertainty could be reduced if further data on population characteristics were 
available, such as the CD4 count and recency of infections at time of HIV diagnosis, as 
well as the CD4 count and viral load distribution of those in care. Nevertheless, the 
modelled estimates provide additional information to that currently available about the 
HIV-positive population in Estonia, and suggest that further research to establish the 
proportion living with undiagnosed better is required. 
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8.4 Overall discussion 
I have demonstrated in this chapter the application of the developed calibration methods 
to three settings with varying levels of surveillance data. The three settings also had 
different sized HIV-positive populations and data features, which enabled me to 
investigate the potential impact it would have on the modelled results. I have found that 
it is valuable to have expert opinion to help inform some of the modelled parameters (to 
reduce the likelihood that model parameters within Synthesis V6 are mis-specified), but 
also to appropriately determine data item and weights to use in the calibration-score. 
This would include insights such as whether treatment guidelines are accurately 
followed, and the degree and possible reasons for which the observed data may be 
inaccurately reported or ascertained. Even if reliability of historical data were to be 
tenuous or completely lacking, I think that these results have shown that having a wide 
range of reliable recent data will still help to calibrate the model to a useful degree. The 
calibrated model parameter sets can then either be used to make inferences about the 
population of interest, or they may inform about possible inconsistencies in the data 
through triangulation. In summary, from comparing the three results together, I think that 
the results from the calibration method are helpful, not only to estimate the size and 
characteristics of the HIV-positive population, but to also establish whether more 
surveillance should be carried out to improve the amount, completeness and reliability of 
the data.  
The results presented in this chapter should be interpreted with caution, bearing in mind 
the extent of the calibration to the observed data. The outcomes are based on 
calibration method I developed and on my understanding of each country’s HIV 
epidemic. It may still be the case that country experts would want further refining of 
model parameters and assumptions. However despite these limitations, I have shown in 
this chapter that it is possible to quantify and describe the state of an HIV epidemic for a 
country. This is the case even where there is a shortage of observed data, although in 
such circumstances the modelled estimates will have wide PRs reflecting the associated 
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uncertainty. This calibration method provides a useful alternative approach to generate 
HIV estimates, which can be used together with other estimates to improve our 
understanding of key aspects about the affected populations.  
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Chapter 9 Summary and Conclusions 
9.1 Summary of main findings 
Despite the availability of effective ART, HIV remains a key public health issue in Europe. 
The size of the HIV-positive population continues to grow and is expected to rise further 
in coming years due to new infections and a decline in death rates in most regions[1065]. 
It is therefore important to be able to understand and assess the current state of the 
epidemic better by utilising the available epidemiological data on HIV, to help inform and 
monitor the impact of policies and interventions. 
9.1.1 Reviewing the literature 
In Chapter 1, I reviewed the natural history of HIV and the effect of ART extensively, 
because all these concepts were captured and modelled in Synthesis V5, the model 
which I further developed and used in subsequent chapters of this thesis. 
In Chapter 2, I firstly reviewed concepts used to describe disease epidemiology, the 
types of data collected for surveillance of diseases and currently used methods to 
quantify the state of the HIV epidemic in Europe. The epidemiological status and 
characteristics of HIV-positive populations for 18 European countries were then 
described. I found that HIV infection has impacted countries across Europe in very 
different ways and the approach by which each country has handled it also differed due 
to the affected sub-populations, available resources and structure of healthcare systems 
and surveillance. A review summarising the current status of HIV in Western Europe 
including results from this chapter was published in Current HIV/AIDS Reports in March 
2014 and can be found in Appendix XIII. 
9.1.2 HIV disease modelling and Synthesis V5 
In Chapter 3, I explained the types of mathematical models which are available and how 
they are used in the context of HIV disease modelling. I then described some properties 
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and applications of two other individual-based stochastic simulation models which have 
been developed. In the latter half of this chapter, I describe in detail the HIV Synthesis 
V5 model, which was originally developed by Phillips and colleagues, including the 
model structure and main parameters modelled.       
9.1.3 Life expectancy in HIV-positive people 
In the first part of Chapter 4, I defined life expectancy, outlined the main methods of 
calculation and then reviewed the life expectancy in people living with HIV, which has 
changed greatly over time as a result of increasingly better treatment and care. The 
review on life expectancy was published as a manuscript in Current Opinion in Infectious 
Diseases in February 2013 and can be found in Appendix XIII. In the second part of the 
chapter, I estimate the projected life expectancy of HIV-positive MSM with access to 
good HIV care and treatment. A manuscript of this modelling analysis was published in 
AIDS in January 2012 and can be found in Appendix XIII. This part also illustrated how 
the model works, in terms of the structure it takes, how the simulations are run and used, 
and the types of outputs it can generate.   
Before combination therapy was introduced, HIV-positive people had very poor 
prognosis; the mean time from seroconversion to AIDS was estimated to be less than 
ten years and the mean survival time following an AIDS diagnosis was approximately 
only one year. After the introduction of effective ART in HIC however, mortality declined 
dramatically and life expectancy has correspondingly increased. The gap between life 
expectancy in HIV-positive people and HIV-negative people has continued to narrow 
over time to the extent that some studies published in the last few years have concluded 
that some people on suppressive treatment regimens have the same life expectancy as 
the general population. As seen in the general population, females and non-smokers 
have longer life expectancy. Among people living with HIV, factors associated with lower 
life expectancy include lower CD4 count at ART initiation, late presentation to care, not 
achieving viral suppression, non-white race, history of IDU and suboptimal adherence.       
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The modelling study performed in Chapter 4 used Synthesis V5 to estimate the 
projected life expectancy of MSM infected with drug-sensitive HIV in 2010 in the UK, 
assuming that current standards of care are maintained. I found that under the 
assumption of a diagnosis rate similar to that currently observed, the projected median 
age at death was 75.0 years. This estimate is consistent with several other projections in 
similar settings. The projected median age at death decreased to 71.5 years if diagnosis 
(in the absence of any HIV-related symptoms) was negligibly low. Results from this 
chapter therefore showed that delays in diagnosis not only leads to excess mortality in 
people with HIV, but limits individuals from initiating ART earlier thereby not reducing 
onward transmission whilst naïve to treatment. 
9.1.4 Development of Synthesis V6  
The development of the new version of the model, Synthesis V6, is documented in 
Chapter 5. The developments and modifications made to the model were based on the 
results of a number of statistical analyses performed using cohort data and on a series 
of literature reviews. Synthesis V6 was the model used in Chapters 6, 7 and 8 as part of 
the calibration method developed to make estimates for European countries.  
The main changes which I made to the Synthesis model, based on the statistical 
analyses performed on data from the COHERE cohort collaboration are described below. 
The initial CD4 count soon after seroconversion was modified so that it is now higher in 
younger people and people of white race, and the effect of viral load is now not as large. 
The viral load set point was also modified such that it was higher in older people and 
lower in females. The annual change in viral load in ART-naïve people was modified so 
that older people experienced a faster rise over time. For the annual change in CD4 
count in ART-naïve people, the effect of most recent viral load was modified, the effect 
of age was removed and a race effect was added. This analysis on the short-term 
changes in viral load and CD4 count was published as a manuscript in AIDS in June 
2014 and can be found in Appendix XIII. Finally for the annual change in CD4 count in 
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people on ART, I modified the overall size of the rise depending on the current CD4 
count and added further effects such that the rise was greater in younger people, 
females and for people on PI-based regimens. The rise in CD4 count was also modelled 
to be greater in the first few years of starting a new regimen compared to subsequent 
years.   
For specific aspects of the model, I reviewed the literature to find evidence on how to 
inform or re-inform parameter values and/or the model structure. First, I found that there 
was sufficient evidence that older age is associated with both better adherence and 
virologic response but that people who acquired HIV through IDU have both worse 
adherence and virologic response. I updated the resistance mutations modelled and 
their effects on specific antiretroviral drugs. The changes include the reduction in 
susceptibility of DRV if V32I or I47V is present, the reduction in susceptibility of LPV/r if 
L76V is present, the reduction in susceptibility of 3TC or FTC containing regimens if 
K65R or Q151M is present, modelling K103N, Y181C and G190A instead of a non-
specific NNRTI mutation and modelling primary and secondary mutations to INIs. 
Alongside these changes I also updated the probability of resistance mutations arising 
when on a particular drug-containing regimen. One major change I made to the model 
was to double the drug activity level for RTV-boosted PIs based on accumulating 
evidence that such drugs are highly effective on their own, to the extent that they have 
been considered as an option for mono-therapy regimens in this era of combination 
therapy. The probability of treatment interruption in Synthesis V6 now depends on the 
age, calendar year and whether the person acquired HIV through IDU. The probability 
was also modified to incorporate results from the SMART trial. The toxicities modelled 
were also thoroughly reviewed and updated in collaboration with clinicians and other 
experts within the SSOPHIE project working group. Finally, I included a new variable to 
model a woman’s pregnancy status, where the incidence differs by the woman’s age, 
race, diagnosis status, health and calendar year. Pregnancy was also modelled to affect 
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a woman’s probability of getting diagnosed with HIV, the antiretrovirals used and short-
term adherence post-partum.     
9.1.5 Development and application of the model calibration method 
At the start of Chapter 6, I explained the novel approach I developed and used, based 
on Approximate Bayesian Computation methods, to calibrate Synthesis V6 to country-
specific surveillance data on HIV. The aim of this approach was to reconstruct the HIV-
positive population of interest, in order to make inferences about the population and 
generate suitable estimates with PRs. The calibration method developed was then 
described and applied to data on MSM in the UK. The method in this chapter was 
developed for settings where the infections primarily occur within that setting (i.e. 
excluding infections in migrants). I presented this calibration method at two conferences 
and the poster presentation and published abstract can be found in Appendix XIII. Using 
the developed method, I estimated that 51,000 MSM were living with HIV in the UK in 
2013, of which 11,500 were undiagnosed. From the modelled results, I found that 
incidence remained high among MSM: an estimated 3,270 new infections per year 
occurred on average between 2010 and 2013. I also performed further analyses using 
pseudo data simulated using Synthesis V6 to assess the impact of different availability 
of data on calibration of the model. The results from these analyses indicated that more 
reliable estimates can be made using the calibration method, if there is a wide range of 
surveillance data available for longer periods of time.  
Since many European countries have historical links with countries in SSA, I modified 
the calibration method to take into account migration of people who originate from 
countries in that region. This modification, presented in Chapter 7, therefore allowed the 
calibration method to be used at a national level, explicitly accounting for infections 
which occur abroad. The method was applied to data from the UK in order to estimate 
the size and characteristics of the HIV-positive population stratified by the main HIV 
exposure groups: MSM, black African heterosexual men and women and non-black 
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African heterosexual men and women. In 2013, the method estimated that there were 
112,700 people living with HIV in the UK. I found that it was possible to generate HIV 
estimates even when migrants are included, providing that there are some data 
available regarding infections which occurred outside the country of interest, such as the 
year of arrival.  
Finally in Chapter 8, I demonstrated the application of the calibration method to three 
additional settings in Europe: MSM in the Netherlands, Spain and Estonia. The three 
settings not only had completely different composition of their HIV-positive populations, 
but also varying levels of data availability, in terms of data collected through routine 
surveillance as well as additional observational data. The numbers of people estimated 
to be living with HIV in 2013 for the three settings were 12,100, 135,600 and 7,700 
respectively. On the whole, these estimates were consistent with other existing 
estimates of the total size of the population. There were large differences seen between 
the certainties of the modelled estimates, as reflected in the widths of the PRs. 
Consistent with the analysis results using the pseudo data in Chapter 6, wider ranges 
were seen for settings with less data (i.e. Estonia) available to calibrate the model.  
9.2 Relevance and limitations of main findings 
The focus of this thesis was to use available surveillance and observational data to 
enhance our understanding of the epidemiological characteristics of HIV-positive 
populations in European countries. Here, I have achieved that by developing a novel 
approach involving a simulation model of HIV. To my knowledge, this is the only 
example of the use of an individual-based stochastic simulation model in order to make 
inference about the size and detailed characteristics of an HIV-positive population. This 
thesis therefore adds to the existing literature on estimation methods in HIV, which may 
also be of use for other chronic or long-term infectious diseases with similarly long 
periods until diagnosis. 
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The statistical analyses performed in Chapter 5 used data from the largest cohort 
collaboration study in Europe. This has the advantage that analyses had maximum 
power to detect any associations and that the estimates are more likely to be 
representative of the European population. However, a limitation of research using data 
from cohort studies is that unmeasured or unknown confounding factors cannot be 
adjusted for, which means that it is possible for some bias to have been inevitably 
introduced. With treatment guidelines changing to recommend earlier initiation of 
ART[260], it will become increasingly challenging to conduct research with regards to 
the natural progression of HIV disease.  
Mathematical models are generally developed in order to answer specific research 
questions. Often, these models are simple, including only the minimal number of 
parameters necessary to capture the essence of a process. This has the inherent 
advantage that the model itself is simple to understand and that it runs more efficiently. 
In contrast, Synthesis V6 is a general model of HIV progression, incorporating a detailed 
understanding of the progression of HIV and the effect of ART to simulate a hypothetical 
population of people with HIV. The calibration method presented in this thesis to 
generate HIV estimates would only have been possible with such a complex model, 
because it requires replication of an array of disease outcomes in order to compare with 
the vast range of available surveillance data. A detailed model allows the researcher to 
answer various questions using the same structure and assess the impact of alternative 
scenarios, based on different assumptions that can be made. An advantage of modelling 
the full spectrum of clinical outcomes using Synthesis V6 is that it is possible to perform 
data triangulation. That is, to cross-validate multiple datasets collected by a country with 
outputs of the model, as the model itself has been fit and validated to a range of 
observational data. In other words, triangulation within a Bayesian framework therefore 
involves checking different sources of data with one another to identify whether a 
particular dataset is biased or whether there are any data which are particularly lacking. 
Different sources of data can be used to calibrate the model, but some are likely to be 
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more reliable than others. If the modelled outcomes cannot consistently be closely 
calibrated to one source of data but calibrate well to the rest, then it may indicate that 
there are problems or bias associated with that source of data. In such a situation, 
efforts may need to be made to investigate if there is a plausible reason for such a bias 
to exist and whether the data can be adjusted accordingly or otherwise consider not 
fitting to that particular data source. Another advantage of using an approach based on 
a mechanistic reconstruction of the population, is that it is also possible to consider 
effects of various interventions on the HIV-positive population, which can’t necessarily 
be done with other estimation methods.  
One way to simplify the model is to reduce the number of variables. There are a number 
of variables, such as those associated with resistance which may seem unnecessary to 
model, particularly as part of the calibration method. However, as described in Chapter 3, 
many processes modelled in the HIV Synthesis model are jointly determined. For 
example, it is not possible to ‘switch off’ the resistance variables because virologic 
failure (and hence changes in CD4 counts and clinical failure) is determined as a result 
of resistance accumulation together with sub-optimal adherence. If countries have data 
on prevalence of resistance mutations say, then it would be useful to calibrate to these 
data so that other resistance-related estimates can be inferred from the model.  
A major limitation of using detailed individual-based stochastic simulation models like 
Synthesis V6 is the computational time required for each simulation. This makes the 
calibration method detailed in Chapters 6 and 7 seem inefficient, particularly due to the 
time it takes for the large number of simulations to be run in order to find sets of 
parameter values which calibrate well to the data. In the calibration method I developed, 
the number of simulations required depends heavily on the choice of prior distributions 
used. In all cases presented in this thesis, I assumed little was known about the 
historical incidence and diagnosis rate for a setting, which meant that the parameter 
spaces sampled were very extensive. However, once the calibration method is applied 
for a setting and knowledge of the likely range of incidence and diagnosis rate over time 
   
429 
 
is gained, then in any subsequent applications of the calibration method, the sampled 
parameter space can be significantly reduced (as the prior distributions of parameters 
can be informed further by the previous results). Alternatively, if there are estimates of 
the incidence and diagnosis rate already available through other methods or research 
studies, then it is also possible to use these to inform the prior distributions.    
There are already a number of approaches which exist to achieve similar objectives as 
this thesis, which aim to maximise the use of HIV surveillance data to inform national 
and international decision making processes. One notable approach, mentioned also in 
previous chapters, is the package of methods used by UNAIDS: Workbook, EPP and 
Spectrum[454-462]. It has been possible to apply the UNAIDS approach to most 
countries in the world, aided by its straightforward program and user interface. It is an 
approach that relies mainly on data from prevalence surveys and is thus more suitable 
to countries with generalised epidemics. Case report data are not used. However, as the 
number of parameters estimated is fairly restricted, it is difficult to customise certain 
inputs to take into account nuances of data which may be known to inform the models 
better. Another approach is the MPES method, which is perhaps more similar to the 
modelling approach in my thesis. The MPES method also attempts to combine multiple 
sources of data (mainly prevalence surveys but also surveillance data on the diagnosed 
population), to generate HIV estimates over time[465-467]. The calibration method I 
developed in order to fully utilise Synthesis V6, allows the modelled outputs to be 
compared and calibrated against a wide range of available clinical and epidemiological 
information, due to the level of detail simulated by the model. It is therefore able to 
consider and incorporate information from a wide array of data sources, regardless of 
the definitions used or nuances which may be present, as the modelled outputs can 
generally be customised to suit the data available. For example, since the actual viral 
load (true underlying value and measurement error) are modelled, data on the 
proportion of people with viral suppression need not necessarily be defined as a 
measurement <50 copies/ml as is often used, but instead <200 copies/ml, or two 
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consecutive measurements <400 copies/ml. Most back-calculation methods to estimate 
the number of undiagnosed people are able to estimate the CD4 count distribution or at 
least whether they have developed AIDS. This is because the natural disease 
progression needs to be modelled to determine the incidence of HIV. However, to my 
knowledge, none can generate further characteristics such as the viral load distribution, 
resistance profiles and treatment history, which makes the estimation method that I have 
developed different from others.   
Given the structure of the model, the duration of the simulated epidemic can be simply 
extended to project future outcomes. The resulting estimates will depend on the 
assumed future trajectories of incidence and diagnosis rate (in addition to assumptions 
relating to the standards of HIV care and treatment) and therefore short-term estimates 
would have less uncertainty compared to long-term estimates. Such ‘what-if’ scenarios 
would be useful to help inform future decisions about healthcare services relating to HIV. 
Yet increasingly more relevant recently are research questions relating to prevention of 
HIV in people not yet infected. Effective ART has not only improved the prognosis of 
HIV-positive people, but there is now ample evidence that it can also reduce onward HIV 
transmission through the reduction of viral load[284, 824, 1066]. One important future 
work would be to extend the model to include HIV-negative individuals and thus model 
transmission of HIV. This then requires data on HIV acquisition risk behaviour, such as 
rates of condomless sex or sharing of injection equipment. 
There are a number of data considerations which should be discussed here to aid with 
interpreting the findings of this present modelling work and to consider for future 
calibration of the model to other European settings. Firstly, in order to estimate the 
number of people currently living with HIV, accurate data on the number of HIV-positive 
people who have died is required. In the UK for example, it is possible within the 
structure of the established surveillance system for deaths among people diagnosed 
with HIV to be linked with national data on deaths. Therefore, countries that have 
completely anonymous case reporting of HIV diagnoses may not be able to easily 
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determine the size of the total infected population. Surveillance systems usually lack the 
resource capacity to follow-up individual records and are therefore likely to experience 
under-ascertainment of deaths. It is also important to fully utilise the expertise and 
knowledge of epidemiologists and surveillance experts of the country being modelled. 
This would be useful for situations where there may not be data available to directly 
inform some of the model parameters.  
I believe the results presented in Chapters 6, 7 and 8 provide useful insights about each 
of the HIV-positive populations modelled. Although for some countries such as the UK 
and the Netherlands, a number of methods and models have already been developed 
with similar aims, I think that it is important to have a range of options available. No two 
approaches will use exactly the same set of data and models rarely have the same set 
of assumptions either. Providing the estimates and PRs are in line with one another, 
multiple results will offer reassurance to estimates generated from models which can 
sometimes be viewed as a ‘black box’. Sensitivity analyses can confirm the robustness 
of results generated by models. For countries with little experience on estimation 
methods, I hope that my work has highlighted the importance of good data collection 
practices. This is the case particularly for the work using limited data from Estonia, 
where the fit to the data was modest and had room for improvement. In this instance, 
data triangulation identified the fit to data on the number of AIDS cases was suboptimal, 
so to improve the fit, it would be ideal to have data on the number of deaths among HIV-
positive people to resolve the cause of the discrepancy.  
Whilst this method was developed with the European situation in mind, with careful 
consideration of the available surveillance system and data collected, it would also be 
possible to apply it outside this region, such as in the US or in sub-Saharan Africa where 
it may provide additional information to those produced using direct methods. Indeed my 
work presented here has attracted interest from both national and international 
organisations, including Public Health England, ECDC and WHO Europe. Estimates 
produced using this calibration method can add further insight into the affected 
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populations because of the detailed nature of the outputs. Findings from using this 
method thus also has the scope to refine policy and practices which are in place, to help 
with efficient and effective use of resources. 
9.3 Further work 
In revising the model from Synthesis V5 to V6, although the process was systematically 
and logically done, it was also somewhat informal due to the large number of variables 
and the complex relationships between them. Instead of assessing the impact of and 
changing one parameter at a time, an alternative method would have been to modify 
multiple parameters simultaneously.  
The multi-stage calibration procedure was developed to try and make the fitting 
procedure more efficient by limiting the number of simulations runs necessary by 
reducing the parameter space of the prior distributions. If computation time was less 
restricted then it may have been preferable to not manually reduce the parameter 
spaces but instead allowing time for all the multiple combinations of parameter values to 
be explored spontaneously. Alternatively, I could have made the prior distributions 
narrower one parameter at a time so work out which parameters were the most 
influential on the final outputs. 
Each European county has different surveillance systems with large differences in the 
amount and type of data collected. So as further research, the calibration method could 
be applied to and assessed in other settings. If a situation arises such that the model fit 
to a data source is found to be poor, then first it needs to be decided whether there is a 
plausible explanation for this, such as knowledge of potential bias in the data. If there is 
no obvious explanation then the next step, if time allowed, would be to reconsider the 
choice of the prior distributions and modify them if necessary in conjunction with country 
experts. This would require the multi-stage calibration procedure to be repeated. 
Otherwise if after calibration to several settings and the fit to a particular source is 
   
433 
 
suboptimal in many of these then there is the potential that the model parameters 
describing the disease progression and effect of ART may need modifying.  
Synthesis V6 could also be extended to incorporate more precise modelling of 
comorbidities such as non-AIDS-defining illnesses, given the rising incidence of non-HIV 
related causes of deaths[826, 1067, 1068], or it could incorporate hepatitis progression 
and the effect of hepatitis treatment, as co-infections are commonly seen in Eastern and 
Southern regions of Europe[1069]. 
9.4 Concluding remarks 
Policymakers and key public health officials require in-depth information about the 
epidemiological status of affected populations, in order to make informed decisions 
about matters including prevention, diagnosis and treatment of HIV. The aim of this 
thesis was to develop a method to reconstruct and hence better understand HIV-positive 
populations in Europe, by using an individual-based stochastic progression model of HIV. 
By calibrating the model to routinely collected surveillance data, I have shown that this 
modelling approach is able to estimate the size and characteristics of HIV-positive 
populations, whilst capturing the uncertainty associated with the estimates generated. In 
addition, as the detail of the model reconstructions corresponds to data collected as part 
of clinical care, the modelled outputs can be used in conjunction with other available 
clinical and epidemiological information for data triangulation. It is hoped that the method 
and findings presented in this thesis will add to the literature on estimation methods by 
providing an alternative approach to estimating the features of HIV-positive populations, 
and will also help inform decision-making processes regarding the management of 
current and future use of healthcare services.  
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Appendix I. CDC list of AIDS-defining 
conditions 
 
Source: MMWR. Appendix A. AIDS-defining conditions. 57[RR10];9. Available at 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm (accessed 14 November 
2014)  
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 Bacterial infections, multiple or recurrent*  
 Candidiasis of bronchi, trachea, or lungs  
 Candidiasis of esophagus†  
 Cervical cancer, invasive§  
 Coccidioidomycosis, disseminated or extrapulmonary  
 Cryptococcosis, extrapulmonary  
 Cryptosporidiosis, chronic intestinal (>1 month's duration)  
 Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month  
 Cytomegalovirus retinitis (with loss of vision)†  
 Encephalopathy, HIV related  
 Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or 
esophagitis (onset at age >1 month)  
 Histoplasmosis, disseminated or extrapulmonary  
 Isosporiasis, chronic intestinal (>1 month's duration)  
 Kaposi sarcoma†  
 Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex*†  
 Lymphoma, Burkitt (or equivalent term)  
 Lymphoma, immunoblastic (or equivalent term)  
 Lymphoma, primary, of brain  
 Mycobacterium avium complex or Mycobacterium kansasii, disseminated or 
extrapulmonary†  
 Mycobacterium tuberculosis of any site, pulmonary,†§ disseminated,† or 
extrapulmonary†  
 Mycobacterium, other species or unidentified species, disseminated† or 
extrapulmonary†  
 Pneumocystis jirovecii pneumonia†  
 Pneumonia, recurrent†§  
 Progressive multifocal leukoencephalopathy  
 Salmonella septicemia, recurrent  
 Toxoplasmosis of brain, onset at age >1 month†  
 Wasting syndrome attributed to HIV  
 
* Only among children aged <13 years. (CDC. 1994 Revised classification system for human 
immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43[No. 
RR-12].)  
† Condition that might be diagnosed presumptively.  
§ Only among adults and adolescents aged >13 years. (CDC. 1993 Revised classification 
system for HIV infection and expanded surveillance case definition for AIDS among 
adolescents and adults. MMWR 1992;41[No. RR-17].)  
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Appendix II. Antiretroviral drugs licenced 
in the European Union as of October 2014  
 
Source: NAM aidsmap. Antiretroviral drugs chart. Available at 
www.aidsmap.com/resources/Antiretroviral-drugs-chart/page/1412453/ (accessed 16 
January 2015)  
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Brand name  
within EU 
Generic name [abbreviations] EMA 
approval  
date 
Main side effects1 
Nucleoside reverse transcriptase inhibitors (NRTIs) 
Emtriva Emtricitabine [FTC] 24/10/2003 Common: nausea, dizziness, weakness, difficulty sleeping, 
abnormal dreams, vomiting, stomach pain, rash, changes in skin 
colour. Uncommon: anaemia. Rare: lactic acidosis, lipodystrophy, 
hyperlipaemia. 
Epivir Lamivudine [3TC] 08/08/1996 Common: headache, nausea, vomiting, diarrhoea, stomach 
pains, tiredness, lack of energy, fever, general feeling of being 
unwell, muscle pain and discomfort, joint pain, insomnia, rash, 
alopecia. Uncommon: anaemia. Rare: lactic acidosis, 
pancreatitis, liver-related disorders. 
Retrovir Zidovudine2 [AZT] - Common: nausea, headache, vomiting, difficulty sleeping, loss of 
appetite, anaemia, fever. Rare: lactic acidosis, lipodystrophy. 
Viread Tenofovir3 (disoproxil Fumarate) 
[TDF]  
05/02/2002 Common: diarrhoea, vomiting, nausea, dizziness, rash, 
weakness, flatulence. 
Rare: lactic acidosis, nephrotoxicity. 
Ziagen  Abacavir [ABC] 08/07/1999 Common: hypersensitivity reaction, nausea, headache, vomiting, 
diarrhoea, loss of appetite, tiredness, lack of energy, fever, skin 
rash. Rare: hypersensitivity reaction, lactic acidosis, pancreatitis. 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Edurant Rilpivirine [RPV] 28/11/2011 Common: insomnia, abnormal dreams, nausea, headache, 
dizziness, stomach pain, rash, weakness, depression. 
Intelence Etravirine [ETV] 28/08/2008 Common: rash, headache, tiredness, insomnia, anxiety, 
diarrhoea, nausea, vomiting, abdominal pain. 
Sustiva/Stocrin Efavirenz [EFV] 28/05/1999 Common: rash, abnormal dreams, insomnia, headache, 
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dizziness, abdominal pain, diarrhoea, nausea, vomiting, 
tiredness. Rare: liver failure, suicide.  
Viramune4 Nevirapine [NVP] 05/02/1998 Common: rash, hypersensitivity, nausea, vomiting, abdominal 
pain, diarrhoea, fatigue, fever, hepatotoxicity. Uncommon: Allergic 
reaction, severe rash. 
Protease inhibitors (PIs) 
Aptivus Tipranavir [TPV] 25/10/2005 Common: diarrhoea, nausea, vomiting, abdominal pain, 
flatulence, tiredness, headache, rash. Rare: abnormal liver 
function, bleeding in the brain. 
Kaletra Lopinavir + Ritonavir [LPV/RTV or 
LPV/r] 
20/03/2001 Common: diarrhoea, nausea, upper respiratory tract infection, 
abdominal pain, pancreatitis, hyperlipidaemia. Rare: abnormal 
dreams, lipodystrophy 
Norvir Ritonavir [RTV] 26/08/1996 Common: nausea, diarrhoea, vomiting, abdominal pain, 
headache, dizziness, rash, fever, weakness, hyperlipidaemia, 
lipodystrophy, loss of appetite, bad taste in mouth, joint pain, 
insomnia. 
Prezista Darunavir [DRV] 12/02/2007 Common: diarrhoea, vomiting, nausea, abdominal pain, 
flatulence, headache, tiredness, dizziness, nausea, numbness, 
weakness, insomnia, lipodystrophy, diabetes. Rare: severe rash, 
pancreatitis. 
Reyataz Atazanavir [ATV] 02/03/2004 Common: diarrhoea, headache, vomiting, abdominal pain, 
nausea, jaundice, rash, lipodystrophy, fatigue. Rare: 
nephrotoxicity, diabetes. 
Telzir Fosamprenavir [FPV] 12/07/2004 Common: diarrhoea, nausea, hyperlipidaemia, rash, weakness, 
muscle pain, headache, liver-related disorders. Rare: severe 
rash.  
Integrase inhibitors (INIs) 
Isentress Raltegravir [RAL] 20/12/2007 Common: loss of appetite, insomnia, headache, abdominal pain, 
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diarrhoea, nausea, vomiting, rash, tiredness. Uncommon: 
anaemia, liver-related disorders, allergic rash, psychosis, herpes 
infections, nephrotoxicity. 
Tivicay Dolutegravir [DTG] 16/01/2014 Common: headache, diarrhoea, nausea, rash, itching, abdominal 
pains, insomnia, dizziness, abnormal dreams, fatigue, flatulence, 
liver-related disorders. Uncommon: allergic reactions, hepatitis, 
fever. 
Vitekta Elvitegravir [EVG] 13/11/2013 Common: abdominal pain, vomiting, rash, headache, diarrhoea, 
nausea, tiredness. Uncommon: suicidal thoughts, depression, 
insomnia. 
CCR5 inhibitor 
Celsentri Maraviroc [MVC] 18/09/2007 Common: diarrhoea, nausea, abdominal pain, flatulence, 
indigestion, headache, insomnia, depression, rash, weakness, 
anaemia, loss of appetite. Rare: liver-related disorders with 
allergic reactions 
Fixed-dose combinations (FDCs) 
Combivir Lamivudine + Zidovudine 
[3TC+AZT] 
18/03/1998 See lamivudine and zidovudine 
Kivexa Abacavir + Lamivudine [ABC+3TC] 17/12/2004 See abacavir and lamivudine 
Trizivir Abacavir + Lamivudine + 
Zidovudine [ABC+3TC+AZT] 
28/12/2000 See abacavir, lamivudine and zidovudine 
Truvada Emtricitabine + Tenofovir 
[FTC+TDF] 
21/02/2005 See emtrictabine and tenofovir 
Single tablet regimens (STRs) 
Atripla Efavirenz + Emtricitabine + 
Tenofovir [EFV+FTC+TDF] 
13/12/2007 See efavirenz, emtricitabine and tenofovir 
Eviplera Rilpivirine + Emtricitabine + 28/11/2011 See rilpivirine, emtricitabine and tenofovir 
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Tenofovir [RPV+FTC+TDF] 
Stribild Elvitegravir + Cobicistat + 
Emtricitabine + Tenofovir 
[EVG+COBI+FTC+TDF] 
24/05/2013 Common: diarrhoea, vomiting, nausea, weakness, headache, 
dizziness, rash, loss of appetite, insomnia, abdominal pain, 
weakness, flatulence. Uncommon: suicidal thoughts, 
nephrotoxicity. Rare: hepatitis, lactic acidosis. 
Triumeq Dolutegravir + Abacavir + 
Lamivudine [DTG+ABC+3TC] 
01/09/2014 See dolutegravir, abacavir and lamivudine 
EU: European Union; EMA: European Medicines Agency. 
1. Side effects listed here are those found in the package leaflets for the drugs. These are the main side effects associated with use of the drug and there are 
many others which are not listed. Side effects labelled as common may affect up to 1 in 10 people, those labelled uncommon may affect up to 1 in 100 people 
and those labelled as rare may affect up to 1 in 1,000 people.  
2. Zidovudine is also known as azidothymidine. AZT was not licensed in the EU to treat HIV infection but since patent expiry, generic versions can now be 
sold 
3. Tenofovir is a nucleotide reverse transcriptase inhibitor 
4. Also available as Viramune prolonged-release 
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Appendix III. July 2014 update of IAS-USA 
drug resistance mutations list  
  
Source: Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, et al. 
2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014; 
22(3):642-50. 
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Figure not available due to copyright restrictions 
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Figure not available due to copyright restrictions 
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Appendix IV. HIV and AIDS case reporting 
surveillance in Europe 
 
   
 
 
4
4
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Country Main body responsible for 
collection of surveillance data 
Initiation year 
of surveillance 
AIDS       HIV 
Brief description of data collection Source 
UK Public Health England (PHE), 
formerly known as Health 
Protection Agency (HPA) 
1982 1984 Voluntary reports based on confirmed diagnoses from 
laboratories, GUM clinics, GPs and other services which 
conduct HIV testing 
[488, 497] 
Netherlands Stichting HIV Monitoring (SHM) 
and National Institute for Public 
Health and the Environment 
(RIVM) 
1987 2002 National AIDS registry from 1997 to 2002, based on 
voluntary reports by physicians. New HIV/AIDS reporting 
system implemented in 2002.  
[508] 
Spain Centro Nacional de 
Epidemiología, Instituto de Salud 
Carlos III (ISCIII) 
1981 1985 Mandatory notification of AIDS case reports submitted by 
clinicians. As of 2013, HIV case reporting now exists in all 
19 autonomous regions (until 2012, no complete national 
surveillance system for HIV).  
[1070] 
Estonia Estonian Health Board 1987 1987 Passive surveillance of HIV and AIDS case reports. 
Anonymous reports of HIV diagnoses also included until 
2008. 
[545] 
Germany Robert Koch Institute (RKI) 1982 1987 Voluntary anonymous case reporting of AIDS and deaths 
by treating physicians. Obligatory anonymous reporting of 
all confirmed positive HIV diagnoses by HIV laboratories 
until 1998. After June 1998, HIV reporting is voluntary but 
unique identifiers introduced.   
[549] 
France Institut de Veille Sanitaire (InVS) 1986 2003 Mandatory notification of AIDS case reports. Anonymous 
but mandatory notification of HIV case reports.  
[556, 557] 
Italy National AIDS Registry (RAIDS) 
at the Centro Operativo AIDS 
(COA) of the Istituto Superiore di 
Sanitá, Rome, Italy 
1982 2008 AIDS case reporting voluntary initially, then mandatory 
since 1986. Regional surveillance systems in place started 
at different times, from 1985 onwards. National 
surveillance system for mandatory reporting of HIV set up 
in 2008, but data complete for whole of Italy from 2013 
[571, 573, 
576] 
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Country Main body responsible for 
collection of surveillance data 
Initiation year 
of surveillance 
AIDS       HIV 
Brief description of data collection Source 
only. 
Denmark Statens Serum Institut (SSI) 
under the Danish Ministry of 
Health 
1983 1990 Mandatory anonymous HIV case reporting based on 
confirmatory HIV analyses in laboratories. AIDS case 
reporting also mandatory by diagnosing physician. 
[588] 
Switzerland Swiss Federal Office of Public 
Health 
1983 1985 Anonymous mandatory reporting of HIV based on 
laboratory results, supplemented by clinical data. AIDS 
case reports based on mandatory reporting by physicians 
and case-finding based on review of death certificates.  
[607, 
1071-
1073] 
Portugal Instituto Nacional de Saúde 
Doutor Ricardo Jorge, 
I.P./Centro de Vigilância 
Epidemiológica des Doenças 
Transmissíveis 
1983 1983 HIV reporting system modified in 2000, as previously the 
reporting process did not provide accurate data, especially 
of number of HIV infections. 
[488, 492, 
608] 
Belgium Belgian Scientific Institute for 
Public Health (WIV-ISP) 
1983 1986 Only accredited laboratories can confirm HIV diagnoses 
which are submitted voluntarily. Epidemiological data then 
collected from clinicians. AIDS cases validated every 6 
months by WIV-ISP. 
[615, 
1074] 
Greece Hellenic Centre for Disease 
Control and Prevention 
(ΚΕΕΛΠΝΟ) 
1984 1998 Both AIDS and HIV case reporting is anonymous, 
confidential and mandatory. The new surveillance system 
for monitoring HIV infection was implemented at European 
level in January 1999. 
[626] 
Austria Federal Ministry of Health, 
Family and Youth 
1984 1994 HIV case reporting not mandatorily notifiable, all confirmed 
at screening laboratories. AIDS is a statutory notifiable 
disease, reported by diagnosing physicians, coroners or 
pathologists.  
[630] 
Sweden Swedish Institute for 1983 1985 Both HIV and AIDS cases must be notified by both the [609, 655] 
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Country Main body responsible for 
collection of surveillance data 
Initiation year 
of surveillance 
AIDS       HIV 
Brief description of data collection Source 
Communicable Disease Control 
(Smittskyddsinstitutet, SMI) 
doctor and the diagnosing laboratory to the SMI. AIDS 
case reporting was not mandatory after 2005. The national 
AIDS surveillance system was discontinued in 2008.  
Poland National Institute of Public 
Health – National Institute of 
Hygiene (NIZP-PZH) 
1985 
 
1985 Surveillance of HIV and AIDS has been implemented since 
1985. Only AIDS notification is mandatory. The notification 
of a positive HIV test result is carried out by the 
laboratories carrying out the confirmatory tests and 
consequently, records on newly diagnosed cases of HIV 
infection are often incomplete. 
[644, 650] 
Romania National Institute for Infectious 
Diseases (Prof. Dr. Matei Bals) 
1990 1990 The first surveillance system was implemented in 1990. 
Subsequent changes to the system unclear from the 
literature, but both HIV and AIDS are now thought to be 
case-based and confirmed cases only, which are collected 
at hospitals and infectious disease units.  
[663] 
Ukraine National AIDS Center/ Ukrainian 
Center for Socially Dangerous 
Disease Control 
1987 1987 Case-based data on HIV diagnoses are reported 
mandatorily, based on laboratory reporting since 1996/7 
but with need for physician confirmation. AIDS cases 
registered at government AIDS centres.  
[670, 671, 
675] 
Russian 
Federation 
Russian Federal AIDS Centre 1987 1987 HIV case reporting mandatory after referral to health 
institution following screening.   
[670] 
AIDS: acquired immunedeficiency syndrome; GP: general practices; GUM: genitourinary medicine 
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Appendix V. EuroCoord WP15 (SSOPHIE) 
project working group and EuroCoord 
boards and partner members 
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SSOPHIE project working group in EuroCoord: Fumiyo Nakagawa, Alioum Ahmadou, 
Andrew Amato-Gauci, Alison Brown, Jan Albert, Daniela Bezemer, Valentina Cambiano, 
Colin Campbell, Jordi Casabona, Daniel Commenges, Mario Cortina Borja, Dominique 
Costagliola, Daniela de Angelis, Valerie Delpech, Andrea de Luca, Martin Donoghoe, 
Deborah Ford, Geoff Garnett, Peter Ghys, Tim Hallett, Jesper Kjaer, Roger Kouyos, 
Rebecca Lodwick, Jens Lundgren, Nikos Pantazis, Santi Perez-Hoyos, Patrizio Pezzotti, 
Anastasia Pharris, Chantal Quinten, Mika Salminen, Colette Smit, Colette Smith, 
Jonathan Sterne, Virginie Supervie, Rodolphe Thiebaut, Claire Thorne, Pat Tookey, 
Giota Touloumi, Ard van Sighem, Andrew Phillips. 
EuroCoord Executive Board: Fiona Burns, University College London, UK; Geneviève 
Chêne, University of Bordeaux, France; Dominique Costagliola (Scientific Coordinator), 
Institut National de la Santé et de la Recherche Médicale, France; Carlo Giaquinto, 
Fondazione PENTA, Italy; Jesper Grarup, Region Hovedstaden, Denmark; Ole Kirk, 
Region Hovedstaden, Denmark; Laurence Meyer, Institut National de la Santé et de la 
Recherche Médicale, France; Heather Bailey, University College London, UK; Alain 
Volny Anne, European AIDS Treatment Group, France; Alex Panteleev, St. Petersburg 
City AIDS Centre, Russian Federation; Andrew Phillips, University College London, UK, 
Kholoud Porter, University College London, UK; Claire Thorne, University College 
London, UK.  
EuroCoord Council of Partners: Jean-Pierre Aboulker, Institut National de la Santé et 
de la Recherche Médicale, France; Jan Albert, Karolinska Institute, Sweden; Silvia 
Asandi , Romanian Angel Appeal Foundation, Romania; Geneviève Chêne, University of 
Bordeaux, France; Dominique Costagliola (chair), INSERM, France; Antonella d’Arminio 
Monforte, ICoNA Foundation, Italy; Stéphane De Wit, St. Pierre University Hospital, 
Belgium; Peter Reiss, Stichting HIV Monitoring, Netherlands; Julia Del Amo, Instituto de 
Salud Carlos III, Spain; José Gatell, Fundació Privada Clínic per a la Recerca 
Bíomèdica, Spain; Carlo Giaquinto, Fondazione PENTA, Italy; Osamah Hamouda, 
Robert Koch Institut, Germany; Igor Karpov, University of Minsk, Belarus; Bruno 
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Ledergerber, University of Zurich, Switzerland; Jens Lundgren, Region Hovedstaden, 
Denmark; Ruslan Malyuta, Perinatal Prevention of AIDS Initiative, Ukraine; Claus Møller, 
Cadpeople A/S, Denmark; Kholoud Porter, University College London, United Kingdom; 
Maria Prins, Academic Medical Centre, Netherlands; Aza Rakhmanova, St. Petersburg 
City AIDS Centre, Russian Federation; Jürgen Rockstroh, University of Bonn, Germany; 
Magda Rosinska, National Institute of Public Health, National Institute of Hygiene, 
Poland; Manjinder Sandhu, Genome Research Limited; Claire Thorne, University 
College London, UK; Giota Touloumi, National and Kapodistrian University of Athens, 
Greece; Alain Volny Anne, European AIDS Treatment Group, France.  
EuroCoord External Advisory Board: David Cooper, University of New South Wales, 
Australia; Nikos Dedes, Positive Voice, Greece; Kevin Fenton, Public Health England, 
USA; David Pizzuti, Gilead Sciences, USA; Marco Vitoria, World Health Organisation, 
Switzerland.  
EuroCoord Secretariat: Silvia Faggion, Fondazione PENTA, Italy; Lorraine Fradette, 
University College London, UK; Richard Frost, University College London, UK; Andrea 
Cartier, University College London, UK; Dorthe Raben, Region Hovedstaden, Denmark; 
Christine Schwimmer, University of Bordeaux, France; Martin Scott, UCL European 
Research & Innovation Office, UK.   
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Appendix VI. Model details for HIV 
Synthesis V5: natural history 
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Change in viral load for ART-naïve individuals 
v(t) is viral load at time t. vc(t-1) is the change in viral load from time t-1 to t. Both are 
measured in log copies/ml. 
 
Initial viral load 
An initial viral load ‘set point’ is defined: vset ~ Normal(4,0.52). Therefore the viral load at 
start of period (t=1): v(1) = vset. 
  
Changes in viral load from time t-1 to t 
vset vc(t-1) 
<3.0 0.11/4 + Normal(0,0.32) 
3.0-3.49 0.13/4 + Normal(0,0.32) 
3.5-3.99 0.14/4 + Normal(0,0.32) 
4.0-4.49 0.15/4 + Normal(0,0.32) 
4.5-4.99 0.17/4 + Normal(0,0.32) 
5.0-5.49 0.18/4 + Normal(0,0.32) 
5.5-5.99 0.20/4 + Normal(0,0.32) 
≥6.0 0.21/4 + Normal(0,0.32) 
 
v(t) = v(t-1) + vc(t-1)  
If v(t) > 6.5 then v(t)=6.5  (so maximum allowable viral load is 6.5 log copies/ml). 
 
Measured viral load 
The values above determine the underlying viral load.  The measured viral load, vm(t), is 
given by: vm(t) = v(t) + Normal(0,0.25
2
). 
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Change in CD4 count for ART-naïve individuals 
c(t) is the CD4 count at time t. Therefore c(1) is the initial CD4 count (CD4 count at 
seroconversion). csqr(t) is the square root of the CD4 count at time t.   
cc(t-1) is the change in CD4 count between t-1 and t. ccsqr(t-1) is the change in root 
CD4 count between t-1 and t.   
 
Initial CD4 count 
The initial CD4 count is defined as: csqr(1) = 34 - (2 x vset) + Normal(0,2
2
).  
If c(1) > 1500 then c(1) = 1500 (so maximum allowable initial CD4 count is 1500 
cells/mm
3
). 
 
Changes in CD4 count from time t-1 to t 
CD4 count changes in ART-naïve patients are determined on the square root scale. 
Greater loss with higher viral load:  
v(t-1) ccsqr(t-1) 
<3.0 -0.030 + Normal(0,1.22)  
3.0-3.49 -0.080 + Normal(0,1.22) 
3.5-3.99 -0.015 + Normal(0,1.22) 
4.0-4.49 -0.200 + Normal(0,1.22) 
4.5-4.99 -0.500 + Normal(0,1.22) 
5.0-5.49 -1.000 + Normal(0,1.22) 
5.5-5.99 -2.000 + Normal(0,1.22) 
≥6.0 -2.500 + Normal(0,1.22) 
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Greater loss at older age:  
Take the value of ccsqr(t-1) determined above based on viral load and add 
additional effect of age: 
age(t) New value of ccsqr(t-1) 
<20 ccsqr(t-1) + 0.15 
20-24.75 ccsqr(t-1) + 0.09 
25-29.75 ccsqr(t-1) + 0.06 
30-34.75 ccsqr(t-1) + 0.00 
35-39.75 ccsqr(t-1) – 0.00 
40-44.75 ccsqr(t-1) – 0.06 
45-49.75 ccsqr(t-1) – 0.09 
50-59.75 ccsqr(t-1) – 0.15 
≥60 ccsqr(t-1) – 0.20 
 
Greater loss with X4 virus: 
Take the value of ccsqr(t-1) determined above based on viral load and age, and add 
additional effect of X4 virus: 
If X4 virus present at t-1 then ccsqr(t-1) = ccsqr(t-1) - 0.25 
 
Measured CD4 count 
These values above determine the underlying CD4 count. The measured CD4 
count, cm(t), is given by: cm(t) = ( sqrt(c(t)) + Normal(0,1.22) )2 
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Occurrence of AIDS diseases  
Rate of AIDS diseases according to CD4 count  
c(t) Rate  c(t) rate 
≥650 0.006  150-174 0.10 
500-650 0.010  125-149 0.13 
450-499 0.013  100-124 0.17 
400-449 0.016  90-99 0.20 
375-399 0.020  80-89 0.23 
350-374 0.022  70-79 0.28 
325-349 0.025  60-69 0.32 
300-324 0.030  50-59 0.40 
275-299 0.037  40-49 0.50 
250-274 0.045  30-39 0.80 
225-249 0.055  20-29 1.10 
200-224 0.065  10-19 1.80 
175-199 0.080  <10 2.50 
 
Independent effect of viral load: 
Take the rate determined above based on CD4 count and add additional effect of 
viral load: 
v(t) New value of rate 
<3.0 rate x 0.2 
3.0-3.99 rate x 0.3 
4.0-4.49 rate x 0.6 
4.5-4.99 rate x 0.9 
5.0-5.49 rate x 1.2 
≥5.5 rate x 1.4 
 
Independent effect of age: 
Take the rate determined above based on CD4 count and viral load, and add 
additional effect of age: 
rate = rate x (age(t) / 38)
1.2
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Independent effect of PCP prophylaxis: 
Take the rate determined above based on CD4 count, viral load and age, and add 
additional effect of being on PCP prophylaxis: 
rate = rate x 0.8 
 
Independent effect of being on ART: 
For patients on a single drug regimen the rate is further multiplied by 0.9, for patients on 
a two drug regimen it is further multiplied by 0.85 and for patients on a triple drug 
regimen it is further multiplied by 0.8, to reflect that being on cART has a positive effect 
on risk of AIDS and death independent of latest CD4 count and viral load.  
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Appendix VII. Model details for HIV 
Synthesis V5: effect of ART 
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Determination of viral load, CD4 count, acquisition of new resistance 
mutations between t-1 and t (variable newmut(t)) in ART-experienced 
individuals 
These depend on adherence between t-1 and t, number of active drugs, nactive(t-1), 
time on the current regimen and the current viral load itself. The way the values are 
generated is detailed on the following pages. 
 
   
 
 
4
6
3
 
Viral load (mean change from viral load max, vmax), CD4 count change (mean change between t-1 and t), and new mutation risk in first 3 
months 
For 0 active drugs, these are the changes regardless of time from start of regimen.  
The initial 3-month change in viral load is described as the mean change from the patient’s maximum viral load to that point (vmax) on the log 
scale. This is the mean of a normal distribution with standard deviation 0.2, from which the patient’s value/change is sampled.  
The change in CD4 count is described as the mean change between periods (t-1) to t. This change is then multiplied by a factor which 
represents each individual’s underlying propensity for CD4 count rise whilst on ART (given by pt_cd4_rise_art). If the mean CD4 count change 
obtained from the table below is positive, then the mean value is subsequently multiplied by this factor. However, if the CD4 count change in 
the table is a negative value (i.e. not a CD4 count rise), then it is not multiplied by this factor.  
For the new mutation risk, this is a number that is multiplied by the viral load (mean of values at t-1 to t). The resulting number, newmut(t), is 
used when assessing whether a new mutation or mutations have arisen (see Appendix VIII).   
  Number of active drugs 
  
‘Effective 
adherence’ 
between t-1 & t 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
Viral load (log 
change from 
vmax) 
> 0.8 -3 -2.6 -2.2 -1.8 -1.5 -1.25 -0.9 -0.8 -0.7 -0.55 -0.4 -0.3 
> 0.5, < 0.8 -2 -1.6 -1.2 -1.1 -0.9 -0.8 -0.6 -0.5 -0.4 -0.25 -0.1 -0.05 
< 0.5  -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 0 0.05 0.1 0.1 0.1 0.1 
              
CD4 count 
change (t-1 to t) 
> 0.8 70 45 40 35 30 25 20 17 13 10 5 -2 
> 0.5, < 0.8 30 30 23 20 15 13 10 8 5 3 0 -7 
< 0.5  5 4 3 2 1 -1 -3 -6 -10 -11 -12 -13 
              
New mutation 
risk (x log viral 
load) 
> 0.8 0.002 0.01 0.03 0.05 0.1 0.15 0.2 0.3 0.4 0.45 0.5 0.5 
> 0.5, < 0.8 0.15 0.15 0.2 0.25 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
< 0.5  0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
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Summary of viral load (mean absolute value or mean change from viral load max) between 3-6 months, and after 6 months if viral load at t-1 
>4 log copies/ml   
This table applies to patients for whom it has been between 3 and 6 months since starting their current regimen, as well as patients who have 
been on their current regimen for more than 6 months but who have a viral load > 4 log copies/ml (e.g. due to previous poor adherence). The 
change in viral load is described as the mean change from the patient’s maximum viral load to that point (vmax) on the log scale. Otherwise, if 
the number in the table is underlined, it is the mean absolute value. This is the mean of a normal distribution with standard deviation 0.2, from 
which the patient’s value/change is sampled. 
  Number of active drugs 
‘Effective 
adherence’ 
between t-2 & t-1  
‘Effective 
adherence’ 
between t-1 & t 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
> 0.8 > 0.8 0.5 0.8 1.2 1.4 2.0 2.7 -1.7 -1.15 -0.9 -0.75 -0.6 -0.4 
> 0.5, < 0.8 > 0.8 1.2 1.2 1.2 1.4 -2.0 -1.6 -1.2 -1.05 -0.9 -0.7 -0.5 -0.35 
< 0.5  > 0.8 1.2 1.2 1.2 1.4 -2.0 -1.6 -1.2 -1.0 -0.9 -0.7 -0.5 -0.2 
              
> 0.8 > 0.5, < 0.8 1.2 1.6 1.8 2.2 2.4 -2.4 -1.5 -0.9 -0.7 -0.55 -0.4 -0.3 
> 0.5, < 0.8 > 0.5, < 0.8 2.5 2.5 2.5 2.5 -1.2 -1.1 -0.8 -0.65 -0.5 -0.35 -0.2 -0.05 
< 0.5  > 0.5, < 0.8 -2.0 -1.8 -1.5 -1.35 -1.2 -1.1 -0.8 -0.65 -0.5 -0.2 -0.2 -0.05 
              
> 0.8 < 0.5 -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0 +0 +0 +0 
> 0.5, < 0.8 < 0.5 -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0 +0 +0 +0 
< 0.5  < 0.5  -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0 +0 +0 +0 
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Summary of CD4 count change (mean change between t-1 and t) between 3-6 months since starting current regimen and after 6 months if 
viral load at t-1 >4 log copies/ml 
This table applies to patients for whom it has been between 3 and 6 months since starting their current regimen, as well as patients who have 
been on their current regimen for more than 6 months but who have a viral load > 4 log/copies/ml (e.g. due to previous poor adherence). 
The change in CD4 count is described as the mean change between periods t-1 to t. This change is then multiplied by a factor which 
represents each individual’s underlying propensity for CD4 count rise whilst on ART (given by pt_cd4_rise_art). If the mean CD4 count change 
obtained from the table below is positive, then the mean value is subsequently multiplied by this factor. However, if the CD4 count change in 
the table is a negative value (i.e. not a CD4 count rise) then it is not multiplied by this factor. 
  Number of active drugs 
‘Effective 
adherence’ 
between t-2 & t-1  
‘Effective 
adherence’ 
between t-1 & t 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
> 0.8 > 0.8 +30 +28 +25 +23 +21 +19 +3 -5 -9 -10.5 -12 -14 
> 0.5, < 0.8 > 0.8 +30 +28 +25 +23 +7.5 +1.5 -4.5 -7 -9 -11 -13 -14.5 
< 0.5  > 0.8 +30 +28 +25 +23 +7.5 +1.5 -4.5 -7.5 -9 -11 -13 -16 
              
> 0.8 > 0.5, < 0.8 +15 +13 +10 +8 +7 +4 +0 -9 -11 -12.5 -14 -15 
> 0.5, < 0.8 > 0.5, < 0.8 +15 +13 +10 +8 -4.5 -6 -10 -11.5 -13 -14.5 -16 -17.5 
< 0.5  > 0.5, < 0.8 +7.5 +4.5 +0 -2 -4.5 -6 -10 -11.5 -13 -16 -16 -17.5 
              
> 0.8 < 0.5 -13 -14 -15 -15.5 -16 -16.5 -17 -17.5 -18 -18 -18 -18 
> 0.5, < 0.8 < 0.5 -13 -14 -15 -15.5 -16 -16.5 -17 -17.5 -18 -18 -18 -18 
< 0.5  < 0.5  -13 -14 -15 -15.5 -16 -16.5 -17 -17.5 -18 -18 -18 -18 
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Summary of new mutation risk between 3-6 months, and after 6 months if viral load at t-1 >4 log copies/ml 
This table applies to patients for whom it has been between 3 and 6 months since starting their current period of continuous therapy, as well as 
for patients whom it has been more than 6 months since their current period of continuous therapy but who have a high viral load (e.g. due to 
previous poor adherence). The numbers given in the table below correspond to the ‘new mutation factor’, which is a number that is multiplied 
by the viral load (mean of values at t-1 to t). The resulting probability, newmut(t), is used when assessing whether a new mutation or mutations 
have arisen (see Appendix VIII). 
  Number of active drugs 
‘Effective 
adherence’ 
between t-2 & t-1  
‘Effective 
adherence’ 
between t-1 & t 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
> 0.8 > 0.8 0.002 0.01 0.03 0.05 0.05 0.1 0.2 0.3 0.4 0.45 0.5 0.5 
> 0.5, < 0.8 > 0.8 0.002 0.01 0.03 0.05 0.05 0.1 0.2 0.3 0.4 0.45 0.5 0.5 
< 0.5  > 0.8 0.05 0.05 0.03 0.05 0.05 0.1 0.2 0.3 0.4 0.45 0.5 0.25 
              
> 0.8 > 0.5, < 0.8 0.10 0.15 0.2 0.2 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
> 0.5, < 0.8 > 0.5, < 0.8 0.10 0.15 0.2 0.2 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
< 0.5  > 0.5, < 0.8 0.10 0.15 0.2 0.2 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.25 
              
> 0.8 < 0.5 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
> 0.5, < 0.8 < 0.5 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
< 0.5  < 0.5  0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
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Summary of viral load (mean change from viral load max), CD4 count change (mean change between t-1 and t), after 6 months, where viral 
load at t-1 <4 log copies/ml 
Summary of viral load (mean change from viral load max), CD4 count change (mean change between t-1 and t), and new mutation risk after 6 
months, where viral load at t-1 <4 log copies/ml.  For viral load this is the mean of a Normal distribution with standard deviation 0.2, from which 
the patient's value/change is sampled.  For the CD4 count patients vary in their underlying propensity for CD4 rise on ART (given by given by 
pt_cd4_rise_art) and the CD4 count change given here is multiplied by this factor.  For the new mutation number, this is a number that is 
multiplied by the viral load (mean of values at t-1 to t). The resulting probability, newmut(t), is used when assessing whether a new mutation or 
mutations have arisen (see Appendix VIII). 
  Number of active drugs 
  
‘Effective 
adherence’ 
between t-1 & t 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
Viral load (log 
change from 
vmax) 
> 0.8 0.5 0.9 1.2 1.6 -2.5 -2.0 -1.4 -1.15 -0.9 -0.75 -0.6 -0.3 
> 0.5, < 0.8 1.2 1.2 1.2 1.4 -1.2 -1.0 -0.7 -0.6 -0.5 -0.4 -0.3 -0.1 
< 0.5  -0.5 -0.4 -0.3 -0.25 -0.2 -0.2 -0.1 -0.1 -0.1 -0.1 -0.1 0 
              
CD4 count 
change (t-1 to t) 
> 0.8 +30 +28 +25 +23 +21 +19 +3 -5 -9 -10.5 -12 -12 
> 0.5, < 0.8 +15 +13 +10 +8 -4.5 -7.5 -10 -12 -13 -14 -15 -15 
< 0.5  -13 -14 -15 -15.5 -16 -16.5 -17 -17 -18 -17 -17 -17 
              
New mutation 
risk (x log viral 
load) 
> 0.8 0.002 0.01 0.03 0.08 0.1 0.15 0.2 0.3 0.4 0.45 0.5 0.5 
> 0.5, < 0.8 0.15 0.18 0.2 0.25 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
< 0.5  0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
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Adherence in patients on ART 
There are two components, each patient has a fixed ‘tendency to adhere’ but their 
actual adherence varies from period to period, both at random and according to the 
presence of symptoms. 
Component which is fixed over time for a given patient 
Average adherence (a measure of the patient’s tendency to adhere, adhav) is a 
fixed value for a patient. adhvar is the variance of the adherence from period to 
period. One example for the population distribution of adhav and adhvar is: 
Probability adhav adhvar 
5% 0.5 0.2 
10% 0.8 0.2 
65% 0.9 0.06 
20% 0.95 0.05 
 
If adhav < 0 then adhav=0. Likewise, if adhav > 1 then adhav=1  
 
Actual adherence level in a period 
adh(t) is the actual level of adherence between t-1 and t and is determined as 
follows: 
adh(t)=adhav  
 
Effect of calendar year, caldate(t): 
caldate(t) New value of adh(t) 
<1996 adh(t) - 0.12 
1996-1996.75 adh(t) - 0.10 
1997-1997.75 adh(t) - 0.09 
1998-1998.75 adh(t) - 0.08 
1999-1999.75 adh(t) - 0.07 
2000-2000.75 adh(t) - 0.06 
2001-2001.75 adh(t) - 0.05 
2002-2002.75 adh(t) - 0.04 
2003-2003.75 adh(t) - 0.03 
2004-2004.75 adh(t) - 0.02 
2005-2005.75 adh(t) - 0.01 
>2006 adh(t) - 0.00 
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If adh(t) < 0 then adh(t) = 0. Likewise, if adh(t) > 1 then adh(t) = 1. 
adh(t) = adhav + Normal(0,advar) 
 
If adh(t) > 1 then adh(t)=1. 
 
Adherence patterns 
There are various adherence pattern distributions considered which describe the 
population distribution of underlying levels of ART adherence. adh_pattern is a 
categorical variable. The value of this variable is sampled from (1,2,3,4,5), each 
representing a different distribution of the adherence levels in a population. 1 represents 
a very good population level of adherence (around 95% of people on treatment with 
suppressed viral load) to 5 which represents a poor population level of adherence 
(around 60% of people on treatment with suppressed viral load): 
Adherence pattern Probability adhav adhvar 
1 
3% 0.5 0.2 
3% 0.8 0.2 
14% 0.9 0.06 
80% 0.95 0.05 
2 
5% 0.5 0.2 
10% 0.8 0.2 
27% 0.9 0.06 
38% 0.9 0.05 
20% 0.95 0.05 
3 
15% 0.5 0.2 
15% 0.7 0.2 
50% 0.9 0.06 
20% 0.95 0.05 
4 
30% 0.5 0.2 
30% 0.7 0.2 
10% 0.9 0.06 
30% 0.95 0.05 
5 
30% 0.5 0.2 
30% 0.6 0.2 
10% 0.7 0.06 
30% 0.9 0.05 
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Appendix VIII. Model details for HIV 
Synthesis V5: resistance 
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Presence of resistance acquired at infection in ART-naïve patients 
In the following, c_rt184m1 indicates whether the M184V mutation is present in majority 
virus (1 = yes, 0 =no) at infection, etc. e_rt184m1 indicates whether virus with mutation 
is present at all, etc. Once e_rt184m(t) this takes the value 1 it can never revert to 0. 
caldate1 is calendar date of infection. 
No resistance is assumed at infection in heterosexuals infected outside UK (sub-
Saharan Africa). 50% of those infected sexually assumed to be infected from an ART-
experienced person. Amongst those the following risks are assumed: 
Reverse transcriptase 
If caldate1 > 1993 then 12% chance that c_rttams1=1, 5% chance that c_rttams1=2. 
If caldate1 > 1996 then 4% chance that e_rt184m1=1 (unlike all other mutations, M184V 
is assumed not to persist in majority virus after infection) 
0.1% chance that c_rt74m1 = 1 
Before 2000, 0.1% chance that c_rt65m1 = 1  
After 2000, 0.3% chance that c_rt65m1 =1  
If 1996.5 <= caldate1 < 2000 then 4% chance that c_rtnnm1=1 
If 2000 <= caldate1 then 14% chance that c_rtnnm1=1 
 
 
Protease  
If caldate1 > 1997 then 2% chance that c_pr30m1=1 
If caldate1 > 2000 then 2% chance that c_pr33m1=1 
If caldate1 > 1996 then 2% chance that c_pr46m1=1 
If caldate1 > 1996 then 2% chance that c_pr48m1=1 
If caldate1 > 2000 then 2% chance that c_pr50vm1=1 
If caldate1 > 2005 then 2% chance that c_pr50lm1=1 
If caldate1 > 1996 then 2% chance that c_pr82m1=1 
If caldate1 > 1996 then 2% chance that c_pr84m1=1 
If caldate1 > 1997 then 2% chance that c_pr90m1=1 
If caldate1 > 2007 then 2% chance that c_prpixm1=1 
 
 
CCR5 antagonist 
c_ccrm1=0 (i.e. assumed negligible risk of acquiring this at infection) 
Enfuvirtide 
c_enfm1=0 (i.e. assumed negligible risk of acquiring this at infection) 
Integrase inhibitor 
c_inin1=0 (ie assumed negligible risk of acquiring this at infection) 
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Accumulation of resistance mutations in ART-experienced patients 
newmut(t) is a probability used to indicate the level of risk of new mutations arising in a 
given three-month period. Values of newmut(t) are given in Appendix VII. If this chance 
comes up in a given three-month period (determined by sampling from the binomial 
distribution) then the following criteria operate: 
Resistance 
mutation 
Probability 
of arising 
Conditions 
M184 30% if on 3TC 
# TAMS 
increases by 1 
20% if (on AZT or d4T) and (not on 3TC nor FTC) 
 12% if (on AZT or D4T) and (on 3TC or FTC) 
# TAMS 
increases by 2 
1% if (on AZT or D4T) and (not on 3TC nor FTC) 
 1% if (on AZT or D4T) and (on 3TC or FTC) 
K65 2% if (on TDF or ABC or ddI) and (on AZT or d4T)  
 10% If (on TDF or ABC or ddI) and (not on AZT nor 
d4T)  
L74 1% if (on ddI or ddC or ABC)  
Q151 2% if (on ddI or d4T or AZT or ABC)  
NUCX 10% if on other new NRTIs 
NN 80% If (on NVP or EFV) 
NNX 30% If on ETV 
D30 15% if on NFV 
V32 4% if on LPV 
L33 4% If on TPV 
M46 12% If (on IDV) and (caldate(t) < July 2000) 
 5% If (on IDV) and (caldate(t)≥ July 2000) 
 12% If on RTV 
I47 4% If on LPV 
G48 60% If (on SQV) and (caldate(t) < 1997) 
 12% If (on SQV) and (1997 ≤ caldate(t) < 1999) 
 4% If (on SQV) and (caldate(t) ≥ 1999) 
I50V 4% If (on APV)  
 4% If on DRV 
I50L 3% If on ATV 
I54 4% If on DRV 
L76 4% If on DRV 
V82 12% If (on IDV) and (caldate(t) < July 2000) 
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Resistance 
mutation 
Probability 
of arising 
Conditions 
 5% If (on IDV) and (caldate(t) ≥ July 2000) 
 12% If on RTV 
 4% If on LPV 
 4% If on TPV 
I84 12% If (on IDV) and (caldate(t) < July 2000) 
 5% If (on IDV) and (caldate(t) ≥ July 2000) 
 12% If on RTV 
 4% If on APV 
 4% If on ATV 
 4% If on DRV 
 4% If on TPV 
N88 4% If on ATV 
L90 60% If (on SQV) and (caldate(t) < 1997) 
 12% If (on SQV) and (1997 ≤ caldate(t) < 1999) 
 4% If (on SQV) and (caldate(t) ≥ 1999) 
 15% If on NFV 
CCR5m 7% If on MVC 
IIm 7% If on RAL 
FIm 8% If on T-20 
caldate(t) refers to the calendar date at time t. 
Different accumulation is assumed on boosted-PI regimens (LPV, IDV and SQV). 
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Appendix IX. Estimates of life expectancy 
based on studies published from 2011 
onwards 
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Authors, 
region 
(Publication 
year) 
reference 
Study population Method Life expectancy defined as ’expected age at death’ unless stated otherwise 
May et al., UK 
(2014) [810] 
21,388 adults (aged 
>20 years) in UK 
CHIC study who 
started cART during 
2000-2010 (excluding 
PWID)  
Construction of 
abridged life 
tables 
For males:  
68, 73 and 77 years at ages 20, 35 and 50 years respectively. 
57, 73 and 77 years at age 20, HIV RNA ≤400 copies/ml and after 5 years from 
start of cART for CD4 count <200, 200-349 and ≥350 cells/mm3 respectively. 
For females:  
69, 74 and 78 years at ages 20, 35 and 50 years respectively.  
64, 78 and 82 years at age 20, HIV RNA ≤400 copies/ml and after 5 years from 
start of cART for CD4 count <200, 200-349 and ≥350 cells/mm3 respectively. 
May et al., UK 
(2011) [806] 
17661 adults with 
CD4 count ≤350 
cells/mm
3
 at start of 
cART between 1996 
and 2008 
Construction of 
abridged life 
tables 
At age 20: 
30.0 and 45.8 additional years of life for 1996-9 and 2006-8 respectively 
For 1996-2006, 39.5 and 50.2 additional years of life for males and females 
respectively  
37.9, 41.0 and 53.4 additional years of life in those starting cART with CD4 count 
<100, 100-199 and 200-350 cells/mm
3
 respectively 
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Authors, 
region 
(Publication 
year) 
reference 
Study population Method Life expectancy defined as ’expected age at death’ unless stated otherwise 
Sloan et al., 
France (2012) 
[818] 
10 million HIV-
positive individuals in 
each modelled 
scenario, with the 
same characteristics 
as the newly 
diagnosed French 
HIV-positive 
population in 2005 
First-order 
state-transition 
Monte Carlo 
simulation 
model 
If cART was initiated at CD4 count <350 cells/mm
3
: 
23.8, 26.5 and 27.5 additional years of life if mean CD4 count at presentation to 
care was 97, 372 and 510 cells/mm3 respectively 
If cART was initiated at CD4 count <500 cells/mm
3
 or viral load >100,000 
copies/ml or if presenting with an ADC: 
26.4 and 27.4 additional years of life if mean CD4 count at presentation to care 
was 372 and 510 cells/mm
3
 respectively 
Guaraldi et al., 
Italy (2014) 
[812] 
9,671 adults receiving 
cART at some point 
between 1985 and 
2011. 
Construction of 
abridged life 
tables 
At age 25, 50.6, 42.7 and 34.3 additional years of life in the immune recovery
a
, 
post-cART and no immune recovery groups
b
 respectively 
Helleberg et al., 
Europe and US 
(2014) [811] 
17,995 individuals 
enrolled in ART-CC, 
who did not acquire 
HIV through IDU 
Construction of 
abridged life 
tables 
At age 35, 41.4 and 33.5 additional years of life for non-smokers and smokers 
respectively. At age 65, 16.1 and 9.5 additional years of life for non-smokers and 
smokers respectively.   
For those with CD4 ≥200 cells/mm3, 43.4 and 37.8 additional years of life for non-
smokers and smokers respectively.  
For those with viral suppression (<400 copies/ml), 43.5 and 35.0 additional years 
of life for non-smokers and smokers respectively. 
Wada et al., US 
(2013) [813] 
8,771 individuals 
enrolled in MACS or 
WIHS between 1984 
and 2008. 
Parametric and 
semiparametric 
competing risks 
methods 
In pre-cART era (1984-1995), 49.0 and 42.7 years for those who died of non-AIDS-
related causes and AIDS-related causes respectively.  
In cART era (1996-2008), 66.0 and 48.2 years for those who died of non-AIDS-
related causes and AIDS-related causes respectively. 
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Authors, 
region 
(Publication 
year) 
reference 
Study population Method Life expectancy defined as ’expected age at death’ unless stated otherwise 
Samji et al., US 
& Canada 
(2013) [814] 
22,937 adults (aged 
≥20 years) on cART 
enrolled in NA-
ACCORD from 2000-
2007 
Construction of 
abridged life 
tables 
At age 20: 
35.9, 44.3 and 53.4 years for males in 2000-2, 2003-5 and 2006-7 respectively. 
36.6, 48.4 and 47.3 years for females in 2000-2, 2003-5 and 2006-7 respectively. 
29.5, 31.0 and 28.8 years in 2000-2, 2003-5 and 2006-7 respectively if acquired 
HIV via IDU. 
53.3, 57.4 and 69.3 years in 2000-2, 2003-5 and 2006-7 respectively if MSM. 
52.7, 53.6 and 56.9 years if white race in 2000-2, 2003-5 and 2006-7 respectively. 
29.7, 40.7 and 48.4 years if non-white race in 2000-2, 2003-5 and 2006-7 
respectively. 
Farnham et al., 
US (2013) [815] 
10,000 HIV-positive 
individuals in each 
modelled scenario 
Monte Carlo 
health-state 
transition 
simulation 
model 
At age 35, assuming that CD4 count at infection was between 750 and 900 
cells/mm
3
 and cART was initiated at CD4 count ≤500 cells/mm3, additional years of 
life from time of infection were 30.7, 36.6, 38.0 and 38.1 years if CD4 count at 
diagnosis were ≤200, 201–350, 351–500 and 501–900 cells/mm3 respectively. 
Bor et al., 
South Africa 
(2013) [800] 
101,286 people in a 
rural population 
cohort 
Survival curves 
using Kaplan-
Meier 
estimation 
52.3, 49.2 and 60.5 years in 2000, 2003 and 2011 respectively. 
For males, 49.0, 46.9 and 55 years in 2000, 2003 and 2011 respectively. 
For females, 55.4, 51.3 and 64.6 years in 2000, 2003 and 2011 respectively. 
Johnson et al. 
South Africa, 
(2013) [816] 
37,740 HIV-positive 
adults in the IeDEA-
SA starting cART for 
the first time 
A relative 
survival 
approach to 
model the 
excess 
mortality 
attributable to 
If cART was initiated at CD4 count ≥200 cells/mm3: 
31.2 and 11.5 additional years of life for males at age 20 and 60 respectively. 
43.1 and 16.4 additional years of life for females at age 20 and 60 respectively. 
If cART was initiated at CD4 count <50 cells/mm
3
: 
21.7 and 8.0 additional years of life for males at age 20 and 60 respectively. 
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Authors, 
region 
(Publication 
year) 
reference 
Study population Method Life expectancy defined as ’expected age at death’ unless stated otherwise 
HIV 29.5 and 11.7 additional years of life for females at age 20 and 60 respectively. 
Mills et al., 
Uganda (2011) 
[817] 
22315 patients aged 
14 years or older, 
who initiated cART 
between 2000 and 
2009 
Construction of 
abridged life 
tables 
At age 20: 
26.7 additional years of life for overall cohort; 
19.7 and 30.6 additional years of life for males and females respectively 
13.5 and 37.4 additional years of life if baseline CD4 count <50 and ≥250 
cells/mm
3
 respectively 
ADC: AIDS-defining condition; ART-CC: Antiretroviral therapy cohort-collaboration; cART: combination antiretroviral therapy; IDU: injecting drug use; IeDEA-
SA: International epidemiologic Databases to Evaluate AIDS South Africa; MACS: Multicentre AIDS Cohort Study; NA-ACCORD: North American AIDS 
Cohort Collaboration on Research and Design; PWID: people who inject drugs; UK CHIC: UK Collaborative HIV Cohort; WIHS: Women’s Interagency HIV 
Study 
a. immune recovery group: patients who started cART with a nadir CD4 count of ≤350 cells/mm
3
 and who had attained a CD4 count of ≥500 cells/mm
3
 by 
study censoring data 
b. no immune recovery group: patients who started cART in the post-cART era with a nadir CD4 count of ≤350 cells/mm
3
 and who had not attained a CD4 
count of ≥500 cells/mm
3
 by study censoring data 
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Appendix X. Model parameters varied in 
multivariable uncertainty analysis for life 
expectancy estimate 
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Parameter  
Value 
in model 
Distribution in 
uncertainty analysis 
2.5
th
 and 
97.5
th
 
percentile 
of 
distribution 
Probability of willingness to take enfuvirtide 0.85 Beta(15,59/17) 0.65,0.93 
Mean of viral load set point (log copies/ml) 4 Normal(4,0.2
2
) 3.67,4.33 
Standard deviation of viral load set point (log copies/ml) 0.5 Normal(0.5,0.1
2
) 0.33,0.67 
Standard deviation of viral load change when ART-naïve (log copies/ml) 0.05 Normal(0.05,0.01
2
) 0.033,0.067 
Maximum value that the viral load set point can take (log copies/ml) 6.5 Normal(6,0.2
2
) 5.67,6.33 
Maximum value that actual viral load can take (log copies/ml) 6.5 Normal(6,0.2
2
) 5.67,6.33 
Standard deviation of the measured CD4 count (cells/mm
3
) 1.2 Normal(1.2,0.2
2
) 0.87,1.53 
Standard deviation of the actual CD4 cell count (cells/mm
3
) 1.2 Normal(1.2,0.2
2
) 0.87,1.53 
Maximum value that the actual CD4 count can take (cells/mm
3
) 800 Normal(800,20
2
) 767,834 
Additional variability given to change in CD4 count whilst on ART (cells/mm
3
) 0 Normal(0,5
2
) -8.23,8.24 
Probability that initiation of ART depends on the underlying tendency to adhere 1 Beta(10,52) 0.09,0.24 
Probability of initiating ART given that, 350 ≤ measured CD4 count < 500 (cells/mm3) 0.02 Beta(10,442) 0.012,0.034 
Probability of initiating ART given that, 300 ≤ measured CD4 count < 350 (cells/mm3) 0.95 Beta(20,2) 0.80,0.98 
Probability of initiating ART given that, 250 ≤ measured CD4 count < 300 (cells/mm3) 0.95 Beta(20,2) 0.80,0.98 
Probability of initiating ART given that, 200 ≤ measured CD4 count < 250 (cells/mm3) 0.95 Beta(20,2) 0.80,0.98 
Probability of initiating ART given that, 100 ≤ measured CD4 count < 200 (cells/mm3) 0.95 Beta(20,2) 0.80,0.98 
Probability of initiating ART given that, 0 ≤ measured CD4 count < 100 (cells/mm3) 0.95 Beta(20,2) 0.80,0.98 
Value used to calculate individual’s underlying propensity for CD4 rise on ART1 0.5 Normal(0.5,0.12) 0.33,0.67 
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Parameter  
Value 
in model 
Distribution in 
uncertainty analysis 
2.5
th
 and 
97.5
th
 
percentile 
of 
distribution 
Change in reduction of underlying propensity of CD4 rise after 4 years
2
 4 6 + Uniform(0,4) 6.2,9.8 
Multiplicative factor given to rate of interruption in those with low tendency to adhere 1.5 0.5+lnNormal(ln1,2.5
2
) 0.98,2.60 
Multiplicative factor given to overall rate of interruption 1 Normal(1,0.1
2
) 0.83,1.16 
Probability of re-initiating ART given that, 300 ≤ measured CD4 count (cells/mm3) 0.01 Beta(5,397) 0.005,0.022 
Probability of re-initiating ART given that, 200 ≤ measured CD4 count < 300 (cells/mm3) 0.03 Beta(5,391/3) 0.014,0.067 
Probability of re-initiating ART given that, 100 ≤ measured CD4 count < 200 (cells/mm3) 0.8 Beta(20,23/4) 0.63,0.89 
Probability of re-initiating ART given that, 50 ≤ measured CD4 count < 100 (cells/mm3) 0.9 Beta(20,28/9) 0.74,0.96 
Probability of re-initiating ART given that, measured CD4 count < 50 (cells/mm
3
) 0.95 Beta(20,2) 0.79,0.98 
Multiplicative factor given to probability of new mutations arising 1 0.5+lnNormal(ln1,2
2
) 0.57,1.78 
Virological failure threshold
3 
(log copies/ml)  500 Normal(500,50
2
) 418,583 
Probability of use of PCP prophylaxis (only if person has CD4 <200 cells/mm
3
) 0.9 Beta(25,5) 0.71,0.93 
Multiplicative factor given to rate used to calculate occurrence of AIDS and death 1 0.5+lnNormal(ln1,2
2
) 0.57,1.77 
Raised risk of AIDS occurring at HIV diagnosis 3 3+lnNormal(ln1,1.5
2
) 2.15,4.19 
Raised risk of all-cause mortality due to HIV infection 1.5 Normal(1.5,0.2
2
) 1.17,1.82 
Decreased risk of death for non-smokers
5
 5/7 Normal(5/7,0.04
2
) 0.65,0.78 
1) As seen Appendix VII, patients vary in their underlying propensity for CD4 rise on ART, which is given by sampling from lnNormal(ln1,0.5
2
). So here, 
the standard deviation is varied. 
2) If a patient has been on their current regimen for longer than two years, their underlying propensity for CD4 count rise reduces 4-fold to reflect the fact 
that the rate of CD4 count increase decreases over time. So in this uncertainty analysis, the rise has been reduced by (6+uniform(0,4))-fold if a 
patients has been on their current regimen for longer than 4 years. 
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3) The viral failure threshold is varied for each 3-month period for each individual, rather than for each simulation. 
4) 40% of MSM are assumed to be smokers for life. The risk of death for smokers is calculated according to the value sampled from Normal(5/7,0.04
2
) 
using the formula: risk of death for smokers = [1 – (risk of death for non-smokers x 0.6)] / 0.4, such that the risk of smoking on all-cause mortality is 2-
fold. 
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Appendix XI. Changes made to the 
probability of developing toxicities and the 
probability of switching a regimen once 
toxicity has developed in HIV Synthesis 
model 
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Probability of developing a new current toxicity in any given 3-month period whilst on a given antiretroviral drug (as part 
of ART regimen) 
Drug Synthesis V5 Synthesis V6 (Changes highlighted in blue) 
All drugs 3% general toxicity with unknown profile No changes 
ABA 
10% hypersensitivity reaction (only if been on drug for 3 months) 
0.1% lactic acidosis 
No changes 
d4T 
7% lipodystrophy 
5% peripheral neuropathy (1.5-fold increased risk in first year of 
taking drug) 
0.1% pancreatitis (0.2% if also on ddI) 
0.1% lactic acidosis 
5% lipodystrophy (0.5-fold risk in first year of taking drug) 
2% peripheral neuropathy (3% if also on ddI) (1.5-fold increased 
risk in first year of taking drug) 
0.1% pancreatitis (0.2% if also on ddI) 
0.2% lactic acidosis (1% if also on ddI) 
AZT 
10% nausea (2.5-fold increased risk in first year of taking drug) 
2% lipodystrophy 
3% anaemia (1.5-fold increased risk in first year of taking drug) 
10% headache (1.5-fold increased risk in first year of taking drug) 
0.1% lactic acidosis 
3% nausea (5-fold increased risk in first 6 months of taking drug) 
1.5% lipodystrophy (0.5-fold risk in first year of taking drug) 
1% anaemia (5-fold increased risk in first 6 months of taking drug) 
10% headache (1.5-fold increased risk in first year of taking drug) 
0.1% lactic acidosis 
ddC 
5% peripheral neuropathy (1.5-fold increased risk in first year of 
taking drug) 
2% peripheral neuropathy (1.5-fold increased risk in first year of 
taking drug) 
ddI 
10% nausea (2.5-fold increased risk in first year of taking ddi) 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 
1% peripheral neuropathy (1.5-fold increased risk in first year of 
taking drug) 
0.1% pancreatitis (0.2% if also on d4T) 
0.1% lactic acidosis 
3% nausea (5-fold increased risk in first year of taking drug) 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 
1% peripheral neuropathy (3% if also on d4T) (1.5-fold increased 
risk in first year of taking drug) 
0.1% pancreatitis (0.2% if also on d4T) 
0.2% lactic acidosis (1% if also on d4T) 
3% headache 
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3% rash 
TDF 
0.1% pancreatitis 
1% renal dysfunction 
0.1% lactic acidosis 
0.1% pancreatitis 
0.35 % renal dysfunction 
0.2% lactic acidosis 
Other 
new 
NRTIs 
None, other than 3% general toxicity No changes 
EFV 
3% rash (only if been on drug for ≤ 3 months) 
10% CNS toxicity (only if been on drug for ≤ 9 months) 
3% rash (only if been on drug for ≤ 3 months) 
10% CNS toxicity  (only if been on drug for ≤ 6 months) 
NVP 
10% rash (only if been on drug for ≤ 3months) 
5% hepatotoxicity (only if been on drug for ≤ 6 months) 
10% rash (only if been on drug for ≤ 3 months) 
2% hepatotoxicity (only if been on drug for ≤ 6 months) 
ETV None, other than 3% general toxicity None, other than 3% general toxicity 
SQV 
10% nausea (2.5-fold increased risk in first year of taking drug) 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 
3% nausea (5-fold increased risk in first year of taking drug) 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 
RTV 
50% nausea 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 
50% nausea 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 
Headache (very common) 
Peripheral neuropathy (very common) 
Hepatotoxicity (common) 
Rash (very common) 
IDV 
10% nausea (2.5-fold increased risk in first year of taking drug) 
25% nephrolithiasis (1.5-fold increased risk in first year of taking 
drug) 
3% nausea (5-fold increased risk in first year of taking drug) 
5% nephrolithiasis if administered with ritonavir (1.5-fold increased 
risk in first year of taking drug)  
2% nephrolithiasis if administered without ritonavir, i.e. pre-2003.5 
(1.5-fold increased risk in first year of taking drug) 
Headache (very common) 
Diarrhoea (very common) 
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LPV 
3% diarrhoea (2.5-fold increased risk in first year of taking drug) 3% nausea (5-fold increased risk in first year of taking drug) 
2% diarrhoea (2.5-fold increased risk in first year of taking drug) 
NFV 7% diarrhoea (2.5-fold increased risk in first year of taking drug) No changes 
APV 
10% nausea (2.5-fold increased risk in first year of taking drug) 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 
3% nausea (5-fold increased risk in first year of taking drug) 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 
ATV 
5% diarrhoea (2.5-fold increased risk in first year of taking drug) 1% nausea (5-fold increased risk in first year of taking drug) 
1% diarrhoea (2.5-fold increased risk in first year of taking drug) 
0.1% nephrolithiasis 
DRV 
10% nausea (2.5-fold increased risk in first year of taking drug) 1% nausea (5-fold increased risk in first year of taking drug) 
1% diarrhoea (2.5-fold increased risk in first year of taking drug) 
T-20 None, other than 3% general toxicity No changes 
MVC None, other than 3% general toxicity No changes 
RAL None, other than 3% general toxicity No changes 
 
Probability of switching an individual drug due to toxicity in any given 3-month period 
Drug Synthesis V5 Synthesis V6 (Changes highlighted in blue) 
ABC 
100% if hypersensitivity reaction currently present 
10% if other general toxicity currently present 
100% if hypersensitivity reaction currently present 
10% if other general toxicity currently present 
100% if lactic acidosis currently present 
d4T 
Between 4 and 16% if lipodystrophy currently present, depending 
on calendar year 
Between 4 and 16% if lipodystrophy currently present, depending 
on calendar year 
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15% if peripheral neuropathy currently present 
100% if pancreatitis currently present 
15% if peripheral neuropathy currently present 
100% if pancreatitis currently present 
100% if lactic acidosis currently present 
AZT 
8% if nausea currently present (switch only post-1992) 
3% if lipodystrophy currently present (switch only post-1992) 
20% if anaemia currently present (switch only post-1992) 
2% if headache currently present (switch only post-1992) 
8% if nausea currently present (switch only post-1992) 
3% if lipodystrophy currently present (switch only post-1992) 
20% if anaemia currently present (switch only post-1992) 
2% if headache currently present (switch only post-1992) 
100% if lactic acidosis currently present (switch only post-1992) 
ddC 40% if peripheral neuropathy currently present 40% if peripheral neuropathy currently present 
ddI 
20% if nausea currently present 
20% if diarrhoea currently present 
40% if peripheral neuropathy currently present 
100% if pancreatitis currently present 
20% if nausea currently present 
20% if diarrhoea currently present 
40% if peripheral neuropathy currently present 
100% if pancreatitis currently present 
100% if lactic acidosis currently present 
TDF 
10% if other general toxicity currently present 
100% if renal dysfunction currently present 
10% if other general toxicity currently present 
80% if renal dysfunction currently present 
100% if lactic acidosis currently present 
Other 
new 
NRTIs 
10% if other general toxicity currently present No changes 
EFV 
0.8% if CNS toxicities currently present 
5% if rash currently present 
2% if CNS toxicities currently present 
5% if rash currently present 
NVP 
40% if rash currently present 
80% if hepatotoxicity currently present  
No changes 
ETV 
40% if rash currently present 
30% if other general toxicity currently present 
No changes 
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SQV 
25% if nausea currently present 
25% if diarrhoea currently present 
30% if other general toxicity currently present 
No changes 
RTV 
40% if nausea currently present 
25% if diarrhoea currently present 
No changes 
IDV 
25% if nausea currently present 
40% if nephrolithiasis currently present 
No changes 
LPV 
25% if nausea currently present 
25% if diarrhoea currently present 
15% if nausea currently present 
15% if diarrhoea currently present 
NFV 25% if diarrhoea currently present No changes 
APV 
25% if nausea currently present 
25% if diarrhoea currently present 
No changes 
ATV 25% if diarrhoea currently present No changes 
DRV 20% if nausea currently present No changes 
T-20 10% if other general toxicity currently present No changes 
MVC 5% if other general toxicity currently present No changes 
RAL 5% if other general toxicity currently present No changes 
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Appendix XII. Age-specific fertility rates for 
the UK 
 
Source: UNdata. Fertility rate, births per 1,000 women. https://data.un.org/Default.aspx  
(accessed 30 November 2014)  
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Age-specific fertility rate for the UK 
The fertility rate is measured in births per 1,000 women.  
Subgroup Year Value 
Female 15-19 years 2000-2005 27.2 
Female 15-19 years 1995-2000 29.8 
Female 20-24 years 2000-2005 70.2 
Female 20-24 years 1995-2000 74 
Female 25-29 years 2000-2005 94.3 
Female 25-29 years 1995-2000 101.3 
Female 30-34 years 2000-2005 92.8 
Female 30-34 years 1995-2000 88.5 
Female 35-39 years 2000-2005 44.9 
Female 35-39 years 1995-2000 38.9 
Female 40-44 years 2000-2005 9.5 
Female 40-44 years 1995-2000 7.6 
Female 45-49 years 2000-2005 0.1 
Female 45-49 years 1995-2000 - 
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Appendix XIII. Publications arising from 
this work 
 
[Chapter 2] Nakagawa, F., Phillips A.N., Lundgren J.D. Update on HIV in Western 
Europe. Curr HIV/AIDS Rep. 2014; 11:177-185.  
[Chapter 4] Nakagawa, F., May, M., & Phillips, A. Life expectancy living with HIV: recent 
estimates and future implications. Curr Opin Infect Dis. 2013; 26(1):17-25.  
[Chapter 4] Nakagawa F., Lodwick R.K., Smith C.J., et al. Projected life expectancy of 
people with HIV according to timing of diagnosis. AIDS. 2012; 26(3):335-43. 
[Chapter 5] The Natural History Project Writing Group for Collaboration of Observational 
HIV Epidemiological Research In Europe (COHERE) in EuroCoord. Factors associated 
with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naive 
individuals. AIDS. 2014; 28(9):1351-1356. 
[Chapter 6] Nakagawa F on behalf of the Stochastic Simulation of Outcomes of People 
with HIV In Europe (SSOPHIE) project working group in EuroCoord. Estimating HIV-
infected Populations in Europe: Pilot Study Using Data on Men who Have Sex with Men 
(MSM) in the UK. 14th European AIDS Conference, 16th-19th October 2013. Brussels, 
Belgium. Abstract PE21/10 
[Chapter 6] Nakagawa F on behalf of the Stochastic Simulation of Outcomes of People 
with HIV In Europe (SSOPHIE) project working group in EuroCoord. Estimation of HIV-
infected populations in Europe: a pilot study using data for men who have sex with men 
in the UK. Meeting abstract for Public Health Science: A National Conference Dedicated 
to New Research in UK Public Health, 29th November 2013. London, UK. Lancet, 
382(Suppl 3), S77. 
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